

JCS4 U.S. PTO
06/23/00

06-26-00

PATENT

BOXSEA
A

Attorney Docket No. GENSET.063AUS

Date: June 23, 2000

Page 1

ASSISTANT COMMISSIONER FOR PATENTS

WASHINGTON, D.C. 20231

ATTENTION: BOX PATENT APPLICATION

Sir:

Transmitted herewith for filing is the patent application of

Inventor(s): **Caroline Barry, Lydie Bougueleret, Ilya Chumakov and Annick Cohen-Akenine**

For: **A NOVEL BAP28 GENE AND PROTEIN**

Enclosed are:

(X) Thirty (30) sheets of drawing.

(X) This application claims priority to U.S. Provisional Patent Application Serial No. 60/141,323, filed June 25, 1999 and U.S. Provisional Patent Application Serial No. 60/176,880, filed January 18, 2000, the disclosures of which are incorporated herein by reference in their entireties.

(X) Return prepaid postcard.

(X) Sequence Submission Statement in one (1) page)

(X) Sequence Listing in 101 pages

(X) Sequence Listing in computer readable form (CD ROM)

JCS4 U.S. PTO
09/603665
06/23/00

CLAIMS AS FILED

FOR	NUMBER FILED	NUMBER EXTRA	RATE	FEE
Basic Fee			\$690	\$690
Total Claims	84 - 20 =	64 ×	\$18	\$1,152
Independent Claims	27 - 3 =	24 ×	\$78	\$1,872
If application contains any multiple dependent claims(s), then add			\$260	\$260

FILING FEE TO BE PAID
AT A LATER DATE

\$3,974

PATENT

Attorney Docket No. GENSET.063AUS

Date: June 23, 2000

Page 2

(X) Please use Customer No. 20,995 for the correspondence address.



Daniel Hart

Registration No. 40,637

Attorney of Record

S:\DOCS\DOH\DOH-4555.DOC
062300

062300.5533960

KNOBBE, MARTENS, OLSON & BEAR

A LIMITED LIABILITY PARTNERSHIP INCLUDING

PROFESSIONAL CORPORATIONS
PATENT, TRADEMARK AND COPYRIGHT CAUSES

620 NEWPORT CENTER DRIVE

SIXTEENTH FLOOR

NEWPORT BEACH, CALIFORNIA 92660-8016

(949) 760-0404

FAX (949) 760-9502

INTERNET WWW.KNOBBE.COM

THOMAS F. SNEGAL, JR.
MICHAEL M. BERNHOLZ
DIANE M. REED
JOHNATHAN A. BARNY
RONALD J. SCHENBAUM
JOHN R. KING
FREDERICK S. BERRETTA
NANCY WAYS VENSKO
JOHN G. GIEZENTANNER
ADEL S. KOKTAR
GINGER R. DREGER
THOMAS R. ANDO
DAVID N. WEISS
DANIEL HART, PH.D.
DOUGLAS G. MUEHLHAUSER
LOUI LEE YAMATO
MICHAEL M. FRIEDLAND
STEPHEN W. LOBBIN
STACEY R. HALPERN
DALE C. HUNT, PH.D.
LEE W. HENDERSON, PH.D.
DEBORAH S. SHEPHERD
RICHARD E. LANFEBELL
MARK M. ABUEVER
JOHN N. GURVA
ERIC W. NELSON
MARK R. BENDICHT, PH.D.
PAUL R. CONOVER
ROBERT J. ROBY
SABINE H. LEE
KAROL NE A. STANLEY
JOHN W. POLLOCK
JAMES J. MULLER, III, PH.D.

JOSEPH S. CIANFRANI
JOSEPH M. REISMAN, PH.D.
WILLIAM S. ZIMMERMAN
WEN L. NUTTALL
ERIC S. FURMAN, PH.D.
THERAN ABE LOWE
GEOFFREY Y. HOA
ALEXANDER S. FRANCO
SANJIVPAL S. GILL
SUSAN M. MOSS
JAMES W. HILL, M.D.
ROSE M. THIESSEN, PH.D.
MICHAEL L. FULLER
MICHAEL A. GUILIANA
MARK J. KERTZ
RABINDER N. NARULA
BRUCE S. TICHENKOWITZ, PH.D.
PETER M. MIDDLEY
THOMAS S. MCCLERAHAN
MICHAEL S. OKAMOTO
JOHN M. GROVER
MALLARY K. DE MERIER
JIFAN A. LATEEF
AMY C. CHRISTENSEN
SHARON S. NG
MARK J. GALLAGHER, PH.D.
DAVID G. JANOWSKI, PH.D.
BRIAN C. HORNE
PAYSON J. LEMELLEUR
WILLIAM S. BERRY
DIANA M. PRICE

OF LOUISIANA
JERRY R. BARNETT
JAPANESE PATENT
KATSLIB
EUROPEAN PATENT
MARTIN HEINRICH
KOREAN PATENT
MINCHON
SCIENTISTS & ENGINEERS
(NON-LAWYERS)
RAINOLD J. SALENKERS**
NEIL S. BARTFELD, PH.D.**
DANIEL E. JOHNSON, PH.D.**
JEFFERY KOEPLER, PH.D.
KHURAM RAHMAN, PH.D.
JENNIFER A. HAYNES, PH.D.
BRENDAN P. D. NEILL, PH.D.
THOMAS Y. NAGATA
LINDA H. LIU
YASUNARI VAISHNAV, PH.D.
MEGUMI TANAKA
CHE S. CHESKIN, PH.D.**
ERIN M. ARCHOLD
PHILIP C. HARTSTEIN
JULIE A. HOPPER
CHRIS S. CASTLE
JAMES W. AUSLEY
B. P. CARON, PH.D.
JENNIFER HAYES
KIRK E. PASTORIAN, PH.D.
CHARLES T. RIDGELY

* A PROFESSIONAL CORPORATION
** ALSO BARRETT AT LAW, L.L.C.
** U.S. PATENT AGENT

Assistant Commissioner for Patents
Washington, D.C. 20231

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

Attorney Docket No. : GENSET.063AUS
Applicant(s) : Barry, et al.
For : A NOVEL BAP28 GENE AND PROTEIN
Attorney : Daniel Hart
"Express Mail"
Mailing Label No. : EL501132085US
Date of Deposit : June 23, 2000

I hereby certify that the accompanying

Transmittal in Duplicate; Specification in 169 pages; 30 sheets of drawings; Sequence Submission Statement in 1 page; Sequence Listing in 101 pages; Sequence Listing in computer readable form (CD ROM), Return Prepaid Postcard

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and are addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

John Riedel

S:\DOCS\DO\DOH-4556.DOC
062300

A NOVEL BAP28 GENE AND PROTEIN

5

Related Applications

The present application claims priority to U.S. Provisional Patent Application Serial No. 60/141,323, filed June 25, 1999 and U.S. Provisional Patent Application Serial No. 60/176,880, filed January 18, 2000, the disclosures of which are incorporated herein by reference in their entireties.

FIELD OF THE INVENTION

10 The present invention is directed to polynucleotides encoding a human BAP28 polypeptide as well as a regulatory regions located at the 5'- and 3'-ends of said coding region. The invention also concerns polypeptides encoded by the BAP28 gene. The invention also deals with antibodies directed specifically against such polypeptides that are useful as diagnostic reagents. The invention further encompasses biallelic markers of the *BAP28* gene useful in genetic analysis, and more particularly
15 associated with prostate cancer and useful in diagnosis.

BACKGROUND OF THE INVENTION**Prostate Cancer**

The incidence of prostate cancer has dramatically increased over the last decades. It averages 30-50/100,000 males in Western European countries as well as within the US White male
20 population. In these countries, it has recently become the most commonly diagnosed malignancy, being one of every four cancers diagnosed in American males. Prostate cancer's incidence is very much population specific, since it varies from 2/100,000 in China, to over 80/100,000 among African-American males.

In France, the incidence of prostate cancer is 35/100,000 males and it is increasing by
25 10/100,000 per decade. Mortality due to prostate cancer is also growing accordingly. It is the second cause of cancer death among French males, and the first one among French males aged over 70. This makes prostate cancer a serious burden in terms of public health.

Prostate cancer is a latent disease. Many men carry prostate cancer cells without overt signs of disease. Autopsies of individuals dying of other causes show prostate cancer cells in 30 % of men
30 at age 50 and in 60 % of men at age 80. Furthermore, prostate cancer can take up to 10 years to kill a patient after the initial diagnosis.

The progression of the disease usually goes from a well-defined mass within the prostate to a breakdown and invasion of the lateral margins of the prostate, followed by metastasis to regional lymph nodes, and metastasis to the bone marrow. Cancer metastasis to bone is common and often
35 associated with uncontrollable pain.

Unfortunately, in 80 % of cases, diagnosis of prostate cancer is established when the disease has already metastasized to the bones. Of special interest is the observation that prostate cancers frequently grow more rapidly in sites of metastasis than within the prostate itself.

Early-stage diagnosis of prostate cancer mainly relies today on Prostate Specific Antigen (PSA) dosage, and allows the detection of prostate cancer seven years before clinical symptoms become apparent. The effectiveness of PSA dosage diagnosis is however limited, due to its inability to discriminate between malignant and non-malignant affections of the organ and because not all prostate cancers give rise to an elevated serum PSA concentration. Furthermore, PSA dosage and other currently available approaches such as physical examination, tissue biopsy and bone scans are of limited value in predicting disease progression.

Therefore, there is a strong need for a reliable diagnostic procedure which would enable a more systematic early-stage prostate cancer prognosis.

Although an early-stage prostate cancer prognosis is important, the possibility of measuring the period of time during which treatment can be deferred is also interesting as currently available medicaments are expensive and generate important adverse effects. However, the aggressiveness of prostate tumors varies widely. Some tumors are relatively aggressive, doubling every six months whereas others are slow-growing, doubling once every five years. In fact, the majority of prostate cancers grows relatively slowly and never becomes clinically manifest. Very often, affected patients are among the elderly and die from another disease before prostate cancer actually develops. Thus, a significant question in treating prostate carcinoma is how to discriminate between tumors that will progress and those that will not progress during the expected lifetime of the patient.

Hence, there is also a strong need for detection means which may be used to evaluate the aggressiveness or the development potential of prostate cancer tumors once diagnosed.

Furthermore, at the present time, there is no means to predict prostate cancer susceptibility. It would also be very beneficial to detect individual susceptibility to prostate cancer. This could allow preventive treatment and a careful follow up of the development of the tumor.

A further consequence of the slow growth rate of prostate cancer is that few cancer cells are actively dividing at any one time, rendering prostate cancer generally resistant to radiation and chemotherapy. Surgery is the mainstay of treatment but it is largely ineffective and removes the ejaculatory ducts, resulting in impotence. Oral oestrogens and luteinizing releasing hormone analogs are also used for treatment of prostate cancer. These hormonal treatments provide marked improvement for many patients, but they only provide temporary relief. Indeed, most of these cancers soon relapse with the development of hormone-resistant tumor cells and the oestrogen treatment can lead to serious cardiovascular complications. Consequently, there is a strong need for preventive and curative treatment of prostate cancer.

Efficacy/tolerance prognosis could be precious in prostate cancer therapy. Indeed, hormonal therapy, the main treatment currently available, presents important side effects. The use of

chemotherapy is limited because of the small number of patients with chemosensitive tumors. Furthermore the age profile of the prostate cancer patient and intolerance to chemotherapy make the systematic use of this treatment very difficult.

- Therefore, a valuable assessment of the eventual efficacy of a medicament to be
5 administered to a prostate cancer patient as well as the patient's eventual tolerance to it may permit to enhance the benefit/risk ratio of prostate cancer treatment.

BAP28

- Bowcock et al. (1998) conducted studies to identify proteins interacting with the the first 304 amino terminal amino acid residues of breast cancer related gene, BRCA1. Bowcock et al. thereby
10 identified a BAP28 cDNA encoding a 515 amino acid protein associating with BRCA1 in a yeast two-hybrid screen, but whose association with BRCA1 could not be confirmed in a two-hybrid screen in mammalian cells.

SUMMARY OF THE INVENTION

- The present invention pertains to nucleic acid molecules comprising the genomic sequence
15 of a novel human *BAP28* gene and BAP28 protein. The *BAP28* genomic sequence comprises regulatory sequences located upstream and downstream of the transcribed portion of said gene, these regulatory sequences being also part of the invention.

The invention also deals with complete cDNA sequences encoding the BAP28 protein, as well as with the corresponding translation product.

- 20 Oligonucleotide probes or primers hybridizing specifically with a *BAP28* genomic or cDNA sequence are also part of the present invention, as well as DNA amplification and detection methods using said primers and probes.

- A further object of the invention consists of recombinant vectors comprising any of the nucleic acid sequences described herein, and in particular of recombinant vectors comprising a *BAP28*
25 regulatory sequence or a sequence encoding a BAP28 protein, as well as of cell hosts and transgenic non human animals comprising said nucleic acid sequences or recombinant vectors.

- The invention is also directed to BAP28 polymorphisms and BAP28-related biallelic markers as well as use of the of BAP28-related biallelic markers in establishing genetic associations with disease. BAP28-related biallelic markers can be used for diagnosis, staging, prognosis and monitoring
30 of disease, and the efficient design and evaluation of suitable therapeutic solutions including individualized strategies for optimizing drug usage, and screening of potential new medicament candidates. More particularly, the invention concerns an association between BAP28-related biallelic markers and prostate cancer.

- Finally, the invention is directed to methods for the screening of substances or molecules that
35 inhibit the expression of *BAP28*, as well as with methods for the screening of substances or molecules that interact with a BAP28 polypeptide or that modulate the activity of a BAP28 polypeptide.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a diagram showing the genomic structure of the genes BAP28 and PCTA-1. The arrow represent the DNA with the 5' to 3' direction. The boxes represent the exons.

Figure 2 is a diagram showing some alternative cDNA forms of the PCTA-1 gene.

- 5 Figure 3 is an alignment of the human BAP28 protein **H** with its homologues from *Drosophila melanogaster* (ORF from AE003615) **D**, *Arabidopsis thaliana* (AAF63640) **A**, *Schizosaccharomyces pombe* (O60179) **S**, *Caenorhabditis elegans* (Q23495) **C**, and *Saccharomyces cerevisiae* (YJK9_YEAST) **Y**. In C terminal part of the protein alignment, a box indicates the position of a conserved HEAT_REPEAT which is described to be involved in protein-protein interaction. For 10 *Drosophila melanogaster*, the sequence AE003615 describes a gene CG10805 with 6 exons. A new analysis showed that the exons 2, 3, 4, 5, and 6 present an homology with BAP28. Therefore, a new cDNA has been generated consisting with 21 bp upstream to exon 2, exon 2, intron 2, exons 3, 4, 5, and 6. This cDNA encodes a protein of 2096 amino acids which is described as **D** in the Figure 3.

- Figure 4 is an alignment of the human BAP28 protein and 3 protein segments from 15 *Tetraodon nigroviridis*, likely part of the same protein. The following sequences from Genbank have been contiguated in order to generate 3 segments of the genomic sequence of Tetraodon (CNS01RV3 + CNS03LT9 --> tetraodon3 ; CNS02AXF + CNS03INT --> tetraodon1 ; CNS02AXG + CNS01RV4 + CNS03LTA + CNS03INS --> tetraodon2). The 3 protein fragments which are similar to BAP28 have been found in these contiguated regions. Furthermore, the exons encoding the 3 protein segments have 20 the same size and the same structure in human BAP28 and in *Tetraodon*. The amino acid sequences encoding by these exons have been aligned with the human BAP28 protein.

Figure 5 is a diagram showing the allelic association analysis in chromosomal region 1q43.

Figure 6 is a diagram showing the genotypic association analysis in chromosomal region 1q43.

- Figure 7 is a table demonstrating the results of a haplotype association analysis between 25 prostate cancer cases and haplotypes comprising *BAP28*-related biallelic markers. Figure 7A presents the results for the two-marker haplotypes. Figure 7B presents the results for the three-marker haplotypes.

- Figure 8 is a table demonstrating the results of a haplotype association analysis between 30 familial prostate cancer cases and haplotypes comprising *BAP28*-related biallelic markers. Figure 8A presents the results for the two-marker haplotypes. Figure 8B presents the results for the three-marker haplotypes.

- Figure 9 is a table demonstrating the results of a haplotype association analysis between early onset familial prostate cancer cases (less than 65 years old) and haplotypes comprising *BAP28*-related biallelic markers. Figure 9A presents the results for the two-marker haplotypes. Figure 9B presents 35 the results for the three-marker haplotypes.

Figure 10 is a table demonstrating the results of a haplotype association analysis between sporadic prostate cancer cases and haplotypes comprising *BAP28*-related biallelic markers. Figure 10A

a presents the results for the two-marker haplotypes. Figure 10B presents the results for the three-marker haplotypes.

Figure 11 is a table demonstrating the results of a haplotype association analysis between informative sporadic prostate cancer cases and haplotypes comprising *BAP28*-related biallelic markers. Figure 11A a presents the results for the two-marker haplotypes. Figure 11B presents the results for the three-marker haplotypes.

Figures 12A and 12B are tables summarizing the results of haplotype frequency analyses between prostate cancer and three preferred haplotypes.

Figure 13 is a half-tome reproduction of the gels showing the tissular specificity of the *BAP28* expression, more particularly the segment comprising the exons 43 to A. Figure 13 A : Wells 1 and 13 : Molecular weight markers X - 300ng ; Well 2 : Mix PCR water = negative control ; Well 3 : Marathon Ready cDNA Human Testis : positive Tissue (CLONTECH Lot N°9110553) ; Well 4 : Marathon Ready cDNA Human Brain : negative Tissue ; Well 5 : Marathon Ready cDNA Human Cerebellum : negative Tissue ; Well 6 : Marathon Ready cDNA Human Cerebral Cortex : negative Tissue ; Well 7 : Marathon Ready cDNA Human Hippocampus : positive Tissue (CLONTECH Lot N°9040528) ; Well 8 : Marathon Ready cDNA Human Hypothalamus : negative Tissue ; Well 9 : Marathon Ready cDNA Human Fetal Kidney : negative Tissue ; Well 10 : Marathon Ready cDNA Human Thyroid : negative Tissue ; Well 11 : Marathon Ready cDNA Human Bone Marrow : negative Tissue ; Well 11 : Marathon Ready cDNA Human Leukemia, promyelocytic HL60 : negative Tissue.

Figure 13 B : Wells 1 and 7 : Molecular weight markers X - 300ng ; Well 2 : Marathon Ready cDNA Human Leukemia, lymphoblastic MOLT4 : negative Tissue ; Well 3 : Marathon Ready cDNA Human Leukemia, chronic myelogenous K-562 : positive Tissue (CLONTECH Lot N°9120565) ; Well 4 : Marathon Ready cDNA Human Fetal Liver : negative Tissue ; Well 5 : Marathon Ready cDNA Human Stomach : negative Tissue ; Well 6 : Marathon Ready cDNA Human Prostate : negative Tissue.

Figure 13 C : Wells 1 and 13 : Molecular weight markers X - 300ng ; Well 2 : cDNA Human Testis : negative Tissue ; Well 3 : cDNA Human Cerebellum : positive Tissue (RNA PolyA+ CLONTECH - Lot N°8070047 - Réf Cat:6543-1) ; Well 4 : cDNA Human Corpus Callosum : negative Tissue ; Well 5 : cDNA Human Substantia Nigra : positive Tissue (RNA PolyA+ CLONTECH - Lot N°8090745 - Réf Cat:6580-1) ; Well 6 : cDNA Human Amygdala : negative Tissue ; Well 7 : cDNA Human Thalamus : positive Tissue (RNA PolyA+ CLONTECH - Lot N°9031131 - Réf Cat:6582-1) ; Well 8 : cDNA Human Hippocampus : positive Tissue (RNA PolyA+ CLONTECH - Lot N°8040059 - Réf Cat:6578-1) ; Well 9 : cDNA Human Caudate Nucleus : positive Tissue (RNA PolyA+ CLONTECH - Lot N°6120286 - Réf Cat:6575-1) ; Well 10 : cDNA Human Fetal Brain : negative Tissue ; Well 11 : cDNA Human Skeletal Muscle : negative Tissue ; Well 12 : cDNA Human Lung : negative Tissue.

Figure 13 D : Wells 1 and 13 : Molecular weight markers X - 300ng ; Well 2 : cDNA Human Kidney : negative Tissue ; Well 3 : cDNA Human Placenta : negative Tissue ; Well 4 : cDNA Human Spleen : negative Tissue ; Well 5 : cDNA Human Fetal Liver : negative Tissue ; Well 6 :

cDNA Human Thyroid Gland : negative Tissue ; Well 7 : cDNA Human Leukemia, lymphoblastic : negative Tissue ; Well 8 : cDNA Human Spinal Cord : positive Tissue (RNA PolyA+ CLONTECH - Lot N°9040709 - Réf Cat:6593-1) ; Well 9 : cDNA Human Pituitary Gland : positive Tissue (RNA PolyA+ CLONTECH - Lot N°6080167 - Réf Cat:6584-1) ; Well 10 : cDNA Human Adrenal Gland : negative Tissue ; Well 11 : cDNA Human Trachea : negative Tissue ; Well 12 : cDNA Human Leukemia, chronic myelogenous : negative Tissue. Figure 13 E : Wells 1 and 13 : Molecular weight markers X - 300ng ; Well 2 : cDNA Human Salivary Gland : negative Tissue ; Well 3 : cDNA Human Leukemia, promyelocytic : negative Tissue ; Well 4 : cDNA Human Small Intestine : negative Tissue ; Well 5 : cDNA Human Pancreas : negative Tissue ; Well 6 : cDNA Human Stomach : negative Tissue ; Well 7 : cDNA Human Mammary Gland : positive Tissue (RNA PolyA+ CLONTECH - Lot N°9031125 - Réf Cat:6545-1) ; Well 8 : cDNA Human Bone Marrow : negative Tissue ; Well 9 : cDNA Human Thymus : negative Tissue ; Well 10 : cDNA Human Uterus : negative Tissue ; Well 11 : cDNA Human Prostate : negative Tissue ; Well 12 : cDNA Human Prostate : negative Tissue.

Figure 14 is a block diagram of an exemplary computer system.

Figure 15 is a flow diagram illustrating one embodiment of a process 200 for comparing a new nucleotide or protein sequence with a database of sequences in order to determine the homology levels between the new sequence and the sequences in the database.

Figure 16 is a flow diagram illustrating one embodiment of a process 250 in a computer for determining whether two sequences are homologous.

Figure 17 is a flow diagram illustrating one embodiment of an identifier process 300 for detecting the presence of a feature in a sequence.

Brief Description of the sequences provided in the Sequence Listing

SEQ ID No 1 contains the genomic sequence of the *BAP28* gene comprising the exons and introns, and the 5' and 3' regulatory regions (respectively the upstream and downstream untranscribed regions). Furthermore, SEQ ID No 1 also contains the genomic sequence of the PCTA-1 gene. The coding strand of PCTA-1 gene is on the opposite of the coding strand of BAP28.

SEQ ID No 2 contains a first cDNA sequence of the *BAP28* gene consisting of the exons 1 to 45. SEQ ID No 3 contains a second cDNA sequence of the *BAP28* gene consisting of the exons 1 to 44, 45b and A'. SEQ ID No 4 contains a sequence of the *BAP28* cDNA segment consisting of the exons B' and A'. SEQ ID No 5 contains the BAP28 amino acid sequence encoded by the cDNAs of SEQ ID Nos 2, and 3.

SEQ ID No 6 contains a first cDNA sequence of the *PCTA-1* gene consisting of the exons 0 to 9. SEQ ID No 7 contains a second cDNA sequence of the *PCTA-1* gene consisting of the exons 0, 1, 2, 3, 4, 5, 6, 6bis, 7, 8, and 9. SEQ ID No 8 contains a third cDNA sequence of the *PCTA-1* gene consisting of the exons 0 to 8, 9bis and 9ter. SEQ ID No 9 contains the sequence of a cDNA fragment of the *PCTA-1* gene comprising exons C and A. SEQ ID No 10 contains the sequence of a cDNA

fragment of the *PCTA-1* gene comprising exons B, 0, 1 and 2. SEQ ID No 11 contains the sequence of a cDNA fragment of the *PCTA-1* gene comprising exons A, 1 and 2. SEQ ID No 12 contains the sequence of a cDNA fragment of the *PCTA-1* gene comprising exons A, D, 0, 1, and 2. SEQ ID No 13 contains a fourth cDNA sequence of the *PCTA-1* gene comprising exons A, 0, 1, 2, 3, 9bis and 9ter.

- 5 SEQ ID No 14 contains the PCTA-1 amino acid sequence encoded by the cDNAs of SEQ ID No 6. SEQ ID No 15 contains the PCTA-1 amino acid sequence encoded by the cDNAs of SEQ ID No 7. SEQ ID No 16 contains the PCTA-1 amino acid sequence encoded by the cDNAs of SEQ ID No 8. SEQ ID No 17 contains the PCTA-1 amino acid sequence encoded by the cDNAs of SEQ ID No 13.

- SEQ ID Nos 18-31 contain the genomic amplicons respectively designated as 99-7177, 99-7212, 99-7193, 99-7186, 99-7182, 99-1585, 99-1587, 99-13798, 99-1601, 99-13808, 99-13810, 99-13790, 99-13809, and 99-1597.

- SEQ ID Nos 31-61 contain the sequence of the following primers : BAP283Ra6283, BAP283Ra6324n, BAP28-exALF7311, BAP28-exALF7319n, PCTAexALF12, PCTAexALF13n, PCTAexALR60, PCTAexALR12n, PCTAexBLF33, PCTAexBLF120n, PCTAexBLR140, 15 PCTAexBLR40n, PCTA5Ra220n, PCTA5Ra230, PCTA_5Ra400, PCTA_5Ran_400, PCTA_5Ra_394, PCTA_exD5Ra, PCTA_exD5Ran, PCTA_exC5Ra, PCTA_exC5Ran, PCTAex9terLR330, PCTAex9terLR325n, PCTAexCLF120, PCTAexCLF130n, BAP28polyTcour, BAP281LF12.1, BAP28LR6726.1, BAP28LF26SalI and BAP28LR67175SalI, respectively.

- SEQ ID No 62 contains a primer containing the additional PU 5' sequence described further 20 in Example 2. SEQ ID No 63 contains a primer containing the additional RP 5' sequence described further in Example 2.

- In accordance with the regulations relating to Sequence Listings, the following codes have been used in the Sequence Listing to indicate the locations of biallelic markers within the sequences and to identify each of the alleles present at the polymorphic base. The code "r" in the sequences 25 indicates that one allele of the polymorphic base is a guanine, while the other allele is an adenine. The code "y" in the sequences indicates that one allele of the polymorphic base is a thymine, while the other allele is a cytosine. The code "m" in the sequences indicates that one allele of the polymorphic base is an adenine, while the other allele is an cytosine. The code "k" in the sequences indicates that one allele of the polymorphic base is a guanine, while the other allele is a thymine. The code "s" in the 30 sequences indicates that one allele of the polymorphic base is a guanine, while the other allele is a cytosine. The code "w" in the sequences indicates that one allele of the polymorphic base is an adenine, while the other allele is an thymine. The nucleotide code of the original allele for each biallelic marker is the following:

Biallelic marker	Original allele
A1	G
A2	C
A3	T
A4	C

A5	C
A6	T
A7	T
A8	G
A9	T

A10	G
A11	G
A12	A
A13	T
A14	T
A15	A
A16	G
A17	T
A18	T
A19	C
A20	G
Biallelic marker	Original allele
A21	G
A22	T
A23	G
A24	G

A25	G
A26	C
A27	A
A28	A
A29	C
A30	A
A31	C
A32	G
A33	G
A34	A
A35	G
A36	G
A37	T
A38	A
A39	C
A40	C

In some instances, the polymorphic bases of the biallelic markers alter the identity of an amino acids in the encoded polypeptide. This is indicated in the accompanying Sequence Listing by use of the feature VARIANT, placement of an Xaa at the position of the polymorphic amino acid, and definition of Xaa as the two alternative amino acids. For example if one allele of a biallelic marker is the codon CAC, which encodes histidine, while the other allele of the biallelic marker is CAA, which encodes glutamine, the Sequence Listing for the encoded polypeptide will contain an Xaa at the location of the polymorphic amino acid. In this instance, Xaa would be defined as being histidine or glutamine.

In other instances, Xaa may indicate an amino acid whose identity is unknown because of nucleotide sequence ambiguity. In this instance, the feature UNSURE is used, placement of an Xaa at the position of the unknown amino acid and definition of Xaa as being any of the 20 amino acids or a limited number of amino acids suggested by the genetic code.

DETAILED DESCRIPTION OF THE INVENTION

The present invention concerns polynucleotides and polypeptides related to the *BAP28* gene. Oligonucleotide probes and primers hybridizing specifically with a genomic or the cDNA sequences of *BAP28* are also part of the invention. A further object of the invention consists of recombinant vectors comprising any of the nucleic acid sequences described in the present invention, and in particular recombinant vectors comprising a regulatory region of *BAP28* or a sequence encoding the *BAP28* protein, as well as cell hosts comprising said nucleic acid sequences or recombinant vectors. The invention also encompasses methods of screening of molecules which inhibit the expression of the *BAP28* gene or which modulate the activity of, or interact with, the *BAP28* protein. The invention also deals with antibodies directed specifically against such polypeptides that are useful as diagnostic reagents.

The invention also concerns *BAP28*-related biallelic markers which can be used in any method of genetic analysis including linkage studies in families, linkage disequilibrium studies in populations and association studies of case-control populations. An important aspect of the present invention is that some *BAP28*-related biallelic markers present an association with the prostate
5 cancer.

Definitions

Before describing the invention in greater detail, the following definitions are set forth to illustrate and define the meaning and scope of the terms used to describe the invention herein.

The terms "*BAP28* gene", when used herein, encompasses genomic, mRNA and cDNA
10 sequences encoding the *BAP28* protein, including the untranslated regulatory regions of the genomic DNA.

The term "heterologous protein", when used herein, is intended to designate any protein or polypeptide other than the *BAP28* protein. More particularly, the heterologous protein is a compound which can be used as a marker in further experiments with a *BAP28* regulatory region.

15 The term "isolated" requires that the material be removed from its original environment (e.g., the natural environment if it is naturally occurring). For example, a naturally-occurring polynucleotide or polypeptide present in a living animal is not isolated, but the same polynucleotide or DNA or polypeptide, separated from some or all of the coexisting materials in the natural system, is isolated. Such polynucleotide could be part of a vector and/or such polynucleotide or polypeptide
20 could be part of a composition, and still be isolated in that the vector or composition is not part of its natural environment.

As used herein, the term "purified" does not require absolute purity; rather, it is intended as a relative definition. Purification of starting material or natural material is at least one order of magnitude, preferably two or three orders, and more preferably four or five orders of magnitude is
25 expressly contemplated. As an example, purification from 0.1 % concentration to 10 % concentration is two orders of magnitude.

To illustrate, individual cDNA clones isolated from a cDNA library have been conventionally purified to electrophoretic homogeneity. The sequences obtained from these clones could not be obtained directly either from the library or from total human DNA. The cDNA clones
30 are not naturally occurring as such, but rather are obtained via manipulation of a partially purified naturally occurring substance (messenger RNA). The conversion of mRNA into a cDNA library involves the creation of a synthetic substance (cDNA) and pure individual cDNA clones can be isolated from the synthetic library by clonal selection. Thus, creating a cDNA library from messenger RNA and subsequently isolating individual clones from that library results in an
35 approximately 10^4 - 10^6 fold purification of the native message.

The term "purified" is further used herein to describe a polypeptide or polynucleotide of the invention which has been separated from other compounds including, but not limited to,

polypeptides or polynucleotides, carbohydrates, lipids, etc. The term "purified" may be used to specify the separation of monomeric polypeptides of the invention from oligomeric forms such as homo- or hetero- dimers, trimers, etc. The term "purified" may also be used to specify the separation of covalently closed polynucleotides from linear polynucleotides. A polynucleotide is substantially

5 pure when at least about 50%, preferably 60 to 75% of a sample exhibits a single polynucleotide sequence and conformation (linear versus covalently close). A substantially pure polypeptide or polynucleotide typically comprises about 50%, preferably 60 to 90% weight/weight of a polypeptide or polynucleotide sample, respectively, more usually about 95%, and preferably is over about 99% pure. Polypeptide and polynucleotide purity, or homogeneity, is indicated by a number of means

10 well known in the art, such as agarose or polyacrylamide gel electrophoresis of a sample, followed by visualizing a single band upon staining the gel. For certain purposes higher resolution can be provided by using HPLC or other means well known in the art. As an alternative embodiment, purification of the polypeptides and polynucleotides of the present invention may be expressed as "at least" a percent purity relative to heterologous polypeptides and polynucleotides (DNA, RNA or both).

15 As a preferred embodiment, the polypeptides and polynucleotides of the present invention are at least; 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 96%, 98%, 99%, or 100% pure relative to heterologous polypeptides and polynucleotides, respectively. As a further preferred embodiment the polypeptides and polynucleotides have a purity ranging from any number, to the thousandth position, between 90% and 100% (e.g., a polypeptide or polynucleotide at least 99.995%

20 pure) relative to either heterologous polypeptides or polynucleotides, respectively, or as a weight/weight ratio relative to all compounds and molecules other than those existing in the carrier. Each number representing a percent purity, to the thousandth position, may be claimed as individual species of purity.

The term "polypeptide" refers to a polymer of amino acids without regard to the length of

25 the polymer; thus, peptides, oligopeptides, and proteins are included within the definition of polypeptide. This term also does not specify or exclude post-expression modifications of polypeptides, for example, polypeptides which include the covalent attachment of glycosyl groups, acetyl groups, phosphate groups, lipid groups and the like are expressly encompassed by the term polypeptide. Also included within the definition are polypeptides which contain one or more

30 analogs of an amino acid (including, for example, non-naturally occurring amino acids, amino acids which only occur naturally in an unrelated biological system, modified amino acids from mammalian systems etc.), polypeptides with substituted linkages, as well as other modifications known in the art, both naturally occurring and non-naturally occurring.

The term "recombinant polypeptide" is used herein to refer to polypeptides that have been

35 artificially designed and which comprise at least two polypeptide sequences that are not found as contiguous polypeptide sequences in their initial natural environment, or to refer to polypeptides which have been expressed from a recombinant polynucleotide.

As used herein, the term "non-human animal" refers to any non-human vertebrate, birds and more usually mammals, preferably primates, farm animals such as swine, goats, sheep, donkeys, and horses, rabbits or rodents, more preferably rats or mice. As used herein, the term "animal" is used to refer to any vertebrate, preferable a mammal. Both the terms "animal" and "mammal" expressly embrace human subjects unless preceded with the term "non-human".

As used herein, the term "antibody" refers to a polypeptide or group of polypeptides which are comprised of at least one binding domain, where an antibody binding domain is formed from the folding of variable domains of an antibody molecule to form three-dimensional binding spaces with an internal surface shape and charge distribution complementary to the features of an antigenic determinant of an antigen, which allows an immunological reaction with the antigen. Antibodies include recombinant proteins comprising the binding domains, as wells as fragments, including Fab, Fab', F(ab)₂, and F(ab')₂ fragments.

As used herein, an "antigenic determinant" is the portion of an antigen molecule, in this case a BAP28 polypeptide, that determines the specificity of the antigen-antibody reaction. An "epitope" refers to an antigenic determinant of a polypeptide. An epitope can comprise as few as 3 amino acids in a spatial conformation which is unique to the epitope. Generally an epitope consists of at least 6 such amino acids, and more usually at least 8-10 such amino acids. Methods for determining the amino acids which make up an epitope include x-ray crystallography, 2-dimensional nuclear magnetic resonance, and epitope mapping e.g. the Pepscan method described by Geysen et al. 1984; PCT Publication No WO 84/03564; and PCT Publication No WO 84/03506.

Throughout the present specification, the expression "nucleotide sequence" may be employed to designate indifferently a polynucleotide or a nucleic acid. More precisely, the expression "nucleotide sequence" encompasses the nucleic material itself and is thus not restricted to the sequence information (i.e. the succession of letters chosen among the four base letters) that biochemically characterizes a specific DNA or RNA molecule.

As used interchangeably herein, the terms "nucleic acids", "oligonucleotides", and "polynucleotides" include RNA, DNA, or RNA/DNA hybrid sequences of more than one nucleotide in either single chain or duplex form. The term "nucleotide" as used herein as an adjective to describe molecules comprising RNA, DNA, or RNA/DNA hybrid sequences of any length in single stranded or duplex form. The term "nucleotide" is also used herein as a noun to refer to individual nucleotides or varieties of nucleotides, meaning a molecule, or individual unit in a larger nucleic acid molecule, comprising a purine or pyrimidine, a ribose or deoxyribose sugar moiety, and a phosphate group, or phosphodiester linkage in the case of nucleotides within an oligonucleotide or polynucleotide. Although the term "nucleotide" is also used herein to encompass "modified nucleotides" which comprise at least one modifications (a) an alternative linking group, (b) an analogous form of purine, (c) an analogous form of pyrimidine, or (d) an analogous sugar, for examples of analogous linking groups, purine, pyrimidines, and sugars see for example PCT

publication No WO 95/04064. The polynucleotide sequences of the invention may be prepared by any known method, including synthetic, recombinant, *ex vivo* generation, or a combination thereof, as well as utilizing any purification methods known in the art.

A sequence which is "operably linked" to a regulatory sequence such as a promoter means that said regulatory element is in the correct location and orientation in relation to the nucleic acid to control RNA polymerase initiation and expression of the nucleic acid of interest.

As used herein, the term "operably linked" refers to a linkage of polynucleotide elements in a functional relationship. For instance, a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the coding sequence.

The terms "trait" and "phenotype" are used interchangeably herein and refer to any visible, detectable or otherwise measurable property of an organism such as symptoms of, or susceptibility to a disease for example. Typically the terms "trait" or "phenotype" are used herein to refer to symptoms of, or susceptibility to a disease, a beneficial response to or side effects related to a treatment. Preferably, said trait can be, without to be limited to, cancers, developmental diseases, and neurological diseases. More preferably, the term "trait" or "phenotype", when used herein, encompasses, but is not limited to, prostate cancer, an early onset of prostate cancer, a beneficial response to or side effects related to treatment or a vaccination against prostate cancer, a susceptibility to prostate cancer, the level of aggressiveness of prostate cancer tumors.

The term "allele" is used herein to refer to variants of a nucleotide sequence. A biallelic polymorphism has two forms. Typically the first identified allele is designated as the original allele whereas other alleles are designated as alternative alleles. The two alleles of a biallelic marker can also be referred to as allele 1 and allele 2. Diploid organisms may be homozygous or heterozygous for an allelic form.

The term "heterozygosity rate" is used herein to refer to the incidence of individuals in a population which are heterozygous at a particular allele. In a biallelic system, the heterozygosity rate is on average equal to $2P_a(1-P_a)$, where P_a is the frequency of the least common allele. In order to be useful in genetic studies, a genetic marker should have an adequate level of heterozygosity to allow a reasonable probability that a randomly selected person will be heterozygous.

The term "genotype" as used herein refers the identity of the alleles present in an individual or a sample. In the context of the present invention, a genotype preferably refers to the description of the biallelic marker alleles present in an individual or a sample. The term "genotyping" a sample or an individual for a biallelic marker consists of determining the specific allele or the specific nucleotide carried by an individual at a biallelic marker.

The term "polymorphism" as used herein refers to the occurrence of two or more alternative genomic sequences or alleles between or among different genomes or individuals. "Polymorphic" refers to the condition in which two or more variants of a specific genomic sequence can be found in a population. A "polymorphic site" is the locus at which the variation occurs. A

single nucleotide polymorphism is the replacement of one nucleotide by another nucleotide at the polymorphic site. Deletion of a single nucleotide or insertion of a single nucleotide also gives rise to single nucleotide polymorphisms. In the context of the present invention, "single nucleotide polymorphism" preferably refers to a single nucleotide substitution.

- 5 The term "biallelic polymorphism" and "biallelic marker" are used interchangeably herein to refer to a single nucleotide polymorphism having two alleles at a fairly high frequency in the population. A "biallelic marker allele" refers to the nucleotide variants present at a biallelic marker site. Typically, the frequency of the less common allele of the biallelic markers of the present invention has been validated to be greater than 1%, preferably the frequency is greater than 10%,
10 more preferably the frequency is at least 20% (i.e. heterozygosity rate of at least 0.32), even more preferably the frequency is at least 30% (i.e. heterozygosity rate of at least 0.42). A biallelic marker wherein the frequency of the less common allele is 30% or more is termed a "high quality biallelic marker".

- The location of nucleotides in a polynucleotide with respect to the center of the
15 polynucleotide are described herein in the following manner. When a polynucleotide has an odd number of nucleotides, the nucleotide at an equal distance from the 3' and 5' ends of the polynucleotide is considered to be "at the center" of the polynucleotide, and any nucleotide immediately adjacent to the nucleotide at the center, or the nucleotide at the center itself is considered to be "within 1 nucleotide of the center." With an odd number of nucleotides in a
20 polynucleotide any of the five nucleotides positions in the middle of the polynucleotide would be considered to be within 2 nucleotides of the center, and so on. When a polynucleotide has an even number of nucleotides, there would be a bond and not a nucleotide at the center of the polynucleotide. Thus, either of the two central nucleotides would be considered to be "within 1 nucleotide of the center" and any of the four nucleotides in the middle of the polynucleotide would
25 be considered to be "within 2 nucleotides of the center", and so on.

- As used herein the term "BAP28-related biallelic marker" relates to a set of biallelic markers in linkage disequilibrium with the BAP28 gene or a BAP28 nucleotide sequence. The term "BAP28-related biallelic marker" relates to the biallelic markers located in a sequence selected from the group consisting of SEQ ID Nos 1-4, and 18-31, a fragment thereof and/or the complementary
30 sequence thereto. The term *BAP28*-related biallelic marker encompasses the biallelic markers A1 to A58 disclosed in Table 2 and any biallelic markers in linkage disequilibrium therewith.

- The terms "complementary" or "complement thereof" are used herein to refer to the sequences of polynucleotides which is capable of forming Watson & Crick base pairing with another specified polynucleotide throughout the entirety of the complementary region. For the purpose of the
35 present invention, a first polynucleotide is deemed to be complementary to a second polynucleotide when each base in the first polynucleotide is paired with its complementary base. Complementary bases are, generally, A and T (or A and U), or C and G. "Complement" is used herein as a synonym

from "complementary polynucleotide", "complementary nucleic acid" and "complementary nucleotide sequence". These terms are applied to pairs of polynucleotides based solely upon their sequences and not any particular set of conditions under which the two polynucleotides would actually bind.

5

Variants and Fragments

1- Polynucleotides

The invention also relates to variants and fragments of the polynucleotides described herein, particularly of a *BAP28* gene containing one or more biallelic markers according to the invention.

- 10 Variants of polynucleotides, as the term is used herein, are polynucleotides that differ from a reference polynucleotide. A variant of a polynucleotide may be a naturally occurring variant such as a naturally occurring allelic variant, or it may be a variant that is not known to occur naturally. Such non-naturally occurring variants of the polynucleotide may be made by mutagenesis techniques, including those applied to polynucleotides, cells or organisms. Generally, differences
15 are limited so that the nucleotide sequences of the reference and the variant are closely similar overall and, in many regions, identical.

- 20 Variants of polynucleotides according to the invention include, without being limited to, nucleotide sequences which are at least 95% identical to a polynucleotide selected from the group consisting of the nucleotide sequences of SEQ ID Nos 1-4, and 9-13 or to any polynucleotide fragment of at least 12, 15, 18, 20, 25, 30, 50, 80, 100, 150, 200, 250, 300, 350, 400, 450, 500, 600 or 1000 consecutive nucleotides of a polynucleotide selected from the group consisting of the nucleotide sequences of SEQ ID Nos 1-4 and 9-13, and preferably at least 99% identical, more particularly at least 99.5% identical, and most preferably at least 99.8% identical to a polynucleotide
25 selected from the group consisting of the nucleotide sequences of SEQ ID Nos 1-4 and 9-13, or to any polynucleotide fragment of at least 12, 15, 18, 20, 25, 30, 50, 80, 100, 150, 200, 250, 300, 350, 400, 450, 500, 600 or 1000 consecutive nucleotides of a polynucleotide selected from the group consisting of the nucleotide sequences of SEQ ID No 1-4 and 9-13.

- Nucleotide changes present in a variant polynucleotide may be silent, which means that they do not alter the amino acids encoded by the polynucleotide. However, nucleotide changes may
30 also result in amino acid substitutions, additions, deletions, fusions and truncations in the polypeptide encoded by the reference sequence. The substitutions, deletions or additions may involve one or more nucleotides. The variants may be altered in coding or non-coding regions or both. Alterations in the coding regions may produce conservative or non-conservative amino acid substitutions, deletions or additions.

- 35 In the context of the present invention, particularly preferred embodiments are those in which the polynucleotides encode polypeptides which retain substantially the same biological function or activity as the mature BAP28 protein, or those in which the polynucleotides encode

polypeptides which maintain or increase a particular biological activity, while reducing a second biological activity

A polynucleotide fragment is a polynucleotide having a sequence that is entirely the same as part but not all of a given nucleotide sequence, preferably the nucleotide sequence of a *BAP28* gene, and variants thereof. The fragment can be a portion of an intron or an exon of a *BAP28* gene. It can also be a portion of the regulatory regions of *BAP28*. In some embodiments, the fragments may comprise at least one polymorphism or biallelic marker of the invention.

Such fragments may be "free-standing", i.e. not part of or fused to other polynucleotides, or they may be comprised within a single larger polynucleotide of which they form a part or region. Indeed, several of these fragments may be present within a single larger polynucleotide.

In some embodiments, such fragments may comprise, consist of, or consist essentially of a contiguous span of at least 8, 10, 12, 15, 18, 20, 25, 35, 40, 50, 70, 80, 100, 250, 500 or 1000 nucleotides in length.

2- Polypeptides

The invention also relates to variants, fragments, analogs and derivatives of the polypeptides described herein, including mutated *BAP28* proteins.

The variant may be 1) one in which one or more of the amino acid residues are substituted with a conserved or non-conserved amino acid residue and such substituted amino acid residue may or may not be one encoded by the genetic code, or 2) one in which one or more of the amino acid residues includes a substituent group, or 3) one in which the mutated *BAP28* is fused with another compound, such as a compound to increase the half-life of the polypeptide (for example, polyethylene glycol), or 4) one in which the additional amino acids are fused to the mutated *BAP28*, such as a leader or secretory sequence or a sequence which is employed for purification of the mutated *BAP28* or a preprotein sequence. Such variants are deemed to be within the scope of those skilled in the art.

A polypeptide fragment is a polypeptide having a sequence that entirely is the same as part but not all of a given polypeptide sequence, preferably a polypeptide encoded by a *BAP28* gene and variants thereof.

In the case of an amino acid substitution in the amino acid sequence of a polypeptide according to the invention, one or several amino acids can be replaced by "equivalent" amino acids. The expression "equivalent" amino acid is used herein to designate any amino acid that may be substituted for one of the amino acids having similar properties, such that one skilled in the art of peptide chemistry would expect the secondary structure and hydrophobic nature of the polypeptide to be substantially unchanged. Generally, the following groups of amino acids represent equivalent changes: (1) Ala, Pro, Gly, Glu, Asp, Gln, Asn, Ser, Thr; (2) Cys, Ser, Tyr, Thr; (3) Val, Ile, Leu, Met, Ala, Phe; (4) Lys, Arg, His; (5) Phe, Tyr, Trp, His.

A specific embodiment of a modified BAP28 peptide molecule of interest according to the present invention, includes, but is not limited to, a peptide molecule which is resistant to proteolysis, is a peptide in which the -CONH- peptide bond is modified and replaced by a (CH₂NH) reduced bond, a (NHCO) retro inverso bond, a (CH₂-O) methylene-oxy bond, a (CH₂-S) thiomethylene bond, a (CH₂CH₂) carba bond, a (CO-CH₂) cetomethylene bond, a (CHOH-CH₂) hydroxyethylene bond), a (N-N) bound, a E-alcene bond or also a -CH=CH- bond. The invention also encompasses a human BAP28 polypeptide or a fragment or a variant thereof in which at least one peptide bond has been modified as described above.

Such fragments may be "free-standing", i.e. not part of or fused to other polypeptides, or they may be comprised within a single larger polypeptide of which they form a part or region. However, several fragments may be comprised within a single larger polypeptide.

As representative examples of polypeptide fragments of the invention, there may be mentioned those which have at least 6 amino acids, preferably at least 8 to 10 amino acids, more preferably at least 12, 15, 20, 25, 30, 40, 50, 100 or 200 amino acids long. A specific embodiment of a BAP28 fragment is a fragment containing at least one amino acid mutation in the BAP28 protein.

Identity Between Nucleic Acids Or Polypeptides

The terms "percentage of sequence identity" and "percentage homology" are used interchangeably herein to refer to comparisons among polynucleotides and polypeptides, and are determined by comparing two optimally aligned sequences over a comparison window, wherein portion of the polynucleotide or polypeptide sequence in the comparison window may comprise additions or deletions (i.e., gaps) as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the identical nucleic acid base or amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison and multiplying the result by 100 to yield the percentage of sequence identity. Homology is evaluated using any of the variety of sequence comparison algorithms and programs known in the art. Such algorithms and programs include, but are by no means limited to, TBLASTN, BLASTP, FASTA, TFASTA, and CLUSTALW (Pearson and Lipman, 1988; Altschul et al., 1990; Thompson et al., 1994; Higgins et al., 1996; Altschul et al., 1990; Altschul et al., 1993). In a particularly preferred embodiment, protein and nucleic acid sequence homologies are evaluated using the Basic Local Alignment Search Tool ("BLAST") which is well known in the art (see, e.g., Karlin and Altschul, 1990; Altschul et al., 1990, 1993, 1997). In particular, five specific BLAST programs are used to perform the following task: (1) BLASTP and BLAST3 compare an amino acid query sequence against a protein sequence database; (2) BLASTN compares a nucleotide query sequence against a nucleotide sequence database; (3) BLASTX compares the six-frame conceptual translation products of a query nucleotide sequence (both strands) against a protein sequence database; (4) TBLASTN compares a

query protein sequence against a nucleotide sequence database translated in all six reading frames (both strands); and, (5) TBLASTX compares the six-frame translations of a nucleotide query sequence against the six-frame translations of a nucleotide sequence database.

- The BLAST programs identify homologous sequences by identifying similar segments, which are referred to herein as "high-scoring segment pairs," between a query amino or nucleic acid sequence and a test sequence which is preferably obtained from a protein or nucleic acid sequence database. High-scoring segment pairs are preferably identified (i.e., aligned) by means of a scoring matrix, many of which are known in the art. Preferably, the scoring matrix used is the BLOSUM62 matrix (Gonnet et al., 1992; Henikoff and Henikoff, 1993). Less preferably, the PAM or PAM250 matrices may also be used (see, e.g., Schwartz and Dayhoff, eds., 1978). The BLAST programs evaluate the statistical significance of all high-scoring segment pairs identified, and preferably selects those segments which satisfy a user-specified threshold of significance, such as a user-specified percent homology. Preferably, the statistical significance of a high-scoring segment pair is evaluated using the statistical significance formula of Karlin (see, e.g., Karlin and Altschul, 1990).

Stringent Hybridization Conditions

For the purpose of defining such a hybridizing nucleic acid according to the invention, the stringent hybridization conditions are the followings :

the hybridization step is realized at 65°C in the presence of 6 x SSC buffer, 5 x Denhardt's solution, 0.5% SDS and 100µg/ml of salmon sperm DNA.

- The hybridization step is followed by four washing steps :

- two washings during 5 min, preferably at 65°C in a 2 x SSC and 0.1% SDS buffer;
 - one washing during 30 min, preferably at 65°C in a 2 x SSC and 0.1% SDS buffer,
 - one washing during 10 min, preferably at 65°C in a 0.1 x SSC and 0.1% SDS buffer,
- these hybridization conditions being suitable for a nucleic acid molecule of about 20

- nucleotides in length. There is no need to say that the hybridization conditions described above are to be adapted according to the length of the desired nucleic acid, following techniques well known to the one skilled in the art. The suitable hybridization conditions may for example be adapted according to the teachings disclosed in the book of Hames and Higgins (1985).

Table A

Exon	Position in SEQ ID No 1		Intron	Position in SEQ ID No 1	
	Beginning	End		Beginning	End
1	4997	5076	1-2	5077	5370
2	5371	5544	2-3	5545	6120
3	6121	6337	3-4	6338	9876
4	9877	10018	4-5	10019	11521
5	11522	11623	5-6	11624	12520
6	12521	12661	6-7	12662	13452
7	13453	13664	7-8	13665	13823
8	13824	13957	8-9	13958	15375

9	15376	15478	9-10	15479	16854
10	16855	16965	10-11	16966	17377
11	17378	17495	11-12	17496	18534
12	18535	18642	12-13	18643	21445
13	21446	21541	13-14	21542	21998
14	21999	22087	14-15	22088	23035
15	23036	23247	15-16	23248	23545
16	23546	23667	16-17	23668	24269
17	24270	24461	17-18	24462	26286
18	26287	26470	18-19	26471	26610
19	26611	26747	19-20	26748	28067
20	28068	28260	20-21	28261	32539
21	32540	32709	21-22	32710	33111
22	33112	33270	22-23	33271	34585
23	34586	34828	23-24	34829	35155
24	35156	35287	24-25	35288	36659
25	36660	36763	25-26	36764	36933
26	36934	37077	26-27	37078	37802
27	37803	37921	27-28	37922	38016
28	38017	38138	28-29	38139	40364
29	40365	40493	29-30	40494	42617
30	42618	42848	30-31	42849	43451
31	43452	43578	31-32	43579	44835
32	44836	44999	32-33	45000	48222
33	48223	48269	33-34	48270	49655
34	49656	49779	34-35	49780	50357
35	50358	50498	35-36	50499	50963
36	50964	51256	36-37	51257	52147
37	52148	52298	37-38	52299	53234
38	53235	53393	38-39	53394	53553
39	53554	53688	39-40	53689	53837
40	53838	53942	40-41	53943	54028
41	54029	54197	41-42	54198	54740
42	54741	54895	42-43	54896	55753
43	55754	55912	43-44	55913	57385
44	57386	57494	44-45	57495	58503
45	58504	58827	45-B'	58828	85946
45b	58504	59354	45b-B'	59355	85946
B'	85947	86168	B'-A'	86169	91228
A'	91229	91851			

Genomic Sequences Of The Human *BAP28* Gene

- The present invention concerns the genomic sequence of *BAP28* comprising the sequence of SEQ ID No 1. The present invention encompasses *BAP28* gene, or *BAP28* genomic sequence
- 5 consisting of, consisting essentially of, or comprising a sequence selected from the group consisting of SEQ ID No 1, a sequence complementary thereto, as well as fragments and variants thereof.
- These polynucleotides may be purified, isolated, or recombinant.

BAP28 was localized by the present inventors to the chromosome 1q43 region.

The human *BAP28* genomic nucleic acid comprises at least 47 exons. The exon positions in SEQ ID No 1 are detailed below in the Table A.

The exons B' and A' of the *Bap28* gene have been found through the study of the *PCTA-1* gene which is described in the PCT application WO 99/64590, incorporated herein by reference.

- 5 One public cDNA (Genbank Accession Number AF074001) shows an additional 5' exon in comparison of the cDNA described in the above-referenced application. This exon has been called exon B. It does not seem to comprise a splice site in 5'. So this exon will be a first exon. Long range PCR experiments with a first couple of primers PCTAexBLF33/PCTA5Ra230 (SEQ ID No 40/SEQ ID No 45) and a second one PCTAexBLF120n/PCTA5Ra220n (SEQ ID No 41/SEQ ID No 44)
- 10 confirm the existence of a cDNA comprising at least the exon B and the exons 0, 1, and 2 (SEQ ID No 10).

Three additional exons have been also identified, namely exons A, C and D. Exon C is the most upstream exon. Exons A and D have a 5' splice site. Long range PCR with a first couple of primers PCTAexALF12/ PCTAex9terLR330 (SEQ ID No 36/SEQ ID No 53) and a second one

- 15 PCTAexALF13n/ PCTAex9terLR325n (SEQ ID No 37/SEQ ID No 54) showed an alternative PCTA-1 cDNA consisting with the exons A, 0, 1, 2, 3, 9bis and 9ter (SEQ ID No 13). Other alternative PCTA-1 cDNAs comprise consecutively the exons A, D, 0, 1, and 2 (SEQ ID No 12), the exons A, 1 and 2 (SEQ ID No 11), or the exons C and A (SEQ ID No 9). The form AD012 and A12 have been amplified with the first couple of primers PCTAexALF12 / PCTA5Ra230 (SEQ ID No 36/SEQ ID No 45) and the second one PCTAexALF13n /PCTA5Ra220n (SEQ ID No 37/SEQ ID No 44). The exon C have been identified by a RACE experiment with PCTAexALR60 primer (SEQ ID No 38) from the exon A. The figure 2 shows the alternative cDNAs of *PCTA-1* and the alternative 5' ends of *PCTA-1* cDNAs.
- 20

The first identified *BAP28* cDNAs comprise either the exons 1 to 45 or 1 to 44 and 45b.

- 25 They are detailed in the section "*BAP28* cDNA sequences". The exon 45 of the *BAP28* cDNA comprises a polyadenylation site and some RACE experiments failed not show any additional sequence downstream of the exon 45, which was the last identified exon.

The study of the PCTA-1 new exons for an alternative cDNA comprising both the exons A and B provides two additional *BAP28* exons, the exons A' and B'. Indeed, two upstream PCR

- 30 primers were designed; one in the exon A (PCTAexALF12 (SEQ ID No 36 following by PCTAexALF13n (SEQ ID No 37)) and the other in exon B (PCTAexBLF33 (SEQ ID No 40) following by PCTAexBLF120n (SEQ ID No 41)). The downstream primer was generated in previously identified PCTA-1 exons (PCTA5Ra230 (SEQ ID No 45) following by PCTA5Ra220n (SEQ ID No 44)). No alternative cDNA comprising both exons has been observed. Therefore, two
- 35 couples of primers was designed with the upstream primer in exon A and the downstream primer in exon B. More particularly, the amplification was done with a first couple of primers PCTAexALF12/ PCTAexBLR140 (SEQ ID No 36/SEQ ID No 42) and a second one

PCTAexALF13n/ PCTAexBLR40n (SEQ ID No 37/SEQ ID No 43). An amplification product was obtained. However, the exons were slightly moved and the splice sites were only available on the opposite strand. Therefore, the amplification product was not from the *PCTA-1* gene but rather than was supposed to be from the *BAP28* gene which is on the opposite strand. This amplification product contains the exons A' and B' (SEQ ID No 4). In order to check that the amplification product comes from BAP28, a PCR amplification was proceeded with a downstream primer in the exon A and an upstream primer in exon 43 of BAP28 gene. More particularly, the PCR was done with a first couple of primers PCTAexALF12/ BAP283Ra6283 (SEQ ID No 36/SEQ ID No 32) and a second one PCTAexALF13n/ BAP283Ra6324n (SEQ ID No 37/SEQ ID No 33) The amplification product confirmed that the slightly moved exons A and B are part of the *BAP28* cDNA. The sequencing of the amplification product showed a cDNA comprising the exons 44, 45b, and A. The *BAP28* cDNA with the exons B' and A' likely consists to an other alternative cDNA form.

Thus, the invention embodies purified, isolated, or recombinant polynucleotides comprising a nucleotide sequence selected from the group consisting of the exons of the *BAP28* gene, or a sequence complementary thereto. Preferred are nucleotide sequences selected from the group consisting of the exons of the *BAP28* gene having the nucleotide position ranges listed in Table A, or a complementary sequence thereto or a fragment or a variant thereof.

Encompassed by the invention are purified, isolated, or recombinant nucleic acids comprising a combination of at least two exons of the *BAP28* gene, wherein the polynucleotides are arranged within the nucleic acid, from the 5'-end to the 3'-end of said nucleic acid, in the same order as in SEQ ID No 1. The invention further deals with purified, isolated, or recombinant nucleic acids comprising a combination of at least two exons of the *BAP28* gene, wherein the nucleic acids comprise at least one exon selected from the group consisting of exons 1 to 45, 45b, B' and A', wherein the polynucleotides are arranged within the nucleic acid, from the 5'-end to the 3'-end of said nucleic acid, in the same order as in SEQ ID No 1.

Preferred polynucleotides of the invention embody purified, isolated, or recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 50, 80, 100, 150, or 200 nucleotides, to the extent that such a length is consistent with the lengths of the particular nucleotide position, of SEQ ID No 1 or the complement thereof, wherein said contiguous span comprises at least 1, 2, 3, 5, 10, 20, 30, 40 or 50 nucleotides selected from the group consisting of the following nucleotide positions of SEQ ID No 1: 4997-5076, 5371-5544, 6121-6337, 9877-10018, 11522-11623, 12521-12661, 13453-13664, 13824-13957, 15376-15478, 16855-16965, 17378-17495, 18535-18642, 21446-21541, 21999-22087, 23036-23247, 23546-23667, 24270-24461, 26287-26470, 26611-26747, 28068-28260, 32540-32709, 33112-33270, 34586-34828, 35156-35287, 36660-36763, 36934-37077, 37803-37921, 38017-38138, 40365-40493, 42618-42848, 43452-43578, 44836-44999, 48223-48269, and 49656-49779.

The position of the introns is detailed in Table A. Thus, the invention embodies purified, isolated, or recombinant polynucleotides comprising a nucleotide sequence selected from the group consisting of the introns of the *BAP28* gene, or a sequence complementary thereto.

The invention also encompasses a purified, isolated, or recombinant polynucleotides
5 comprising a nucleotide sequence having at least 70, 75, 80, 85, 90, or 95% nucleotide identity with a nucleotide sequence of SEQ ID No 1 or a complementary sequence thereto or a fragment thereof. The nucleotide differences as regards to the nucleotide sequences of SEQ ID No 1 may be generally randomly distributed throughout the entire nucleic acid. Nevertheless, preferred nucleic acids are those wherein the nucleotide differences as regards to the nucleotide sequences of SEQ ID No 1 are
10 predominantly located outside the coding sequences contained in the exons. These nucleic acids, as well as their fragments and variants, may be used as oligonucleotide primers or probes in order to detect the presence of a copy of the *BAP28* gene in a test sample, or alternatively in order to amplify a target nucleotide sequence within the *BAP28* sequences.

Another object of the invention consists of a purified, isolated, or recombinant nucleic
15 acids that hybridizes with a nucleotide sequence selected from the group consisting of SEQ ID No 1 or a complementary sequence thereto or a variant thereof, under the stringent hybridization conditions as defined above.

Particularly preferred nucleic acids of the invention include isolated, purified, or recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 50, 80,
20 100, 150, 200, 250, 300, 350, 400, 450, 500, 600 or 1000 nucleotides, to the extent that such a length is consistent with the lengths of the particular nucleotide position, of SEQ ID No 1 or the complement thereof, wherein said contiguous span comprises at least 1, 2, 3, 5, 10, 20, 30, 40 or 50 of the following nucleotide positions of SEQ ID No 1: 1-50357, 50499-50963, 51257-52147, 52299-53234, 53394-53553, 53689-53837, 53943-54028, 54198-54740, 54896-55753, 55913-57385,
25 57495-58503, 58828-85946, 59355-85946, 86169-91228, and/or 91852 to 97662.

Further preferred nucleic acids of the invention include isolated, purified, or recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 50, 80, 100, 150, 200, 250, 300, 350, 400, 450, 500, 600 or 1000 nucleotides, to the extent that such a length is consistent with the lengths of the particular nucleotide position, of SEQ ID No 1 or the complement
30 thereof, wherein said contiguous span comprises at least 1, 2, 3, 5, 10, 20, 30, 40 or 50 of the following nucleotide positions of SEQ ID No 1: 1-2500, 2501-5000, 5001-7500, 7501-10000, 10001-12500, 12501-15000, 15001-17500, 17501-20000, 20001-22500, 22501-25000, 25001-27500, 27501-30000, 30001-32500, 32501-35000, 35001-37500, 37501-40000, 40001-42500, 42501-45000, 45001-47500, 47501-50000, 50001-50357, 50499-50963, 51257-52147, 52299-53234, 53394-53553, 53689-53837, 53943-54028, 54198-54740, 54896-55753, 55913-57385,
35 57495-58503, 58828-85946, 59355-85946, 86169-91228, and/or 91852 to 97662.

Other preferred nucleic acids of the invention include isolated, purified, or recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, or 1000 nucleotides, to the extent that such a length is consistent with the lengths of the particular nucleotide position, of SEQ ID No 1, or the complements thereof, wherein said contiguous span comprises at least one *BAP28*-related biallelic marker selected from the group consisting of A1 to A58, preferably A1 to A27, A34, A37 to A41, A43 to A49, A52, and A54 to A58, more preferably at least one of the biallelic markers A1, A4, 16, A30, A31, A42, A50, A51, and A53.

It should be noted that nucleic acid fragments of any size and sequence may also be comprised by the polynucleotides described in this section.

In another aspect, the invention concerns polymorphisms of *BAP28*.

While this section is entitled "Genomic Sequences of *BAP28*," it should be noted that nucleic acid fragments of any size and sequence may also be comprised by the polynucleotides described in this section, flanking the genomic sequences of *BAP28* on either side or between two or more such genomic sequences.

***BAP28* cDNA Sequences**

Another object of the invention is a purified, isolated, or recombinant nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID Nos 2 and 3, complementary sequences thereto, as well as allelic variants, and fragments thereof. Moreover, preferred polynucleotides of the invention include purified, isolated, or recombinant *BAP28* cDNAs consisting of, consisting essentially of, or comprising a nucleotide sequence selected from the group consisting of SEQ ID Nos 2 and 3. The two *BAP28* cDNAs have to a different 3' end. The first one, namely the cDNA of the SEQ ID No 2, comprises the exons 1 to 44 and 45. The second one, namely the cDNA of the SEQ ID No 3, comprises the exons 1 to 44, 45b and A'. The cDNA of SEQ ID No 2 or 3 are described in Table B.

Consequently, the invention concerns a purified, isolated, and recombinant nucleic acids comprising a nucleotide sequence of the 5'UTR of the *BAP28* cDNA, a sequence complementary thereto, or an allelic variant thereof. The invention also concerns a purified, isolated, and recombinant nucleic acids comprising a nucleotide sequence of the 3'UTR of the *BAP28* cDNA, a sequence complementary thereto, or an allelic variant thereof.

Table B

cDNA	Position range of 5'UTR		Position range of ORF		Position range of 3'UTR	
cDNA1	1	112	113	6547	6548	6782
cDNA2	1	112	113	6547	6548	7932

As described in the section "Genomic Sequences of the human *Bap28* gene", an alternative form of the *BAP28* cDNA comprises the exons B' and A'. Therefore, the invention concerns a cDNA of BAP28 comprising the nucleotide sequence of SEQ ID No 4.

Particularly preferred embodiments of the invention include isolated, purified, or
5 recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 50, 80, 100, 150, 200, 250, 300, 350, 400, 450, 500, 600 or 1000 nucleotides of a nucleic acid sequence selected from the group consisting of SEQ ID Nos 2 and 3 or the complements thereof, wherein said contiguous span comprises at least 1, 2, 3, 5, or 10 of nucleotide positions 1 to 4995 of SEQ ID No 2 or 3. Further preferred polynucleotides include isolated, purified, or recombinant polynucleotides
10 comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 50, 80, 100, 150, 200, 250, 300, 350, 400, 450, 500, 600 or 1000 nucleotides of a nucleic acid sequence selected from the group consisting of SEQ ID Nos 2 and 3 or the complements thereof, wherein said contiguous span comprises at least 1, 2, 3, 5, or 10 of the following nucleotide positions of SEQ ID No 2 or 3: 1 to 2033, 2160 to 2348, and 2676 to 4995. Additional preferred nucleic acids of the invention include isolated, purified, or
15 recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 50, 80, 100, 150, 200, 250, 300, 350, 400, 450, 500, 600 or 1000 nucleotides of SEQ ID No 2, or the complements thereof, wherein said contiguous span comprises at least 1, 2, 3, 5, or 10 nucleotide positions of any one of the following ranges of nucleotide positions of SEQ ID No 2: 1 to 500, 501 to 1000, 1001 to 1500, 1501 to 2000, 2001 to 2500, 2501 to 3000, 3001 to 3500, 3501 to 4000, 4001 to 4500, 4501 to 4995, 5000 to 5500, 5501 to 6000, 6001 to 6500, and 6501 to 6782. Additional
20 preferred nucleic acids of the invention include isolated, purified, or recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 50, 80, 100, 150, 200, 250, 300, 350, 400, 450, 500, 600 or 1000 nucleotides of SEQ ID No 3, or the complements thereof, wherein said contiguous span comprises at least 1, 2, 3, 5, or 10 nucleotide positions of any one of the following
25 ranges of nucleotide positions of SEQ ID No 3: 1 to 500, 501 to 1000, 1001 to 1500, 1501 to 2000, 2001 to 2500, 2501 to 3000, 3001 to 3500, 3501 to 4000, 4001 to 4500, 4501 to 4995, 5000 to 5500, 5501 to 6000, 6001 to 6500, 6501 to 7000, 7001 to 7500, 7501 to 7932.

The invention also pertains to a purified or isolated nucleic acid having at least 95% of nucleotide identity with a nucleotide sequence selected from the group consisting of SEQ ID Nos 2
30 and 3 or a fragment thereof or a complementary sequence thereto, advantageously 99 %, preferably 99.5% nucleotide identity and most preferably 99.8% nucleotide identity with a nucleotide sequence selected from the group consisting of SEQ ID Nos 2 and 3 or a fragment thereof or a complementary sequence thereto.

Another object of the invention consists of a purified, isolated, or recombinant nucleic
35 acids that hybridizes with a nucleotide sequence selected from the group consisting of SEQ ID Nos 2 and 3 or a complementary sequence thereto or a variant thereof, under the stringent hybridization conditions as defined above.

The invention concerns a PCTA-1 cDNA comprising an exon selected from the group consisting of exons A, B, C, and D. More particularly, the invention concerns a PCTA-1 cDNA comprising a polynucleotide sequence selected from the group consisting of SEQ ID Nos 9-13 or a fragment thereof or a complementary sequence thereto.

5 Encompassed by the invention are purified, isolated, or recombinant nucleic acids comprising a combination of at least two exons of the *PCTA-1* gene, wherein the polynucleotides are arranged within the nucleic acid, from the 5'-end to the 3'-end of said nucleic acid, in the same order as in SEQ ID No 1. The invention further deals with purified, isolated, or recombinant nucleic acids comprising a combination of at least two exons of the *PCTA-1* gene, wherein the nucleic acids
10 comprise at least one exon selected from the group consisting of exons C, A, D, B, 0, 1, 2, 3, 4, 5, 6, 6bis, 7, 8, 9, 9bis and 9ter, wherein the polynucleotides are arranged within the nucleic acid, from the 5'-end to the 3'-end of said nucleic acid, in the same order as in SEQ ID No 1.

While this section is entitled "*BAP28* cDNA Sequences," it should be noted that nucleic acid fragments of any size and sequence may also be comprised by the polynucleotides described in
15 this section, flanking the genomic sequences of *BAP28* on either side or between two or more such genomic sequences.

NATURAL ANTISENSE

Over the last 10 years, an increasing number of natural antisense RNAs has been reported in eukaryotes. Natural antisense RNAs are endogenous transcripts that exhibit complementary
20 sequences to other transcripts, named sense transcripts. Most antisense transcripts are issued from the same locus as sense transcripts. Transcribed from opposite strands of DNA, sense and antisense transcripts overlap each other at least partially, and display perfect complementarity. The reported antisense RNAs are complementary to sense transcripts encoding proteins involved in extremely diverse biological functions : hormonal response, control of proliferation, development, structure,
25 etc...

In some cases, apart from their capability of encoding proteins *per se*, antisense RNAs were found to regulate, generally downregulate, the expression of their sense counterparts. Often changes in sense gene expression were correlated with the presence of antisense RNA. Indeed, an inverse relationship between levels of accumulation of sense and antisense messengers has been
30 documented in several cases. Some examples have been reported in various pathology such as nervous disorders and cancer.

These characteristics suggest that antisense transcripts are found throughout the whole eukaryotic world and might play a role in general antisense-mediated gene regulation as is the cases in prokaryotes. Indeed, antisense -mediated gene regulation is a way of decreasing the abundance of
35 stable transcripts more rapidly than the cessation of transcription. In addition, natural antisense

transcripts are thought to be involved not only in the normal regulation of gene expression but also in the alteration of gene regulation leading to different pathologies.

Indeed, because of their complementarity, antisense transcripts may hybridize to sense transcripts and thus modify the expression of their sense counterparts at any step from transcription
5 to translation.

In the nucleus, antisense RNA may regulate sense expression either at the level of transcription, processing, or nucleocytoplasmic transport. Transcriptional regulation occurs either because the activity of sense and antisense promoters is differentially regulated by cellular conditions or because antisense transcription impedes sense transcription. This interference would
10 involve the collision of two transcription complexes, resulting in premature termination or in reduced elongation of transcription, the transcripts with the highest rate of transcription being predominant. Antisense may also operate at a post-transcriptional level probably by impairing either maturation and/or transport of the sense transcript.

Although some examples have shown that antisense regulation may occur in the nucleus,
15 antisense regulation is generally described as a cytoplasmic event operating mostly at the messenger stability level. Furthermore, the regulation can also be made at the translation stage, particularly when interactions between sense and antisense occur in the 3'UTR.

Two mechanisms of antisense-mediated gene regulation may be envisioned. First, antisense transcripts displaying very similar structural features to sense transcripts may bind proteins
20 actually interacting with their sense counterparts, thus depriving sense messengers from proteins necessary for their functions. The other mechanism of antisense-mediated regulation is thought to operate via duplex formation between complementary sense and antisense transcripts. By simple steric hindrance, RNA duplexes would prevent sense RNA from interacting with diverse cellular components required for normal sense expression, thus impairing maturation, nucleocytoplasmic
25 transport, transcript stability, or translation depending on the cellular components involved. Alternatively, duplexes may represent substrates for double-stranded RNA specific enzymes. It is commonly believed that most duplexes will become targeted for degradation by RNAses and only the most abundant transcripts, either sense or antisense, will persist in the cells. More information on the natural antisense can be found in Vanhee-Brossollet et al. (1998).

30 **BAP28 and PCTA-1 are natural antisense**

BAP28 transcript has been identified as a natural antisense of the *PCTA-1* transcript. Indeed, the coding sequence of *PCTA-1* is on the opposite strand of the coding sequence of *BAP28*. Moreover, the 3'UTR of *BAP28* contains some sequences which are complementary of segments of the 5'UTR and 3'UTR of *PCTA-1*. More particularly, the exons A and B are common for the *PCTA-1*
35 and *BAP28* genes, the exon 44 of *BAP28* gene is antisense of the exons 9 and 9ter of *PCTA-1*, the exons 45 and 45b of *BAP28* gene are antisense of the exon 9 of *PCTA-1*. Therefore, *BAP28*

transcript is the antisense of the *PCTA-1* RNA. The Figure 1 presents the general organization of the *BAP28* and *PCTA-1* genes.

The *PCTA-1* protein has been shown to be a specific antigen of prostate cancer cells (WO 96/21671, incorporated herein by reference). Therefore, one can assume that its expression is closely
5 linked to the development of cancer, particularly prostate cancer.

ESTs from the *PCTA-1* gene were found in a broad range of tissues. As the protein *PCTA-1* is only present in the prostate cancer cells, a regulation of the *PCTA-1* RNA will occur, maybe at the stage of the RNA transcription, splicing, stability and/or translation.

The 5'UTR and 3'UTR regions of a gene are of particular importance in that they often
10 comprise regulatory elements which can play a role in providing appropriate expression levels, particularly through the control of mRNA stability.

As the *BAP28* transcript is the natural antisense of the *PCTA-1* mRNA, the *BAP28* mRNA is likely to be involved in the regulation of the *PCTA-1* expression and, by consequence, in the process of development of prostate cancer.

The involvement of *BAP28* gene in prostate cancer is reported through the clearly
15 significant association of the *BAP28*-related biallelic markers to prostate cancer. Furthermore, the PCT application WO98/12327, incorporated herein by reference, showed that BAP28 should be involved in interaction with BRCA1. Therefore, BAP28 may be a tumor suppressor. During the process of carcinogenesis, BAP28 would become inactive and its expression could decrease. This
20 expression decrease of BAP28 would lead to an increase of the *PCTA-1* mRNA stability and the presence of the *PCTA-1* protein at the cell surface. We can hypothesize that these events correspond to a natural defense against the cancer cells.

Consequently, the invention concerns the use of BAP28 nucleotide sequence from the mRNA as antisense in order to control the *PCTA-1* expression and preferably to inhibit the *PCTA-1*
25 expression. The invention also concerns the use of *PCTA-1* nucleotide sequence from the mRNA as an antisense in order to control the BAP28 expression. These antisense can be used in order to avoid cancer development, preferably prostate cancer development.

An embodiment of the invention concerns the polynucleotide segment common in the *PCTA-1* and *BAP28* cDNAs. More particularly, the invention concerns isolated, purified, or
30 recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 50, 80, 100, 150, 200, 250, 300, 350, 400, 450, 500, 600 or 1000 nucleotides of SEQ ID No 1, or the complements thereof, wherein said contiguous span comprises at least 1, 2, 3, 5, or 10 nucleotide positions of any one of the following ranges of nucleotide positions of SEQ ID No 1: 57386-27494, 58504-59354, 85947-86108, and 91259-91325.

An additional embodiment is the use of a polynucleotide according to the invention, more
35 particularly polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 50, 80, 100, 150, 200, 250, 300, 350, 400, 450, 500, 600 or 1000 nucleotides of SEQ ID No 1, or the

complements thereof, wherein said contiguous span comprises at least 1, 2, 3, 5, or 10 nucleotide positions of any one of the following ranges of nucleotide positions of SEQ ID No 1: 57386-27494, 58504-59354, 85947-86108, and 91259-91325, for regulating the expression of PCTA-1 and/or BAP28.

Coding Regions

The *BAP28* open reading frame is contained in the corresponding mRNAs of SEQ ID No 2 or 3. More precisely, the effective *BAP28* coding sequence (CDS) includes the region between nucleotide position 113 (first nucleotide of the ATG codon) and nucleotide position 6547 (end nucleotide of the TAA codon) of SEQ ID No 2 or 3.

Thus, the present invention deals with a purified or isolated nucleic acid encoding a BAP28 protein or a fragment thereof. More particularly the present invention deals with a purified or isolated nucleic acid encoding a BAP28 protein having the amino acid sequence of SEQ ID No 5 or a peptide fragment or variant thereof. The present invention also embodies isolated, purified, and recombinant polynucleotides which encode a polypeptides comprising a contiguous span of at least 6 amino acids, preferably at least 8 or 10 amino acids, more preferably at least 12, 15, 20, 25, 30, 40, 50, or 100 amino acids of SEQ ID No 5, wherein said contiguous span includes at least 1, 2, 3, 5 or 10 of the amino acid positions 1 to 1629 of the SEQ ID No 5. The present invention further embodies isolated, purified, and recombinant polynucleotides which encode a polypeptides comprising a contiguous span of at least 6 amino acids, preferably at least 8 or 10 amino acids, more preferably at least 12, 15, 20, 25, 30, 40, 50, or 100 amino acids of SEQ ID No 5, wherein said contiguous span contains an amino acid selected from the group consisting of an asparagine at the amino acid position 1694 of SEQ ID No 5, a valine at the amino acid position 1854 of SEQ ID No 5, an asparagine at the amino acid position 1967 of SEQ ID No 5, a glutamic acid at the amino acid position 2017 of SEQ ID No 5 and an alanine at the amino acid position 2050 of SEQ ID No 5. The present invention embodies isolated, purified, and recombinant polynucleotides which encode a polypeptides comprising a contiguous span of at least 6 amino acids, preferably at least 8 or 10 amino acids, more preferably at least 12, 15, 20, 25, 30, 40, 50, or 100 amino acids of SEQ ID No 5, wherein said contiguous span includes at least 1, 2, 3, 5 or 10 of the amino acid positions 1 to 200, 201 to 400, 401 to 600, 601 to 800, 801 to 1000, 1001 to 1200, 1201 to 1400 and/or 1401 to 1629 of the SEQ ID No 5.

The above disclosed polynucleotide that contains the coding sequence of the *BAP28* gene may be expressed in a desired host cell or a desired host organism, when this polynucleotide is placed under the control of suitable expression signals. The expression signals may be either the expression signals contained in the regulatory regions in the *BAP28* gene of the invention or in contrast the signals may be exogenous regulatory nucleic sequences. Such a polynucleotide, when placed under the suitable expression signals, may also be inserted in a vector for its expression and/or amplification.

Regulatory Sequences Of *BAP28*

As mentioned, the genomic sequence of the *BAP28* gene contains regulatory sequences both in the non-coding 5'-flanking region and in the non-coding 3'-flanking region that border the *BAP28* coding region containing the 45 exons of this gene.

- 5 The 5'-regulatory sequence of the *BAP28* gene is localized between the nucleotide in position 2996 and the nucleotide in position 4996 of the nucleotide sequence of SEQ ID No 1. The 5'-regulatory sequence contains the *BAP28* promoter site.

- The genomic sequence of the *BAP28* gene also contains regulatory sequences in the non-coding 3'-flanking region that border the *BAP28* coding region. The 3'-regulatory sequence of the
10 *BAP28* gene is localized between nucleotide position 91852 and nucleotide position 97662 of SEQ ID No 1.

Polynucleotides derived from the 5' and 3' regulatory regions are useful in order to detect the presence of at least a copy of a nucleotide sequence of SEQ ID No 1 or a fragment thereof in a test sample.

- 15 The promoter activity of the 5' regulatory regions contained in *BAP28* can be assessed as described below.

- In order to identify the relevant biologically active polynucleotide fragments or variants of SEQ ID No 1, the one skill in the art will refer to the book of Sambrook et al.(1989) which describes the use of a recombinant vector carrying a marker gene (i.e. beta galactosidase, chloramphenicol
20 acetyl transferase, etc.) the expression of which will be detected when placed under the control of a biologically active polynucleotide fragments or variants of SEQ ID No 1. Genomic sequences located upstream of the first exon of the *BAP28* gene are cloned into a suitable promoter reporter vector, such as the pSEAP-Basic, pSEAP-Enhancer, pβgal-Basic, pβgal-Enhancer, or pEGFP-1 Promoter Reporter vectors available from Clontech, or pGL2-basic or pGL3-basic promoterless
25 luciferase reporter gene vector from Promega. Briefly, each of these promoter reporter vectors include multiple cloning sites positioned upstream of a reporter gene encoding a readily assayable protein such as secreted alkaline phosphatase, luciferase, β galactosidase, or green fluorescent protein. The sequences upstream the *BAP28* coding region are inserted into the cloning sites upstream of the reporter gene in both orientations and introduced into an appropriate host cell. The
30 level of reporter protein is assayed and compared to the level obtained from a vector which lacks an insert in the cloning site. The presence of an elevated expression level in the vector containing the insert with respect to the control vector indicates the presence of a promoter in the insert. If necessary, the upstream sequences can be cloned into vectors which contain an enhancer for increasing transcription levels from weak promoter sequences. A significant level of expression
35 above that observed with the vector lacking an insert indicates that a promoter sequence is present in the inserted upstream sequence.

Promoter sequence within the upstream genomic DNA may be further defined by constructing nested 5' and/or 3' deletions in the upstream DNA using conventional techniques such as Exonuclease III or appropriate restriction endonuclease digestion. The resulting deletion fragments can be inserted into the promoter reporter vector to determine whether the deletion has reduced or obliterated promoter activity, such as described, for example, by Coles et al.(1998). In this way, the boundaries of the promoters may be defined. If desired, potential individual regulatory sites within the promoter may be identified using site directed mutagenesis or linker scanning to obliterate potential transcription factor binding sites within the promoter individually or in combination. The effects of these mutations on transcription levels may be determined by inserting the mutations into cloning sites in promoter reporter vectors. This type of assay is well-known to those skilled in the art and is described in WO 97/17359, US 5,374,544; EP 582 796; US 5,698,389; US 5,643,746; US 5,502,176; and US 5,266,488; incorporated herein by reference.

The strength and the specificity of the promoter of the *BAP28* gene can be assessed through the expression levels of a detectable polynucleotide operably linked to the *BAP28* promoter in different types of cells and tissues. The detectable polynucleotide may be either a polynucleotide that specifically hybridizes with a predefined oligonucleotide probe, or a polynucleotide encoding a detectable protein, including a *BAP28* polypeptide or a fragment or a variant thereof. This type of assay is well-known to those skilled in the art and is described in US 5,502,176; and US 5,266,488; incorporated herein by reference. Some of the methods are discussed in more detail below.

Polynucleotides carrying the regulatory elements located at the 5' end and at the 3' end of the *BAP28* coding region may be advantageously used to control the transcriptional and translational activity of heterologous polynucleotide of interest.

Thus, the present invention also concerns a purified or isolated nucleic acid comprising a polynucleotide which is selected from the group consisting of the 5' and 3' regulatory regions, or a sequence complementary thereto or a biologically active fragment or variant thereof.

The invention also pertains to a purified or isolated nucleic acid comprising a polynucleotide having at least 95% nucleotide identity with a polynucleotide selected from the group consisting of the 5' and 3' regulatory regions, advantageously 99 % nucleotide identity, preferably 99.5% nucleotide identity and most preferably 99.8% nucleotide identity with a polynucleotide selected from the group consisting of the 5' and 3' regulatory regions, or a sequence complementary thereto or a variant thereof or a biologically active fragment thereof.

Another object of the invention consists of purified, isolated or recombinant nucleic acids comprising a polynucleotide that hybridizes, under the stringent hybridization conditions defined herein, with a polynucleotide selected from the group consisting of the nucleotide sequences of the 5'- and 3' regulatory regions, or a sequence complementary thereto or a variant thereof or a biologically active fragment thereof.

Preferred fragments of either the 5' or 3' regulatory region have a length of about 1500 or 1000 nucleotides, preferably of about 500 nucleotides, more preferably about 400 nucleotides, even more preferably 300 nucleotides and most preferably about 200 nucleotides.

- By "biologically active" polynucleotide derivatives of SEQ ID No 1 are polynucleotides
- 5 comprising or alternatively consisting in a fragment of said polynucleotide which is functional as a regulatory region for expressing a recombinant polypeptide or a recombinant polynucleotide in a recombinant cell host. It could act either as an enhancer or as a repressor.

- For the purpose of the invention, a nucleic acid or polynucleotide is "functional" as a regulatory region for expressing a recombinant polypeptide or a recombinant polynucleotide if said
- 10 regulatory polynucleotide contains nucleotide sequences which contain transcriptional and translational regulatory information, and such sequences are "operably linked" to nucleotide sequences which encode the desired polypeptide or the desired polynucleotide.

- The regulatory polynucleotides of the invention may be prepared from the nucleotide sequence of SEQ ID No 1 by cleavage using suitable restriction enzymes, as described for example
- 15 in the book of Sambrook et al.(1989). The regulatory polynucleotides may also be prepared by digestion of SEQ ID No 1 by an exonuclease enzyme, such as Bal31 (Wabiko et al., 1986). These regulatory polynucleotides can also be prepared by nucleic acid chemical synthesis, as described elsewhere in the specification.

- The regulatory polynucleotides according to the invention may be part of a recombinant
- 20 expression vector that may be used to express a coding sequence in a desired host cell or host organism. The recombinant expression vectors according to the invention are described elsewhere in the specification.

A preferred 5'-regulatory polynucleotide of the invention thus includes the 5'-UTR of the *BAP28* cDNA, or a biologically active fragment or variant thereof.

- 25 A preferred 3'-regulatory polynucleotide of the invention includes the 3'-UTR of the *BAP28* cDNA, or a biologically active fragment or variant thereof.

A further object of the invention consists of a purified or isolated nucleic acid comprising:

- a) a nucleic acid comprising a regulatory nucleotide sequence selected from the group consisting of:
- 30 (i) a nucleotide sequence comprising a polynucleotide of the 5' regulatory region or a complementary sequence thereto;
- (ii) a nucleotide sequence comprising a polynucleotide having at least 95% of nucleotide identity with the nucleotide sequence of the 5' regulatory region or a complementary sequence thereto;
- 35 (iii) a nucleotide sequence comprising a polynucleotide that hybridizes under stringent hybridization conditions with the nucleotide sequence of the 5' regulatory region or a complementary sequence thereto; and

(iv) a biologically active fragment or variant of the polynucleotides in (i), (ii) and (iii);

b) a polynucleotide encoding a desired polypeptide or a nucleic acid of interest, operably linked to the nucleic acid defined in (a) above;

5 c) In some embodiments, a nucleic acid comprising a 3'- regulatory polynucleotide, preferably a 3'- regulatory polynucleotide of the *BAP28* gene.

In a specific embodiment of the nucleic acid defined above, said nucleic acid includes the 5'-UTR of the *BAP28* cDNA, or a biologically active fragment or variant thereof.

In a second specific embodiment of the nucleic acid defined above, said nucleic acid
10 includes the 3'-UTR of the *BAP28* cDNA, or a biologically active fragment or variant thereof.

The desired polypeptide encoded by the above-described nucleic acid may be of various nature or origin, encompassing proteins of prokaryotic or eukaryotic origin. Among the polypeptides expressed under the control of a *BAP28* regulatory region include bacterial, fungal or viral antigens. Also encompassed are eukaryotic proteins such as intracellular proteins, like "house
15 keeping" proteins, membrane-bound proteins, like receptors, and secreted proteins like endogenous mediators such as cytokines. The desired polypeptide may be the *BAP28* protein, especially the protein of the amino acid sequence of SEQ ID No 1, or a fragment or a variant thereof.

The desired nucleic acids encoded by the above-described polynucleotide, usually an RNA molecule, may be complementary to a desired coding polynucleotide, for example to the *BAP28*
20 coding sequence, and thus useful as an antisense polynucleotide.

Such a polynucleotide may be included in a recombinant expression vector in order to express the desired polypeptide or the desired nucleic acid in host cell or in a host organism. Suitable recombinant vectors that contain a polynucleotide such as described hereinbefore are disclosed elsewhere in the specification.

25 **Polynucleotide Constructs**

The terms "polynucleotide construct" and "recombinant polynucleotide" are used interchangeably herein to refer to linear or circular, purified or isolated polynucleotides that have been artificially designed and which comprise at least two nucleotide sequences that are not found as contiguous nucleotide sequences in their initial natural environment.

30 **DNA Construct That Enables Directing Temporal And Spatial BAP28 Gene Expression In Recombinant Cell Hosts And In Transgenic Animals.**

In order to study the physiological and phenotypic consequences of a lack of synthesis of the *BAP28* protein, both at the cell level and at the multi cellular organism level, the invention also encompasses DNA constructs and recombinant vectors enabling a conditional expression of a
35 specific allele of the *BAP28* genomic sequence or cDNA and also of a copy of this genomic sequence or cDNA harboring substitutions, deletions, or additions of one or more bases as regards to

the *BAP28* nucleotide sequence of SEQ ID Nos 1-3, or a fragment thereof, these base substitutions, deletions or additions being located either in an exon, an intron or a regulatory sequence, but preferably in an exon of the *BAP28* genomic sequence or within the *BAP28* cDNA of SEQ ID No 2 or 3. In a preferred embodiment, the *BAP28* sequence comprises a biallelic marker of the present

- 5 invention. In a preferred embodiment, the *BAP28* sequence comprises a biallelic marker of the present invention, preferably one of the biallelic markers A1 to A58, preferably A1 to A27, A34, A37 to A41, A43 to A49, A52, and A54 to A58, more preferably one of the biallelic markers A1, A4, 16, A30, A31, A42, A50, A51, and A53.

- In an additional embodiment, the invention concerns a DNA construct comprising an exon
10 of *PCTA-1* selected from the group consisting of exons A, B, C, and D.

- The present invention embodies recombinant vectors comprising any one of the polynucleotides described in the present invention. More particularly, the polynucleotide constructs according to the present invention can comprise any of the polynucleotides described in the “Genomic Sequences Of The Human *BAP28* Gene” section, the “*BAP28* cDNA Sequences” section,
15 the “Coding Regions” section, and the “Oligonucleotide Probes And Primers” section.

- A first preferred DNA construct is based on the tetracycline resistance operon *tet* from *E. coli* transposon Tn10 for controlling the *BAP28* gene expression, such as described by Gossen et al.(1992, 1995) and Furth et al.(1994). Such a DNA construct contains seven *tet* operator sequences from Tn10 (*tetop*) that are fused to a minimal promoter, said minimal promoter being operably
20 linked to a polynucleotide of interest that codes either for a sense or an antisense oligonucleotide or for a polypeptide, including a BAP28 polypeptide or a peptide fragment thereof. This DNA construct is functional as a conditional expression system for the nucleotide sequence of interest when the same cell also comprises a nucleotide sequence coding for either the wild type (tTA) or the mutant (rTA) repressor fused to the activating domain of viral protein VP16 of herpes simplex
25 virus, placed under the control of a promoter, such as the HCMVIE1 enhancer/promoter or the MMTV-LTR. Indeed, a preferred DNA construct of the invention comprise both the polynucleotide containing the *tet* operator sequences and the polynucleotide containing a sequence coding for the tTA or the rTA repressor.

- In a specific embodiment, the conditional expression DNA construct contains the sequence
30 encoding the mutant tetracycline repressor rTA, the expression of the polynucleotide of interest is silent in the absence of tetracycline and induced in its presence.

DNA Constructs Allowing Homologous Recombination: Replacement Vectors

- A second preferred DNA construct will comprise, from 5'-end to 3'-end: (a) a first nucleotide sequence that is comprised in the *BAP28* genomic sequence; (b) a nucleotide sequence
35 comprising a positive selection marker, such as the marker for neomycine resistance (*neo*); and (c) a

5 Preferably, the negative selection marker consists of the thymidine kinase (*tk*) gene (Thomas et al., 1986), the hygromycin beta gene (Te Riele et al., 1990), the *hprt* gene (Van der Lugt et al., 1991; Reid et al., 1990) or the Diphtheria toxin A fragment (*Dt-A*) gene (Nada et al., 1993; Yagi et al.1990). Preferably, the positive selection marker is located within a *BAP28* exon sequence so as to interrupt the sequence encoding a *BAP28* protein. These replacement vectors are described, for
10 example, by Thomas et al.(1986; 1987), Mansour et al.(1988) and Koller et al.(1992).

The first and second nucleotide sequences (a) and (c) may be indifferently located within a *BAP28* regulatory sequence, an intronic sequence, an exon sequence or a sequence containing both regulatory and/or intronic and/or exon sequences. The size of the nucleotide sequences (a) and (c) ranges from 1 to 50 kb, preferably from 1 to 10 kb, more preferably from 2 to 6 kb and most preferably from 2 to 4 kb.

These new DNA constructs make use of the site specific recombination system of the P1 phage. The P1 phage possesses a recombinase called Cre which interacts specifically with a 34 base pairs *loxP* site. The *loxP* site is composed of two palindromic sequences of 13 bp separated by a 8 bp conserved sequence (Hoess et al., 1986). The recombination by the Cre enzyme between two *loxP* sites having an identical orientation leads to the deletion of the DNA fragment.

33

of the cell host either by a random insertion event or an homologous recombination event, such as described by Gu et al.(1994).

In a specific embodiment, the vector containing the sequence to be inserted in the *BAP28* gene by homologous recombination is constructed in such a way that selectable markers are flanked by *loxP* sites of the same orientation, it is possible, by treatment by the Cre enzyme, to eliminate the selectable markers while leaving the *BAP28* sequences of interest that have been inserted by an homologous recombination event. Again, two selectable markers are needed: a positive selection marker to select for the recombination event and a negative selection marker to select for the homologous recombination event. Vectors and methods using the Cre-*loxP* system are described by Zou et al.(1994).

Thus, a third preferred DNA construct of the invention comprises, from 5'-end to 3'-end: (a) a first nucleotide sequence that is comprised in the *BAP28* genomic sequence; (b) a nucleotide sequence comprising a polynucleotide encoding a positive selection marker, said nucleotide sequence comprising additionally two sequences defining a site recognized by a recombinase, such as a *loxP* site, the two sites being placed in the same orientation; and (c) a second nucleotide sequence that is comprised in the *BAP28* genomic sequence, and is located on the genome downstream of the first *BAP28* nucleotide sequence (a).

The sequences defining a site recognized by a recombinase, such as a *loxP* site, are preferably located within the nucleotide sequence (b) at suitable locations bordering the nucleotide sequence for which the conditional excision is sought. In one specific embodiment, two *loxP* sites are located at each side of the positive selection marker sequence, in order to allow its excision at a desired time after the occurrence of the homologous recombination event.

In a preferred embodiment of a method using the third DNA construct described above, the excision of the polynucleotide fragment bordered by the two sites recognized by a recombinase, preferably two *loxP* sites, is performed at a desired time, due to the presence within the genome of the recombinant host cell of a sequence encoding the Cre enzyme operably linked to a promoter sequence, preferably an inducible promoter, more preferably a tissue-specific promoter sequence and most preferably a promoter sequence which is both inducible and tissue-specific, such as described by Gu et al.(1994).

The presence of the Cre enzyme within the genome of the recombinant cell host may result of the breeding of two transgenic animals, the first transgenic animal bearing the *BAP28*-derived sequence of interest containing the *loxP* sites as described above and the second transgenic animal bearing the Cre coding sequence operably linked to a suitable promoter sequence, such as described by Gu et al.(1994).

Spatio-temporal control of the Cre enzyme expression may also be achieved with an adenovirus based vector that contains the Cre gene thus allowing infection of cells, or *in vivo*

infection of organs, for delivery of the Cre enzyme, such as described by Anton and Graham (1995) and Kanegae et al.(1995).

The DNA constructs described above may be used to introduce a desired nucleotide sequence of the invention, preferably a *BAP28* genomic sequence or a *BAP28* cDNA sequence, and most preferably an altered copy of a *BAP28* genomic or cDNA sequence, within a predetermined location of the targeted genome, leading either to the generation of an altered copy of a targeted gene (knock-out homologous recombination) or to the replacement of a copy of the targeted gene by another copy sufficiently homologous to allow an homologous recombination event to occur (knock-in homologous recombination). In a specific embodiment, the DNA constructs described above may be used to introduce a *BAP28* genomic sequence or a *BAP28* cDNA sequence. In some embodiments, said sequence comprises at least one biallelic marker of the present invention, preferably at least one biallelic marker selected from the group consisting of A1 to A58, preferably A1 to A27, A34, A37 to A41, A43 to A49, A52, and A54 to A58, more preferably one of the biallelic markers A1, A4, 16, A30, A31, A42, A50, A51, and A53.

15 Nuclear Antisense DNA Constructs

Other compositions containing a vector of the invention comprising an oligonucleotide fragment of the nucleic sequence SEQ ID No 2 or 3, preferably a fragment including the start codon of the *BAP28* gene, as an antisense tool that inhibits the expression of the corresponding *BAP28* gene or the expression of the *PCTA-1* gene. Preferred methods using antisense polynucleotide according to the present invention are the procedures described by Sczakiel et al.(1995) or those described in PCT Application No WO 95/24223.

Preferably, the antisense tools are chosen among the polynucleotides (15-200 bp long) that are complementary to the 5' end or 3' end of the *BAP28* mRNA. In one embodiment, a combination of different antisense polynucleotides complementary to different parts of the desired targeted gene are used.

A preferred antisense according to the invention is a polynucleotide according to the invention, more particularly polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 50, 80, 100, 150, 200, 250, 300, 350, 400, 450, 500, 600 or 1000 nucleotides of SEQ ID No 1, or the complements thereof, wherein said contiguous span comprises at least 1, 2, 3, 5, or 10 nucleotide positions of any one of the following ranges of nucleotide positions of SEQ ID No 1: 57386-27494, 58504-59354, 85947-86108, and 91259-91325.

Preferred antisense polynucleotides according to the present invention are complementary to a sequence of the mRNAs of *BAP28* that contains either the translation initiation codon ATG or a splicing site. Further preferred antisense polynucleotides according to the invention are complementary of the splicing site of the *BAP28* mRNA.

The antisense nucleic acids should have a length and melting temperature sufficient to permit formation of an intracellular duplex having sufficient stability to inhibit the expression of the *BAP28* mRNA in the duplex. Strategies for designing antisense nucleic acids suitable for use in gene therapy are disclosed in Green et al., (1986) and Izant and Weintraub, (1984), the disclosures of which are incorporated herein by reference.

In some strategies, antisense molecules are obtained by reversing the orientation of the *BAP28* coding region with respect to a promoter so as to transcribe the opposite strand from that which is normally transcribed in the cell. The antisense molecules may be transcribed using in vitro transcription systems such as those which employ T7 or SP6 polymerase to generate the transcript.

Another approach involves transcription of *BAP28* antisense nucleic acids in vivo by operably linking DNA containing the antisense sequence to a promoter in a suitable expression vector.

Alternatively, suitable antisense strategies are those described by Rossi et al.(1991), in the International Applications Nos. WO 94/23026, WO 95/04141, WO 92/18522 and in the European Patent Application No EP 0 572 287 A2.

Preferably, the antisense polynucleotides of the invention have a 3' polyadenylation signal that has been replaced with a self-cleaving ribozyme sequence, such that RNA polymerase II transcripts are produced without poly(A) at their 3' ends, these antisense polynucleotides being incapable of export from the nucleus, such as described by Liu et al.(1994). In a preferred embodiment, these *BAP28* antisense polynucleotides also comprise, within the ribozyme cassette, a histone stem-loop structure to stabilize cleaved transcripts against 3'-5' exonucleolytic degradation, such as the structure described by Eckner et al.(1991).

An alternative to the antisense technology that is used according to the present invention consists in using ribozymes that will bind to a target sequence via their complementary polynucleotide tail and that will cleave the corresponding RNA by hydrolyzing its target site (namely "hammerhead ribozymes"). Briefly, the simplified cycle of a hammerhead ribozyme consists of (1) sequence specific binding to the target RNA via complementary antisense sequences; (2) site-specific hydrolysis of the cleavable motif of the target strand; and (3) release of cleavage products, which gives rise to another catalytic cycle. Indeed, the use of long-chain antisense polynucleotide (at least 30 bases long) or ribozymes with long antisense arms are advantageous. A preferred delivery system for antisense ribozyme is achieved by covalently linking these antisense ribozymes to lipophilic groups or to use liposomes as a convenient vector. Preferred antisense ribozymes according to the present invention are prepared as described by Sczakiel et al.(1995), the specific preparation procedures being referred to in said article being herein incorporated by reference.

Oligonucleotide Probes And Primers

Polynucleotides derived from the *BAP28* gene are useful in order to detect the presence of at least a copy of a nucleotide sequence of SEQ ID Nos 1-3, or a fragment, complement, or variant thereof in a test sample.

- 5 Preferred probes and primers of the invention include isolated, purified, or recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 50, 80, 100, 150, or 200 nucleotides, to the extent that such a length is consistent with the lengths of the particular nucleotide position, of SEQ ID No 1 or the complement thereof, wherein said contiguous span comprises at least 1, 2, 3, 5, 10, 20, 30, 40 or 50 nucleotides selected from the group consisting of
- 10 the following nucleotide positions of SEQ ID No 1: 4997-5076, 5371-5544, 6121-6337, 9877-10018, 11522-11623, 12521-12661, 13453-13664, 13824-13957, 15376-15478, 16855-16965, 17378-17495, 18535-18642, 21446-21541, 21999-22087, 23036-23247, 23546-23667, 24270-24461, 26287-26470, 26611-26747, 28068-28260, 32540-32709, 33112-33270, 34586-34828, 35156-35287, 36660-36763, 36934-37077, 37803-37921, 38017-38138, 40365-40493, 42618-
- 15 42848, 43452-43578, 44836-44999, 48223-48269, and 49656-49779. Particularly preferred probes and primers of the invention include isolated, purified, or recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, or 1000 a nucleotide of SEQ ID No 1 or the complements thereof, wherein said contiguous span comprises at least 1, 2, 3, 5, or 10 of the following nucleotide positions of SEQ ID No 1: 1-50357,
- 20 50499-50963, 51257-52147, 52299-53234, 53394-53553, 53689-53837, 53943-54028, 54198-54740, 54896-55753, 55913-57385, 57495-58503, 58828-85946, 59355-85946, 86169-91228, and/or 91852 to 97662.

- Particularly preferred embodiments of the invention include isolated, purified, or recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40,
- 25 50, 60, 70, 80, 90, 100, 150, 200, 500, or 1000 nucleotides of a nucleic acid sequence selected from the group consisting of SEQ ID Nos 2 and 3 or the complements thereof, wherein said contiguous span comprises at least 1, 2, 3, 5, or 10 of nucleotide positions 1 to 4995 of SEQ ID No 2 or 3. Further embodiments of the invention include isolated, purified, or recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150,
- 30 200, 500, or 1000 nucleotides of a nucleic acid sequence selected from the group consisting of SEQ ID Nos 2 and 3 or the complements thereof, wherein said contiguous span comprises at least 1, 2, 3, 5, or 10 of the following nucleotide positions of SEQ ID No 2 or 3: 1 to 2033, 2160 to 2348, and 2676 to 4995.

- Additional preferred probes and primers of the invention include isolated, purified, or
- 35 recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, or 1000 nucleotides of a nucleic acid sequence selected from the group consisting of SEQ ID Nos 1-3, or the complements thereof, wherein said contiguous span

comprises at least 1, 2, 3, 5, or 10 nucleotide positions of any one of the following ranges of nucleotide positions of:

(a) SEQ ID No 1: 1-2500, 2501-5000, 5001-7500, 7501-10000, 10001-12500, 12501-15000, 15001-17500, 17501-20000, 20001-22500, 22501-25000, 25001-27500, 27501-30000, 30001-32500, 32501-35000, 35001-37500, 37501-40000, 40001-42500, 42501-45000, 45001-47500, 47501-50000, 50001-50357, 50499-50963, 51257-52147, 52299-53234, 53394-53553, 53689-53837, 53943-54028, 54198-54740, 54896-55753, 55913-57385, 57495-58503, 58828-85946, 59355-85946, 86169-91228, and/or 91852 to 97662;

(b) SEQ ID No 2: 1 to 500, 501 to 1000, 1001 to 1500, 1501 to 2000, 2001 to 2500, 2501 to 3000, 3001 to 3500, 3501 to 4000, 4001 to 4500, 4501 to 4995, 5000 to 5500, 5501 to 6000, 6001 to 6500, and 6501 to 6782; and,

(c) SEQ ID No 3: 1 to 500, 501 to 1000, 1001 to 1500, 1501 to 2000, 2001 to 2500, 2501 to 3000, 3001 to 3500, 3501 to 4000, 4001 to 4500, 4501 to 4995, 5000 to 5500, 5501 to 6000, 6001 to 6500, 6501 to 7000, 7001 to 7500, 7501 to 7932.

Thus, the invention also relates to nucleic acid probes characterized in that they hybridize specifically, under the stringent hybridization conditions defined above, with a nucleic acid selected from the group consisting of the nucleotide sequences:

a) 1-50357, 50499-50963, 51257-52147, 52299-53234, 53394-53553, 53689-53837, 53943-54028, 54198-54740, 54896-55753, 55913-57385, 57495-58503, 58828-85946, 59355-85946, 86169-91228, and/or 91852 to 97662 of SEQ ID No 1 or a variant thereof or a sequence complementary thereto; or

b) 1 to 4995 of SEQ ID No 2 or 3 or a variant thereof or a sequence complementary thereto; and,

c) at least one of nucleotide ranges 1 to 2033, 2160 to 2348, 2676 to 4995 of SEQ ID No 2 or 3, or a variant thereof or a sequence complementary thereto.

Additionally, another preferred embodiment of a probe according to the invention consists of a nucleic acid comprising a biallelic marker selected from the group consisting of A1 to A58 or the complements thereto, for which the respective locations in the sequence listing are provided in Table 2. Preferably, a probe according to the present invention consists of a nucleic acid comprising one of the biallelic markers A1 to A27, A34, A37 to A41, A43 to A49, A52, and A54 to A58. More preferably, a probe according to the present invention consists of a nucleic acid comprising one of the biallelic markers A1, A4, A16, A30, A31, A42, A50, A51, and A53.

In one embodiment the invention encompasses isolated, purified, and recombinant polynucleotides comprising, consisting of, or consisting essentially of a contiguous span of 8 to 50 nucleotides of SEQ ID Nos 1, 2, or 3 and the complement thereof, wherein said span includes a *BAP28*-related biallelic marker in said sequence; In some embodiments said *BAP28*-related biallelic marker is selected from the group consisting of A1 to A58, and the complements thereof, or the

biallelic markers in linkage disequilibrium therewith; In some embodiments said *BAP28*-related biallelic marker is selected from the group consisting of A1 to A27, A34, A37 to A41, A43 to A49, A52, and A54 to A58, and the complements thereof, or the biallelic markers in linkage disequilibrium therewith; In some embodiments said *BAP28*-related biallelic marker is selected from the group consisting of A1, A4, 16, A30, A31, A42, A50, A51, and A53, and the complements thereof or the biallelic markers in linkage disequilibrium therewith; In some embodiments said contiguous span is 18 to 35 nucleotides in length and said biallelic marker is within 4 nucleotides of the center of said polynucleotide; In some embodiments, said polynucleotide consists of said contiguous span and said contiguous span is 25 nucleotides in length and said biallelic marker is at the center of said polynucleotide; In some embodiments, the 3' end of said contiguous span is present at the 3' end of said polynucleotide; In some embodiments, the 3' end of said contiguous span is located at the 3' end of said polynucleotide and said biallelic marker is present at the 3' end of said polynucleotide. In a preferred embodiment, said probes comprises, consists of, or consists essentially of a sequence selected from the following sequences: P1 to P58, preferably P1 to P27, P34, P37 to P41, P43 to P49, P52, and P54 to P58, and the complementary sequences thereto.

In another embodiment the invention encompasses isolated, purified and recombinant polynucleotides comprising, consisting of, or consisting essentially of a contiguous span of 8 to 50 nucleotides of SEQ ID Nos 1, 2, or 3 or the complements thereof, wherein the 3' end of said contiguous span is located at the 3' end of said polynucleotide, and wherein the 3' end of said polynucleotide is located within 20 nucleotides upstream of a *BAP28*-related biallelic marker in said sequence; In some embodiments, said *BAP28*-related biallelic marker is selected from the group consisting of A1 to A58, and the complements thereof or the biallelic markers in linkage disequilibrium therewith; In some embodiments, said *BAP28*-related biallelic marker is selected from the group consisting of A1 to A27, A34, A37 to A41, A43 to A49, A52, and A54 to A58, and the complements thereof, or the biallelic markers in linkage disequilibrium therewith; In some embodiments said *BAP28*-related biallelic marker is selected from the group consisting of A1, A4, 16, A30, A31, A42, A50, A51, and A53, and the complements thereof, or the biallelic markers in linkage disequilibrium therewith; optionally, In some embodiments, the 3' end of said polynucleotide is located 1 nucleotide upstream of said *BAP28*-related biallelic marker in said sequence; In some embodiments, said polynucleotide consists essentially of a sequence selected from the following sequences: D1 to D58 and E1 to E58, preferably D1 to D27, D34, D37 to D41, D43 to D49, D52, D54 to D58, E1 to E27, E34, E37 to E41, E43 to E49, E52, and E54 to E58.

In a further embodiment, the invention encompasses isolated, purified, or recombinant polynucleotides comprising, consisting of, or consisting essentially of a sequence selected from the following sequences: B1 to B38 and C1 to C38, preferably B1 to B15, B22, B24, B25, B27 to 29, B32, B34 to B38, C1 to C15, C22, C24, C25, C27 to 29, C32, and C34 to C38.

In an additional embodiment, the invention encompasses polynucleotides for use in hybridization assay, sequencing assays, and enzyme-based mismatch detection assays for determining the identity of the nucleotide at a *BAP28*-related biallelic marker in SEQ ID No 1, or the complements thereof, as well as polynucleotides for use in amplifying segments of nucleotides comprising a *BAP28*-related biallelic marker in SEQ ID No 1 or the complements thereof; In some 5 embodiments, said *BAP28*-related biallelic marker is selected from the group consisting of A1 to A58, and the complements thereof, or the biallelic markers in linkage disequilibrium therewith; In some embodiments, said *BAP28*-related biallelic marker is selected from the group consisting of A1 to A27, A34, A37 to A41, A43 to A49, A52, and A54 to A58, and the complements thereof, or the 10 biallelic markers in linkage disequilibrium therewith; In some embodiments, said *BAP28*-related biallelic marker is selected from the group consisting of A1, A4, 16, A30, A31, A42, A50, A51, and A53, and the complements thereof, or the biallelic markers in linkage disequilibrium therewith.

Furthermore, the present invention also concerns the use of the oligonucleotide probes and primers according to the invention for determining the identity of the nucleotide at a *BAP28*-related 15 biallelic marker. The use of these oligonucleotides in diagnostic is contemplated.

The formation of stable hybrids depends on the melting temperature (T_m) of the DNA. The T_m depends on the length of the primer or probe, the ionic strength of the solution and the G+C content. The higher the G+C content of the primer or probe, the higher is the melting temperature because G:C pairs are held by three H bonds whereas A:T pairs have only two. The GC content in 20 the probes of the invention usually ranges between 10 and 75 %, preferably between 35 and 60 %, and more preferably between 40 and 55 %.

A probe or a primer according to the invention has between 8 and 1000 nucleotides in length, or is specified to be at least 12, 15, 18, 20, 25, 35, 40, 50, 60, 70, 80, 100, 250, 500 or 1000 nucleotides in length. More particularly, the length of these probes and primers can range from 8, 25 10, 15, 20, or 30 to 100 nucleotides, preferably from 10 to 50, more preferably from 15 to 30 nucleotides. Shorter probes and primers tend to lack specificity for a target nucleic acid sequence and generally require cooler temperatures to form sufficiently stable hybrid complexes with the template. Longer probes and primers are expensive to produce and can sometimes self-hybridize to form hairpin structures. The appropriate length for primers and probes under a particular set of 30 assay conditions may be empirically determined by one of skill in the art. A preferred probe or primer consists of a nucleic acid comprising a polynucleotide selected from the group of the nucleotide sequences of P1 to P58 and the complementary sequences thereto, B1 to B38 and C1 to C38, D1 to D58, E1 to E58, for which the respective locations in the sequence listing are provided in Tables 1, 3, and 4, preferably a nucleic acid comprising a polynucleotide selected from the group of 35 the nucleotide sequences of P1 to P27, P34, P37 to P41, P43 to P49, P52, and P54 to P58, and the complementary sequences thereto, B1 to B15, B22, B24, B25, B27 to 29, B32, B34 to B38, C1 to

C15, C22, C24, C25, C27 to 29, C32, C34 to C38, D1 to D27, D34, D37 to D41, D43 to D49, D52, D54 to D58, E1 to E27, E34, E37 to E41, E43 to E49, E52, and E54 to E58.

The primers and probes can be prepared by any suitable method, including, for example, cloning and restriction of appropriate sequences and direct chemical synthesis by a method such as the phosphodiester method of Narang et al.(1979), the phosphodiester method of Brown et al.(1979), the diethylphosphoramidite method of Beaucage et al.(1981) and the solid support method described in EP 0 707 592. The disclosures of all these documents are incorporated herein by reference.

Detection probes are generally nucleic acid sequences or uncharged nucleic acid analogs such as, for example peptide nucleic acids which are disclosed in International Patent Application WO 92/20702, morpholino analogs which are described in U.S. Patents Numbered 5,185,444; 5,034,506 and 5,142,047. The probe may have to be rendered "non-extendable" in that additional dNTPs cannot be added to the probe. In and of themselves analogs usually are non-extendable and nucleic acid probes can be rendered non-extendable by modifying the 3' end of the probe such that the hydroxyl group is no longer capable of participating in elongation. For example, the 3' end of the probe can be functionalized with the capture or detection label to thereby consume or otherwise block the hydroxyl group. Alternatively, the 3' hydroxyl group simply can be cleaved, replaced or modified, U.S. Patent Application Serial No 07/049,061 filed April 19, 1993 describes modifications, which can be used to render a probe non-extendable.

Any of the polynucleotides of the present invention can be labeled, if desired, by incorporating a label detectable by spectroscopic, photochemical, biochemical, immunochemical, or chemical means. For example, useful labels include radioactive substances (^{32}P , ^{35}S , ^3H , ^{125}I), fluorescent dyes (5-bromodesoxyuridin, fluorescein, acetylaminofluorene, digoxigenin) or biotin. Preferably, polynucleotides are labeled at their 3' and 5' ends. Examples of non-radioactive labeling of nucleic acid fragments are described in the French patent No FR-7810975 or by Urdea et al (1988) or Sanchez-Pescador et al (1988). In addition, the probes according to the present invention may have structural characteristics such that they allow the signal amplification, such structural characteristics being, for example, branched DNA probes as those described by Urdea et al. in 1991 or in the European patent No EP 0 225 807 (Chiron).

A label can also be used to capture the primer, so as to facilitate the immobilization of either the primer or a primer extension product, such as amplified DNA, on a solid support. A capture label is attached to the primers or probes and can be a specific binding member which forms a binding pair with the solid's phase reagent's specific binding member (e.g. biotin and streptavidin). Therefore depending upon the type of label carried by a polynucleotide or a probe, it may be employed to capture or to detect the target DNA. Further, it will be understood that the polynucleotides, primers or probes provided herein, may, themselves, serve as the capture label. For example, in the case where a solid phase reagent's binding member is a nucleic acid sequence, it may be selected such that it binds a complementary portion of a primer or probe to thereby

immobilize the primer or probe to the solid phase. In cases where a polynucleotide probe itself serves as the binding member, those skilled in the art will recognize that the probe will contain a sequence or "tail" that is not complementary to the target. In the case where a polynucleotide primer itself serves as the capture label, at least a portion of the primer will be free to hybridize with a nucleic acid on a solid phase. DNA Labeling techniques are well known to the skilled technician.

The probes of the present invention are useful for a number of purposes. They can be notably used in Southern hybridization to genomic DNA. The probes can also be used to detect PCR amplification products. They may also be used to detect mismatches in the *BAP28* gene or mRNA using other techniques.

- Any of the polynucleotides, primers and probes of the present invention can be conveniently immobilized on a solid support. Solid supports are known to those skilled in the art and include the walls of wells of a reaction tray, test tubes, polystyrene beads, magnetic beads, nitrocellulose strips, membranes, microparticles such as latex particles, sheep (or other animal) red blood cells, duracytes and others. The solid support is not critical and can be selected by one skilled in the art. Thus, latex particles, microparticles, magnetic or non-magnetic beads, membranes, plastic tubes, walls of microtiter wells, glass or silicon chips, sheep (or other suitable animal's) red blood cells and duracytes are all suitable examples. Suitable methods for immobilizing nucleic acids on solid phases include ionic, hydrophobic, covalent interactions and the like. A solid support, as used herein, refers to any material which is insoluble, or can be made insoluble by a subsequent reaction. The solid support can be chosen for its intrinsic ability to attract and immobilize the capture reagent. Alternatively, the solid phase can retain an additional receptor which has the ability to attract and immobilize the capture reagent. The additional receptor can include a charged substance that is oppositely charged with respect to the capture reagent itself or to a charged substance conjugated to the capture reagent. As yet another alternative, the receptor molecule can be any specific binding member which is immobilized upon (attached to) the solid support and which has the ability to immobilize the capture reagent through a specific binding reaction. The receptor molecule enables the indirect binding of the capture reagent to a solid support material before the performance of the assay or during the performance of the assay. The solid phase thus can be a plastic, derivatized plastic, magnetic or non-magnetic metal, glass or silicon surface of a test tube, microtiter well, sheet, bead, microparticle, chip, sheep (or other suitable animal's) red blood cells, duracytes® and other configurations known to those of ordinary skill in the art. The polynucleotides of the invention can be attached to or immobilized on a solid support individually or in groups of at least 2, 5, 8, 10, 12, 15, 20, or 25 distinct polynucleotides of the invention to a single solid support. In addition, polynucleotides other than those of the invention may be attached to the same solid support as one or more polynucleotides of the invention.

Consequently, the invention also deals with a method for detecting the presence of a nucleic acid comprising a nucleotide sequence selected from a group consisting of SEQ ID Nos 1-4,

9-13, a fragment or a variant thereof and a complementary sequence thereto in a sample, said method comprising the following steps of:

- a) bringing into contact a nucleic acid probe or a plurality of nucleic acid probes which can hybridize with a nucleotide sequence included in a nucleic acid selected from the group consisting of the nucleotide sequences of SEQ ID Nos 1-4, 9-13, a fragment or a variant thereof and a complementary sequence thereto and the sample to be assayed; and
- b) detecting the hybrid complex formed between the probe and a nucleic acid in the sample.

The invention further concerns a kit for detecting the presence of a nucleic acid comprising a nucleotide sequence selected from a group consisting of SEQ ID Nos 1-4, 9-13, a fragment or a variant thereof and a complementary sequence thereto in a sample, said kit comprising:

- a) a nucleic acid probe or a plurality of nucleic acid probes which can hybridize with a nucleotide sequence included in a nucleic acid selected from the group consisting of the nucleotide sequences of SEQ ID Nos 1-4, 9-13, a fragment or a variant thereof and a complementary sequence thereto; and
- b) in some embodiments, the kit also comprises reagents necessary for performing the hybridization reaction.

In a first preferred embodiment of this detection method and kit, said nucleic acid probe or the plurality of nucleic acid probes are labeled with a detectable molecule. In a second preferred embodiment of said method and kit, said nucleic acid probe or the plurality of nucleic acid probes has been immobilized on a substrate. In a third preferred embodiment, the nucleic acid probe or the plurality of nucleic acid probes comprise either a sequence which is selected from the group consisting of the nucleotide sequences of P1 to P58 and the complementary sequences thereto, B1 to B38, C1 to C38, D1 to D58, E1 to E58 or a biallelic marker selected from the group consisting of A1 to A58 and the complements thereto, preferably a nucleic acid comprising a polynucleotide selected from the group of the nucleotide sequences of P1 to P27, P34, P37 to P41, P43 to P49, P52, and P54 to P58, and the complementary sequences thereto, B1 to B15, B22, B24, B25, B27 to 29, B32, B34 to B38, C1 to C15, C22, C24, C25, C27 to 29, C32, C34 to C38, D1 to D27, D34, D37 to D41, D43 to D49, D52, D54 to D58, E1 to E27, E34, E37 to E41, E43 to E49, E52, and E54 to E58, or a biallelic marker selected from the group consisting of A1 to A27, A34, A37 to A41, A43 to A49, A52, and A54 to A58, and the complements thereof.

Oligonucleotide Arrays

A substrate comprising a plurality of oligonucleotide primers or probes of the invention may be used either for detecting or amplifying targeted sequences in the *BAP28* gene and may also be used for detecting mutations in the coding or in the non-coding sequences of the *BAP28* gene.

Any polynucleotide provided herein may be attached in overlapping areas or at random locations on the solid support. Alternatively the polynucleotides of the invention may be attached in an ordered array wherein each polynucleotide is attached to a distinct region of the solid support which does not overlap with the attachment site of any other polynucleotide. Preferably, such an ordered array of polynucleotides is designed to be "addressable" where the distinct locations are recorded and can be accessed as part of an assay procedure. Addressable polynucleotide arrays typically comprise a plurality of different oligonucleotide probes that are coupled to a surface of a substrate in different known locations. The knowledge of the precise location of each polynucleotides location makes these "addressable" arrays particularly useful in hybridization assays. Any addressable array technology known in the art can be employed with the polynucleotides of the invention. One particular embodiment of these polynucleotide arrays is known as the Genechips™, and has been generally described in US Patent 5,143,854; PCT publications WO 90/15070 and 92/10092. These arrays may generally be produced using mechanical synthesis methods or light directed synthesis methods which incorporate a combination of photolithographic methods and solid phase oligonucleotide synthesis (Fodor et al., 1991). The immobilization of arrays of oligonucleotides on solid supports has been rendered possible by the development of a technology generally identified as "Very Large Scale Immobilized Polymer Synthesis" (VLSIPSTM) in which, typically, probes are immobilized in a high density array on a solid surface of a chip. Examples of VLSIPSTM technologies are provided in US Patents 5,143,854; and 5,412,087 and in PCT Publications WO 90/15070, WO 92/10092 and WO 95/11995, which describe methods for forming oligonucleotide arrays through techniques such as light-directed synthesis techniques. In designing strategies aimed at providing arrays of nucleotides immobilized on solid supports, further presentation strategies were developed to order and display the oligonucleotide arrays on the chips in an attempt to maximize hybridization patterns and sequence information. Examples of such presentation strategies are disclosed in PCT Publications WO 94/12305, WO 94/11530, WO 97/29212 and WO 97/31256.

In another embodiment of the oligonucleotide arrays of the invention, an oligonucleotide probe matrix may advantageously be used to detect mutations occurring in the *BAP28* gene and in its regulatory region. For this particular purpose, probes are specifically designed to have a nucleotide sequence allowing their hybridization to the genes that carry known mutations (either by deletion, insertion or substitution of one or several nucleotides). By known mutations, it is meant, mutations on the *BAP28* gene that have been identified according, for example to the technique used by Huang et al.(1996) or Samson et al.(1996).

Another technique that is used to detect mutations in the *BAP28* gene is the use of a high-density DNA array. Each oligonucleotide probe constituting a unit element of the high density DNA array is designed to match a specific subsequence of the *BAP28* genomic DNA or cDNA. Thus, an array consisting of oligonucleotides complementary to subsequences of the target gene sequence is

used to determine the identity of the target sequence with the wild gene sequence, measure its amount, and detect differences between the target sequence and the reference wild gene sequence of the *BAP28* gene. In one such design, termed 4L tiled array, is implemented a set of four probes (A, C, G, T), preferably 15-nucleotide oligomers. In each set of four probes, the perfect complement will hybridize more strongly than mismatched probes. Consequently, a nucleic acid target of length L is scanned for mutations with a tiled array containing 4L probes, the whole probe set containing all the possible mutations in the known wild reference sequence. The hybridization signals of the 15-mer probe set tiled array are perturbed by a single base change in the target sequence. As a consequence, there is a characteristic loss of signal or a "footprint" for the probes flanking a mutation position. This technique was described by Chee et al. in 1996, which is herein incorporated by reference.

Consequently, the invention concerns an array of nucleic acid molecules comprising at least one polynucleotide described above as probes and primers. Preferably, the invention concerns an array of nucleic acid comprising at least two polynucleotides described above as probes and primers.

A further object of the invention consists of an array of nucleic acid sequences comprising either at least one of the sequences selected from the group consisting of P1 to P58, B1 to B38, C1 to C38, D1 to D58, E1 to E58, the sequences complementary thereto, a fragment thereof of at least 8, 10, 12, 15, 18, 20, 25, 30, or 40 consecutive nucleotides thereof, or at least one sequence comprising a biallelic marker selected from the group consisting of A1 to A58 and the complements thereto. preferably either at least one of the sequences selected from the group consisting of P1 to P27, P34, P37 to P41, P43 to P49, P52, P54 to P58, B1 to B15, B22, B24, B25, B27 to 29, B32, B34 to B38, C1 to C15, C22, C24, C25, C27 to 29, C32, C34 to C38, D1 to D27, D34, D37 to D41, D43 to D49, D52, D54 to D58, E1 to E27, E34, E37 to E41, E43 to E49, E52, and E54 to E58, or at least one sequence comprising a biallelic marker selected from the group consisting of A1 to A27, A34, A37 to A41, A43 to A49, A52, and A54 to A58, and the complements thereof.

The invention also pertains to an array of nucleic acid sequences comprising either at least two of the sequences selected from the group consisting of P1 to P58, B1 to B38, C1 to C38, D1 to D58, E1 to E58, the sequences complementary thereto, a fragment thereof of at least 8 consecutive nucleotides thereof, or at least two sequences comprising a biallelic marker selected from the group consisting of A1 to A58 and the complements thereof. preferably either at least two of the sequences selected from the group consisting of P1 to P27, P34, P37 to P41, P43 to P49, P52, P54 to P58, B1 to B15, B22, B24, B25, B27 to 29, B32, B34 to B38, C1 to C15, C22, C24, C25, C27 to 29, C32, C34 to C38, D1 to D27, D34, D37 to D41, D43 to D49, D52, D54 to D58, E1 to E27, E34, E37 to E41, E43 to E49, E52, and E54 to E58 or at least two sequences comprising a biallelic marker selected from the group consisting of A1 to A27, A34, A37 to A41, A43 to A49, A52, and A54 to A58, and the complements thereof.

Amplification of the *BAP28* gene.**1. DNA extraction**

As for the source of the genomic DNA to be subjected to analysis, any test sample can be foreseen without any particular limitation. These test samples include biological samples which can be tested by the methods of the present invention described herein and include human and animal body fluids such as whole blood, serum, plasma, cerebrospinal fluid, urine, lymph fluids, and various external secretions of the respiratory, intestinal and genitourinary tracts, tears, saliva, milk, white blood cells, myelomas and the like; biological fluids such as cell culture supernatants; fixed tissue specimens including tumor and non-tumor tissue and lymph node tissues; bone marrow aspirates and fixed cell specimens. The preferred source of genomic DNA used in the context of the present invention is from peripheral venous blood of each donor.

The techniques of DNA extraction are well-known to the skilled technician. Such techniques are described notably by Mackey et al. (1998).

2. DNA amplification

DNA amplification techniques are well-known to those skilled in the art. Amplification techniques that can be used in the context of the present invention include, but are not limited to, the ligase chain reaction (LCR) described in EP-A- 320 308, WO 9320227 and EP-A-439 182, the disclosures of which are incorporated herein by reference, the polymerase chain reaction (PCR, RT-PCR) and techniques such as the nucleic acid sequence based amplification (NASBA) described in Guatelli JC, et al. (1990) and in Compton J. (1991), Q-beta amplification as described in European Patent Application no 4544610, strand displacement amplification as described in Walker et al. (1996) and EP A 684 315 and, target mediated amplification as described in PCT Publication WO 9322461, the disclosure of which is incorporated herein by reference.

LCR and Gap LCR are exponential amplification techniques, both depend on DNA ligase to join adjacent primers annealed to a DNA molecule. In Ligase Chain Reaction (LCR), probe pairs are used which include two primary (first and second) and two secondary (third and fourth) probes, all of which are employed in molar excess to target. The first probe hybridizes to a first segment of the target strand and the second probe hybridizes to a second segment of the target strand, the first and second segments being contiguous so that the primary probes abut one another in 5' phosphate-3' hydroxyl relationship, and so that a ligase can covalently fuse or ligate the two probes into a fused product. In addition, a third (secondary) probe can hybridize to a portion of the first probe and a fourth (secondary) probe can hybridize to a portion of the second probe in a similar abutting fashion. Of course, if the target is initially double stranded, the secondary probes also will hybridize to the target complement in the first instance. Once the ligated strand of primary probes is separated from the target strand, it will hybridize with the third and fourth probes which can be ligated to form a complementary, secondary ligated product. It is important to realize that the ligated products are

functionally equivalent to either the target or its complement. By repeated cycles of hybridization and ligation, amplification of the target sequence is achieved. A method for multiplex LCR has also been described (WO 9320227). Gap LCR (GLCR) is a version of LCR where the probes are not adjacent but are separated by 2 to 3 bases.

5 For amplification of mRNAs, it is within the scope of the present invention to reverse transcribe mRNA into cDNA followed by polymerase chain reaction (RT-PCR); or, to use a single enzyme for both steps as described in U.S. Patent No 5,322,770 or, to use Asymmetric Gap LCR (RT-AGLCR) as described by Marshall et al. (1994). AGLCR is a modification of GLCR that allows the amplification of RNA.

10 The PCR technology is the preferred amplification technique used in the present invention. A variety of PCR techniques are familiar to those skilled in the art. For a review of PCR technology, see White (1997) and the publication entitled "PCR Methods and Applications" (1991, Cold Spring Harbor Laboratory Press). In each of these PCR procedures, PCR primers on either side of the nucleic acid sequences to be amplified are added to a suitably prepared nucleic acid
15 sample along with dNTPs and a thermostable polymerase such as Taq polymerase, Pfu polymerase, or Vent polymerase. The nucleic acid in the sample is denatured and the PCR primers are specifically hybridized to complementary nucleic acid sequences in the sample. The hybridized primers are extended. Thereafter, another cycle of denaturation, hybridization, and extension is initiated. The cycles are repeated multiple times to produce an amplified fragment containing the
20 nucleic acid sequence between the primer sites. PCR has further been described in several patents including US Patents 4,683,195, 4,683,202 and 4,965,188. Each of these publications is incorporated by reference.

One of the aspects of the present invention is a method for the amplification of the human *BAP28* gene, particularly of the genomic sequences of SEQ ID No 1 or of the cDNA sequence of
25 SEQ ID No 2, or a fragment or a variant thereof in a test sample, preferably using the PCR technology. The method comprises the steps of contacting a test sample suspected of containing the target *BAP28* encoding sequence or portion thereof with amplification reaction reagents comprising a pair of amplification primers, and eventually in some instances a detection probe that can hybridize with an internal region of amplicon sequences to confirm that the desired amplification reaction has
30 taken place.

Thus, the present invention also relates to a method for the amplification of a human *BAP28* gene sequence, particularly of a portion of the genomic sequences of SEQ ID No 1 or of the cDNA sequence of SEQ ID No 2, 3 or 4, or a variant thereof in a test sample, said method comprising the steps of:

35 a) contacting a test sample suspected of containing the targeted *BAP28* gene sequence comprised in a nucleotide sequence selected from a group consisting of SEQ ID Nos 1-4, or fragments or variants thereof with amplification reaction reagents comprising a pair of amplification

primers as described above and located on either side of the polynucleotide region to be amplified; and

b) in some embodiments, the method also comprises detecting the amplification products.

The invention also concerns a kit for the amplification of a human *BAP28* gene sequence, particularly of a portion of the genomic sequence of SEQ ID No 1 or of the cDNA sequence of SEQ ID No 2, 3 or 4, or a variant thereof in a test sample, wherein said kit comprises:

a) a pair of oligonucleotide primers located on either side of the *BAP28* region to be amplified; and

b) in some embodiments, the kit also comprises the reagents necessary for performing the amplification reaction.

In a first preferred embodiment of the above amplification method or kit, the amplification product is detected by hybridization with a labeled probe having a sequence which is complementary to the amplified region. In another embodiment of the above amplification method and kit, primers comprise a sequence which is selected from the group consisting of the nucleotide sequences of B1 to B38, C1 to C38, D1 to D58, and E1 to E58, preferably B1 to B15, B22, B24, B25, B27 to 29, B32, B34 to B38, C1 to C15, C22, C24, C25, C27 to 29, C32, C34 to C38, D1 to D27, D34, D37 to D41, D43 to D49, D52, D54 to D58, E1 to E27, E34, E37 to E41, E43 to E49, E52, and E54 to E58

The primers are more particularly characterized in that they have sufficient complementarity with any sequence of a strand of the genomic sequence close to the region to be amplified, for example with a non-coding sequence adjacent to exons to amplify.

BAP28 Proteins and Polypeptide Fragments:

The BAP28 protein has 2144 amino acids in length. This protein is highly conserved in various species such as *Drosophila melanogaster*, *Arabidopsis thaliana*, *Schizosaccharomyces pombe*, *Caenorhabditis elegans*, *Saccharomyces cerevisiae* and *Tetraodon nigroviridis*. The protein alignment between the human BAP28 and the proteins from *Drosophila melanogaster*, *Arabidopsis thaliana*, *Schizosaccharomyces pombe*, *Caenorhabditis elegans*, *Saccharomyces cerevisiae* is disclosed in the Figure 3. The protein alignment between the human BAP28 and the protein from *Tetraodon nigroviridis* is disclosed in the Figure 4. The BAP28 protein is also well conserved among the mammalian. Indeed, several ESTs with a good homology with the human BAP28 have been identified. Some examples of ESTs are the following (Genbank Accession Number/species) : AW423202/zebrafish ; AW481398/Bos taurus ; AW325866/Bos taurus ; AW353291/Bos taurus ; AW315340/Bos taurus ; AA681616/mouse ; AV120680/Mus musculus ; and, D77458/ mouse.

Analysis of the BAP28 protein sequence provided several potential phosphorylation sites and N-glycosylation sites in BAP28. More particularly, protein kinase C phosphorylation sites have been identified in positions 199-201, 269-271, 387-389, 415-417, 508-510, 650-652, 717-719, 778-780, 792-794, 884-886, 903-905, 999-1001, 1091-1093, 1349-1351, 1506-1508, 1573-1575, 1614-1616, 1632-1634, 1673-1675, 1743-1745, 1808-1810, 1829-1831, 1911-1913, and 2077-2079 of

SEQ ID No4; casein kinase II phosphorylation sites have been identified in positions 22-25, 50-53, 253-256, 363-366, 408-411, 409-412, 508-511, 539-542, 590-593, 689-692, 717-720, 745-748, 961-964, 979-982, 1091-1094, 1105-1108, 1195-1198, 1492-1495, 1723-1726, 1882-1885, 1972-1975, and 1981-1984 of SEQ ID No4. Otherwise, several potential N-glycosylation sites have been

5 identified in positions 93-96, 154-157, 776-779, 882-885, 1347-1350, 1488-1491, 1630-1633, 1746-1749, and 1970-1973 of SEQ ID No 5. A conserved HEAT_REPEAT motif has been identified in positions 2106-2139 of SEQ ID No 5. The HEAT_REPEAT motif are generally involved in protein-protein interaction. The PCT application WO98/12327 showed that BAP28 should be involved in interaction with BRCA1.

10 The term "BAP28 polypeptides" is used herein to embrace all of the proteins and polypeptides of the present invention. Also forming part of the invention are polypeptides encoded by the polynucleotides of the invention, as well as fusion polypeptides comprising such polypeptides. The invention embodies BAP28 proteins from humans, including isolated or purified BAP28 proteins consisting, consisting essentially, or comprising the sequence of SEQ ID No 5 or

15 fragments thereof. The present invention also embodies isolated, purified, and recombinant polypeptides comprising a contiguous span of at least 6 amino acids, preferably at least 8 to 10 amino acids, more preferably at least 12, 15, 20, 25, 30, 40, 50, or 100 amino acids of SEQ ID No 5, wherein said contiguous span includes at least 1, 2, 3, 5 or 10 of the amino acid positions 1 to 1629 of the SEQ ID No 5. The present invention also embodies isolated, purified, and recombinant

20 polypeptides comprising a contiguous span of at least 6 amino acids, preferably at least 8 to 10 amino acids, more preferably at least 12, 15, 20, 25, 30, 40, 50, or 100 amino acids of SEQ ID No 5, wherein said contiguous span include an amino acid selected from the group consisting of an asparagine at the amino acid position 1694 of SEQ ID No 5, a valine at the amino acid position 1854 of SEQ ID No 5, an asparagine at the amino acid position 1967 of SEQ ID No 5, a glutamic acid at

25 the amino acid position 2017 of SEQ ID No 5, and an alanine at the amino acid position 2050 of SEQ ID No 5. In other preferred embodiments the BAP28 protein contains an alanine residue at amino acid position 2050 in SEQ ID No 5.

Four biallelic markers of the present invention, namely A16, A19, A21 and A25, provide an amino acid sequence change. Indeed, the biallelic marker A16 encodes a Ser or Asn residue at the

30 position 1694 of the BAP28 protein; the biallelic marker A19 encodes a Ala or Val residue at the position 1854 of the BAP28 protein; the biallelic marker A21 encodes a Asp or Asn at the position 1967 of the BAP28 protein; and the biallelic marker A25 encodes a Gly or Glu at the position 2017 of the BAP28 protein. The invention encompasses the BAP28 proteins comprising all the combinations of the above-described residues at the positions 1694, 1854, 1967, and 2017.

35 The variant protein and fragments thereof which contain an asparagine at the amino acid position 1694 of SEQ ID No 5 are collectively referred to herein as "1694-Asn variants". The variant protein and fragments thereof which contain a valine at the amino acid position 1854 of SEQ ID No

5 are collectively referred to herein as "1854-Val variants". The variant protein and fragments thereof which contain an asparagine at the amino acid position 1967 of SEQ ID No 5 are collectively referred to herein as "1967-Asn variants". The variant protein and fragments thereof which contain a glutamic acid at the amino acid position 2017 of SEQ ID No 5 are collectively referred to herein as "2017-Glu variants". The variant protein and fragments thereof which contain an alanine at the amino acid position 2050 of SEQ ID No 5 are collectively referred to herein as "2050-Ala variants". In other preferred embodiments of the polypeptides of the present invention, the contiguous stretch of amino acids comprises the site of a mutation or functional mutation, including a deletion, addition, swap or truncation of the amino acids in the BAP28 protein sequence.

10 The invention also encompasses a purified, isolated, or recombinant polypeptide comprising an amino acid sequence having at least 70, 75, 80, 85, 90, 95, 98 or 99% amino acid identity with the amino acid sequence of SEQ ID No 5 or a fragment thereof.

The invention concerns the polypeptide which are encoded by a nucleic acid comprising a sequence selected from the group consisting of the sequence SEQ ID Nos 1-3 or fragments thereof.

15 BAP28 proteins are preferably isolated from human or mammalian tissue samples or expressed from human or mammalian genes. The BAP28 polypeptides of the invention can be made using routine expression methods known in the art. The polynucleotide encoding the desired polypeptide is ligated into an expression vector suitable for any convenient host. Both eukaryotic and prokaryotic host systems may be used in forming recombinant polypeptides, and a summary of some of the more common systems. The polypeptide is then isolated from lysed cells or from the culture medium and purified to the extent needed for its intended use. Purification is by any technique known in the art, for example, differential extraction, salt fractionation, chromatography, centrifugation, and the like. See, for example, Methods in Enzymology for a variety of methods for purifying proteins.

25 In addition, shorter protein fragments is produced by chemical synthesis. Alternatively the proteins of the invention is extracted from cells or tissues of humans or non-human animals. Methods for purifying proteins are known in the art, and include the use of detergents or chaotropic agents to disrupt particles followed by differential extraction and separation of the polypeptides by ion exchange chromatography, affinity chromatography, sedimentation according to density, and gel electrophoresis.

30 Any *BAP28* cDNA, including SEQ ID Nos 2 and 3, or fragments thereof is used to express BAP28 proteins and polypeptides. The nucleic acid encoding the BAP28 protein or fragments thereof to be expressed is operably linked to a promoter in an expression vector using conventional cloning technology. The *BAP28* insert in the expression vector may comprise the full coding sequence for the BAP28 protein or a portion thereof. For example, the *BAP28* derived insert may encode a polypeptide comprising at least 10 consecutive amino acids of the BAP28 protein of SEQ ID No 5, wherein said

contiguous span includes at least 1, 2, 3, 5 or 10 of the amino acid positions 1 to 1629 of the SEQ ID No 5, or wherein polypeptide is a 2050-Ala variant BAP28 polypeptide.

The expression vector is any of the mammalian, yeast, insect or bacterial expression systems known in the art. Commercially available vectors and expression systems are available from a variety of suppliers including Genetics Institute (Cambridge, MA), Stratagene (La Jolla, California), Promega (Madison, Wisconsin), and Invitrogen (San Diego, California). If desired, to enhance expression and facilitate proper protein folding, the codon context and codon pairing of the sequence is optimized for the particular expression organism in which the expression vector is introduced, as explained by Hatfield, et al., U.S. Patent No 5,082,767.

- 10 In one embodiment, the entire coding sequence of the *BAP28* cDNA through the poly A signal of the cDNA are operably linked to a promoter in the expression vector. Alternatively, if the nucleic acid encoding a portion of the *BAP28* protein lacks a methionine to serve as the initiation site, an initiating methionine can be introduced next to the first codon of the nucleic acid using conventional techniques. Similarly, if the insert from the *BAP28* cDNA lacks a poly A signal, this sequence can be added to the construct by, for example, splicing out the Poly A signal from pSG5 (Stratagene) using BglII and SalI restriction endonuclease enzymes and incorporating it into the mammalian expression vector pXT1 (Stratagene). pXT1 contains the LTRs and a portion of the gag gene from Moloney Murine Leukemia Virus. The position of the LTRs in the construct allow efficient stable transfection. The vector includes the Herpes Simplex Thymidine Kinase promoter and the selectable neomycin gene.
- 20 The nucleic acid encoding the *BAP28* protein or a portion thereof is obtained by PCR from a bacterial vector containing the *BAP28* cDNA of SEQ ID No 2 or 3 using oligonucleotide primers complementary to the *BAP28* cDNA or portion thereof and containing restriction endonuclease sequences for Pst I incorporated into the 5' primer and BglIII at the 5' end of the corresponding cDNA 3' primer, taking care to ensure that the sequence encoding the *BAP28* protein or a portion thereof is positioned properly with respect to the poly A signal. The purified fragment obtained from the resulting PCR reaction is digested with PstI, blunt ended with an exonuclease, digested with Bgl II, purified and ligated to pXT1, now containing a poly A signal and digested with BglIII.
- 25

- The ligated product is transfected into mouse NIH 3T3 cells using Lipofectin (Life Technologies, Inc., Grand Island, New York) under conditions outlined in the product specification.
- 30 Positive transfectants are selected after growing the transfected cells in 600ug/ml G418 (Sigma, St. Louis, Missouri).

Alternatively, the nucleic acids encoding the *BAP28* protein or a portion thereof is cloned into pED6dpc2 (Genetics Institute, Cambridge, MA). The resulting pED6dpc2 constructs is transfected into a suitable host cell, such as COS 1 cells. Methotrexate resistant cells are selected and expanded.

- 35 The above procedures may also be used to express a mutant *BAP28* protein responsible for a detectable phenotype or a portion thereof.

The expressed proteins are purified using conventional purification techniques such as ammonium sulfate precipitation or chromatographic separation based on size or charge. The protein encoded by the nucleic acid insert may also be purified using standard immunochromatography techniques. In such procedures, a solution containing the expressed BAP28 protein or portion thereof, such as a cell extract, is applied to a column having antibodies against the BAP28 protein or portion thereof is attached to the chromatography matrix. The expressed protein is allowed to bind the immunochromatography column. Thereafter, the column is washed to remove non-specifically bound proteins. The specifically bound expressed protein is then released from the column and recovered using standard techniques.

To confirm expression of the BAP28 protein or a portion thereof, the proteins expressed from host cells containing an expression vector containing an insert encoding the BAP28 protein or a portion thereof can be compared to the proteins expressed in host cells containing the expression vector without an insert. The presence of a band in samples from cells containing the expression vector with an insert which is absent in samples from cells containing the expression vector without an insert indicates that the BAP28 protein or a portion thereof is being expressed. Generally, the band will have the mobility expected for the BAP28 protein or portion thereof. However, the band may have a mobility different than that expected as a result of modifications such as glycosylation, ubiquitination, or enzymatic cleavage.

Antibodies capable of specifically recognizing the expressed BAP28 protein or a portion thereof are described below.

If antibody production is not possible, the nucleic acids encoding the BAP28 protein or a portion thereof is incorporated into expression vectors designed for use in purification schemes employing chimeric polypeptides. In such strategies the nucleic acid encoding the BAP28 protein or a portion thereof is inserted in frame with the gene encoding the other half of the chimera. The other half of the chimera is β -globin or a nickel binding polypeptide encoding sequence. A chromatography matrix having antibody to β -globin or nickel attached thereto is then used to purify the chimeric protein. Protease cleavage sites is engineered between the β -globin gene or the nickel binding polypeptide and the BAP28 protein or portion thereof. Thus, the two polypeptides of the chimera is separated from one another by protease digestion.

One useful expression vector for generating β -globin chimerics is pSG5 (Stratagene), which encodes rabbit β -globin. Intron II of the rabbit β -globin gene facilitates splicing of the expressed transcript, and the polyadenylation signal incorporated into the construct increases the level of expression. These techniques are well known to those skilled in the art of molecular biology. Standard methods are published in methods texts such as Davis et al., (1986) and many of the methods are available from Stratagene, Life Technologies, Inc., or Promega. Polypeptide may additionally be produced from the construct using in vitro translation systems such as the In vitro ExpressTM Translation Kit (Stratagene).

Antibodies That Bind BAP28 Polypeptides of the Invention

Any BAP28 polypeptide or whole protein may be used to generate antibodies capable of specifically binding to expressed BAP28 protein or fragments thereof as described. The antibody compositions of the invention are capable of specifically binding or specifically bind to the BAP28 protein. For an antibody composition to specifically bind to the BAP28 protein it must demonstrate at least a 5%, 10%, 15%, 20%, 25%, 50%, or 100% greater binding affinity for full length BAP28 protein than for any full length protein in an ELISA, RIA, or other antibody-based binding assay. For an antibody composition to specifically bind to the 1694-Asn, 1854-Val, 1967-Asn, 2017-Glu, or 2050-Ala variant BAP28 protein, it must demonstrate at least a 5%, 10%, 15%, 20%, 25%, 50%, or 100% greater binding affinity for full length 1694-Asn, 1854-Val, 1967-Asn, 2017-Glu, or 2050-Ala variant BAP28 protein than for respectively a 1694-Ser, 1854-Ala, 1967-Asp, 2017-Gly or 2050-Val full length protein in an ELISA, RIA, or other antibody-based binding assay. The present invention also contemplates the antibodies which are specific of a protein BAP28 comprising one combination of the above-described residues at the positions 1694, 1854, 1967, and 2017.

In a preferred embodiment of the invention antibody compositions are capable of selectively binding, or selectively bind to an epitope-containing fragment of a polypeptide comprising a contiguous span of at least 6 amino acids, preferably at least 8 to 10 amino acids, more preferably at least 12, 15, 20, 25, 30, 40, 50, or 100 amino acids of SEQ ID No 5, wherein said epitope comprises at least 1, 2, 3, 5 or 10 of the amino acid positions selected from the group consisting of 1 to 1629 and 2050 of SEQ ID No 5, wherein said antibody composition is optionally either polyclonal or monoclonal. In a other preferred embodiment, antibody compositions are capable of selectively binding, or selectively bind to an epitope-containing fragment of a polypeptide comprising a contiguous span of at least 6 amino acids, preferably at least 8 to 10 amino acids, more preferably at least 12, 15, 20, 25, 30, 40, 50, or 100 amino acids of SEQ ID No 5, wherein said epitope comprises an amino acid selected from the group consisting of an asparagine at the amino acid position 1694 of SEQ ID No 5, a valine at the amino acid position 1854 of SEQ ID No 5, an asparagine at the amino acid position 1967 of SEQ ID No 5, a glutamic acid at the amino acid position 2017 of SEQ ID No 5, and an alanine at the amino acid position 2050 of SEQ ID No 5, wherein said antibody composition is optionally either polyclonal or monoclonal.

The present invention also contemplates the use of polypeptides comprising a contiguous span of at least 6 amino acids, preferably at least 8 to 10 amino acids, more preferably at least 12, 15, 20, 25, 50, or 100 amino acids of a BAP28 polypeptide in the manufacture of antibodies, wherein said contiguous span comprises at least 1, 2, 3, 5 or 10 of the amino acid positions selected from the group consisting of 1 to 1629 of SEQ ID No 5. The present invention further contemplates the use of polypeptides comprising a contiguous span of at least 6 amino acids, preferably at least 8 to 10 amino acids, more preferably at least 12, 15, 20, 25, 50, or 100 amino acids of a BAP28 polypeptide in the manufacture of antibodies, wherein said contiguous span comprises an amino acid

selected from the group consisting of an asparagine at the amino acid position 1694 of SEQ ID No 5, a valine at the amino acid position 1854 of SEQ ID No 5, an asparagine at the amino acid position 1967 of SEQ ID No 5, a glutamic acid at the amino acid position 2017 of SEQ ID No 5, and an alanine at the amino acid position 2050 of SEQ ID No 5. In a preferred embodiment such

- 5 polypeptides are useful in the manufacture of antibodies to detect the presence and absence of the BAP28 protein.

Non-human animals or mammals, whether wild-type or transgenic, which express a different species of BAP28 than the one to which antibody binding is desired, and animals which do not express BAP28 (i.e. a BAP28 knock out animal as described in herein) are particularly useful for
10 preparing antibodies. BAP28 knock out animals will recognize all or most of the exposed regions of BAP28 as foreign antigens, and therefore produce antibodies with a wider array of BAP28 epitopes. Moreover, smaller polypeptides with only 10 to 30 amino acids may be useful in obtaining specific binding to the BAP28 protein. In addition, the humoral immune system of animals which produce a species of BAP28 that resembles the antigenic sequence will preferentially recognize the differences
15 between the animal's native BAP28 species and the antigen sequence, and produce antibodies to these unique sites in the antigen sequence. Such a technique will be particularly useful in obtaining antibodies that specifically bind to the BAP28 protein.

Antibody preparations prepared according to either protocol are useful in quantitative immunoassays which determine concentrations of antigen-bearing substances in biological samples;
20 they are also used semi-quantitatively or qualitatively to identify the presence of antigen in a biological sample. The antibodies may also be used in therapeutic compositions for killing cells expressing the protein or reducing the levels of the protein in the body.

The antibodies of the invention may be labeled, either by a radioactive, a fluorescent or an enzymatic label.

- 25 Consequently, the invention is also directed to a method for detecting specifically the presence of a human BAP28 polypeptide according to the invention in a biological sample, said method comprising the following steps:

a) bringing into contact the biological sample with a polyclonal or monoclonal antibody directed against the BAP28 polypeptide of the amino acid sequence of SEQ ID No 5, or to a peptide
30 fragment or variant thereof;

b) detecting the antigen-antibody complex formed.

The invention also concerns a diagnostic kit for detecting *in vitro* the presence of a human BAP28 polypeptide according to the present invention in a biological sample, wherein said kit comprises :

- 35 a) a polyclonal or monoclonal antibody directed against the BAP28 polypeptide of the amino acid sequence of SEQ ID No 5, or to a peptide fragment or variant thereof. In some embodiments, the antibody may be labeled;

b) a reagent allowing the detection of the antigen-antibody complexes formed, said reagent optionally being labelled, or being able to be recognized itself by a labeled reagent, more particularly in the case when the above-mentioned monoclonal or polyclonal antibody is not labeled by itself.

***BAP28* -related Biallelic Markers**

Advantages Of The Biallelic Markers Of The Present Invention

The *BAP28*-related biallelic markers of the present invention offer a number of important advantages over other genetic markers such as RFLP (Restriction fragment length polymorphism) and VNTR (Variable Number of Tandem Repeats) markers.

The first generation of markers, were RFLPs, which are variations that modify the length of a restriction fragment. But methods used to identify and to type RFLPs are relatively wasteful of materials, effort, and time. The second generation of genetic markers were VNTRs, which can be categorized as either minisatellites or microsatellites. Minisatellites are tandemly repeated DNA sequences present in units of 5-50 repeats which are distributed along regions of the human chromosomes ranging from 0.1 to 20 kilobases in length. Since they present many possible alleles, their informative content is very high. Minisatellites are scored by performing Southern blots to identify the number of tandem repeats present in a nucleic acid sample from the individual being tested. However, there are only 10^4 potential VNTRs that can be typed by Southern blotting. Moreover, both RFLP and VNTR markers are costly and time-consuming to develop and assay in large numbers.

Single nucleotide polymorphism or biallelic markers can be used in the same manner as RFLPs and VNTRs but offer several advantages. SNP are densely spaced in the human genome and represent the most frequent type of variation. An estimated number of more than 10^7 sites are scattered along the 3×10^9 base pairs of the human genome. Therefore, SNP occur at a greater frequency and with greater uniformity than RFLP or VNTR markers which means that there is a greater probability that such a marker will be found in close proximity to a genetic locus of interest. SNP are less variable than VNTR markers but are mutationally more stable.

Also, the different forms of a characterized single nucleotide polymorphism, such as the biallelic markers of the present invention, are often easier to distinguish and can therefore be typed easily on a routine basis. Biallelic markers have single nucleotide based alleles and they have only two common alleles, which allows highly parallel detection and automated scoring. The biallelic markers of the present invention offer the possibility of rapid, high throughput genotyping of a large number of individuals.

Biallelic markers are densely spaced in the genome, sufficiently informative and can be assayed in large numbers. The combined effects of these advantages make biallelic markers extremely valuable in genetic studies. Biallelic markers can be used in linkage studies in families, in allele sharing methods, in linkage disequilibrium studies in populations, in association studies of

case-control populations or of trait positive and trait negative populations. An important aspect of the present invention is that biallelic markers allow association studies to be performed to identify genes involved in complex traits. Association studies examine the frequency of marker alleles in unrelated case- and control-populations and are generally employed in the detection of polygenic or sporadic traits. Association studies may be conducted within the general population and are not limited to studies performed on related individuals in affected families (linkage studies). Biallelic markers in different genes can be screened in parallel for direct association with disease or response to a treatment. This multiple gene approach is a powerful tool for a variety of human genetic studies as it provides the necessary statistical power to examine the synergistic effect of multiple genetic factors on a particular phenotype, drug response, sporadic trait, or disease state with a complex genetic etiology.

Although most valuable in association studies, the biallelic markers of the present invention can have a wide range of uses, and may for example also be used in forensic identification of individual humans, such as for identification of descendants, determination of paternity, criminal identification, and the like. For example, a DNA sample is obtained from a person or from a cellular sample (e.g., crime scene evidence such as blood, saliva, semen, and the like) and the identity of the allele present at any one or preferably multiple biallelic markers is determined according to any of the detection methods described herein. On the basis of the allele(s) present at the specified positions, the individual from which the sample originated will be identified with respect to his/her genotype. The biallelic markers of the invention may be used alone or in conjunction with other genetic markers, including RFLP and VNTR to conclusively identify an individual or to rule out the individual as a possible perpetrator.

BAP28-Related Biallelic Markers And Polynucleotides Related Thereto

The invention also concerns *BAP28*-related biallelic markers. A portion of the biallelic markers of the present invention designated A1 to A58 are disclosed in Table 2, including their location on the *BAP28* gene. These biallelic markers are also each listed as a single base polymorphism in the features of SEQ ID No 1.

The invention also relates to a purified and/or isolated nucleotide sequence comprising a polymorphic base of a *BAP28*-related biallelic marker, preferably of a biallelic marker selected from the group consisting of A1 to A58, more preferably one of the biallelic markers A1 to A27, A34, A37 to A41, A43 to A49, A52, and A54 to A58, still more preferably one of the biallelic markers A1, A4, 16, A30, A31, A42, A50, A51, and A53, and the complements thereof. The sequence has between 8 and 1000 nucleotides in length, and preferably comprises at least 8, 10, 12, 15, 18, 20, 25, 35, 40, 50, 60, 70, 80, 100, 250, 500 or 1000 contiguous nucleotides of a nucleotide sequence selected from the group consisting of SEQ ID Nos 1, 2 or 3, or a variant thereof or a complementary sequence thereto. These nucleotide sequences comprise the polymorphic base of either allele 1 or

allele 2 of the respective biallelic marker. In some embodiments, said biallelic marker may be within 6, 5, 4, 3, 2, or 1 nucleotides of the center of said polynucleotide or at the center of said polynucleotide. In some embodiments, the 3' end of said contiguous span may be present at the 3' end of said polynucleotide. In some embodiments, a *BAP28*-related biallelic marker biallelic marker
5 may be present at the 3' end of said polynucleotide. In some embodiments, the 3' end of said polynucleotide may be located within or at least 2, 4, 6, 8, 10, 12, 15, 18, 20, 25, 50, 100, 250, 500, or 1000 nucleotides upstream of a *BAP28*-related biallelic marker in said sequence. In some
embodiments, the 3' end of said polynucleotide may be located 1 nucleotide upstream of a *BAP28*-related biallelic marker in said sequence. In some embodiments, said polynucleotide may further
10 comprise a label. In some embodiments, said polynucleotide can be attached to solid support. In a further embodiment, the polynucleotides defined above can be used alone or in any combination.

The invention further concerns a nucleic acid encoding the *BAP28* protein, wherein said nucleic acid comprises a polymorphic base of a biallelic marker selected from the group consisting of A1 to A58 and the complements thereof, preferably A1 to A27, A34, A37 to A41, A43 to A49,
15 A52, and A54 to A58.

The invention also encompasses the use of any polynucleotide for, or any polynucleotide for use in, determining the identity of one or more nucleotides at a *BAP28*-related biallelic marker. In addition, the polynucleotides of the invention for use in determining the identity of one or more nucleotides at a *BAP28*-related biallelic marker encompass polynucleotides with any further
20 limitation described in this disclosure, or those following, specified alone or in any combination. In some embodiments, said *BAP28*-related biallelic marker is selected from the group consisting of A1 to A58, and the complements thereof, or the biallelic markers in linkage disequilibrium therewith; In some embodiments, said *BAP28*-related biallelic marker is selected from the group consisting of A1 to A27, A34, A37 to A41, A43 to A49, A52, and A54 to A58, and the complements thereof, or
25 the biallelic markers in linkage disequilibrium therewith; In some embodiments, said *BAP28*-related biallelic marker is selected from the group consisting of A1, A4, 16, A30, A31, A42, A50, A51, and A53, and the complements thereof, or the biallelic markers in linkage disequilibrium therewith; In some embodiments, said polynucleotide may comprise a sequence disclosed in the present specification; In some embodiments, said polynucleotide may comprise, consist of, or consist
30 essentially of any polynucleotide described in the present specification; In some embodiments, said determining may be performed in a hybridization assay, sequencing assay, microsequencing assay, or an enzyme-based mismatch detection assay; In some embodiments, said polynucleotide may be attached to a solid support, array, or addressable array; In some embodiments, said polynucleotide may be labeled. A preferred polynucleotide may be used in a hybridization assay for determining
35 the identity of the nucleotide at a *BAP28*-related biallelic marker. Another preferred polynucleotide may be used in a sequencing or microsequencing assay for determining the identity of the nucleotide at a *BAP28*-related biallelic marker. A third preferred polynucleotide may be used in an enzyme-

based mismatch detection assay for determining the identity of the nucleotide at a *BAP28*-related biallelic marker. A fourth preferred polynucleotide may be used in amplifying a segment of polynucleotides comprising a *BAP28*-related biallelic marker. In some embodiments, any of the polynucleotides described above may be attached to a solid support, array, or addressable array; In
5 some embodiments, said polynucleotide may be labeled.

Additionally, the invention encompasses the use of any polynucleotide for, or any polynucleotide for use in, amplifying a segment of nucleotides comprising a *BAP28*-related biallelic marker. In addition, the polynucleotides of the invention for use in amplifying a segment of nucleotides comprising a *BAP28*-related biallelic marker encompass polynucleotides with any
10 further limitation described in this disclosure, or those following, specified alone or in any combination: In some embodiments, said *BAP28*-related biallelic marker is selected from the group consisting of A1 to A58, and the complements thereof, or the biallelic markers in linkage disequilibrium therewith; In some embodiments, wherein said *BAP28*-related biallelic marker is selected from the group consisting of A1 to A27, A34, A37 to A41, A43 to A49, A52, and A54 to
15 A58, and the complements thereof, or the biallelic markers in linkage disequilibrium therewith; In some embodiments, said *BAP28*-related biallelic marker is selected from the group consisting of A1, A4, 16, A30, A31, A42, A50, A51, and A53, and the complements thereof, or the biallelic markers in linkage disequilibrium therewith; In some embodiments, said polynucleotide may comprise a sequence disclosed in the present specification; In some embodiments, said polynucleotide may
20 comprise, consist of, or consist essentially of any polynucleotide described in the present specification; In some embodiments, said amplifying may be performed by a PCR or LCR. In some embodiments, said polynucleotide may be attached to a solid support, array, or addressable array. In some embodiments, said polynucleotide may be labeled.

The primers for amplification or sequencing reaction of a polynucleotide comprising a
25 biallelic marker of the invention may be designed from the disclosed sequences for any method known in the art. A preferred set of primers are fashioned such that the 3' end of the contiguous span of identity with a sequence selected from the group consisting of SEQ ID Nos 1, 2 or 3, or a sequence complementary thereto or a variant thereof is present at the 3' end of the primer. Such a configuration allows the 3' end of the primer to hybridize to a selected nucleic acid sequence and
30 dramatically increases the efficiency of the primer for amplification or sequencing reactions. Allele specific primers may be designed such that a polymorphic base of a biallelic marker is at the 3' end of the contiguous span and the contiguous span is present at the 3' end of the primer. Such allele specific primers tend to selectively prime an amplification or sequencing reaction so long as they are used with a nucleic acid sample that contains one of the two alleles present at a biallelic marker.
35 The 3' end of the primer of the invention may be located within or at least 2, 4, 6, 8, 10, 12, 15, 18, 20, 25, 50, 100, 250, 500, or 1000 nucleotides upstream of a *BAP28*-related biallelic marker in said sequence or at any other location which is appropriate for their intended use in sequencing,

amplification or the location of novel sequences or markers. Thus, another set of preferred amplification primers comprise an isolated polynucleotide consisting essentially of a contiguous span of 8 to 50 nucleotides in a sequence selected from the group consisting of SEQ ID Nos 1, 2 or 3 or a sequence complementary thereto or a variant thereof, wherein the 3' end of said contiguous span

- 5 is located at the 3' end of said polynucleotide, and wherein the 3' end of said polynucleotide is located upstream of a *BAP28*-related biallelic marker in said sequence. Preferably, those amplification primers comprise a sequence selected from the group consisting of the sequences B1 to B38 and C1 to C38, preferably B1 to B15, B22, B24, B25, B27 to 29, B32, B34 to B38, C1 to C15, C22, C24, C25, C27 to 29, C32, and C34 to C38. Primers with their 3' ends located 1
10 nucleotide upstream of a biallelic marker of *BAP28* have a special utility as microsequencing assays. Preferred microsequencing primers are described in Table 4. In some embodiments, microsequencing primers are selected from the group consisting of the nucleotide sequences D1 to D58 and E1 to E58, preferably D1 to D27, D34, D37 to D41, D43 to D49, D52, D54 to D58, E1 to E27, E34, E37 to E41, E43 to E49, E52, and E54 to E58.

- 15 The probes of the present invention may be designed from the disclosed sequences for any method known in the art, particularly methods which allow for testing if a marker disclosed herein is present. A preferred set of probes may be designed for use in the hybridization assays of the invention in any manner known in the art such that they selectively bind to one allele of a biallelic marker, but not the other under any particular set of assay conditions. Preferred hybridization
20 probes comprise the polymorphic base of either allele 1 or allele 2 of the considered biallelic marker. In some embodiments, said biallelic marker may be within 6, 5, 4, 3, 2, or 1 nucleotides of the center of the hybridization probe or at the center of said probe. In a preferred embodiment, the probes are selected in the group consisting of the sequences P1 to P58 and the complementary sequence thereto (Table 3), preferably P1 to P27, P34, P37 to P41, P43 to P49, P52, and P54 to P58.

- 25 It should be noted that the polynucleotides of the present invention are not limited to having the exact flanking sequences surrounding the polymorphic bases which are enumerated in Sequence Listing. Rather, it will be appreciated that the flanking sequences surrounding the biallelic markers may be lengthened or shortened to any extent compatible with their intended use and the present invention specifically contemplates such sequences. The flanking regions outside of the
30 contiguous span need not be homologous to native flanking sequences which actually occur in human subjects. The addition of any nucleotide sequence which is compatible with the nucleotides intended use is specifically contemplated.

- Primers and probes may be labeled or immobilized on a solid support as described in "Oligonucleotide probes and primers". The polynucleotides of the invention which are attached to a
35 solid support encompass polynucleotides with any further limitation described in this disclosure, or those following, specified alone or in any combination: In some embodiments, said polynucleotides may be specified as attached individually or in groups of at least 2, 5, 8, 10, 12, 15, 20, or 25 distinct

polynucleotides of the invention to a single solid support. In some embodiments, polynucleotides other than those of the invention may be attached to the same solid support as polynucleotides of the invention. In some embodiments, when multiple polynucleotides are attached to a solid support they may be attached at random locations, or in an ordered array. In some embodiments, said ordered array may be addressable.

The present invention also encompasses diagnostic kits comprising one or more polynucleotides of the invention with a portion or all of the necessary reagents and instructions for genotyping a test subject by determining the identity of a nucleotide at a *BAP28*-related biallelic marker. The polynucleotides of a kit may optionally be attached to a solid support, or be part of an array or addressable array of polynucleotides. The kit may provide for the determination of the identity of the nucleotide at a marker position by any method known in the art including, but not limited to, a sequencing assay method, a microsequencing assay method, a hybridization assay method, or an enzyme-based mismatch detection assay method.

Methods For *De Novo* Identification Of Biallelic Markers

Any of a variety of methods can be used to screen a genomic fragment for single nucleotide polymorphisms such as differential hybridization with oligonucleotide probes, detection of changes in the mobility measured by gel electrophoresis or direct sequencing of the amplified nucleic acid. A preferred method for identifying biallelic markers involves comparative sequencing of genomic DNA fragments from an appropriate number of unrelated individuals.

In a first embodiment, DNA samples from unrelated individuals are pooled together, following which the genomic DNA of interest is amplified and sequenced. The nucleotide sequences thus obtained are then analyzed to identify significant polymorphisms. One of the major advantages of this method resides in the fact that the pooling of the DNA samples substantially reduces the number of DNA amplification reactions and sequencing reactions, which must be carried out. Moreover, this method is sufficiently sensitive so that a biallelic marker obtained thereby usually demonstrates a sufficient frequency of its less common allele to be useful in conducting association studies.

In a second embodiment, the DNA samples are not pooled and are therefore amplified and sequenced individually. This method is usually preferred when biallelic markers need to be identified in order to perform association studies within candidate genes. Preferably, highly relevant gene regions such as promoter regions or exon regions may be screened for biallelic markers. A biallelic marker obtained using this method may show a lower degree of informativeness for conducting association studies, e.g. if the frequency of its less frequent allele may be less than about 10%. Such a biallelic marker will, however, be sufficiently informative to conduct association studies and it will further be appreciated that including less informative biallelic markers in the genetic analysis studies of the present invention, may allow in some cases the direct identification of causal mutations, which may, depending on their penetrance, be rare mutations.

The following is a description of the various parameters of a preferred method used by the inventors for the identification of the biallelic markers of the present invention.

Genomic DNA Samples

The genomic DNA samples from which the biallelic markers of the present invention are generated are preferably obtained from unrelated individuals corresponding to a heterogeneous population of known ethnic background. The number of individuals from whom DNA samples are obtained can vary substantially, preferably from about 10 to about 1000, preferably from about 50 to about 200 individuals. It is usually preferred to collect DNA samples from at least about 100 individuals in order to have sufficient polymorphic diversity in a given population to identify as many markers as possible and to generate statistically significant results.

As for the source of the genomic DNA to be subjected to analysis, any test sample can be foreseen without any particular limitation. These test samples include biological samples, which can be tested by the methods of the present invention described herein, and include human and animal body fluids such as whole blood, serum, plasma, cerebrospinal fluid, urine, lymph fluids, and various external secretions of the respiratory, intestinal and genitourinary tracts, tears, saliva, milk, white blood cells, myelomas and the like; biological fluids such as cell culture supernatants; fixed tissue specimens including tumor and non-tumor tissue and lymph node tissues; bone marrow aspirates and fixed cell specimens. The preferred source of genomic DNA used in the present invention is from peripheral venous blood of each donor. Techniques to prepare genomic DNA from biological samples are well known to the skilled technician. Details of a preferred embodiment are provided in Example 1. The person skilled in the art can choose to amplify pooled or unpooled DNA samples.

DNA Amplification

The identification of biallelic markers in a sample of genomic DNA may be facilitated through the use of DNA amplification methods. DNA samples can be pooled or unpooled for the amplification step. DNA amplification techniques are well known to those skilled in the art. Various methods to amplify DNA fragments carrying biallelic markers are further described hereinbefore in "Amplification of the *BAP28* gene". The PCR technology is the preferred amplification technique used to identify new biallelic markers. A typical example of a PCR reaction suitable for the purposes of the present invention is provided in Example 2.

In a first embodiment of the present invention, biallelic markers are identified using genomic sequence information generated by the inventors. Sequenced genomic DNA fragments are used to design primers for the amplification of 500 bp fragments. These 500 bp fragments are amplified from genomic DNA and are scanned for biallelic markers. Primers may be designed using the OSP software (Hillier L. and Green P., 1991). All primers may contain, upstream of the specific

target bases, a common oligonucleotide tail that serves as a sequencing primer. Those skilled in the art are familiar with primer extensions, which can be used for these purposes.

- Preferred primers, useful for the amplification of genomic sequences encoding the candidate genes, focus on promoters, exons and splice sites of the genes. A biallelic marker presents a higher probability to be an eventual causal mutation if it is located in these functional regions of the gene. Preferred amplification primers of the invention include the nucleotide sequences B1 to B38 and C1 to C38, preferably B1 to B15, B22, B24, B25, B27 to 29, B32, B34 to B38, C1 to C15, C22, C24, C25, C27 to 29, C32, and C34 to C38, detailed further in Example 2, Table 1.

Sequencing Of Amplified Genomic DNA And Identification Of Single Nucleotide

10 Polymorphisms

The amplification products generated as described above, are then sequenced using any method known and available to the skilled technician. Methods for sequencing DNA using either the dideoxy-mediated method (Sanger method) or the Maxam-Gilbert method are widely known to those of ordinary skill in the art. Such methods are for example disclosed in Sambrook et al.(1989).

- 15 Alternative approaches include hybridization to high-density DNA probe arrays as described in Chee et al.(1996).

Preferably, the amplified DNA is subjected to automated dideoxy terminator sequencing reactions using a dye-primer cycle sequencing protocol. The products of the sequencing reactions are run on sequencing gels and the sequences are determined using gel image analysis. The

- 20 polymorphism search is based on the presence of superimposed peaks in the electrophoresis pattern resulting from different bases occurring at the same position. Because each dideoxy terminator is labeled with a different fluorescent molecule, the two peaks corresponding to a biallelic site present distinct colors corresponding to two different nucleotides at the same position on the sequence.

- However, the presence of two peaks can be an artifact due to background noise. To exclude such an artifact, the two DNA strands are sequenced and a comparison between the peaks is carried out. In order to be registered as a polymorphic sequence, the polymorphism has to be detected on both strands.

- The above procedure permits those amplification products, which contain biallelic markers to be identified. The detection limit for the frequency of biallelic polymorphisms detected by sequencing pools of 100 individuals is approximately 0.1 for the minor allele, as verified by sequencing pools of known allelic frequencies. However, more than 90% of the biallelic polymorphisms detected by the pooling method have a frequency for the minor allele higher than 0.25. Therefore, the biallelic markers selected by this method have a frequency of at least 0.1 for the minor allele and less than 0.9 for the major allele. Preferably at least 0.2 for the minor allele and less than 0.8 for the major allele, more preferably at least 0.3 for the minor allele and less than 0.7 for the

major allele, thus a heterozygosity rate higher than 0.18, preferably higher than 0.32, more preferably higher than 0.42.

In another embodiment, biallelic markers are detected by sequencing individual DNA samples, the frequency of the minor allele of such a biallelic marker may be less than 0.1.

5 **Validation Of The Biallelic Markers Of The Present Invention**

The polymorphisms are evaluated for their usefulness as genetic markers by validating that both alleles are present in a population. Validation of the biallelic markers is accomplished by genotyping a group of individuals by a method of the invention and demonstrating that both alleles are present. Microsequencing is a preferred method of genotyping alleles. The validation by
10 genotyping step may be performed on individual samples derived from each individual in the group or by genotyping a pooled sample derived from more than one individual. The group can be as small as one individual if that individual is heterozygous for the allele in question. Preferably the group contains at least three individuals, more preferably the group contains five or six individuals, so that a single validation test will be more likely to result in the validation of more of the biallelic
15 markers that are being tested. It should be noted, however, that when the validation test is performed on a small group it may result in a false negative result if as a result of sampling error none of the individuals tested carries one of the two alleles. Thus, the validation process is less useful in demonstrating that a particular initial result is an artifact, than it is at demonstrating that there is a *bona fide* biallelic marker at a particular position in a sequence. All of the genotyping,
20 haplotyping, association, and interaction study methods of the invention may optionally be performed solely with validated biallelic markers.

Evaluation Of The Frequency Of The Biallelic Markers Of The Present Invention

The validated biallelic markers are further evaluated for their usefulness as genetic markers by determining the frequency of the least common allele at the biallelic marker site. The higher the
25 frequency of the less common allele the greater the usefulness of the biallelic marker is association and interaction studies. The determination of the least common allele is accomplished by genotyping a group of individuals by a method of the invention and demonstrating that both alleles are present. This determination of frequency by genotyping step may be performed on individual samples derived from each individual in the group or by genotyping a pooled sample derived from
30 more than one individual. The group must be large enough to be representative of the population as a whole. Preferably the group contains at least 20 individuals, more preferably the group contains at least 50 individuals, most preferably the group contains at least 100 individuals. Of course the larger the group the greater the accuracy of the frequency determination because of reduced sampling error. A biallelic marker wherein the frequency of the less common allele is 30% or more is termed a "high
35 quality biallelic marker." All of the genotyping, haplotyping, association, and interaction study methods of the invention may optionally be performed solely with high quality biallelic markers.

Methods For Genotyping An Individual For Biallelic Markers

Methods are provided to genotype a biological sample for one or more biallelic markers of the present invention, all of which may be performed *in vitro*. Such methods of genotyping comprise determining the identity of a nucleotide at a *BAP28* biallelic marker site by any method known in the art. These methods find use in genotyping case-control populations in association studies as well as individuals in the context of detection of alleles of biallelic markers which are known to be associated with a given trait, in which case both copies of the biallelic marker present in individual's genome are determined so that an individual may be classified as homozygous or heterozygous for a particular allele.

- 10 These genotyping methods can be performed on nucleic acid samples derived from a single individual or pooled DNA samples.

Genotyping can be performed using similar methods as those described above for the identification of the biallelic markers, or using other genotyping methods such as those further described below. In preferred embodiments, the comparison of sequences of amplified genomic fragments from different individuals is used to identify new biallelic markers whereas microsequencing is used for genotyping known biallelic markers in diagnostic and association study applications.

- In one embodiment the invention encompasses methods of genotyping comprising determining the identity of a nucleotide at a *BAP28*-related biallelic marker or the complement thereof in a biological sample; In some embodiments, said *BAP28*-related biallelic marker is selected from the group consisting of A1 to A58, and the complements thereof, or the biallelic markers in linkage disequilibrium therewith; In some embodiments, wherein said *BAP28*-related biallelic marker is selected from the group consisting of A1 to A27, A34, A37 to A41, A43 to A49, A52, and A54 to A58, and the complements thereof, or the biallelic markers in linkage disequilibrium therewith; In some embodiments, said *BAP28*-related biallelic marker is selected from the group consisting of A1, A4, 16, A30, A31, A42, A50, A51, and A53, and the complements thereof, or the biallelic markers in linkage disequilibrium therewith; In some embodiments, said biological sample is derived from a single subject; In some embodiments, the identity of the nucleotides at said biallelic marker is determined for both copies of said biallelic marker present in said individual's genome; In some embodiments, said biological sample is derived from multiple subjects; In some embodiments, the method further comprises amplifying a portion of said sequence comprising the biallelic marker prior to said determining step; In some embodiments, said amplifying is performed by PCR; In some embodiments, said determining is performed by a hybridization assay, a sequencing assay, a microsequencing assay, or an enzyme-based mismatch detection assay.

Source of DNA for genotyping

Any source of nucleic acids, in purified or non-purified form, can be utilized as the starting nucleic acid, provided it contains or is suspected of containing the specific nucleic acid sequence desired. DNA or RNA may be extracted from cells, tissues, body fluids and the like as described
5 above. While nucleic acids for use in the genotyping methods of the invention can be derived from any mammalian source, the test subjects and individuals from which nucleic acid samples are taken are generally understood to be human.

Amplification Of DNA Fragments Comprising Biallelic Markers

Methods and polynucleotides are provided to amplify a segment of nucleotides comprising
10 one or more biallelic marker of the present invention. It will be appreciated that amplification of DNA fragments comprising biallelic markers may be used in various methods and for various purposes and is not restricted to genotyping. Nevertheless, many genotyping methods, although not all, require the previous amplification of the DNA region carrying the biallelic marker of interest. Such methods specifically increase the concentration or total number of sequences that span the
15 biallelic marker or include that site and sequences located either distal or proximal to it. Diagnostic assays may also rely on amplification of DNA segments carrying a biallelic marker of the present invention. Amplification of DNA may be achieved by any method known in the art. Amplification techniques are described above in the section entitled, "Amplification of the *BAP28* gene".

Some of these amplification methods are particularly suited for the detection of single
20 nucleotide polymorphisms and allow the simultaneous amplification of a target sequence and the identification of the polymorphic nucleotide as it is further described below.

The identification of biallelic markers as described above allows the design of appropriate oligonucleotides, which can be used as primers to amplify DNA fragments comprising the biallelic markers of the present invention.

25 In some embodiments the present invention provides primers for amplifying a DNA fragment containing one or more biallelic markers of the present invention.

The spacing of the primers determines the length of the segment to be amplified. In the context of the present invention, amplified segments carrying biallelic markers can range in size from at least about 25 bp to 35 kbp. Amplification fragments from 25-3000 bp are typical,
30 fragments from 50-1000 bp are preferred and fragments from 100-600 bp are highly preferred. It will be appreciated that amplification primers for the biallelic markers may be any sequence which allow the specific amplification of any DNA fragment carrying the markers. Amplification primers may be labeled or immobilized on a solid support as described in "Oligonucleotide probes and primers".

Methods of Genotyping DNA samples for Biallelic Markers

Any method known in the art can be used to identify the nucleotide present at a biallelic marker site. Since the biallelic marker allele to be detected has been identified and specified in the present invention, detection will prove simple for one of ordinary skill in the art by employing any of a number of techniques. Many genotyping methods require the previous amplification of the DNA region carrying the biallelic marker of interest. While the amplification of target or signal is often preferred at present, ultrasensitive detection methods which do not require amplification are also encompassed by the present genotyping methods. Methods well-known to those skilled in the art that can be used to detect biallelic polymorphisms include methods such as, conventional dot blot analyzes, single strand conformational polymorphism analysis (SSCP) described by Orita et al.(1989), denaturing gradient gel electrophoresis (DGGE), heteroduplex analysis, mismatch cleavage detection, and other conventional techniques as described in Sheffield et al.(1991), White et al.(1992), Grompe et al.(1989 and 1993). Another method for determining the identity of the nucleotide present at a particular polymorphic site employs a specialized exonuclease-resistant nucleotide derivative as described in US patent 4,656,127.

Preferred methods involve directly determining the identity of the nucleotide present at a biallelic marker site by sequencing assay, enzyme-based mismatch detection assay, or hybridization assay. The following is a description of some preferred methods. A highly preferred method is the microsequencing technique. The term "sequencing" is used herein to refer to polymerase extension of duplex primer/template complexes and includes both traditional sequencing and microsequencing.

1) Sequencing Assays

The nucleotide present at a polymorphic site can be determined by sequencing methods. In a preferred embodiment, DNA samples are subjected to PCR amplification before sequencing as described above. DNA sequencing methods are described in "Sequencing Of Amplified Genomic DNA And Identification Of Single Nucleotide Polymorphisms".

Preferably, the amplified DNA is subjected to automated dideoxy terminator sequencing reactions using a dye-primer cycle sequencing protocol. Sequence analysis allows the identification of the base present at the biallelic marker site.

2) Microsequencing Assays

In microsequencing methods, the nucleotide at a polymorphic site in a target DNA is detected by a single nucleotide primer extension reaction. This method involves appropriate microsequencing primers which, hybridize just upstream of the polymorphic base of interest in the target nucleic acid. A polymerase is used to specifically extend the 3' end of the primer with one single ddNTP (chain terminator) complementary to the nucleotide at the polymorphic site. Next the identity of the incorporated nucleotide is determined in any suitable way.

Typically, microsequencing reactions are carried out using fluorescent ddNTPs and the extended microsequencing primers are analyzed by electrophoresis on ABI 377 sequencing

machines to determine the identity of the incorporated nucleotide as described in EP 412 883. Alternatively capillary electrophoresis can be used in order to process a higher number of assays simultaneously. An example of a typical microsequencing procedure that can be used in the context of the present invention is provided in Example 4.

- 5 Different approaches can be used for the labeling and detection of ddNTPs. A homogeneous phase detection method based on fluorescence resonance energy transfer has been described by Chen and Kwok (1997) and Chen et al.(1997). In this method, amplified genomic DNA fragments containing polymorphic sites are incubated with a 5'-fluorescein-labeled primer in the presence of allelic dye-labeled dideoxyribonucleoside triphosphates and a modified Taq
- 10 polymerase. The dye-labeled primer is extended one base by the dye-terminator specific for the allele present on the template. At the end of the genotyping reaction, the fluorescence intensities of the two dyes in the reaction mixture are analyzed directly without separation or purification. All these steps can be performed in the same tube and the fluorescence changes can be monitored in real time. Alternatively, the extended primer may be analyzed by MALDI-TOF Mass Spectrometry.
- 15 The base at the polymorphic site is identified by the mass added onto the microsequencing primer (see Haff and Smirnov, 1997).

- Microsequencing may be achieved by the established microsequencing method or by developments or derivatives thereof. Alternative methods include several solid-phase microsequencing techniques. The basic microsequencing protocol is the same as described
- 20 previously, except that the method is conducted as a heterogeneous phase assay, in which the primer or the target molecule is immobilized or captured onto a solid support. To simplify the primer separation and the terminal nucleotide addition analysis, oligonucleotides are attached to solid supports or are modified in such ways that permit affinity separation as well as polymerase extension. The 5' ends and internal nucleotides of synthetic oligonucleotides can be modified in a
- 25 number of different ways to permit different affinity separation approaches, e.g., biotinylation. If a single affinity group is used on the oligonucleotides, the oligonucleotides can be separated from the incorporated terminator reagent. This eliminates the need of physical or size separation. More than one oligonucleotide can be separated from the terminator reagent and analyzed simultaneously if more than one affinity group is used. This permits the analysis of several nucleic acid species or
- 30 more nucleic acid sequence information per extension reaction. The affinity group need not be on the priming oligonucleotide but could alternatively be present on the template. For example, immobilization can be carried out via an interaction between biotinylated DNA and streptavidin-coated microtitration wells or avidin-coated polystyrene particles. In the same manner, oligonucleotides or templates may be attached to a solid support in a high-density format. In such
- 35 solid phase microsequencing reactions, incorporated ddNTPs can be radiolabeled (Syvänen, 1994) or linked to fluorescein (Livak and Hainer, 1994). The detection of radiolabeled ddNTPs can be achieved through scintillation-based techniques. The detection of fluorescein-linked ddNTPs can be

based on the binding of antiluorescein antibody conjugated with alkaline phosphatase, followed by incubation with a chromogenic substrate (such as *p*-nitrophenyl phosphate). Other possible reporter-detection pairs include: ddNTP linked to dinitrophenyl (DNP) and anti-DNP alkaline phosphatase conjugate (Harju et al., 1993) or biotinylated ddNTP and horseradish peroxidase-conjugated streptavidin with *o*-phenylenediamine as a substrate (WO 92/15712). As yet another alternative solid-phase microsequencing procedure, Nyren et al.(1993) described a method relying on the detection of DNA polymerase activity by an enzymatic luminometric inorganic pyrophosphate detection assay (ELIDA).

- 10 Patinen et al.(1997) describe a method for multiplex detection of single nucleotide polymorphism in which the solid phase minisequencing principle is applied to an oligonucleotide array format. High-density arrays of DNA probes attached to a solid support (DNA chips) are further described below.

In one aspect the present invention provides polynucleotides and methods to genotype one or more biallelic markers of the present invention by performing a microsequencing assay. Preferred microsequencing primers include the nucleotide sequences D1 to D58 and E1 to E58, preferably D1 to D27, D34, D37 to D41, D43 to D49, D52, D54 to D58, E1 to E27, E34, E37 to E41, E43 to E49, E52, and E54 to E58. It will be appreciated that the microsequencing primers listed in Example 4 are merely exemplary and that, any primer having a 3' end immediately adjacent to the polymorphic nucleotide may be used. Similarly, it will be appreciated that microsequencing analysis may be performed for any biallelic marker or any combination of biallelic markers of the present invention. One aspect of the present invention is a solid support which includes one or more microsequencing primers listed in Example 4, or fragments comprising at least 8, 12, 15, 20, 25, 30, 40, or 50 consecutive nucleotides thereof and having a 3' terminus immediately upstream of the corresponding biallelic marker, for determining the identity of a nucleotide at a biallelic marker site.

25 3) Mismatch detection assays based on polymerases and ligases

In one aspect the present invention provides polynucleotides and methods to determine the allele of one or more biallelic markers of the present invention in a biological sample, by mismatch detection assays based on polymerases and/or ligases. These assays are based on the specificity of polymerases and ligases. Polymerization reactions places particularly stringent requirements on correct base pairing of the 3' end of the amplification primer and the joining of two oligonucleotides hybridized to a target DNA sequence is quite sensitive to mismatches close to the ligation site, especially at the 3' end. Methods, primers and various parameters to amplify DNA fragments comprising biallelic markers of the present invention are further described above in "Amplification Of DNA Fragments Comprising Biallelic Markers".

35 **Allele Specific Amplification Primers**

Discrimination between the two alleles of a biallelic marker can also be achieved by allele specific amplification, a selective strategy, whereby one of the alleles is amplified without

amplification of the other allele. This is accomplished by placing the polymorphic base at the 3' end of one of the amplification primers. Because the extension forms from the 3' end of the primer, a mismatch at or near this position has an inhibitory effect on amplification. Therefore, under appropriate amplification conditions, these primers only direct amplification on their complementary 5 allele. Determining the precise location of the mismatch and the corresponding assay conditions are well with the ordinary skill in the art.

Ligation/Amplification Based Methods

The "Oligonucleotide Ligation Assay" (OLA) uses two oligonucleotides which are designed to be capable of hybridizing to abutting sequences of a single strand of a target molecules. 10 One of the oligonucleotides is biotinylated, and the other is detectably labeled. If the precise complementary sequence is found in a target molecule, the oligonucleotides will hybridize such that their termini abut, and create a ligation substrate that can be captured and detected. OLA is capable of detecting single nucleotide polymorphisms and may be advantageously combined with PCR as described by Nickerson et al.(1990). In this method, PCR is used to achieve the exponential 15 amplification of target DNA, which is then detected using OLA.

Other amplification methods which are particularly suited for the detection of single nucleotide polymorphism include LCR (ligase chain reaction), Gap LCR (GLCR) which are described above in "Amplification of the *BAP28* gene". LCR uses two pairs of probes to exponentially amplify a specific target. The sequences of each pair of oligonucleotides, is selected 20 to permit the pair to hybridize to abutting sequences of the same strand of the target. Such hybridization forms a substrate for a template-dependant ligase. In accordance with the present invention, LCR can be performed with oligonucleotides having the proximal and distal sequences of the same strand of a biallelic marker site. In one embodiment, either oligonucleotide will be designed to include the biallelic marker site. In such an embodiment, the reaction conditions are 25 selected such that the oligonucleotides can be ligated together only if the target molecule either contains or lacks the specific nucleotide that is complementary to the biallelic marker on the oligonucleotide. In an alternative embodiment, the oligonucleotides will not include the biallelic marker, such that when they hybridize to the target molecule, a "gap" is created as described in WO 90/01069. This gap is then "filled" with complementary dNTPs (as mediated by DNA polymerase), 30 or by an additional pair of oligonucleotides. Thus at the end of each cycle, each single strand has a complement capable of serving as a target during the next cycle and exponential allele-specific amplification of the desired sequence is obtained.

Ligase/Polymerase-mediated Genetic Bit AnalysisTM is another method for determining the identity of a nucleotide at a preselected site in a nucleic acid molecule (WO 95/21271). This method 35 involves the incorporation of a nucleoside triphosphate that is complementary to the nucleotide present at the preselected site onto the terminus of a primer molecule, and their subsequent ligation

to a second oligonucleotide. The reaction is monitored by detecting a specific label attached to the reaction's solid phase or by detection in solution.

4) Hybridization Assay Methods

A preferred method of determining the identity of the nucleotide present at a biallelic marker site involves nucleic acid hybridization. The hybridization probes, which can be conveniently used in such reactions, preferably include the probes defined herein. Any hybridization assay may be used including Southern hybridization, Northern hybridization, dot blot hybridization and solid-phase hybridization (see Sambrook et al., 1989).

Hybridization refers to the formation of a duplex structure by two single stranded nucleic acids due to complementary base pairing. Hybridization can occur between exactly complementary nucleic acid strands or between nucleic acid strands that contain minor regions of mismatch. Specific probes can be designed that hybridize to one form of a biallelic marker and not to the other and therefore are able to discriminate between different allelic forms. Allele-specific probes are often used in pairs, one member of a pair showing perfect match to a target sequence containing the original allele and the other showing a perfect match to the target sequence containing the alternative allele. Hybridization conditions should be sufficiently stringent that there is a significant difference in hybridization intensity between alleles, and preferably an essentially binary response, whereby a probe hybridizes to only one of the alleles. Stringent, sequence specific hybridization conditions, under which a probe will hybridize only to the exactly complementary target sequence are well known in the art (Sambrook et al., 1989). Stringent conditions are sequence dependent and will be different in different circumstances. Generally, stringent conditions are selected to be about 5°C lower than the thermal melting point (T_m) for the specific sequence at a defined ionic strength and pH. Although such hybridizations can be performed in solution, it is preferred to employ a solid-phase hybridization assay. The target DNA comprising a biallelic marker of the present invention may be amplified prior to the hybridization reaction. The presence of a specific allele in the sample is determined by detecting the presence or the absence of stable hybrid duplexes formed between the probe and the target DNA. The detection of hybrid duplexes can be carried out by a number of methods. Various detection assay formats are well known which utilize detectable labels bound to either the target or the probe to enable detection of the hybrid duplexes. Typically, hybridization duplexes are separated from unhybridized nucleic acids and the labels bound to the duplexes are then detected. Those skilled in the art will recognize that wash steps may be employed to wash away excess target DNA or probe as well as unbound conjugate. Further, standard heterogeneous assay formats are suitable for detecting the hybrids using the labels present on the primers and probes.

Two recently developed assays allow hybridization-based allele discrimination with no need for separations or washes (see Landegren U. et al., 1998). The TaqMan assay takes advantage of the 5' nuclease activity of Taq DNA polymerase to digest a DNA probe annealed specifically to the accumulating amplification product. TaqMan probes are labeled with a donor-acceptor dye pair

that interacts via fluorescence energy transfer. Cleavage of the TaqMan probe by the advancing polymerase during amplification dissociates the donor dye from the quenching acceptor dye, greatly increasing the donor fluorescence. All reagents necessary to detect two allelic variants can be assembled at the beginning of the reaction and the results are monitored in real time (see Livak et al., 5 1995). In an alternative homogeneous hybridization based procedure, molecular beacons are used for allele discriminations. Molecular beacons are hairpin-shaped oligonucleotide probes that report the presence of specific nucleic acids in homogeneous solutions. When they bind to their targets they undergo a conformational reorganization that restores the fluorescence of an internally quenched fluorophore (Tyagi et al., 1998).

- 10 The polynucleotides provided herein can be used to produce probes which can be used in hybridization assays for the detection of biallelic marker alleles in biological samples. These probes are characterized in that they preferably comprise between 8 and 50 nucleotides, and in that they are sufficiently complementary to a sequence comprising a biallelic marker of the present invention to hybridize thereto and preferably sufficiently specific to be able to discriminate the targeted sequence
- 15 for only one nucleotide variation. A particularly preferred probe is 25 nucleotides in length. Preferably the biallelic marker is within 4 nucleotides of the center of the polynucleotide probe. In particularly preferred probes, the biallelic marker is at the center of said polynucleotide. Preferred probes comprise a nucleotide sequence selected from the group consisting of amplicons listed in Table 1 and the sequences complementary thereto, or a fragment thereof, said fragment comprising
- 20 at least about 8 consecutive nucleotides, preferably 10, 15, 20, more preferably 25, 30, 40, 47, or 50 consecutive nucleotides and containing a polymorphic base. Preferred probes comprise a nucleotide sequence selected from the group consisting of P1 to P58 and the sequences complementary thereto, preferably P1 to P27, P34, P37 to P41, P43 to P49, P52, P54 to P58. In preferred embodiments the polymorphic base(s) are within 5, 4, 3, 2, 1, nucleotides of the center of the said polynucleotide,
- 25 more preferably at the center of said polynucleotide.

Preferably the probes of the present invention are labeled or immobilized on a solid support. Labels and solid supports are further described in "Oligonucleotide Probes and Primers". The probes can be non-extendable as described in "Oligonucleotide Probes and Primers".

- By assaying the hybridization to an allele specific probe, one can detect the presence or
- 30 absence of a biallelic marker allele in a given sample. High-Throughput parallel hybridizations in array format are specifically encompassed within "hybridization assays" and are described below.

5) Hybridization To Addressable Arrays Of Oligonucleotides

- Hybridization assays based on oligonucleotide arrays rely on the differences in hybridization stability of short oligonucleotides to perfectly matched and mismatched target
- 35 sequence variants. Efficient access to polymorphism information is obtained through a basic structure comprising high-density arrays of oligonucleotide probes attached to a solid support (e.g.,

the chip) at selected positions. Each DNA chip can contain thousands to millions of individual synthetic DNA probes arranged in a grid-like pattern and miniaturized to the size of a dime.

The chip technology has already been applied with success in numerous cases. For example, the screening of mutations has been undertaken in the BRCA1 gene, in *S. cerevisiae* mutant strains, and in the protease gene of HIV-1 virus (Hacia et al., 1996; Shoemaker et al., 1996; Kozal et al., 1996). Chips of various formats for use in detecting biallelic polymorphisms can be produced on a customized basis by Affymetrix (GeneChip™), Hyseq (HyChip and HyGnostics), and Protogene Laboratories.

In general, these methods employ arrays of oligonucleotide probes that are complementary to target nucleic acid sequence segments from an individual which, target sequences include a polymorphic marker. EP 785280 describes a tiling strategy for the detection of single nucleotide polymorphisms. Briefly, arrays may generally be "tiled" for a large number of specific polymorphisms. By "tiling" is generally meant the synthesis of a defined set of oligonucleotide probes which is made up of a sequence complementary to the target sequence of interest, as well as preselected variations of that sequence, e.g., substitution of one or more given positions with one or more members of the basis set of monomers, i.e. nucleotides. Tiling strategies are further described in PCT application No WO 95/11995. In a particular aspect, arrays are tiled for a number of specific, identified biallelic marker sequences. In particular, the array is tiled to include a number of detection blocks, each detection block being specific for a specific biallelic marker or a set of biallelic markers. For example, a detection block may be tiled to include a number of probes, which span the sequence segment that includes a specific polymorphism. To ensure probes that are complementary to each allele, the probes are synthesized in pairs differing at the biallelic marker. In addition to the probes differing at the polymorphic base, monosubstituted probes are also generally tiled within the detection block. These monosubstituted probes have bases at and up to a certain number of bases in either direction from the polymorphism, substituted with the remaining nucleotides (selected from A, T, G, C and U). Typically the probes in a tiled detection block will include substitutions of the sequence positions up to and including those that are 5 bases away from the biallelic marker. The monosubstituted probes provide internal controls for the tiled array, to distinguish actual hybridization from artefactual cross-hybridization. Upon completion of hybridization with the target sequence and washing of the array, the array is scanned to determine the position on the array to which the target sequence hybridizes. The hybridization data from the scanned array is then analyzed to identify which allele or alleles of the biallelic marker are present in the sample. Hybridization and scanning may be carried out as described in PCT application No WO 92/10092 and WO 95/11995 and US patent No 5,424,186.

Thus, in some embodiments, the chips may comprise an array of nucleic acid sequences of fragments of about 15 nucleotides in length. In further embodiments, the chip may comprise an array including at least one sequences comprising at least about 8 consecutive nucleotides,

preferably 10, 15, 20, more preferably 25, 30, 40, 47, or 50 consecutive nucleotides and containing a polymorphic base. In preferred embodiments the polymorphic base is within 5, 4, 3, 2, 1, nucleotides of the center of the said polynucleotide, more preferably at the center of said polynucleotide. In some embodiments, the chip may comprise an array of at least 2, 3, 4, 5, 6, 7, 8 or more of these polynucleotides of the invention. Solid supports and polynucleotides of the present invention attached to solid supports are further described in "oligonucleotide probes and primers".

6) Integrated Systems

Another technique, which may be used to analyze polymorphisms, includes multicomponent integrated systems, which miniaturize and compartmentalize processes such as PCR and capillary electrophoresis reactions in a single functional device. An example of such technique is disclosed in US patent 5,589,136, which describes the integration of PCR amplification and capillary electrophoresis in chips.

Integrated systems can be envisaged mainly when microfluidic systems are used. These systems comprise a pattern of microchannels designed onto a glass, silicon, quartz, or plastic wafer included on a microchip. The movements of the samples are controlled by electric, electroosmotic or hydrostatic forces applied across different areas of the microchip to create functional microscopic valves and pumps with no moving parts.

For genotyping biallelic markers, the microfluidic system may integrate nucleic acid amplification, microsequencing, capillary electrophoresis and a detection method such as laser-induced fluorescence detection.

Methods Of Genetic Analysis Using The Biallelic Markers Of The Present Invention

Different methods are available for the genetic analysis of complex traits (see Lander and Schork, 1994). The search for disease-susceptibility genes is conducted using two main methods: the linkage approach in which evidence is sought for cosegregation between a locus and a putative trait locus using family studies, and the association approach in which evidence is sought for a statistically significant association between an allele and a trait or a trait causing allele (Khoury et al., 1993). In general, the biallelic markers of the present invention find use in any method known in the art to demonstrate a statistically significant correlation between a genotype and a phenotype. The biallelic markers may be used in parametric and non-parametric linkage analysis methods.

Preferably, the biallelic markers of the present invention are used to identify genes associated with detectable traits using association studies, an approach which does not require the use of affected families and which permits the identification of genes associated with complex and sporadic traits.

The genetic analysis using the biallelic markers of the present invention may be conducted on any scale. The whole set of biallelic markers of the present invention or any subset of biallelic markers of the present invention corresponding to the candidate gene may be used. Further, any set of genetic markers including a biallelic marker of the present invention may be used. A set of biallelic polymorphisms that could be used as genetic markers in combination with the biallelic

markers of the present invention has been described in WO 98/20165. As mentioned above, it should be noted that the biallelic markers of the present invention may be included in any complete or partial genetic map of the human genome. These different uses are specifically contemplated in the present invention and claims.

5 **Linkage Analysis**

Linkage analysis is based upon establishing a correlation between the transmission of genetic markers and that of a specific trait throughout generations within a family. Thus, the aim of linkage analysis is to detect marker loci that show cosegregation with a trait of interest in pedigrees.

Parametric Methods

10 When data are available from successive generations there is the opportunity to study the degree of linkage between pairs of loci. Estimates of the recombination fraction enable loci to be ordered and placed onto a genetic map. With loci that are genetic markers, a genetic map can be established, and then the strength of linkage between markers and traits can be calculated and used to indicate the relative positions of markers and genes affecting those traits (Weir, 1996). The
15 classical method for linkage analysis is the logarithm of odds (lod) score method (see Morton, 1955; Ott, 1991). Calculation of lod scores requires specification of the mode of inheritance for the disease (parametric method). Generally, the length of the candidate region identified using linkage analysis is between 2 and 20Mb. Once a candidate region is identified as described above, analysis of recombinant individuals using additional markers allows further delineation of the candidate
20 region. Linkage analysis studies have generally relied on the use of a maximum of 5,000 microsatellite markers, thus limiting the maximum theoretical attainable resolution of linkage analysis to about 600 kb on average.

Linkage analysis has been successfully applied to map simple genetic traits that show clear Mendelian inheritance patterns and which have a high penetrance (i.e., the ratio between the number
25 of trait positive carriers of allele a and the total number of a carriers in the population). However, parametric linkage analysis suffers from a variety of drawbacks. First, it is limited by its reliance on the choice of a genetic model suitable for each studied trait. Furthermore, as already mentioned, the resolution attainable using linkage analysis is limited, and complementary studies are required to refine the analysis of the typical 2Mb to 20Mb regions initially identified through linkage analysis.
30 In addition, parametric linkage analysis approaches have proven difficult when applied to complex genetic traits, such as those due to the combined action of multiple genes and/or environmental factors. It is very difficult to model these factors adequately in a lod score analysis. In such cases, too large an effort and cost are needed to recruit the adequate number of affected families required for applying linkage analysis to these situations, as recently discussed by Risch, N. and Merikangas,
35 K. (1996).

Non-Parametric Methods

The advantage of the so-called non-parametric methods for linkage analysis is that they do not require specification of the mode of inheritance for the disease, they tend to be more useful for the analysis of complex traits. In non-parametric methods, one tries to prove that the inheritance pattern of a chromosomal region is not consistent with random Mendelian segregation by showing that affected relatives inherit identical copies of the region more often than expected by chance. Affected relatives should show excess "allele sharing" even in the presence of incomplete penetrance and polygenic inheritance. In non-parametric linkage analysis the degree of agreement at a marker locus in two individuals can be measured either by the number of alleles identical by state (IBS) or by the number of alleles identical by descent (IBD). Affected sib pair analysis is a well-known special case and is the simplest form of these methods.

The biallelic markers of the present invention may be used in both parametric and non-parametric linkage analysis. Preferably biallelic markers may be used in non-parametric methods which allow the mapping of genes involved in complex traits. The biallelic markers of the present invention may be used in both IBD- and IBS- methods to map genes affecting a complex trait. In such studies, taking advantage of the high density of biallelic markers, several adjacent biallelic marker loci may be pooled to achieve the efficiency attained by multi-allelic markers (Zhao et al., 1998).

Population Association Studies

The present invention comprises methods for identifying if the *BAP28* gene is associated with a detectable trait using the biallelic markers of the present invention. In one embodiment the present invention comprises methods to detect an association between a biallelic marker allele or a biallelic marker haplotype and a trait. Further, the invention comprises methods to identify a trait causing allele in linkage disequilibrium with any biallelic marker allele of the present invention.

As described above, alternative approaches can be employed to perform association studies: genome-wide association studies, candidate region association studies and candidate gene association studies. In a preferred embodiment, the biallelic markers of the present invention are used to perform candidate gene association studies. The candidate gene analysis clearly provides a short-cut approach to the identification of genes and gene polymorphisms related to a particular trait when some information concerning the biology of the trait is available. Further, the biallelic markers of the present invention may be incorporated in any map of genetic markers of the human genome in order to perform genome-wide association studies. Methods to generate a high-density map of biallelic markers has been described in US Provisional Patent application serial number 60/082,614. The biallelic markers of the present invention may further be incorporated in any map of a specific candidate region of the genome (a specific chromosome or a specific chromosomal segment for example).

As mentioned above, association studies may be conducted within the general population and are not limited to studies performed on related individuals in affected families. Association studies are extremely valuable as they permit the analysis of sporadic or multifactor traits. Moreover, association studies represent a powerful method for fine-scale mapping enabling much finer mapping of trait causing alleles than linkage studies. Studies based on pedigrees often only narrow the location of the trait causing allele. Association studies using the biallelic markers of the present invention can therefore be used to refine the location of a trait causing allele in a candidate region identified by Linkage Analysis methods. Moreover, once a chromosome segment of interest has been identified, the presence of a candidate gene such as a candidate gene of the present invention, in the region of interest can provide a shortcut to the identification of the trait causing allele. Biallelic markers of the present invention can be used to demonstrate that a candidate gene is associated with a trait. Such uses are specifically contemplated in the present invention.

Determining The Frequency Of A Biallelic Marker Allele Or Of A Biallelic Marker Haplotype In A Population

Association studies explore the relationships among frequencies for sets of alleles between loci.

Determining The Frequency Of An Allele In A Population

Allelic frequencies of the biallelic markers in a populations can be determined using one of the methods described above under the heading "Methods for genotyping an individual for biallelic markers", or any genotyping procedure suitable for this intended purpose. Genotyping pooled samples or individual samples can determine the frequency of a biallelic marker allele in a population. One way to reduce the number of genotypings required is to use pooled samples. A major obstacle in using pooled samples is in terms of accuracy and reproducibility for determining accurate DNA concentrations in setting up the pools. Genotyping individual samples provides higher sensitivity, reproducibility and accuracy and; is the preferred method used in the present invention. Preferably, each individual is genotyped separately and simple gene counting is applied to determine the frequency of an allele of a biallelic marker or of a genotype in a given population.

The invention also relates to methods of estimating the frequency of an allele in a population comprising: a) genotyping individuals from said population for said biallelic marker according to the method of the present invention; b) determining the proportional representation of said biallelic marker in said population. In addition, the methods of estimating the frequency of an allele in a population of the invention encompass methods with any further limitation described in this disclosure, or those following, specified alone or in any combination; In some embodiments, said *BAP28*-related biallelic marker is selected from the group consisting of A1 to A58, and the complements thereof, or the biallelic markers in linkage disequilibrium therewith; In some embodiments, said *BAP28*-related biallelic marker is selected from the group consisting of A1 to

- A27, A34, A37 to A41, A43 to A49, A52, and A54 to A58, and the complements thereof, or the biallelic markers in linkage disequilibrium therewith; In some embodiments, said *BAP28*-related biallelic marker is selected from the group consisting of A1, A4, 16, A30, A31, A42, A50, A51, and A53, and the complements thereof, or the biallelic markers in linkage disequilibrium therewith; In
- 5 some embodiments, the step of determining the frequency of a biallelic marker allele in a population may be accomplished by determining the identity of the nucleotides for both copies of said biallelic marker present in the genome of each individual in said population and calculating the proportional representation of said nucleotide at said *BAP28*-related biallelic marker for the population; In some
- 10 performing a genotyping method of the invention on a pooled biological sample derived from a representative number of individuals, or each individual, in said population, and calculating the proportional amount of said nucleotide compared with the total.

Determining The Frequency Of A Haplotype In A Population

- The gametic phase of haplotypes is unknown when diploid individuals are heterozygous at
- 15 more than one locus. Using genealogical information in families gametic phase can sometimes be inferred (Perlin et al., 1994). When no genealogical information is available different strategies may be used. One possibility is that the multiple-site heterozygous diploids can be eliminated from the analysis, keeping only the homozygotes and the single-site heterozygote individuals, but this approach might lead to a possible bias in the sample composition and the underestimation of low-
- 20 frequency haplotypes. Another possibility is that single chromosomes can be studied independently, for example, by asymmetric PCR amplification (see Newton et al, 1989; Wu et al., 1989) or by isolation of single chromosome by limit dilution followed by PCR amplification (see Ruano et al., 1990). Further, a sample may be haplotyped for sufficiently close biallelic markers by double PCR amplification of specific alleles (Sarkar, G. and Sommer S. S., 1991). These approaches are not
- 25 entirely satisfying either because of their technical complexity, the additional cost they entail, their lack of generalization at a large scale, or the possible biases they introduce. To overcome these difficulties, an algorithm to infer the phase of PCR-amplified DNA genotypes introduced by Clark, A.G.(1990) may be used. Briefly, the principle is to start filling a preliminary list of haplotypes present in the sample by examining unambiguous individuals, that is, the complete homozygotes and
- 30 the single-site heterozygotes. Then other individuals in the same sample are screened for the possible occurrence of previously recognized haplotypes. For each positive identification, the complementary haplotype is added to the list of recognized haplotypes, until the phase information for all individuals is either resolved or identified as unresolved. This method assigns a single haplotype to each multiheterozygous individual, whereas several haplotypes are possible when there
- 35 are more than one heterozygous site. Alternatively, one can use methods estimating haplotype frequencies in a population without assigning haplotypes to each individual. Preferably, a method based on an expectation-maximization (EM) algorithm (Dempster et al., 1977) leading to maximum-

likelihood estimates of haplotype frequencies under the assumption of Hardy-Weinberg proportions (random mating) is used (see Excoffier L. and Slatkin M., 1995). The EM algorithm is a generalized iterative maximum-likelihood approach to estimation that is useful when data are ambiguous and/or incomplete. The EM algorithm is used to resolve heterozygotes into haplotypes. Haplotype
5 estimations are further described below under the heading "Statistical Methods." Any other method known in the art to determine or to estimate the frequency of a haplotype in a population may be used.

The invention also encompasses methods of estimating the frequency of a haplotype for a set of biallelic markers in a population, comprising the steps of: a) genotyping at least one *BAP28*-
10 related biallelic marker according to a method of the invention for each individual in said population; b) genotyping a second biallelic marker by determining the identity of the nucleotides at said second biallelic marker for both copies of said second biallelic marker present in the genome of each individual in said population; and c) applying a haplotype determination method to the identities of the nucleotides determined in steps a) and b) to obtain an estimate of said frequency. In
15 addition, the methods of estimating the frequency of a haplotype of the invention encompass methods with any further limitation described in this disclosure, or those following, specified alone or in any combination: In some embodiments, said *BAP28*-related biallelic marker is selected from the group consisting of A1 to A58, and the complements thereof, or the biallelic markers in linkage disequilibrium therewith; In some embodiments, said *BAP28*-related biallelic marker is selected
20 from the group consisting of A1 to A27, A34, A37 to A41, A43 to A49, A52, and A54 to A58, and the complements thereof, or the biallelic markers in linkage disequilibrium therewith; In some embodiments, said *BAP28*-related biallelic marker is selected from the group consisting of A1, A4, A16, A30, A31, A42, A50, A51, and A53, and the complements thereof, or the biallelic markers in linkage disequilibrium therewith; In some embodiments, said haplotype determination method is
25 performed by asymmetric PCR amplification, double PCR amplification of specific alleles, the Clark algorithm, or an expectation-maximization algorithm.

Linkage Disequilibrium Analysis

Linkage disequilibrium is the non-random association of alleles at two or more loci and represents a powerful tool for mapping genes involved in disease traits (see Ajioka R.S. et al., 1997).
30 Biallelic markers, because they are densely spaced in the human genome and can be genotyped in greater numbers than other types of genetic markers (such as RFLP or VNTR markers), are particularly useful in genetic analysis based on linkage disequilibrium.

When a disease mutation is first introduced into a population (by a new mutation or the immigration of a mutation carrier), it necessarily resides on a single chromosome and thus on a
35 single "background" or "ancestral" haplotype of linked markers. Consequently, there is complete disequilibrium between these markers and the disease mutation: one finds the disease mutation only

in the presence of a specific set of marker alleles. Through subsequent generations recombination events occur between the disease mutation and these marker polymorphisms, and the disequilibrium gradually dissipates. The pace of this dissipation is a function of the recombination frequency, so the markers closest to the disease gene will manifest higher levels of disequilibrium than those that are further away. When not broken up by recombination, "ancestral" haplotypes and linkage disequilibrium between marker alleles at different loci can be tracked not only through pedigrees but also through populations. Linkage disequilibrium is usually seen as an association between one specific allele at one locus and another specific allele at a second locus.

The pattern or curve of disequilibrium between disease and marker loci is expected to exhibit a maximum that occurs at the disease locus. Consequently, the amount of linkage disequilibrium between a disease allele and closely linked genetic markers may yield valuable information regarding the location of the disease gene. For fine-scale mapping of a disease locus, it is useful to have some knowledge of the patterns of linkage disequilibrium that exist between markers in the studied region. As mentioned above the mapping resolution achieved through the analysis of linkage disequilibrium is much higher than that of linkage studies. The high density of biallelic markers combined with linkage disequilibrium analysis provides powerful tools for fine-scale mapping. Different methods to calculate linkage disequilibrium are described below under the heading "Statistical Methods".

Population-Based Case-Control Studies Of Trait-Marker Associations

As mentioned above, the occurrence of pairs of specific alleles at different loci on the same chromosome is not random and the deviation from random is called linkage disequilibrium. Association studies focus on population frequencies and rely on the phenomenon of linkage disequilibrium. If a specific allele in a given gene is directly involved in causing a particular trait, its frequency will be statistically increased in an affected (trait positive) population, when compared to the frequency in a trait negative population or in a random control population. As a consequence of the existence of linkage disequilibrium, the frequency of all other alleles present in the haplotype carrying the trait-causing allele will also be increased in trait positive individuals compared to trait negative individuals or random controls. Therefore, association between the trait and any allele (specifically a biallelic marker allele) in linkage disequilibrium with the trait-causing allele will suffice to suggest the presence of a trait-related gene in that particular region. Case-control populations can be genotyped for biallelic markers to identify associations that narrowly locate a trait causing allele. As any marker in linkage disequilibrium with one given marker associated with a trait will be associated with the trait. Linkage disequilibrium allows the relative frequencies in case-control populations of a limited number of genetic polymorphisms (specifically biallelic markers) to be analyzed as an alternative to screening all possible functional polymorphisms in order

to find trait-causing alleles. Association studies compare the frequency of marker alleles in unrelated case-control populations, and represent powerful tools for the dissection of complex traits.

Case-Control Populations (Inclusion Criteria)

Population-based association studies do not concern familial inheritance but compare the prevalence of a particular genetic marker, or a set of markers, in case-control populations. They are case-control studies based on comparison of unrelated case (affected or trait positive) individuals and unrelated control (unaffected, trait negative or random) individuals. Preferably the control group is composed of unaffected or trait negative individuals. Further, the control group is ethnically matched to the case population. Moreover, the control group is preferably matched to the case-population for the main known confusion factor for the trait under study (for example age-matched for an age-dependent trait). Ideally, individuals in the two samples are paired in such a way that they are expected to differ only in their disease status. The terms "trait positive population", "case population" and "affected population" are used interchangeably herein.

An important step in the dissection of complex traits using association studies is the choice of case-control populations (see Lander and Schork, 1994). A major step in the choice of case-control populations is the clinical definition of a given trait or phenotype. Any genetic trait may be analyzed by the association method proposed here by carefully selecting the individuals to be included in the trait positive and trait negative phenotypic groups. Four criteria are often useful: clinical phenotype, age at onset, family history and severity. The selection procedure for continuous or quantitative traits (such as blood pressure for example) involves selecting individuals at opposite ends of the phenotype distribution of the trait under study, so as to include in these trait positive and trait negative populations individuals with non-overlapping phenotypes. Preferably, case-control populations are phenotypically homogeneous populations. Trait positive and trait negative populations consist of phenotypically uniform populations of individuals representing each between 1 and 98%, preferably between 1 and 80%, more preferably between 1 and 50%, and more preferably between 1 and 30%, most preferably between 1 and 20% of the total population under study, and preferably selected among individuals exhibiting non-overlapping phenotypes. The clearer the difference between the two trait phenotypes, the greater the probability of detecting an association with biallelic markers. The selection of those drastically different but relatively uniform phenotypes enables efficient comparisons in association studies and the possible detection of marked differences at the genetic level, provided that the sample sizes of the populations under study are significant enough.

In preferred embodiments, a first group of between 50 and 300 trait positive individuals, preferably about 100 individuals, are recruited according to their phenotypes. A similar number of control individuals are included in such studies.

In the present invention, typical examples of inclusion criteria include, but are not restricted to, prostate cancer or aggressiveness of prostate cancer tumors. In one preferred

embodiment of the present invention, association studies are carried out on the basis of a presence (trait positive) or absence (trait negative) of prostate cancer.

Associations studies can be carried out by the skilled technician using the biallelic markers of the invention defined above, with different trait positive and trait negative populations. Suitable further examples of association studies using biallelic markers of the *BAP28* gene, including the biallelic markers A1 to A58, preferably A1 to A27, A34, A37 to A41, A43 to A49, A52, and A54 to A58, involve studies on the following populations:

- a trait positive population suffering from a cancer and a healthy unaffected population, or
- a trait positive population suffering from prostate cancer treated with agents acting against prostate cancer and suffering from side-effects resulting from this treatment and a trait negative population suffering from prostate cancer treated with same agents without any substantial side-effects, or
- a trait positive population suffering from prostate cancer treated with agents acting against prostate cancer showing a beneficial response and a trait negative population suffering from prostate cancer treated with same agents without any beneficial response, or
- a trait positive population suffering from prostate cancer presenting highly aggressive prostate cancer tumors and a trait negative population suffering from prostate cancer with prostate cancer tumors devoid of aggressiveness.

Association Analysis

- The invention also comprises methods of detecting an association between a genotype and a phenotype, comprising the steps of: a) determining the frequency of at least one *BAP28*-related biallelic marker in a trait positive population according to a genotyping method of the invention; b) determining the frequency of said *BAP28*-related biallelic marker in a control population according to a genotyping method of the invention; and c) determining whether a statistically significant association exists between said genotype and said phenotype. In addition, the methods of detecting an association between a genotype and a phenotype of the invention encompass methods with any further limitation described in this disclosure, or those following, specified alone or in any combination: In some embodiments, said *BAP28*-related biallelic marker is selected from the group consisting of A1 to A58, and the complements thereof, or the biallelic markers in linkage disequilibrium therewith; In some embodiments, said *BAP28*-related biallelic marker is selected from the group consisting of A1 to A27, A34, A37 to A41, A43 to A49, A52, and A54 to A58, and the complements thereof, or the biallelic markers in linkage disequilibrium therewith; In some embodiments, said *BAP28*-related biallelic marker is selected from the group consisting of A1, A4, A16, A30, A31, A42, A50, A51, and A53, and the complements thereof, or the biallelic markers in linkage disequilibrium therewith; In some embodiments, said control population may be a trait negative population, or a random population; In some embodiments, each of said genotyping steps a) and b) may be performed on a pooled biological sample derived from each of said populations; In

some embodiments, each of said genotyping of steps a) and b) is performed separately on biological samples derived from each individual in said population or a subsample thereof.

The general strategy to perform association studies using biallelic markers derived from a region carrying a candidate gene is to scan two groups of individuals (case-control populations) in order to measure and statistically compare the allele frequencies of the biallelic markers of the present invention in both groups.

If a statistically significant association with a trait is identified for at least one or more of the analyzed biallelic markers, one can assume that: either the associated allele is directly responsible for causing the trait (i.e. the associated allele is the trait causing allele), or more likely the associated allele is in linkage disequilibrium with the trait causing allele. The specific characteristics of the associated allele with respect to the candidate gene function usually give further insight into the relationship between the associated allele and the trait (causal or in linkage disequilibrium). If the evidence indicates that the associated allele within the candidate gene is most probably not the trait causing allele but is in linkage disequilibrium with the real trait causing allele, then the trait causing allele can be found by sequencing the vicinity of the associated marker, and performing further association studies with the polymorphisms that are revealed in an iterative manner.

Association studies are usually run in two successive steps. In a first phase, the frequencies of a reduced number of biallelic markers from the candidate gene are determined in the trait positive and control populations. In a second phase of the analysis, the position of the genetic loci responsible for the given trait is further refined using a higher density of markers from the relevant region. However, if the candidate gene under study is relatively small in length, as is the case for *BAP28*, a single phase may be sufficient to establish significant associations.

Haplotype Analysis

As described above, when a chromosome carrying a disease allele first appears in a population as a result of either mutation or migration, the mutant allele necessarily resides on a chromosome having a set of linked markers: the ancestral haplotype. This haplotype can be tracked through populations and its statistical association with a given trait can be analyzed. Complementing single point (allelic) association studies with multi-point association studies also called haplotype studies increases the statistical power of association studies. Thus, a haplotype association study allows one to define the frequency and the type of the ancestral carrier haplotype. A haplotype analysis is important in that it increases the statistical power of an analysis involving individual markers.

In a first stage of a haplotype frequency analysis, the frequency of the possible haplotypes based on various combinations of the identified biallelic markers of the invention is determined. The haplotype frequency is then compared for distinct populations of trait positive and control individuals. The number of trait positive individuals, which should be, subjected to this analysis to

obtain statistically significant results usually ranges between 30 and 300, with a preferred number of individuals ranging between 50 and 150. The same considerations apply to the number of unaffected individuals (or random control) used in the study. The results of this first analysis provide haplotype frequencies in case-control populations, for each evaluated haplotype frequency a p-value and an odd ratio are calculated. If a statistically significant association is found the relative risk for an individual carrying the given haplotype of being affected with the trait under study can be approximated.

- An additional embodiment of the present invention encompasses methods of detecting an association between a haplotype and a phenotype, comprising the steps of: a) estimating the frequency of at least one haplotype in a trait positive population, according to a method of the invention for estimating the frequency of a haplotype; b) estimating the frequency of said haplotype in a control population, according to a method of the invention for estimating the frequency of a haplotype; and c) determining whether a statistically significant association exists between said haplotype and said phenotype. In addition, the methods of detecting an association between a haplotype and a phenotype of the invention encompass methods with any further limitation described in this disclosure, or those following: In some embodiments, said *BAP28*-related biallelic marker is selected from the group consisting of A1 to A58, and the complements thereof, or the biallelic markers in linkage disequilibrium therewith; In some embodiments, said *BAP28*-related biallelic marker is selected from the group consisting of A1 to A27, A34, A37 to A41, A43 to A49, A52, and A54 to A58, and the complements thereof, or the biallelic markers in linkage disequilibrium therewith; In some embodiments, said *BAP28*-related biallelic marker is selected from the group consisting of A1, A4, 16, A30, A31, A42, A50, A51, and A53, and the complements thereof, or the biallelic markers in linkage disequilibrium therewith; In some embodiments, said control population is a trait negative population, or a random population. In some embodiments, said method comprises the additional steps of determining the phenotype in said trait positive and said control populations prior to step c).

Interaction Analysis

- The biallelic markers of the present invention may also be used to identify patterns of biallelic markers associated with detectable traits resulting from polygenic interactions. The analysis of genetic interaction between alleles at unlinked loci requires individual genotyping using the techniques described herein. The analysis of allelic interaction among a selected set of biallelic markers with appropriate level of statistical significance can be considered as a haplotype analysis. Interaction analysis consists in stratifying the case-control populations with respect to a given haplotype for the first loci and performing a haplotype analysis with the second loci with each subpopulation.

Statistical methods used in association studies are further described below.

Testing For Linkage In The Presence Of Association

The biallelic markers of the present invention may further be used in TDT (transmission/disequilibrium test). TDT tests for both linkage and association and is not affected by population stratification. TDT requires data for affected individuals and their parents or data from unaffected sibs instead of from parents (see Spielmann S. et al., 1993; Schaid D.J. et al., 1996, 5 Spielmann S. and Ewens W.J., 1998). Such combined tests generally reduce the false – positive errors produced by separate analyses.

Association OF Biallelic Markers Of *BAP28* With Prostate Cancer

Trait Positive And Control Populations

Two groups of independent individuals were used: the overall trait positive and the control 10 populations included 491 individuals suffering from prostate cancer and 313 individuals without any sign of prostate cancer. A specific protocol for the collection of DNA samples from trait positive and control individuals is described in Example 5. The 491 affected individuals can be subdivided in 197 familial cases and 294 sporadic cases. The sporadic cases comprises 70 sporadic informatives 15 cases. The 491 individuals suffering from prostate cancer can also be subdivided into a population of individuals who developed prostate cancer under 65 years-old and a population of individuals who developed prostate cancer after the age of 65.

In order to have as much certainty as possible on the absence of prostate cancer in control individuals, it is preferred to conduct a PSA dosage analysis on this population. Several commercial 20 assays can be used (WO 96/21042, herein by reference). In one preferred embodiment, a Hybritech assay is used and control individuals must have a level of PSA less than 2.8 ng/ml of serum in order to be selected as such. In a preferred embodiment, the Yang assay is used and trait negative individuals must have a level of PSA of less than 4 ng/ml of serum in order to be included in the population under study. More preferably, the control population is at least 65 year old.

Association Analysis

25 The association analysis showed an association between *BAP28*-related biallelic markers and prostate cancer, more particularly both familial prostate cancer and sporadic prostate cancer. The results of the association study were further details in example 5.

A single point analysis of the association study showed an association between biallelic 30 markers of the *BAP28* gene and prostate cancer, preferably sporadic prostate cancer is associated most strongly with the biallelic markers A28 (5-14/165), A4 (5-382/316), A1 (5-381/133), and A55 (99-7182/49) which present a particular interest (Figures 5 and 6). These association results constitute new elements for studying the genetic susceptibility of individuals to prostate cancer, preferably to sporadic and familial prostate cancer. Further details concerning this association study 35 are provided in Figures 5 and 6 and in the example 5.

Similar association studies can also be carried out with other biallelic markers within the scope of the invention, preferably with biallelic markers in linkage disequilibrium with the markers associated with prostate cancer as described above, including the biallelic markers A1 to A58.

Haplotype Analysis

- 5 In the context of the present invention, a haplotype can be defined as a combination of biallelic markers found in a given individual and which may be associated more or less significantly, as a result of appropriate statistical analyses, with the expression of a given trait.

The haplotype studies are detailed in Example 5.

Several two-marker haplotypes were significantly associated with familial prostate cancer.

- 10 One preferred two-marker haplotype including markers A30 (99-1572/440) and A32 (5-171/204), alleles TT respectively, was shown to be significantly associated with prostate cancer, preferably with familial prostate cancer. As shown in Figures 8, 9 and 12 A, this haplotype presents a p-value of $2.5 \cdot 10^{-6}$ for the early onset familial prostate cancer (see Example 5).

Several two-marker haplotypes were significantly associated with sporadic prostate cancer.

- 15 One preferred two-marker haplotype including markers A16 (5-370/197), and A1 (5-381/133), alleles GA was shown to be significantly associated with sporadic prostate cancer. As shown in Figures 10, 11 and 12 B, this haplotype presents a p-value of 9.4×10^{-8} for the informative sporadic prostate cancer (see Example 5).

Several two-marker haplotypes were significantly associated with sporadic prostate cancer.

- 20 One preferred two-marker haplotype including markers A53 (99-1601/402), and A4 (5-382/316), alleles TG, was shown to be significantly associated with sporadic prostate cancer. As shown in Figures 10, 11 and 12 C, this haplotype presents a p-value of 1×10^{-5} for the informative sporadic prostate cancer (see Example 5).

Several three-biallelic marker haplotypes are described in the Example 5.

- 25 The permutation tests clearly validated the statistical significance of the association between these haplotypes and the prostate cancer (see Example 5). All these haplotypes can be used in diagnostic of prostate cancer, more particularly either familial prostate cancer or sporadic prostate cancer.

This information is extremely valuable. The knowledge of a potential genetic

- 30 predisposition to prostate cancer, even if this predisposition is not absolute, might contribute in a very significant manner to treatment efficacy of prostate cancer and to the development of new therapeutic and diagnostic tools.

The invention concerns a haplotype comprising at least one biallelic marker selected from the group consisting of A1 to A58, preferably A54, A58, A57, A56, A55, A1, A4, A5, A7, A11,

- 35 A12, A16, A19, A21, A25, A27, A28, A29, A35, A33, A34, A32, A31, A30, A50, A51, A42, A53, A43, and A48, more preferably A1, A4, A30, A31, A42, A51, and A53.

Statistical methods

In general, any method known in the art to test whether a trait and a genotype show a statistically significant correlation may be used.

1) Methods In Linkage Analysis

- 5 Statistical methods and computer programs useful for linkage analysis are well-known to those skilled in the art (see Terwilliger J.D. and Ott J., 1994; Ott J., 1991).

2) Methods To Estimate Haplotype Frequencies In A Population

- As described above, when genotypes are scored, it is often not possible to distinguish heterozygotes so that haplotype frequencies cannot be easily inferred. When the gametic phase is not known, haplotype frequencies can be estimated from the multilocus genotypic data. Any method known to person skilled in the art can be used to estimate haplotype frequencies (see Lange K., 1997; Weir, B.S., 1996) Preferably, maximum-likelihood haplotype frequencies are computed using an Expectation- Maximization (EM) algorithm (see Dempster et al., 1977; Excoffier L. and Slatkin M., 1995). This procedure is an iterative process aiming at obtaining maximum-likelihood estimates of haplotype frequencies from multi-locus genotype data when the gametic phase is unknown. Haplotype estimations are usually performed by applying the EM algorithm using for example the EM-HAPLO program (Hawley M. E. et al., 1994) or the Arlequin program (Schneider et al., 1997). The EM algorithm is a generalized iterative maximum likelihood approach to estimation and is briefly described below.

- 20 Please note that in the present section, "Methods To Estimate Haplotype Frequencies In A Population," of this text, phenotypes will refer to multi-locus genotypes with unknown phase. Genotypes will refer to known-phase multi-locus genotypes.

- A sample of N unrelated individuals is typed for K markers. The data observed are the unknown-phase K-locus phenotypes that can be categorized in F different phenotypes. Suppose that we have H underlying possible haplotypes (in case of K biallelic markers, $H=2^K$).

For phenotype j, suppose that c_j genotypes are possible. We thus have the following equation

$$P_j = \sum_{i=1}^{c_j} pr(genotype_i) = \sum_{i=1}^{c_j} pr(h_k, h_l) \quad \text{Equation 1}$$

- where P_j is the probability of the phenotype j, h_k and h_l are the two haplotypes constituent the genotype i. Under the Hardy-Weinberg equilibrium, $pr(h_k, h_l)$ becomes:

$$pr(h_k, h_l) = pr(h_k)^2 \text{ if } h_k = h_l, pr(h_k, h_l) = 2 pr(h_k) . pr(h_l) \text{ if } h_k \neq h_l. \quad \text{Equation 2}$$

The successive steps of the E-M algorithm can be described as follows:

Starting with initial values of the of haplotypes frequencies, noted $p_1^{(0)}, p_2^{(0)}, \dots, p_H^{(0)}$, these initial values serve to estimate the genotype frequencies (Expectation step) and then estimate

another set of haplotype frequencies (Maximization step), noted $p_1^{(l)}, p_2^{(l)}, \dots, p_H^{(l)}$, these two steps are iterated until changes in the sets of haplotypes frequency are very small.

- A stop criterion can be that the maximum difference between haplotype frequencies between two iterations is less than 10^{-7} . These values can be adjusted according to the desired precision of estimations.

At a given iteration s , the Expectation step consists in calculating the genotypes frequencies by the following equation:

$$\begin{aligned} pr(genotype_i)^{(s)} &= pr(phenotype_j) \cdot pr(genotype_i | phenotype_j)^{(s)} \\ &= \frac{n_j}{N} \cdot \frac{pr(h_k, h_l)^{(s)}}{P_j^{(s)}} \end{aligned} \quad \text{Equation 3}$$

- where genotype i occurs in phenotype j , and where h_k and h_l constitute genotype i . Each probability is derived according to eq. 1, and eq. 2 described above.

Then the Maximization step simply estimates another set of haplotype frequencies given the genotypes frequencies. This approach is also known as the gene-counting method (Smith, 1957).

$$p_i^{(s+1)} = \frac{1}{2} \sum_{j=1}^F \sum_{i=1}^c \delta_{ij} \cdot pr(genotype_i)^{(s)} \quad \text{Equation 4}$$

- Where δ_{ij} is an indicator variable which count the number of time haplotype i in genotype j . It takes the values of 0, 1 or 2.

To ensure that the estimation finally obtained is the maximum-likelihood estimation several values of departures are required. The estimations obtained are compared and if they are different the estimations leading to the best likelihood are kept.

3) Methods To Calculate Linkage Disequilibrium Between Markers

A number of methods can be used to calculate linkage disequilibrium between any two genetic positions, in practice linkage disequilibrium is measured by applying a statistical association test to haplotype data taken from a population.

- Linkage disequilibrium between any pair of biallelic markers comprising at least one of the biallelic markers of the present invention (M_i, M_j) having alleles (a_i/b_i) at marker M_i and alleles (a_j/b_j) at marker M_j can be calculated for every allele combination ($a_i, a_j, a_i, b_j, b_i, a_j$ and b_i, b_j), according to the Piazza formula:

$$\Delta_{aij} = \sqrt{\theta 4} - \sqrt{(\theta 4 + \theta 3)(\theta 4 + \theta 2)}, \text{ where:}$$

- $\theta 4 = - -$ = frequency of genotypes not having allele a_i at M_i and not having allele a_j at M_j
 $\theta 3 = - +$ = frequency of genotypes not having allele a_i at M_i and having allele a_j at M_j
 $\theta 2 = + -$ = frequency of genotypes having allele a_i at M_i and not having allele a_j at M_j

Linkage disequilibrium (LD) between pairs of biallelic markers (M_i, M_j) can also be calculated for every allele combination ($a_i, a_j, a_i, b_j, b_i, a_j$ and b_i, b_j), according to the maximum-likelihood estimate (MLE) for delta (the composite genotypic disequilibrium coefficient), as described by Weir (Weir B. S., 1996). The MLE for the composite linkage disequilibrium is:

$$D_{ai aj} = (2n_1 + n_2 + n_3 + n_4/2)/N - 2(pr(a_i) \cdot pr(a_j))$$

Where $n_1 = \Sigma$ phenotype ($a_i/a_i, a_i/a_j$), $n_2 = \Sigma$ phenotype ($a_i/a_i, a_j/b_j$), $n_3 = \Sigma$ phenotype ($a_i/b_i, a_j/b_j$), $n_4 = \Sigma$ phenotype ($a_j/b_i, a_j/b_j$) and N is the number of individuals in the sample.

This formula allows linkage disequilibrium between alleles to be estimated when only genotype, and not haplotype, data are available.

Another means of calculating the linkage disequilibrium between markers is as follows. For a couple of biallelic markers, $M_i (a_i/b_i)$ and $M_j (a_j/b_j)$, fitting the Hardy-Weinberg equilibrium, one can estimate the four possible haplotype frequencies in a given population according to the approach described above.

The estimation of gametic disequilibrium between a_i and a_j is simply:

$$D_{ai aj} = pr(haplotype(a_i, a_j)) - pr(a_i) \cdot pr(a_j).$$

Where $pr(a_i)$ is the probability of allele a_i and $pr(a_j)$ is the probability of allele a_j and where $pr(haplotype(a_i, a_j))$ is estimated as in [Equation 3](#) above.

For a couple of biallelic marker only one measure of disequilibrium is necessary to describe the association between M_i and M_j .

Then a normalized value of the above is calculated as follows:

$$D'_{ai aj} = D_{ai aj} / \max(-pr(a_i) \cdot pr(a_j), -pr(b_i) \cdot pr(b_j)) \text{ with } D_{ai aj} < 0$$

$$D'_{ai aj} = D_{ai aj} / \max(pr(b_i) \cdot pr(a_j), pr(a_i) \cdot pr(b_j)) \text{ with } D_{ai aj} > 0$$

The skilled person will readily appreciate that other linkage disequilibrium calculation methods can be used.

Linkage disequilibrium among a set of biallelic markers having an adequate heterozygosity rate can be determined by genotyping between 50 and 1000 unrelated individuals, preferably between 75 and 200, more preferably around 100.

4) Testing For Association

Methods for determining the statistical significance of a correlation between a phenotype and a genotype, in this case an allele at a biallelic marker or a haplotype made up of such alleles, may be determined by any statistical test known in the art and with any accepted threshold of statistical significance being required. The application of particular methods and thresholds of significance are well with in the skill of the ordinary practitioner of the art.

Testing for association is performed by determining the frequency of a biallelic marker allele in case and control populations and comparing these frequencies with a statistical test to determine if there is a statistically significant difference in frequency which would indicate a correlation between the trait and the biallelic marker allele under study. Similarly, a haplotype analysis is performed by estimating the frequencies of all possible haplotypes for a given set of biallelic markers in case and control populations, and comparing these frequencies with a statistical test to determine if there is a statistically significant correlation between the haplotype and the phenotype (trait) under study. Any statistical tool useful to test for a statistically significant association between a genotype and a phenotype may be used. Preferably the statistical test employed is a chi-square test with one degree of freedom. A P-value is calculated (the P-value is the probability that a statistic as large or larger than the observed one would occur by chance).

Statistical Significance

In preferred embodiments, significance for diagnosis purposes, either as a positive basis for further diagnostic tests or as a preliminary starting point for early preventive therapy, the p value related to a biallelic marker association is preferably about 1×10^{-2} or less, more preferably about 1×10^{-4} or less, for a single biallelic marker analysis and about 1×10^{-3} or less, still more preferably 1×10^{-6} or less and most preferably of about 1×10^{-8} or less, for a haplotype analysis involving two or more markers. These values are believed to be applicable to any association studies involving single or multiple marker combinations.

The skilled person can use the range of values set forth above as a starting point in order to carry out association studies with biallelic markers of the present invention. In doing so, significant associations between the biallelic markers of the present invention and a trait can be revealed and used for diagnosis and drug screening purposes.

Phenotypic Permutation

In order to confirm the statistical significance of the first stage haplotype analysis described above, it might be suitable to perform further analyses in which genotyping data from case-control individuals are pooled and randomized with respect to the trait phenotype. Each individual genotyping data is randomly allocated to two groups, which contain the same number of individuals as the case-control populations used to compile the data obtained in the first stage. A second stage haplotype analysis is preferably run on these artificial groups, preferably for the markers included in the haplotype of the first stage analysis showing the highest relative risk coefficient. This experiment is reiterated preferably at least between 100 and 10000 times. The repeated iterations allow the determination of the probability to obtain the tested haplotype by chance.

Assessment Of Statistical Association

To address the problem of false positives similar analysis may be performed with the same case-control populations in random genomic regions. Results in random regions and the candidate

region are compared as described in a co-pending US Provisional Patent Application entitled "Methods, Software And Apparati For Identifying Genomic Regions Harboring A Gene Associated With A Detectable Trait," U.S. Serial Number 60/107,986, filed November 10, 1998, the contents of which are incorporated herein by reference.

5) Evaluation Of Risk Factors

The association between a risk factor (in genetic epidemiology the risk factor is the presence or the absence of a certain allele or haplotype at marker loci) and a disease is measured by the odds ratio (OR) and by the relative risk (RR). If $P(R^+)$ is the probability of developing the disease for individuals with R and $P(R^-)$ is the probability for individuals without the risk factor, then

- 10 the relative risk is simply the ratio of the two probabilities, that is:

$$RR = P(R^+) / P(R^-)$$

In case-control studies, direct measures of the relative risk cannot be obtained because of the sampling design. However, the odds ratio allows a good approximation of the relative risk for low-incidence diseases and can be calculated:

$$OR = \left[\frac{F^+}{1 - F^+} \right] / \left[\frac{F^-}{1 - F^-} \right]$$

- 15 $OR = (F^+ / (1 - F^+)) / (F^- / (1 - F^-))$

F^+ is the frequency of the exposure to the risk factor in cases and F^- is the frequency of the exposure to the risk factor in controls. F^+ and F^- are calculated using the allelic or haplotype frequencies of the study and further depend on the underlying genetic model (dominant, recessive, additive...).

- 20 One can further estimate the attributable risk (AR) which describes the proportion of individuals in a population exhibiting a trait due to a given risk factor. This measure is important in quantifying the role of a specific factor in disease etiology and in terms of the public health impact of a risk factor. The public health relevance of this measure lies in estimating the proportion of cases of disease in the population that could be prevented if the exposure of interest were absent.

- 25 AR is determined as follows:

$$AR = P_E (RR - 1) / (P_E (RR - 1) + 1)$$

AR is the risk attributable to a biallelic marker allele or a biallelic marker haplotype. P_E is the frequency of exposure to an allele or a haplotype within the population at large; and RR is the relative risk which, is approximated with the odds ratio when the trait under study has a relatively

- 30 low incidence in the general population.

Identification Of Biallelic Markers In Linkage Disequilibrium With The Biallelic Markers of the Invention

Once a first biallelic marker has been identified in a genomic region of interest, the practitioner of ordinary skill in the art, using the teachings of the present invention, can easily

identify additional biallelic markers in linkage disequilibrium with this first marker. As mentioned before any marker in linkage disequilibrium with a first marker associated with a trait will be associated with the trait. Therefore, once an association has been demonstrated between a given biallelic marker and a trait, the discovery of additional biallelic markers associated with this trait is of great interest in order to increase the density of biallelic markers in this particular region. The causal gene or mutation will be found in the vicinity of the marker or set of markers showing the highest correlation with the trait.

Identification of additional markers in linkage disequilibrium with a given marker involves: (a) amplifying a genomic fragment comprising a first biallelic marker from a plurality of individuals; (b) identifying of second biallelic markers in the genomic region harboring said first biallelic marker; (c) conducting a linkage disequilibrium analysis between said first biallelic marker and second biallelic markers; and (d) selecting said second biallelic markers as being in linkage disequilibrium with said first marker. Subcombinations comprising steps (b) and (c) are also contemplated.

Methods to identify biallelic markers and to conduct linkage disequilibrium analysis are described herein and can be carried out by the skilled person without undue experimentation. The present invention then also concerns biallelic markers which are in linkage disequilibrium with the specific biallelic markers A1 to A58, preferably one of the biallelic markers A1 to A27, A34, A37 to A41, A43 to A49, A52, and A54 to A58, more preferably one of, the biallelic markers A1, A4, 16, A30, A31, A42, A50, A51, and A53, and which are expected to present similar characteristics in terms of their respective association with a given trait. In a preferred embodiment, the invention concerns biallelic markers which are in linkage disequilibrium with the specific biallelic markers

Identification Of Functional Mutations

Mutations in the *BAP28* gene which are responsible for a detectable phenotype or trait may be identified by comparing the sequences of the *BAP28* gene from trait positive and control individuals. Once a positive association is confirmed with a biallelic marker of the present invention, the identified locus can be scanned for mutations. In a preferred embodiment, functional regions such as exons and splice sites, promoters and other regulatory regions of the *BAP28* gene are scanned for mutations. In a preferred embodiment the sequence of the *BAP28* gene is compared in trait positive and control individuals. Preferably, trait positive individuals carry the haplotype shown to be associated with the trait and trait negative individuals do not carry the haplotype or allele associated with the trait. The detectable trait or phenotype may comprise a variety of manifestations of altered *BAP28* function.

The mutation detection procedure is essentially similar to that used for biallelic marker identification. The method used to detect such mutations generally comprises the following steps:

Biallelic Markers Of The Invention In Methods Of Genetic Diagnostics

The diagnostic techniques of the present invention may employ a variety of methodologies to determine whether a test subject has a biallelic marker pattern associated with an increased risk of developing a detectable trait or whether the individual suffers from a detectable trait as a result of a particular mutation, including methods which enable the analysis of individual chromosomes for haplotyping, such as family studies, single sperm DNA analysis or somatic hybrids.

These methods involve obtaining a nucleic acid sample from the individual and, determining, whether the nucleic acid sample contains at least one allele or at least one biallelic

marker haplotype, indicative of a risk of developing the trait or indicative that the individual expresses the trait as a result of possessing a particular *BAP28* polymorphism or mutation (trait-causing allele).

Preferably, in such diagnostic methods, a nucleic acid sample is obtained from the individual and this sample is genotyped using methods described above in "Methods Of Genotyping DNA Samples For Biallelic markers. The diagnostics may be based on a single biallelic marker or a group of biallelic markers.

In each of these methods, a nucleic acid sample is obtained from the test subject and the biallelic marker pattern of one or more of the biallelic markers A1 to A58, preferably one or more of the biallelic markers A1 to A27, A34, A37 to A41, A43 to A49, A52, and A54 to A58, more preferably one or more of the biallelic markers A1, A4, 16, A30, A31, A42, A50, A51, and A53, is determined.

In one embodiment, a PCR amplification is conducted on the nucleic acid sample to amplify regions in which polymorphisms associated with a detectable phenotype have been identified. The amplification products are sequenced to determine whether the individual possesses one or more *BAP28* polymorphisms associated with a detectable phenotype. The primers used to generate amplification products may comprise the primers listed in Table 1. Alternatively, the nucleic acid sample is subjected to microsequencing reactions as described above to determine whether the individual possesses one or more *BAP28* polymorphisms associated with a detectable phenotype resulting from a mutation or a polymorphism in the *BAP28* gene. The primers used in the microsequencing reactions may include the primers listed in Table 4. In another embodiment, the nucleic acid sample is contacted with one or more allele specific oligonucleotide probes which, specifically hybridize to one or more *BAP28* alleles associated with a detectable phenotype. The probes used in the hybridization assay may include the probes listed in Table 3. In another embodiment, the nucleic acid sample is contacted with a second *BAP28* oligonucleotide capable of producing an amplification product when used with the allele specific oligonucleotide in an amplification reaction. The presence of an amplification product in the amplification reaction indicates that the individual possesses one or more *BAP28* alleles associated with a detectable phenotype.

In a preferred embodiment the identity of the nucleotide present at, at least one, biallelic marker selected from the group consisting of A1 to A58 and the complements thereof, preferably A1 to A27, A34, A37 to A41, A43 to A49, A52, and A54 to A58, more preferably A1, A4, 16, A30, A31, A42, A50, A51, and A53, and the complements thereof, is determined and the detectable trait is prostate cancer, more preferably sporadic prostate cancer. Diagnostic kits comprise any of the polynucleotides of the present invention.

These diagnostic methods are extremely valuable as they can, in certain circumstances, be used to initiate preventive treatments or to allow an individual carrying a significant haplotype to foresee warning signs such as minor symptoms.

5 Diagnostics, which analyze and predict response to a drug or side effects to a drug, may be used to determine whether an individual should be treated with a particular drug. For example, if the diagnostic indicates a likelihood that an individual will respond positively to treatment with a particular drug, the drug may be administered to the individual. Conversely, if the diagnostic indicates that an individual is likely to respond negatively to treatment with a particular drug, an alternative course of treatment may be prescribed. A negative response may be defined as either the
10 absence of an efficacious response or the presence of toxic side effects.

Clinical drug trials represent another application for the markers of the present invention. One or more markers indicative of response to an agent acting against prostate cancer or to side effects to an agent acting against prostate cancer may be identified using the methods described above. Thereafter, potential participants in clinical trials of such an agent may be screened to
15 identify those individuals most likely to respond favorably to the drug and exclude those likely to experience side effects. In that way, the effectiveness of drug treatment may be measured in individuals who respond positively to the drug, without lowering the measurement as a result of the inclusion of individuals who are unlikely to respond positively in the study and without risking undesirable safety problems.

20

Treatment Of Prostate Cancer

As the metastasis of prostate cancer can be fatal, it is important to detect prostate cancer susceptibility of individuals. Consequently, the invention also concerns a method for the treatment of prostate cancer comprising the following steps:

- 25 - selecting an individual whose DNA comprises alleles of a biallelic marker or of a group of biallelic markers, preferably *BAP28*-related markers, associated with prostate cancer;
- following up said individual for the appearance (and optionally the development) of tumors in prostate; and
- administering an effective amount of a medicament acting against prostate cancer to said individual at an appropriate stage of the prostate cancer.

30

In one embodiment, said biallelic marker is selected from the group consisting of A1 to A58, and the complements thereof. In a preferred embodiment, said biallelic marker is selected from the group consisting of A1 to A27, A34, A37 to A41, A43 to A49, A52, and A54 to A58 and the complements thereof. In a preferred embodiment, said biallelic marker is selected from the group consisting of A1, A4, 16, A30, A31, A42, A50, A51, and A53, and the complements thereof.

35

The prophylactic administration of a treatment serves to prevent, attenuate or inhibit the growth of cancer cells.

Another embodiment of the present invention consists of a method for the treatment of prostate cancer comprising the following steps:

- selecting an individual whose DNA comprises alleles of a biallelic marker or of a group of biallelic markers, preferably *BAP28*-related markers, associated with prostate cancer;
- 5 - administering to said individual, preferably as a preventive treatment of prostate cancer, an effective amount of a medicament acting against prostate cancer such as 4HPR.

In one embodiment, said biallelic marker is selected from the group consisting of A1 to A58, and the complements thereof. In a preferred embodiment, said biallelic marker is selected from the group consisting of A1 to A27, A34, A37 to A41, A43 to A49, A52, and A54 to A58 and the complements thereof. In a preferred embodiment, said biallelic marker is selected from the group consisting of A1, A4, 16, A30, A31, A42, A50, A51, and A53, and the complements thereof.

In a further embodiment, the present invention concerns a method for the treatment of prostate cancer comprising the following steps:

- selecting an individual whose DNA comprises alleles of a biallelic marker or of a group of biallelic markers, preferably *BAP28*-related markers, associated with a susceptibility to prostate cancer;
- 15 - administering to said individual, as a preventive treatment of prostate cancer, an effective amount of a medicament acting against prostate cancer such as 4HPR;
- following up said individual for the appearance and the development of tumors in prostate; and optionally
- 20 - administering an effective amount of a medicament acting against prostate cancer to said individual at the appropriate stage of the prostate cancer.

In one embodiment, said biallelic marker is selected from the group consisting of A1 to A58, and the complements thereof. In a preferred embodiment, said biallelic marker is selected from the group consisting of A1 to A27, A34, A37 to A41, A43 to A49, A52, and A54 to A58 and the complements thereof. In a preferred embodiment, said biallelic marker is selected from the group consisting of A1, A4, 16, A30, A31, A42, A50, A51, and A53, and the complements thereof.

To enlighten the choice of the appropriate beginning of the treatment of prostate cancer, the present invention also concerns a method for the treatment of prostate cancer comprising the following steps:

- selecting an individual suffering from a prostate cancer whose DNA comprises alleles of a biallelic marker or of a group of biallelic markers, preferably *BAP28*-related markers, associated with the aggressiveness of prostate cancer tumors; and
- 35 - administering an effective amount of a medicament acting against prostate cancer to said individual.

In one embodiment, said biallelic marker is selected from the group consisting of A1 to A58, and the complements thereof. In a preferred embodiment, said biallelic marker is selected from

the group consisting of A1 to A27, A34, A37 to A41, A43 to A49, A52, and A54 to A58 and the complements thereof. In a preferred embodiment, said biallelic marker is selected from the group consisting of A1, A4, 16, A30, A31, A42, A50, A51, and A53, and the complements thereof. In particular embodiments, the individual is selected by genotyping one or more biallelic markers of

5 the present invention.

Recombinant Vectors

The term "vector" is used herein to designate either a circular or a linear DNA or RNA molecule, which is either double-stranded or single-stranded, and which comprise at least one polynucleotide of interest that is sought to be transferred in a cell host or in a unicellular or

10 multicellular host organism.

The present invention encompasses a family of recombinant vectors that comprise a regulatory polynucleotide derived from the *BAP28* genomic sequence, and/or a coding polynucleotide from either the *BAP28* genomic sequence or the cDNA sequence.

Generally, a recombinant vector of the invention may comprise any of the polynucleotides

15 described herein, including regulatory sequences, coding sequences and polynucleotide constructs, as well as any *BAP28* primer or probe as defined above. More particularly, the recombinant vectors of the present invention can comprise any of the polynucleotides described in the "Genomic Sequences Of The *BAP28* Gene" section, the "*BAP28* cDNA Sequences" section, the "Coding Regions" section, the "Polynucleotide constructs" section, and the "Oligonucleotide Probes And

20 Primers" section.

In a first preferred embodiment, a recombinant vector of the invention is used to amplify the inserted polynucleotide derived from a *BAP28* genomic sequence of SEQ ID No 1 or a *BAP28* cDNA, for example the cDNA of SEQ ID No 2, 3 or 4 in a suitable cell host, this polynucleotide being amplified at every time that the recombinant vector replicates.

A second preferred embodiment of the recombinant vectors according to the invention consists of expression vectors comprising either a regulatory polynucleotide or a coding nucleic acid of the invention, or both. Within certain embodiments, expression vectors are employed to express the *BAP28* polypeptide which can be then purified and, for example be used in ligand screening assays or as an immunogen in order to raise specific antibodies directed against the *BAP28* protein.

30 In other embodiments, the expression vectors are used for constructing transgenic animals and also for gene therapy. Expression requires that appropriate signals are provided in the vectors, said signals including various regulatory elements, such as enhancers/promoters from both viral and mammalian sources that drive expression of the genes of interest in host cells. Dominant drug selection markers for establishing permanent, stable cell clones expressing the products are generally

35 included in the expression vectors of the invention, as they are elements that link expression of the drug selection markers to expression of the polypeptide.

In a further embodiment, the invention concerns a vector comprising a polynucleotide sequence selected from the group consisting of SEQ ID Nos 4, and 9-13, a complementary sequence thereto or a fragment thereof.

- More particularly, the present invention relates to expression vectors which include nucleic acids encoding a BAP28 protein, preferably the BAP28 protein of the amino acid sequence of SEQ ID No 5 or variants or fragments thereof.

The invention also pertains to a recombinant expression vector useful for the expression of the *BAP28* coding sequence, wherein said vector comprises a nucleic acid of SEQ ID No 2 or 3.

- Recombinant vectors comprising a nucleic acid containing a *BAP28*-related biallelic marker is also part of the invention. In a preferred embodiment, said biallelic marker is selected from the group consisting of A1 to A58, preferably A1 to A27, A34, A37 to A41, A43 to A49, A52, and A54 to A58, more preferably A1, A4, 16, A30, A31, A42, A50, A51, and A53, and the complements thereof.

- Some of the elements which can be found in the vectors of the present invention are described in further detail in the following sections.

- The present invention also encompasses primary, secondary, and immortalized homologously recombinant host cells of vertebrate origin, preferably mammalian origin and particularly human origin, that have been engineered to: a) insert exogenous (heterologous) polynucleotides into the endogenous chromosomal DNA of a targeted gene, b) delete endogenous chromosomal DNA, and/or c) replace endogenous chromosomal DNA with exogenous polynucleotides. Insertions, deletions, and/or replacements of polynucleotide sequences may be to the coding sequences of the targeted gene and/or to regulatory regions, such as promoter and enhancer sequences, operably associated with the targeted gene.

- The present invention further relates to a method of making a homologously recombinant host cell in vitro or in vivo, wherein the expression of a targeted gene not normally expressed in the cell is altered. Preferably the alteration causes expression of the targeted gene under normal growth conditions or under conditions suitable for producing the polypeptide encoded by the targeted gene. The method comprises the steps of: (a) transfecting the cell in vitro or in vivo with a polynucleotide construct, the a polynucleotide construct comprising: (i) a targeting sequence; (ii) a regulatory sequence and/or a coding sequence; and (iii) an unpaired splice donor site, if necessary, thereby producing a transfected cell; and (b) maintaining the transfected cell in vitro or in vivo under conditions appropriate for homologous recombination.

- The present invention further relates to a method of altering the expression of a targeted gene in a cell in vitro or in vivo wherein the gene is not normally expressed in the cell, comprising the steps of: (a) transfecting the cell in vitro or in vivo with a polynucleotide construct, the a polynucleotide construct comprising: (i) a targeting sequence; (ii) a regulatory sequence and/or a coding sequence; and (iii) an unpaired splice donor site, if necessary, thereby producing a

transfected cell; and (b) maintaining the transfected cell in vitro or in vivo under conditions appropriate for homologous recombination, thereby producing a homologously recombinant cell; and (c) maintaining the homologously recombinant cell in vitro or in vivo under conditions appropriate for expression of the gene.

- 5 The present invention further relates to a method of making a polypeptide of the present invention by altering the expression of a targeted endogenous gene in a cell in vitro or in vivo wherein the gene is not normally expressed in the cell, comprising the steps of: a) transfecting the cell in vitro with a a polynucleotide construct, the a polynucleotide construct comprising: (i) a targeting sequence; (ii) a regulatory sequence and/or a coding sequence; and (iii) an unpaired splice donor site, if necessary, thereby producing a transfected cell; (b) maintaining the transfected cell in vitro or in vivo under conditions appropriate for homologous recombination, thereby producing a homologously recombinant cell; and c) maintaining the homologously recombinant cell in vitro or in vivo under conditions appropriate for expression of the gene thereby making the polypeptide.

- The present invention further relates to a polynucleotide construct which alters the expression of a targeted gene in a cell type in which the gene is not normally expressed. This occurs when the a polynucleotide construct is inserted into the chromosomal DNA of the target cell, wherein the a polynucleotide construct comprises: a) a targeting sequence; b) a regulatory sequence and/or coding sequence; and c) an unpaired splice-donor site, if necessary. Further included are a polynucleotide constructs, as described above, wherein the construct further comprises a polynucleotide which encodes a polypeptide and is in-frame with the targeted endogenous gene after homologous recombination with chromosomal DNA.

- The compositions may be produced, and methods performed, by techniques known in the art, such as those described in U.S. Patent Nos: 6,054,288; 6,048,729; 6,048,724; 6,048,524; 5,994,127; 5,968,502; 5,965,125; 5,869,239; 5,817,789; 5,783,385; 5,733,761; 5,641,670; 5,580,734; 25 ; International Publication Nos: WO96/29411, WO 94/12650; and scientific articles including 1994; Koller et al., Proc. Natl. Acad. Sci. USA 86:8932-8935 (1989) (the disclosures of each of which are incorporated by reference in their entirety).

1. General features of the expression vectors of the invention

- A recombinant vector according to the invention comprises, but is not limited to, a YAC (Yeast Artificial Chromosome), a BAC (Bacterial Artificial Chromosome), a phage, a phagemid, a cosmid, a plasmid or even a linear DNA molecule which may comprise a chromosomal, non-chromosomal, semi-synthetic and synthetic DNA. Such a recombinant vector can comprise a transcriptional unit comprising an assembly of:

- (1) a genetic element or elements having a regulatory role in gene expression, for example promoters or enhancers. Enhancers are cis-acting elements of DNA, usually from about 10 to 300 bp in length that act on the promoter to increase the transcription.

(2) a structural or coding sequence which is transcribed into mRNA and eventually translated into a polypeptide, said structural or coding sequence being operably linked to the regulatory elements described in (1); and

(3) appropriate transcription initiation and termination sequences. Structural units intended for use in yeast or eukaryotic expression systems preferably include a leader sequence enabling extracellular secretion of translated protein by a host cell. Alternatively, when a recombinant protein is expressed without a leader or transport sequence, it may include a N-terminal residue. This residue may or may not be subsequently cleaved from the expressed recombinant protein to provide a final product.

Generally, recombinant expression vectors will include origins of replication, selectable markers permitting transformation of the host cell, and a promoter derived from a highly expressed gene to direct transcription of a downstream structural sequence. The heterologous structural sequence is assembled in appropriate phase with translation initiation and termination sequences, and preferably a leader sequence capable of directing secretion of the translated protein into the periplasmic space or the extracellular medium. In a specific embodiment wherein the vector is adapted for transfecting and expressing desired sequences in mammalian host cells, preferred vectors will comprise an origin of replication in the desired host, a suitable promoter and enhancer, and also any necessary ribosome binding sites, polyadenylation site, splice donor and acceptor sites, transcriptional termination sequences, and 5'-flanking non-transcribed sequences. DNA sequences derived from the SV40 viral genome, for example SV40 origin, early promoter, enhancer, splice and polyadenylation sites may be used to provide the required non-transcribed genetic elements.

The *in vivo* expression of a BAP28 polypeptide of SEQ ID No 5 or fragments or variants thereof may be useful in order to correct a genetic defect related to the expression of the native gene in a host organism or to the production of a biologically inactive BAP28 protein.

Consequently, the present invention also deals with recombinant expression vectors mainly designed for the *in vivo* production of the BAP28 polypeptide of SEQ ID No 5 or fragments or variants thereof by the introduction of the appropriate genetic material in the organism of the patient to be treated. This genetic material may be introduced *in vitro* in a cell that has been previously extracted from the organism, the modified cell being subsequently reintroduced in the said organism, directly *in vivo* into the appropriate tissue.

2. Regulatory Elements

Promoters

The suitable promoter regions used in the expression vectors according to the present invention are chosen taking into account the cell host in which the heterologous gene has to be expressed. The particular promoter employed to control the expression of a nucleic acid sequence of interest is not believed to be important, so long as it is capable of directing the expression of the

nucleic acid in the targeted cell. Thus, where a human cell is targeted, it is preferable to position the nucleic acid coding region adjacent to and under the control of a promoter that is capable of being expressed in a human cell, such as, for example, a human or a viral promoter.

- 5 A suitable promoter may be heterologous with respect to the nucleic acid for which it controls the expression or alternatively can be endogenous to the native polynucleotide containing the coding sequence to be expressed. Additionally, the promoter is generally heterologous with respect to the recombinant vector sequences within which the construct promoter/coding sequence has been inserted.

- 10 Promoter regions can be selected from any desired gene using, for example, CAT (chloramphenicol transferase) vectors and more preferably pKK232-8 and pCM7 vectors.

Preferred bacterial promoters are the LacI, LacZ, the T3 or T7 bacteriophage RNA polymerase promoters, the gpt, lambda PR, PL and trp promoters (EP 0036776), the polyhedrin promoter, or the p10 protein promoter from baculovirus (Kit Novagen) (Smith et al., 1983; O'Reilly et al., 1992), the lambda PR promoter or also the trc promoter.

- 15 Eukaryotic promoters include CMV immediate early, HSV thymidine kinase, early and late SV40, LTRs from retrovirus, and mouse metallothionein-L. Selection of a convenient vector and promoter is well within the level of ordinary skill in the art.

- The choice of a promoter is well within the ability of a person skilled in the field of genetic engineering. For example, one may refer to the book of Sambrook et al.(1989) or also to the
20 procedures described by Fuller et al.(1996).

Other regulatory elements

- Where a cDNA insert is employed, one will typically desire to include a polyadenylation signal to effect proper polyadenylation of the gene transcript. The nature of the polyadenylation signal is not believed to be crucial to the successful practice of the invention, and any such sequence
25 may be employed such as human growth hormone and SV40 polyadenylation signals. Also contemplated as an element of the expression cassette is a terminator. These elements can serve to enhance message levels and to minimize read through from the cassette into other sequences.

3. Selectable Markers

- Such markers would confer an identifiable change to the cell permitting easy identification
30 of cells containing the expression construct. The selectable marker genes for selection of transformed host cells are preferably dihydrofolate reductase or neomycin resistance for eukaryotic cell culture, TRP1 for *S. cerevisiae* or tetracycline, rifampicin or ampicillin resistance in *E. coli*, or levan saccharase for mycobacteria, this latter marker being a negative selection marker.

4. Preferred Vectors.

Bacterial vectors

As a representative but non-limiting example, useful expression vectors for bacterial use can comprise a selectable marker and a bacterial origin of replication derived from commercially available plasmids comprising genetic elements of pBR322 (ATCC 37017). Such commercial
5 vectors include, for example, pKK223-3 (Pharmacia, Uppsala, Sweden), and GEM1 (Promega Biotec, Madison, WI, USA).

Large numbers of other suitable vectors are known to those of skill in the art, and commercially available, such as the following bacterial vectors: pQE70, pQE60, pQE-9 (Qiagen),
10 pbs, pD10, phagescript, psiX174, pbluescript SK, pbsks, pNH8A, pNH16A, pNH18A, pNH46A (Stratagene); ptc99a, pKK223-3, pKK233-3, pDR540, pRIT5 (Pharmacia); pWLNEO, pSV2CAT, pOG44, pXT1, pSG (Stratagene); pSVK3, pBPV, pMSG, pSVL (Pharmacia); pQE-30 (QIAexpress).

Bacteriophage vectors

15 The P1 bacteriophage vector may contain large inserts ranging from about 80 to about 100 kb.

The construction of P1 bacteriophage vectors such as p158 or p158/neo8 are notably described by Sternberg (1992, 1994). Recombinant P1 clones comprising *BAP28* nucleotide sequences may be designed for inserting large polynucleotides of more than 40 kb (Linton et al.,
20 1993). To generate P1 DNA for transgenic experiments, a preferred protocol is the protocol described by McCormick et al.(1994). Briefly, *E. coli* (preferably strain NS3529) harboring the P1 plasmid are grown overnight in a suitable broth medium containing 25 µg/ml of kanamycin. The P1 DNA is prepared from the *E. coli* by alkaline lysis using the Qiagen Plasmid Maxi kit (Qiagen, Chatsworth, CA, USA), according to the manufacturer's instructions. The P1 DNA is purified from
25 the bacterial lysate on two Qiagen-tip 500 columns, using the washing and elution buffers contained in the kit. A phenol/chloroform extraction is then performed before precipitating the DNA with 70% ethanol. After solubilizing the DNA in TE (10 mM Tris-HCl, pH 7.4, 1 mM EDTA), the concentration of the DNA is assessed by spectrophotometry.

When the goal is to express a P1 clone comprising *BAP28* nucleotide sequences in a
30 transgenic animal, typically in transgenic mice, it is desirable to remove vector sequences from the P1 DNA fragment, for example by cleaving the P1 DNA at rare-cutting sites within the P1 polylinker (*SfiI*, *NorI* or *Sall*). The P1 insert is then purified from vector sequences on a pulsed-field agarose gel, using methods similar using methods similar to those originally reported for the isolation of DNA from YACs (Schedl et al., 1993a; Peterson et al., 1993). At this stage, the
35 resulting purified insert DNA can be concentrated, if necessary, on a Millipore Ultrafree-MC Filter Unit (Millipore, Bedford, MA, USA – 30,000 molecular weight limit) and then dialyzed against microinjection buffer (10 mM Tris-HCl, pH 7.4; 250 µM EDTA) containing 100 mM NaCl, 30 µM

spermine, 70 μ M spermidine on a microdialysis membrane (type VS, 0.025 μ M from Millipore). The intactness of the purified P1 DNA insert is assessed by electrophoresis on 1% agarose (Sea Kem GTG; FMC Bio-products) pulse-field gel and staining with ethidium bromide.

Baculovirus vectors

- 5 A suitable vector for the expression of the BAP28 polypeptide of SEQ ID No 5 or fragments or variants thereof is a baculovirus vector that can be propagated in insect cells and in insect cell lines. A specific suitable host vector system is the pVL1392/1393 baculovirus transfer vector (Pharmingen) that is used to transfect the SF9 cell line (ATCC N^oCRL 1711) which is derived from *Spodoptera frugiperda*.
- 10 Other suitable vectors for the expression of the BAP28 polypeptide of SEQ ID No 5 or fragments or variants thereof in a baculovirus expression system include those described by Chai et al.(1993), Vlasak et al.(1983) and Lenhard et al.(1996).

Viral vectors

In one specific embodiment, the vector is derived from an adenovirus. Preferred

- 15 adenovirus vectors according to the invention are those described by Feldman and Steg (1996) or Ohno et al.(1994). Another preferred recombinant adenovirus according to this specific embodiment of the present invention is the human adenovirus type 2 or 5 (Ad 2 or Ad 5) or an adenovirus of animal origin (French patent application N^o FR-93.05954).

- Retrovirus vectors and adeno-associated virus vectors are generally understood to be the
20 recombinant gene delivery systems of choice for the transfer of exogenous polynucleotides *in vivo* , particularly to mammals, including humans. These vectors provide efficient delivery of genes into cells, and the transferred nucleic acids are stably integrated into the chromosomal DNA of the host.

- Particularly preferred retroviruses for the preparation or construction of retroviral *in vitro* or *in vitro* gene delivery vehicles of the present invention include retroviruses selected from the
25 group consisting of Mink-Cell Focus Inducing Virus, Murine Sarcoma Virus, Reticuloendotheliosis virus and Rous Sarcoma virus. Particularly preferred Murine Leukemia Viruses include the 4070A and the 1504A viruses, Abelson (ATCC No VR-999), Friend (ATCC No VR-245), Gross (ATCC No VR-590), Rauscher (ATCC No VR-998) and Moloney Murine Leukemia Virus (ATCC No VR-190; PCT Application No WO 94/24298). Particularly preferred Rous Sarcoma Viruses include
30 Bryan high titer (ATCC Nos VR-334, VR-657, VR-726, VR-659 and VR-728). Other preferred retroviral vectors are those described in Roth et al.(1996), PCT Application No WO 93/25234, PCT Application No WO 94/ 06920, Roux et al., 1989, Julian et al., 1992 and Neda et al., 1991.

- Yet another viral vector system that is contemplated by the invention consists in the adeno-associated virus (AAV). The adeno-associated virus is a naturally occurring defective virus that
35 requires another virus, such as an adenovirus or a herpes virus, as a helper virus for efficient replication and a productive life cycle (Muzyczka et al., 1992). It is also one of the few viruses that may integrate its DNA into non-dividing cells, and exhibits a high frequency of stable integration

(Flotte et al., 1992; Samulski et al., 1989; McLaughlin et al., 1989). One advantageous feature of AAV derives from its reduced efficacy for transducing primary cells relative to transformed cells.

BAC vectors

The bacterial artificial chromosome (BAC) cloning system (Shizuya et al., 1992) has been developed to stably maintain large fragments of genomic DNA (100-300 kb) in *E. coli*. A preferred BAC vector consists of pBeloBAC11 vector that has been described by Kim et al.(1996). BAC libraries are prepared with this vector using size-selected genomic DNA that has been partially digested using enzymes that permit ligation into either the *Bam* HI or *Hind*III sites in the vector. Flanking these cloning sites are T7 and SP6 RNA polymerase transcription initiation sites that can be used to generate end probes by either RNA transcription or PCR methods. After the construction of a BAC library in *E. coli*, BAC DNA is purified from the host cell as a supercoiled circle. Converting these circular molecules into a linear form precedes both size determination and introduction of the BACs into recipient cells. The cloning site is flanked by two *Not* I sites, permitting cloned segments to be excised from the vector by *Not* I digestion. Alternatively, the DNA insert contained in the pBeloBAC11 vector may be linearized by treatment of the BAC vector with the commercially available enzyme lambda terminase that leads to the cleavage at the unique *cos*N site, but this cleavage method results in a full length BAC clone containing both the insert DNA and the BAC sequences.

5. Delivery Of The Recombinant Vectors

In order to effect expression of the polynucleotides and polynucleotide constructs of the invention, these constructs must be delivered into a cell. This delivery may be accomplished *in vitro*, as in laboratory procedures for transforming cell lines, or *in vivo* or *ex vivo*, as in the treatment of certain diseases states.

One mechanism is viral infection where the expression construct is encapsulated in an infectious viral particle.

Several non-viral methods for the transfer of polynucleotides into cultured mammalian cells are also contemplated by the present invention, and include, without being limited to, calcium phosphate precipitation (Graham et al., 1973; Chen et al., 1987), DEAE-dextran (Gopal, 1985), electroporation (Tur-Kaspa et al., 1986; Potter et al., 1984), direct microinjection (Harland et al., 1985), DNA-loaded liposomes (Nicolau et al., 1982; Fraley et al., 1979), and receptor-mediated transfection (Wu and Wu, 1987; 1988). Some of these techniques may be successfully adapted for *in vivo* or *ex vivo* use.

Once the expression polynucleotide has been delivered into the cell, it may be stably integrated into the genome of the recipient cell. This integration may be in the cognate location and orientation via homologous recombination (gene replacement) or it may be integrated in a random, non specific location (gene augmentation). In yet further embodiments, the nucleic acid may be

stably maintained in the cell as a separate, episomal segment of DNA. Such nucleic acid segments or "episomes" encode sequences sufficient to permit maintenance and replication independent of or in synchronization with the host cell cycle.

- One specific embodiment for a method for delivering a protein or peptide to the interior of
- 5 a cell of a vertebrate *in vivo* comprises the step of introducing a preparation comprising a physiologically acceptable carrier and a naked polynucleotide operatively coding for the polypeptide of interest into the interstitial space of a tissue comprising the cell, whereby the naked polynucleotide is taken up into the interior of the cell and has a physiological effect. This is particularly applicable for transfer *in vitro* but it may be applied to *in vivo* as well.
- 10 Compositions for use *in vitro* and *in vivo* comprising a "naked" polynucleotide are described in PCT application N° WO 90/11092 (Vical Inc.) and also in PCT application No WO 95/11307 (Institut Pasteur, INSERM, Université d'Ottawa) as well as in the articles of Tacson et al.(1996) and of Huygen et al.(1996).

- In still another embodiment of the invention, the transfer of a naked polynucleotide of the
- 15 invention, including a polynucleotide construct of the invention, into cells may be proceeded with a particle bombardment (biolistic), said particles being DNA-coated microprojectiles accelerated to a high velocity allowing them to pierce cell membranes and enter cells without killing them, such as described by Klein et al.(1987).

- In a further embodiment, the polynucleotide of the invention may be entrapped in a
- 20 liposome (Ghosh and Bacchawat, 1991; Wong et al., 1980; Nicolau et al., 1987)

- In a specific embodiment, the invention provides a composition for the *in vivo* production of the BAP28 protein or polypeptide described herein. It comprises a naked polynucleotide operatively coding for this polypeptide, in solution in a physiologically acceptable carrier, and suitable for introduction into a tissue to cause cells of the tissue to express the said protein or
- 25 polypeptide.

The amount of vector to be injected to the desired host organism varies according to the site of injection. As an indicative dose, it will be injected between 0,1 and 100 µg of the vector in an animal body, preferably a mammal body, for example a mouse body.

- In another embodiment of the vector according to the invention, it may be introduced *in*
- 30 *vitro* in a host cell, preferably in a host cell previously harvested from the animal to be treated and more preferably a somatic cell such as a muscle cell. In a subsequent step, the cell that has been transformed with the vector coding for the desired BAP28 polypeptide or the desired fragment thereof is reintroduced into the animal body in order to deliver the recombinant protein within the body either locally or systemically.

35

Cell Hosts

Another object of the invention consists of a host cell that has been transformed or transfected with one of the polynucleotides described herein, and in particular a polynucleotide

either comprising a *BAP28* regulatory polynucleotide or the coding sequence of the *BAP28* polypeptide of SEQ ID Nos 1, 2, 3 or 4 or a fragment or a variant thereof. Also included are host cells that are transformed (prokaryotic cells) or that are transfected (eukaryotic cells) with a recombinant vector such as one of those described above. More particularly, the cell hosts of the present invention can comprise any of the polynucleotides described in the "Genomic Sequences Of The *BAP28* Gene" section, the "*BAP28* cDNA Sequences" section, the "Coding Regions" section, the "Polynucleotide constructs" section, and the "Oligonucleotide Probes And Primers" section.

A further recombinant cell host according to the invention comprises a polynucleotide containing a biallelic marker selected from the group consisting of A1 to A58, preferably A1 to A27, A34, A37 to A41, A43 to A49, A52, and A54 to A58, more preferably A1, A4, 16, A30, A31, A42, A50, A51, and A53, and the complements thereof.

Preferred host cells used as recipients for the expression vectors of the invention are the following:

- a) Prokaryotic host cells: *Escherichia coli* strains (I.E.DH5- α strain), *Bacillus subtilis*,
15 *Salmonella typhimurium*, and strains from species like *Pseudomonas*, *Streptomyces* and *Staphylococcus*.
- b) Eukaryotic host cells: HeLa cells (ATCC N^oCCL2; N^oCCL2.1; N^oCCL2.2), Cv 1 cells (ATCC N^oCCL70), COS cells (ATCC N^oCRL1650; N^oCRL1651), Sf-9 cells (ATCC N^oCRL1711), C127 cells (ATCC N^o CRL-1804), 3T3 (ATCC N^o CRL-6361), CHO (ATCC N^o CCL-61), human
20 kidney 293. (ATCC N^o 45504; N^o CRL-1573) and BHK (ECACC N^o 84100501; N^o 84111301).
- c) Other mammalian host cells.

The *BAP28* gene expression in mammalian, and typically human, cells may be rendered defective, or alternatively it may be proceeded with the insertion of a *BAP28* genomic or cDNA sequence with the replacement of the *BAP28* gene counterpart in the genome of an animal cell by a
25 *BAP28* polynucleotide according to the invention. These genetic alterations may be generated by homologous recombination events using specific DNA constructs that have been previously described.

One kind of cell hosts that may be used are mammal zygotes, such as murine zygotes. For example, murine zygotes may undergo microinjection with a purified DNA molecule of interest, for
30 example a purified DNA molecule that has previously been adjusted to a concentration range from 1 ng/ml –for BAC inserts- 3 ng/ μ l –for P1 bacteriophage inserts- in 10 mM Tris-HCl, pH 7.4, 250 μ M EDTA containing 100 mM NaCl, 30 μ M spermine, and 70 μ M spermidine. When the DNA to be microinjected has a large size, polyamines and high salt concentrations can be used in order to avoid mechanical breakage of this DNA, as described by Schedl et al (1993b).

35 Anyone of the polynucleotides of the invention, including the DNA constructs described herein, may be introduced in an embryonic stem (ES) cell line, preferably a mouse ES cell line. ES cell lines are derived from pluripotent, uncommitted cells of the inner cell mass of pre-implantation

blastocysts. Preferred ES cell lines are the following: ES-E14TG2a (ATCC n° CRL-1821), ES-D3 (ATCC n° CRL1934 and n° CRL-11632), YS001 (ATCC n° CRL-11776), 36.5 (ATCC n° CRL-11116). To maintain ES cells in an uncommitted state, they are cultured in the presence of growth inhibited feeder cells which provide the appropriate signals to preserve this embryonic phenotype

- 5 and serve as a matrix for ES cell adherence. Preferred feeder cells comprise primary embryonic fibroblasts that are established from tissue of day 13- day 14 embryos of virtually any mouse strain, that are maintained in culture, such as described by Abbondanzo et al.(1993) and are inhibited in growth by irradiation, such as described by Robertson (1987), or by the presence of an inhibitory concentration of LIF, such as described by Pease and Williams (1990).

- 10 The constructs in the host cells can be used in a conventional manner to produce the gene product encoded by the recombinant sequence.

Following transformation of a suitable host and growth of the host to an appropriate cell density, the selected promoter is induced by appropriate means, such as temperature shift or chemical induction, and cells are cultivated for an additional period.

- 15 Cells are typically harvested by centrifugation, disrupted by physical or chemical means, and the resulting crude extract retained for further purification.

Microbial cells employed in the expression of proteins can be disrupted by any convenient method, including freeze-thaw cycling, sonication, mechanical disruption, or use of cell lysing agents. Such methods are well known by the skill artisan.

- 20 **Transgenic Animals**

The terms "transgenic animals" or "host animals" are used herein designate animals that have their genome genetically and artificially manipulated so as to include one of the nucleic acids according to the invention. Preferred animals are non-human mammals and include those belonging to a genus selected from *Mus* (e.g. mice), *Rattus* (e.g. rats) and *Oryctogalus* (e.g. rabbits) which have

25 their genome artificially and genetically altered by the insertion of a nucleic acid according to the invention. In one embodiment, the invention encompasses non-human host mammals and animals comprising a recombinant vector of the invention or a BAP28 gene disrupted by homologous recombination with a knock out vector.

- The transgenic animals of the invention all include within a plurality of their cells a cloned
- 30 recombinant or synthetic DNA sequence, more specifically one of the purified or isolated nucleic acids comprising a *BAP28* coding sequence, a *BAP28* regulatory polynucleotide, a polynucleotide construct, or a DNA sequence encoding an antisense polynucleotide such as described in the present specification.

- Generally, a transgenic animal according to the present invention comprises any one of the
- 35 polynucleotides, the recombinant vectors and the cell hosts described in the present invention. More particularly, the transgenic animals of the present invention can comprise any of the polynucleotides described in the "Genomic Sequences Of The *BAP28* Gene" section, the "*BAP28* cDNA

Sequences" section, the "Coding Regions" section, the "Polynucleotide constructs" section, the "Oligonucleotide Probes And Primers" section, the "Recombinant Vectors" section and the "Cell Hosts" section.

A further transgenic animals according to the invention contains in their somatic cells and/or in their germ line cells a polynucleotide comprising a biallelic marker selected from the group consisting of A1 to A58, preferably A1 to A27, A34, A37 to A41, A43 to A49, A52, and A54 to A58, more preferably A1, A4, 16, A30, A31, A42, A50, A51, and A53, and the complements thereof.

In a first preferred embodiment, these transgenic animals may be good experimental models in order to study the diverse pathologies related to cell differentiation, in particular concerning the transgenic animals within the genome of which has been inserted one or several copies of a polynucleotide encoding a native BAP28 protein, or alternatively a mutant BAP28 protein.

In a second preferred embodiment, these transgenic animals may express a desired polypeptide of interest under the control of the regulatory polynucleotides of the *BAP28* gene, leading to good yields in the synthesis of this protein of interest, and eventually a tissue specific expression of this protein of interest.

The design of the transgenic animals of the invention may be made according to the conventional techniques well known from the one skilled in the art. For more details regarding the production of transgenic animals, and specifically transgenic mice, it may be referred to US Patents Nos 4,873,191, issued Oct. 10, 1989; 5,464,764 issued Nov 7, 1995; and 5,789,215, issued Aug 4, 1998; these documents being herein incorporated by reference to disclose methods producing transgenic mice.

Transgenic animals of the present invention are produced by the application of procedures which result in an animal with a genome that has incorporated exogenous genetic material. The procedure involves obtaining the genetic material, or a portion thereof, which encodes either a *BAP28* coding sequence, a *BAP28* regulatory polynucleotide or a DNA sequence encoding a *BAP28* antisense polynucleotide such as described in the present specification.

A recombinant polynucleotide of the invention is inserted into an embryonic or ES stem cell line. The insertion is preferably made using electroporation, such as described by Thomas et al.(1987). The cells subjected to electroporation are screened (e.g. by selection via selectable markers, by PCR or by Southern blot analysis) to find positive cells which have integrated the exogenous recombinant polynucleotide into their genome, preferably via an homologous recombination event. An illustrative positive-negative selection procedure that may be used according to the invention is described by Mansour et al.(1988).

Then, the positive cells are isolated, cloned and injected into 3.5 days old blastocysts from mice, such as described by Bradley (1987). The blastocysts are then inserted into a female host animal and allowed to grow to term.

Alternatively, the positive ES cells are brought into contact with embryos at the 2.5 days old 8-16 cell stage (morulae) such as described by Wood et al.(1993) or by Nagy et al.(1993), the ES cells being internalized to colonize extensively the blastocyst including the cells which will give rise to the germ line.

The offspring of the female host are tested to determine which animals are transgenic e.g. include the inserted exogenous DNA sequence and which are wild-type.

Thus, the present invention also concerns a transgenic animal containing a nucleic acid, a recombinant expression vector or a recombinant host cell according to the invention.

Recombinant Cell Lines Derived From The Transgenic Animals Of The Invention.

A further object of the invention consists of recombinant host cells obtained from a transgenic animal described herein. In one embodiment the invention encompasses cells derived from non-human host mammals and animals comprising a recombinant vector of the invention or a *BAP28* gene disrupted by homologous recombination with a knock out vector.

Recombinant cell lines may be established *in vitro* from cells obtained from any tissue of a transgenic animal according to the invention, for example by transfection of primary cell cultures with vectors expressing *onc*-genes such as SV40 large T antigen, as described by Chou (1989) and Shay et al.(1991).

Methods for screening substances interacting with a BAP28 polypeptide

For the purpose of the present invention, a ligand means a molecule, such as a protein, a peptide, an antibody or any synthetic chemical compound capable of binding to the BAP28 protein or one of its fragments or variants or to modulate the expression of the polynucleotide coding for BAP28 or a fragment or variant thereof.

In the ligand screening method according to the present invention, a biological sample or a defined molecule to be tested as a putative ligand of the BAP28 protein is brought into contact with the corresponding purified BAP28 protein, for example the corresponding purified recombinant BAP28 protein produced by a recombinant cell host as described hereinbefore, in order to form a complex between this protein and the putative ligand molecule to be tested.

As an illustrative example, to study the interaction of the BAP28 protein, or a fragment comprising a contiguous span of at least 6 amino acids, preferably at least 8 to 10 amino acids, more preferably at least 12, 15, 20, 25, 30, 40, 50, or 100 amino acids of SEQ ID No 5, wherein said contiguous span includes either at least 1, 2, 3, 5 or 10 of the amino acid positions selected from the group consisting of 1 to 1629 of the SEQ ID No 5, or an amino acid selected from the group consisting of an asparagine at the amino acid position 1694 of SEQ ID No 5, a valine at the amino

acid position 1854 of SEQ ID No 5, an asparagine at the amino acid position 1967 of SEQ ID No 5, a glutamic acid at the amino acid position 2017 of SEQ ID No 5, and an alanine at the amino acid position 2050 of SEQ ID No 5, with drugs or small molecules, such as molecules generated through combinatorial chemistry approaches, the microdialysis coupled to HPLC method described by Wang et al. (1997) or the affinity capillary electrophoresis method described by Bush et al. (1997), the disclosures of which are incorporated by reference, can be used.

In further methods, peptides, drugs, fatty acids, lipoproteins, or small molecules which interact with the BAP28 protein, or a fragment comprising a contiguous span of at least 6 amino acids, preferably at least 8 to 10 amino acids, more preferably at least 12, 15, 20, 25, 30, 40, 50, or 100 amino acids of SEQ ID No 5, wherein said contiguous span includes either at least 1, 2, 3, 5 or 10 of the amino acid positions selected from the group consisting of 1 to 1629 of the SEQ ID No 5 or an amino acid selected from the group consisting of an asparagine at the amino acid position 1694 of SEQ ID No 5, a valine at the amino acid position 1854 of SEQ ID No 5, an asparagine at the amino acid position 1967 of SEQ ID No 5, a glutamic acid at the amino acid position 2017 of SEQ ID No 5, and an alanine at the amino acid position 2050 of SEQ ID No 5, may be identified using assays such as the following. The molecule to be tested for binding is labeled with a detectable label, such as a fluorescent, radioactive, or enzymatic tag and placed in contact with immobilized BAP28 protein, or a fragment thereof under conditions which permit specific binding to occur. After removal of non-specifically bound molecules, bound molecules are detected using appropriate means.

Another object of the present invention consists of methods and kits for the screening of candidate substances that interact with BAP28 polypeptide.

The present invention pertains to methods for screening substances of interest that interact with a BAP28 protein or one fragment or variant thereof. By their capacity to bind covalently or non-covalently to a BAP28 protein or to a fragment or variant thereof, these substances or molecules may be advantageously used both *in vitro* and *in vivo*.

In vitro, said interacting molecules may be used as detection means in order to identify the presence of a BAP28 protein in a sample, preferably a biological sample.

A method for the screening of a candidate substance comprises the following steps :
a) providing a polypeptide consisting of a BAP28 protein or a fragment comprising a contiguous span of at least 6 amino acids, preferably at least 8 to 10 amino acids, more preferably at least 12, 15, 20, 25, 30, 40, 50, or 100 amino acids of SEQ ID No 5, wherein said contiguous span includes either at least 1, 2, 3, 5 or 10 of the amino acid positions selected from the group consisting of 1 to 1629 of the SEQ ID No 5 or an amino acid selected from the group consisting of an asparagine at the amino acid position 1694 of SEQ ID No 5, a valine at the amino acid position 1854 of SEQ ID No 5, an asparagine at the amino acid position 1967 of SEQ ID No 5, a glutamic acid at

the amino acid position 2017 of SEQ ID No 5, and an alanine at the amino acid position 2050 of SEQ ID No 5, or a variant thereof;

- b) obtaining a candidate substance;
- c) bringing into contact said polypeptide with said candidate substance;
- 5 d) detecting the complexes formed between said polypeptide and said candidate substance.

The invention further concerns a kit for the screening of a candidate substance interacting with the BAP28 polypeptide, wherein said kit comprises :

- a) a BAP28 protein having an amino acid sequence selected from the group consisting of the amino acid sequences of SEQ ID No 5 or a peptide fragment comprising a contiguous span of
10 at least 6 amino acids, preferably at least 8 to 10 amino acids, more preferably at least 12, 15, 20, 25, 30, 40, 50, or 100 amino acids of SEQ ID No 5, wherein said contiguous span includes either at least 1, 2, 3, 5 or 10 of the amino acid positions selected from the group consisting of 1 to 1629 of the SEQ ID No 5 or an amino acid selected from the group consisting of an asparagine at the amino acid position 1694 of SEQ ID No 5, a valine at the amino acid position 1854 of SEQ ID No
15 5, an asparagine at the amino acid position 1967 of SEQ ID No 5, a glutamic acid at the amino acid position 2017 of SEQ ID No 5, and an alanine at the amino acid position 2050 of SEQ ID No 5, or a variant thereof ;

- b) in some embodiments, the kit may also comprise means useful to detect the complex formed between the BAP28 protein or a peptide fragment or a variant thereof and the candidate
20 substance.

In a preferred embodiment of the kit described above, the detection means consist in monoclonal or polyclonal antibodies directed against the BAP28 protein or a peptide fragment or a variant thereof.

- Various candidate substances or molecules can be assayed for interaction with a BAP28
25 polypeptide. These substances or molecules include, without being limited to, natural or synthetic organic compounds or molecules of biological origin such as polypeptides. When the candidate substance or molecule consists of a polypeptide, this polypeptide may be the resulting expression product of a phage clone belonging to a phage-based random peptide library, or alternatively the polypeptide may be the resulting expression product of a cDNA library cloned in a vector suitable
30 for performing a two-hybrid screening assay.

- The invention also pertains to kits useful for performing the hereinbefore described screening method. Preferably, such kits comprise a BAP28 polypeptide or a fragment or a variant thereof, and, in some embodiments, means useful to detect the complex formed between the BAP28 polypeptide or its fragment or variant and the candidate substance. In a preferred embodiment the
35 detection means consist in monoclonal or polyclonal antibodies directed against the corresponding BAP28 polypeptide or a fragment or a variant thereof.

A. Candidate ligands obtained from random peptide libraries

In a particular embodiment of the screening method, the putative ligand is the expression product of a DNA insert contained in a phage vector (Parmley and Smith, 1988). Specifically, random peptide phages libraries are used. The random DNA inserts encode for peptides of 8 to 20 amino acids in length (Oldenburg K.R. et al., 1992; Valadon P., et al., 1996; Lucas A.H., 1994; Westerink M.A.J., 1995; Felici F. et al., 1991). According to this particular embodiment, the recombinant phages expressing a protein that binds to the immobilized BAP28 protein is retained and the complex formed between the BAP28 protein and the recombinant phage may be subsequently immunoprecipitated by a polyclonal or a monoclonal antibody directed against the BAP28 protein.

Once the ligand library in recombinant phages has been constructed, the phage population is brought into contact with the immobilized BAP28 protein. Then the preparation of complexes is washed in order to remove the non-specifically bound recombinant phages. The phages that bind specifically to the BAP28 protein are then eluted by a buffer (acid pH) or immunoprecipitated by the monoclonal antibody produced by the hybridoma anti-BAP28, and this phage population is subsequently amplified by an over-infection of bacteria (for example *E. coli*). The selection step may be repeated several times, preferably 2-4 times, in order to select the more specific recombinant phage clones. The last step consists in characterizing the peptide produced by the selected recombinant phage clones either by expression in infected bacteria and isolation, expressing the phage insert in another host-vector system, or sequencing the insert contained in the selected recombinant phages.

B. Candidate ligands obtained by competition experiments.

Alternatively, peptides, drugs or small molecules which bind to the BAP28 protein, or a fragment comprising a contiguous span of at least 6 amino acids, preferably at least 8 to 10 amino acids, more preferably at least 12, 15, 20, 25, 30, 40, 50, or 100 amino acids of SEQ ID No 5, wherein said contiguous span includes either at least 1, 2, 3, 5 or 10 of the amino acid positions selected from the group consisting of 1 to 1629 of the SEQ ID No 5 or an amino acid selected from the group consisting of an asparagine at the amino acid position 1694 of SEQ ID No 5, a valine at the amino acid position 1854 of SEQ ID No 5, an asparagine at the amino acid position 1967 of SEQ ID No 5, a glutamic acid at the amino acid position 2017 of SEQ ID No 5, and an alanine at the amino acid position 2050 of SEQ ID No 5, may be identified in competition experiments. In such assays, the BAP28 protein, or a fragment thereof, is immobilized to a surface, such as a plastic plate. Increasing amounts of the peptides, drugs or small molecules are placed in contact with the immobilized BAP28 protein, or a fragment thereof, in the presence of a detectable labeled known BAP28 protein ligand. For example, the BAP28 ligand may be detectably labeled with a fluorescent, radioactive, or enzymatic tag. The ability of the test molecule to bind the BAP28

protein, or a fragment thereof, is determined by measuring the amount of detectably labeled known ligand bound in the presence of the test molecule. A decrease in the amount of known ligand bound to the BAP28 protein, or a fragment thereof, when the test molecule is present indicated that the test molecule is able to bind to the BAP28 protein, or a fragment thereof.

5 **C. Candidate ligands obtained by affinity chromatography.**

Proteins or other molecules interacting with the BAP28 protein, or a fragment comprising a contiguous span of at least 6 amino acids, preferably at least 8 to 10 amino acids, more preferably at least 12, 15, 20, 25, 30, 40, 50, or 100 amino acids of SEQ ID No 5, wherein said contiguous span includes either at least 1, 2, 3, 5 or 10 of the amino acid positions selected from the group consisting of 1 to 1629 of the SEQ ID No 5 or an amino acid selected from the group consisting of an asparagine at the amino acid position 1694 of SEQ ID No 5, a valine at the amino acid position 1854 of SEQ ID No 5, an asparagine at the amino acid position 1967 of SEQ ID No 5, a glutamic acid at the amino acid position 2017 of SEQ ID No 5, and an alanine at the amino acid position 2050 of SEQ ID No 5, can also be found using affinity columns which contain the BAP28 protein, or a
 15 fragment thereof. The BAP28 protein, or a fragment thereof, may be attached to the column using conventional techniques including chemical coupling to a suitable column matrix such as agarose, Affi Gel®, or other matrices familiar to those of skill in art. In some embodiments of this method, the affinity column contains chimeric proteins in which the BAP28 protein, or a fragment thereof, is fused to glutathion S transferase (GST). A mixture of cellular proteins or pool of expressed proteins
 20 as described above is applied to the affinity column. Proteins or other molecules interacting with the BAP28 protein, or a fragment thereof, attached to the column can then be isolated and analyzed on 2-D electrophoresis gel as described in Ramunsen et al. (1997), the disclosure of which is incorporated by reference. Alternatively, the proteins retained on the affinity column can be purified by electrophoresis based methods and sequenced. The same method can be used to isolate
 25 antibodies, to screen phage display products, or to screen phage display human antibodies.

D. Candidate ligands obtained by optical biosensor methods

Proteins interacting with the BAP28 protein, or a fragment comprising a contiguous span of at least 6 amino acids, preferably at least 8 to 10 amino acids, more preferably at least 12, 15, 20, 25, 30, 40, 50, or 100 amino acids of SEQ ID No 5, wherein said contiguous span includes either at
 30 least 1, 2, 3, 5 or 10 of the amino acid positions selected from the group consisting of 1 to 1629 of the SEQ ID No 5 or an amino acid selected from the group consisting of an asparagine at the amino acid position 1694 of SEQ ID No 5, a valine at the amino acid position 1854 of SEQ ID No 5, an asparagine at the amino acid position 1967 of SEQ ID No 5, a glutamic acid at the amino acid position 2017 of SEQ ID No 5, and an alanine at the amino acid position 2050 of SEQ ID No 5, can
 35 also be screened by using an Optical Biosensor as described in Edwards and Leatherbarrow (1997) and also in Szabo et al. (1995), the disclosure of which is incorporated by reference. This technique

permits the detection of interactions between molecules in real time, without the need of labeled molecules. This technique is based on the surface plasmon resonance (SPR) phenomenon. Briefly, the candidate ligand molecule to be tested is attached to a surface (such as a carboxymethyl dextran matrix). A light beam is directed towards the side of the surface that does not contain the sample to be tested and is reflected by said surface. The SPR phenomenon causes a decrease in the intensity of the reflected light with a specific association of angle and wavelength. The binding of candidate ligand molecules cause a change in the refraction index on the surface, which change is detected as a change in the SPR signal. For screening of candidate ligand molecules or substances that are able to interact with the BAP28 protein, or a fragment thereof, the BAP28 protein, or a fragment thereof, is immobilized onto a surface. This surface consists of one side of a cell through which flows the candidate molecule to be assayed. The binding of the candidate molecule on the BAP28 protein, or a fragment thereof, is detected as a change of the SPR signal. The candidate molecules tested may be proteins, peptides, carbohydrates, lipids, or small molecules generated by combinatorial chemistry. This technique may also be performed by immobilizing eukaryotic or prokaryotic cells or lipid vesicles exhibiting an endogenous or a recombinantly expressed BAP28 protein at their surface.

The main advantage of the method is that it allows the determination of the association rate between the BAP28 protein and molecules interacting with the BAP28 protein. It is thus possible to select specifically ligand molecules interacting with the BAP28 protein, or a fragment thereof, through strong or conversely weak association constants.

E. Candidate ligands obtained through a two-hybrid screening assay.

The yeast two-hybrid system is designed to study protein-protein interactions *in vivo* (Fields and Song, 1989), and relies upon the fusion of a bait protein to the DNA binding domain of the yeast Gal4 protein. This technique is also described in the US Patent No US 5,667,973 and the US Patent No 5,283,173 (Fields et al.) the technical teachings of both patents being herein incorporated by reference.

The general procedure of library screening by the two-hybrid assay may be performed as described by Harper et al. (1993) or as described by Cho et al. (1998) or also Fromont-Racine et al. (1997).

The bait protein or polypeptide consists of a BAP28 polypeptide or a fragment comprising a contiguous span of at least 6 amino acids, preferably at least 8 to 10 amino acids, more preferably at least 12, 15, 20, 25, 30, 40, 50, or 100 amino acids of SEQ ID No 5, wherein said contiguous span includes either at least 1, 2, 3, 5 or 10 of the amino acid positions selected from the group consisting of 1 to 1629 of the SEQ ID No 5 or an amino acid selected from the group consisting of an asparagine at the amino acid position 1694 of SEQ ID No 5, a valine at the amino acid position 1854 of SEQ ID No 5, an asparagine at the amino acid position 1967 of SEQ ID No 5, a glutamic acid at

the amino acid position 2017 of SEQ ID No 5, and an alanine at the amino acid position 2050 of SEQ ID No 5, or a variant thereof.

- More precisely, the nucleotide sequence encoding the BAP28 polypeptide or a fragment or variant thereof is fused to a polynucleotide encoding the DNA binding domain of the GAL4 protein, the fused nucleotide sequence being inserted in a suitable expression vector, for example pAS2 or pM3.

- Then, a human cDNA library is constructed in a specially designed vector, such that the human cDNA insert is fused to a nucleotide sequence in the vector that encodes the transcriptional domain of the GAL4 protein. Preferably, the vector used is the pACT vector. The polypeptides encoded by the nucleotide inserts of the human cDNA library are termed "pray" polypeptides.

A third vector contains a detectable marker gene, such as beta galactosidase gene or CAT gene that is placed under the control of a regulation sequence that is responsive to the binding of a complete Gal4 protein containing both the transcriptional activation domain and the DNA binding domain. For example, the vector pG5EC may be used.

- Two different yeast strains are also used. As an illustrative but non limiting example the two different yeast strains may be the followings :
- Y190, the phenotype of which is (*MATa, Leu2-3, 112 ura3-12, trp1-901, his3-D200, ade2-101, gal4Dgal180D URA3 GAL-LacZ, LYS GAL-HIS3, cyh^r*);
 - Y187, the phenotype of which is (*MATa gal4 gal80 his3 trp1-901 ade2-101 ura3-52 leu2-3, -112 URA3 GAL-lacZme^r*), which is the opposite mating type of Y190.

- Briefly, 20 µg of pAS2/*BAP28* and 20 µg of pACT-cDNA library are co-transformed into yeast strain Y190. The transformants are selected for growth on minimal media lacking histidine, leucine and tryptophan, but containing the histidine synthesis inhibitor 3-AT (50 mM). Positive colonies are screened for beta galactosidase by filter lift assay. The double positive colonies (*His⁺, beta-gal⁺*) are then grown on plates lacking histidine, leucine, but containing tryptophan and cycloheximide (10 mg/ml) to select for loss of pAS2/*BAP28* plasmids but retention of pACT-cDNA library plasmids. The resulting Y190 strains are mated with Y187 strains expressing BAP28 or non-related control proteins; such as cyclophilin B, lamin, or SNF1, as *Gal4* fusions as described by Harper et al. (1993) and by Bram et al. (Bram RJ et al., 1993), and screened for beta galactosidase by filter lift assay. Yeast clones that are *beta gal-* after mating with the control *Gal4* fusions are considered false positives.

- In another embodiment of the two-hybrid method according to the invention, interaction between the BAP28 or a fragment or variant thereof with cellular proteins may be assessed using the Matchmaker Two Hybrid System 2 (Catalog No K1604-1, Clontech). As described in the manual accompanying the Matchmaker Two Hybrid System 2 (Catalog No K1604-1, Clontech), the disclosure of which is incorporated herein by reference, nucleic acids encoding the BAP28 protein or a portion thereof, are inserted into an expression vector such that they are in frame with DNA encoding the DNA

binding domain of the yeast transcriptional activator GAL4. A desired cDNA, preferably human cDNA, is inserted into a second expression vector such that they are in frame with DNA encoding the activation domain of GAL4. The two expression plasmids are transformed into yeast and the yeast are plated on selection medium which selects for expression of selectable markers on each of the expression
 5 vectors as well as GAL4 dependent expression of the HIS3 gene. Transformants capable of growing on medium lacking histidine are screened for GAL4 dependent lacZ expression. Those cells which are positive in both the histidine selection and the lacZ assay contain interaction between BAP28 and the protein or peptide encoded by the initially selected cDNA insert.

Methods For Screening Substances Modulating The Activity Of The BAP28 protein

- 10 The invention also concerns a method for screening new agents, or candidate substances which modulate the activity of the BAP28 protein or a fragment thereof. Preferably, the BAP28 protein or a fragment thereof is a polypeptide code comprising a contiguous span of at least 6 amino acids of SEQ ID No 5, wherein said contiguous span includes either at least 1, 2, 3, 5 or 10 of the amino acid positions selected from the group consisting of 1 to 1629 of the SEQ ID No 5 or an
 15 amino acid selected from the group consisting of an asparagine at the amino acid position 1694 of SEQ ID No 5, a valine at the amino acid position 1854 of SEQ ID No 5, an asparagine at the amino acid position 1967 of SEQ ID No 5, a glutamic acid at the amino acid position 2017 of SEQ ID No 5, and an alanine at the amino acid position 2050 of SEQ ID No 5. Preferably, the candidate substance is mixed with the BAP28 protein and the activity of the BAP28 protein is measured.
 20 Candidate substances include, without being limited to, natural or synthetic organic compounds or molecules of biological origin such as polypeptides.

Method For Screening Substances Interacting With The Regulatory Sequences Of The BAP28 Gene

- The present invention also concerns a method for screening substances or molecules that
 25 are able to interact with the regulatory sequences of the *BAP28* gene, such as for example promoter or enhancer sequences.

- Nucleic acids encoding proteins which are able to interact with the regulatory sequences of the *BAP28* gene, more particularly a nucleotide sequence selected from the group consisting of the polynucleotides of the 5' and 3' regulatory region or a fragment or variant thereof, and
 30 preferably a variant comprising one of the biallelic markers of the invention, may be identified by using a one-hybrid system, such as that described in the booklet enclosed in the Matchmaker One-Hybrid System kit from Clontech (Catalog Ref. n° K1603-1), the technical teachings of which are herein incorporated by reference. Briefly, the target nucleotide sequence is cloned upstream of a selectable reporter sequence and the resulting DNA construct is integrated in the yeast genome
 35 (*Saccharomyces cerevisiae*). The yeast cells containing the reporter sequence in their genome are then transformed with a library consisting of fusion molecules between cDNAs encoding candidate proteins for binding onto the regulatory sequences of the *BAP28* gene and sequences encoding the

activator domain of a yeast transcription factor such as GAL4. The recombinant yeast cells are plated in a culture broth for selecting cells expressing the reporter sequence. The recombinant yeast cells thus selected contain a fusion protein that is able to bind onto the target regulatory sequence of the *BAP28* gene. Then, the cDNAs encoding the fusion proteins are sequenced and may be cloned

- 5 into expression or transcription vectors *in vitro*. The binding of the encoded polypeptides to the target regulatory sequences of the *BAP28* gene may be confirmed by techniques familiar to the one skilled in the art, such as gel retardation assays or DNase protection assays.

Gel retardation assays may also be performed independently in order to screen candidate molecules that are able to interact with the regulatory sequences of the *BAP28* gene, such as

- 10 described by Fried and Crothers (1981), Garner and Revzin (1981) and Dent and Latchman (1993), the teachings of these publications being herein incorporated by reference. These techniques are based on the principle according to which a DNA fragment which is bound to a protein migrates slower than the same unbound DNA fragment. Briefly, the target nucleotide sequence is labeled. Then the labeled target nucleotide sequence is brought into contact with either a total nuclear extract
- 15 from cells containing transcription factors, or with different candidate molecules to be tested. The interaction between the target regulatory sequence of the *BAP28* gene and the candidate molecule or the transcription factor is detected after gel or capillary electrophoresis through a retardation in the migration.

Method For Screening Ligands That Modulate The Expression Of The BAP28

Protein

Another subject of the present invention is a method for screening molecules that modulate the expression of the BAP28 protein. Such a screening method comprises the steps of:

- a) cultivating a prokaryotic or an eukaryotic cell that has been transfected with a nucleotide sequence encoding the BAP28 protein or a variant or a fragment thereof, placed under the control of
- 25 its own promoter;
- b) bringing into contact the cultivated cell with a molecule to be tested;
- c) quantifying the expression of the BAP28 protein or a variant or a fragment thereof.

Using DNA recombination techniques well known by the one skill in the art, the BAP28 protein encoding DNA sequence is inserted into an expression vector, downstream from its promoter

30 sequence. As an illustrative example, the promoter sequence of the *BAP28* gene is contained in the nucleic acid of the 5' regulatory region.

The quantification of the expression of the BAP28 protein may be realized either at the mRNA level or at the protein level. In the latter case, polyclonal or monoclonal antibodies may be used to quantify the amounts of the BAP28 protein that have been produced, for example in an

- 35 ELISA or a RIA assay.

In a preferred embodiment, the quantification of the *BAP28* mRNA is realized by a quantitative PCR amplification of the cDNA obtained by a reverse transcription of the total mRNA of the cultivated *BAP28* -transfected host cell, using a pair of primers specific for *BAP28*.

The present invention also concerns a method for screening substances or molecules that
5 are able to increase, or in contrast to decrease, the level of expression of the *BAP28* gene. Such a method may allow the one skilled in the art to select substances exerting a regulating effect on the expression level of the *BAP28* gene and which may be useful as active ingredients included in pharmaceutical compositions for treating patients suffering from prostate cancer.

Thus, is also part of the present invention a method for screening of a candidate substance
10 or molecule that modulated the expression of the *BAP28* gene, this method comprises the following steps:

- providing a recombinant cell host containing a nucleic acid, wherein said nucleic acid comprises a nucleotide sequence of the 5' regulatory region or a biologically active fragment or variant thereof located upstream a polynucleotide encoding a detectable protein;
- 15 - obtaining a candidate substance; and
- determining the ability of the candidate substance to modulate the expression levels of the polynucleotide encoding the detectable protein.

In a further embodiment, the nucleic acid comprising the nucleotide sequence of the 5' regulatory region or a biologically active fragment or variant thereof also includes a 5'UTR region
20 of the *BAP28* cDNA of SEQ ID No 2 or 3, or one of its biologically active fragments or variants thereof.

Among the preferred polynucleotides encoding a detectable protein, there may be cited polynucleotides encoding beta galactosidase, green fluorescent protein (GFP) and chloramphenicol acetyl transferase (CAT). In some embodiments, the detectable protein can be *BAP28* or a fragment
25 thereof.

The invention also pertains to kits useful for performing the hereinbefore described screening method. Preferably, such kits comprise a recombinant vector that allows the expression of a nucleotide sequence of the 5' regulatory region or a biologically active fragment or variant thereof located upstream and operably linked to a polynucleotide encoding a detectable protein or the
30 *BAP28* protein or a fragment or a variant thereof.

In another embodiment of a method for the screening of a candidate substance or molecule that modulates the expression of the *BAP28* gene, wherein said method comprises the following steps:

- a) providing a recombinant host cell containing a nucleic acid, wherein said nucleic acid
35 comprises a 5'UTR sequence of the *BAP28* cDNA of SEQ ID No 2 or 3, or one of its biologically active fragments or variants, the 5'UTR sequence or its biologically active fragment or variant being operably linked to a polynucleotide encoding a detectable protein;

- b) obtaining a candidate substance; and
- c) determining the ability of the candidate substance to modulate the expression levels of the polynucleotide encoding the detectable protein.

In a specific embodiment of the above screening method, the nucleic acid that comprises a
5 nucleotide sequence selected from the group consisting of the 5'UTR sequence of the *BAP28* cDNA of SEQ ID No 2 or 3 or one of its biologically active fragments or variants, includes a promoter sequence which is endogenous with respect to the *BAP28* 5'UTR sequence.

In another specific embodiment of the above screening method, the nucleic acid that comprises a nucleotide sequence selected from the group consisting of the 5'UTR sequence of the
10 *BAP28* cDNA of SEQ ID No 2 or 3 or one of its biologically active fragments or variants, includes a promoter sequence which is exogenous with respect to the *BAP28* 5'UTR sequence defined therein.

In a further preferred embodiment, the nucleic acid comprising the 5'-UTR sequence of the *BAP28* cDNA or SEQ ID No 2 or 3 or the biologically active fragments thereof includes a biallelic marker selected from the group consisting of A1 to A58, preferably A1 to A27, A34, A37 to A41,
15 A43 to A49, A52, and A54 to A58, more preferably one of the biallelic markers A1, A4, 16, A30, A31, A42, A50, A51, and A53, or the complements thereof.

The invention further deals with a kit for the screening of a candidate substance modulating the expression of the *BAP28* gene, wherein said kit comprises a recombinant vector that comprises a nucleic acid including a 5'UTR sequence of the *BAP28* cDNA of SEQ ID No 2 or 3, or
20 one of their biologically active fragments or variants, the 5'UTR sequence or its biologically active fragment or variant being operably linked to a polynucleotide encoding a detectable protein.

For the design of suitable recombinant vectors useful for performing the screening methods described above, it will be referred to the section of the present specification wherein the preferred recombinant vectors of the invention are detailed.

25 Expression levels and patterns of *BAP28* may be analyzed by solution hybridization with long probes as described in International Patent Application No WO 97/05277, the entire contents of which are incorporated herein by reference. Briefly, the *BAP28* cDNA or the *BAP28* genomic DNA described above, or fragments thereof, is inserted at a cloning site immediately downstream of a bacteriophage (T3, T7 or SP6) RNA polymerase promoter to produce antisense RNA. Preferably,
30 the *BAP28* insert comprises at least 100 or more consecutive nucleotides of the genomic DNA sequence or the cDNA sequences. The plasmid is linearized and transcribed in the presence of ribonucleotides comprising modified ribonucleotides (i.e. biotin-UTP and DIG-UTP). An excess of this doubly labeled RNA is hybridized in solution with mRNA isolated from cells or tissues of interest. The hybridizations are performed under standard stringent conditions (40-50°C for 16
35 hours in an 80% formamide, 0. 4 M NaCl buffer, pH 7-8). The unhybridized probe is removed by digestion with ribonucleases specific for single-stranded RNA (i.e. RNases CL3, T1, Phy M, U2 or A). The presence of the biotin-UTP modification enables capture of the hybrid on a microtitration

plate coated with streptavidin. The presence of the DIG modification enables the hybrid to be detected and quantified by ELISA using an anti-DIG antibody coupled to alkaline phosphatase.

- Quantitative analysis of *BAP28* gene expression may also be performed using arrays. As used herein, the term array means a one dimensional, two dimensional, or multidimensional arrangement of a plurality of nucleic acids of sufficient length to permit specific detection of expression of mRNAs capable of hybridizing thereto. For example, the arrays may contain a plurality of nucleic acids derived from genes whose expression levels are to be assessed. The arrays may include the *BAP28* genomic DNA, the *BAP28* cDNA sequences or the sequences complementary thereto or fragments thereof, particularly those comprising at least one of the biallelic markers according to the present invention, preferably at least one of the biallelic markers A1 to A58, preferably A1 to A27, A34, A37 to A41, A43 to A49, A52, and A54 to A58, more preferably at least one of the biallelic markers A1, A4, 16, A30, A31, A42, A50, A51, and A53. Preferably, the fragments are at least 15 nucleotides in length. In other embodiments, the fragments are at least 25 nucleotides in length. In some embodiments, the fragments are at least 50 nucleotides in length. More preferably, the fragments are at least 100 nucleotides in length. In another preferred embodiment, the fragments are more than 100 nucleotides in length. In some embodiments the fragments may be more than 500 nucleotides in length.

- For example, quantitative analysis of *BAP28* gene expression may be performed with a complementary DNA microarray as described by Schena et al.(1995 and 1996). Full length *BAP28* cDNAs or fragments thereof are amplified by PCR and arrayed from a 96-well microtiter plate onto silylated microscope slides using high-speed robotics. Printed arrays are incubated in a humid chamber to allow rehydration of the array elements and rinsed, once in 0.2% SDS for 1 min, twice in water for 1 min and once for 5 min in sodium borohydride solution. The arrays are submerged in water for 2 min at 95°C, transferred into 0.2% SDS for 1 min, rinsed twice with water, air dried and stored in the dark at 25°C.

- Cell or tissue mRNA is isolated or commercially obtained and probes are prepared by a single round of reverse transcription. Probes are hybridized to 1 cm² microarrays under a 14 x 14 mm glass coverslip for 6-12 hours at 60°C. Arrays are washed for 5 min at 25°C in low stringency wash buffer (1 x SSC/0.2% SDS), then for 10 min at room temperature in high stringency wash buffer (0.1 x SSC/0.2% SDS). Arrays are scanned in 0.1 x SSC using a fluorescence laser scanning device fitted with a custom filter set. Accurate differential expression measurements are obtained by taking the average of the ratios of two independent hybridizations.

- Quantitative analysis of *BAP28* gene expression may also be performed with full length *BAP28* cDNAs or fragments thereof in complementary DNA arrays as described by Pietu et al.(1996). The full length *BAP28* cDNA or fragments thereof is PCR amplified and spotted on membranes. Then, mRNAs originating from various tissues or cells are labeled with radioactive nucleotides. After hybridization and washing in controlled conditions, the hybridized mRNAs are

detected by phospho-imaging or autoradiography. Duplicate experiments are performed and a quantitative analysis of differentially expressed mRNAs is then performed.

Alternatively, expression analysis using the *BAP28* genomic DNA, the *BAP28* cDNA, or fragments thereof can be done through high density nucleotide arrays as described by Lockhart et al.(1996) and Sosnowsky et al.(1997). Oligonucleotides of 15-50 nucleotides from the sequences of the *BAP28* genomic DNA, the *BAP28* cDNA sequences particularly those comprising at least one of biallelic markers according to the present invention, preferably at least one biallelic marker selected from the group consisting of A1 to A58, preferably A1 to A27, A34, A37 to A41, A43 to A49, A52, and A54 to A58, more preferably at least one of the biallelic markers A1, A4, 16, A30, A31, A42, A50, A51, and A53, or the sequences complementary thereto, are synthesized directly on the chip (Lockhart et al., supra) or synthesized and then addressed to the chip (Sosnowski et al., supra). Preferably, the oligonucleotides are about 20 nucleotides in length.

BAP28 cDNA probes labeled with an appropriate compound, such as biotin, digoxigenin or fluorescent dye, are synthesized from the appropriate mRNA population and then randomly fragmented to an average size of 50 to 100 nucleotides. The said probes are then hybridized to the chip. After washing as described in Lockhart et al., supra and application of different electric fields (Sosnowsky et al., 1997), the dyes or labeling compounds are detected and quantified. Duplicate hybridizations are performed. Comparative analysis of the intensity of the signal originating from cDNA probes on the same target oligonucleotide in different cDNA samples indicates a differential expression of *BAP28* mRNA.

Computer-Related Embodiments

As used herein the term "nucleic acid codes of the invention" encompass the nucleotide sequences comprising, consisting essentially of, or consisting of any one of the following:

- a) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, or 1000 nucleotides of SEQ ID No 1, wherein said contiguous span comprises at least 1, 2, 3, 5, or 10 of the following nucleotide positions of SEQ ID No 1: 1-50357, 50499-50963, 51257-52147, 52299-53234, 53394-53553, 53689-53837, 53943-54028, 54198-54740, 54896-55753, 55913-57385, 57495-58503, 58828-85946, 59355-85946, 86169-91228, and/or 91852 to 97662;
- b) a contiguous span of at least 12, 15, 18, 20, 25, 30, 50, 80, 100, 150, 200, 250, 300, 350, 400, 450, or 500 nucleotides of SEQ ID No 1 or the complement thereof, wherein said contiguous span comprises at least 1, 2, 3, 5, 10, 20, 30, 40 or 50 nucleotides selected from the group consisting of the following nucleotide positions of SEQ ID No 1: 4997-5076, 5371-5544, 6121-6337, 9877-10018, 11522-11623, 12521-12661, 13453-13664, 13824-13957, 15376-15478, 16855-16965, 17378-17495, 18535-18642, 21446-21541, 21999-22087, 23036-23247, 23546-23667, 24270-24461, 26287-26470, 26611-26747, 28068-28260, 32540-32709, 33112-33270, 34586-34828, 35156-35287, 36660-36763, 36934-37077, 37803-37921, 38017-38138, 40365-40493, 42618-42848, 43452-43578, 44836-44999, 48223-48269, and 49656-49779;

- c) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, or 1000 nucleotides of SEQ ID No 1 or the complements thereof, wherein said contiguous span comprises at least one BAP28-related biallelic marker selected from the group consisting of A1 to A58, preferably A1 to A27, A34, A37 to A41, A43 to A49, A52, and A54 to A58, more preferably one of the biallelic markers A1, A4, 16, A30, A31, A42, A50, A51, and A53;
- d) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, or 1000 nucleotides of a nucleic acid sequence selected from the group consisting of SEQ ID Nos 2 and 3 or the complements thereof, wherein said contiguous span comprises at least 1, 2, 3, 5, or 10 of nucleotide positions 1 to 4995 of SEQ ID No 2 or 3;
- e) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, or 1000 nucleotides of a nucleic acid sequence selected from the group consisting of SEQ ID Nos 2 and 3 or the complements thereof, wherein said contiguous span comprises at least 1, 2, 3, 5, or 10 of nucleotide positions 1 to 2033, 2160 to 2348 and 2676 to 4995 of SEQ ID No 2 or 3;
- f) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, or 1000 nucleotides of a nucleic acid sequence selected from the group consisting of SEQ ID Nos 1-3 or the complements thereof, wherein said contiguous span comprises at least 1, 2, 3, 5, or 10 of any one of the following ranges of nucleotide positions of:
- (1) SEQ ID No 1: 1-2500, 2501-5000, 5001-7500, 7501-10000, 10001-12500, 12501-15000, 15001-17500, 17501-20000, 20001-22500, 22501-25000, 25001-27500, 27501-30000, 30001-32500, 32501-35000, 35001-37500, 37501-40000, 40001-42500, 42501-45000, 45001-47500, 47501-50000, 50001-50357, 50499-50963, 51257-52147, 52299-53234, 53394-53553, 53689-53837, 53943-54028, 54198-54740, 54896-55753, 55913-57385, 57495-58503, 58828-85946, 59355-85946, 86169-91228, and/or 91852 to 97662;
- (2) SEQ ID No 2: 1 to 500, 501 to 1000, 1001 to 1500, 1501 to 2000, 2001 to 2500, 2501 to 3000, 3001 to 3500, 3501 to 4000, 4001 to 4500, 4501 to 4995, 5000 to 5500, 5501 to 6000, 6001 to 6500, and 6501 to 6782; and,
- (3) SEQ ID No 3: 1 to 500, 501 to 1000, 1001 to 1500, 1501 to 2000, 2001 to 2500, 2501 to 3000, 3001 to 3500, 3501 to 4000, 4001 to 4500, 4501 to 4995, 5000 to 5500, 5501 to 6000, 6001 to 6500, 6501 to 7000, 7001 to 7500, 7501 to 7932; and
- g) a nucleotide sequence selected from the group consisting of SEQ ID Nos 4, and 9-13; and,
- h) a nucleotide sequence complementary to any one of the preceding nucleotide sequences.

The "nucleic acid codes of the invention" further encompass nucleotide sequences homologous to:

- a) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, or 1000 nucleotides of SEQ ID No 1, wherein said contiguous span comprises at least 1, 2, 3, 5, or 10 of the following nucleotide positions of SEQ ID No 1: 1-50357, 50499-50963, 51257-

52147, 52299-53234, 53394-53553, 53689-53837, 53943-54028, 54198-54740, 54896-55753, 55913-57385, 57495-58503, 58828-85946, 59355-85946, 86169-91228, and/or 91852 to 97662;

b) a contiguous span of at least 12, 15, 18, 20, 25, 30, 50, 80, 100, 150, 200, 250, 300, 350, 400, 450, or 500 nucleotides of SEQ ID No 1 or the complement thereof, wherein said contiguous span comprises at least 1, 2, 3, 5, 10, 20, 30, 40 or 50 nucleotides selected from the group consisting of the following nucleotide positions of SEQ ID No 1: 4997-5076, 5371-5544, 6121-6337, 9877-10018, 11522-11623, 12521-12661, 13453-13664, 13824-13957, 15376-15478, 16855-16965, 17378-17495, 18335-18642, 21446-21541, 21999-22087, 23036-23247, 23546-23667, 24270-24461, 26287-26470, 26611-26747, 28068-28260, 32540-32709, 33112-33270, 34586-34828, 35156-35287, 36660-36763, 36934-37077, 37803-37921, 38017-38138, 40365-40493, 42618-42848, 43452-43578, 44836-44999, 48223-48269, and 49656-49779;

c) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, or 1000 nucleotides of SEQ ID No 1 or the complements thereof, wherein said contiguous span comprises at least one BAP28-related biallelic marker selected from the group consisting of A1 to A58, preferably A1 to A27, A34, A37 to A41, A43 to A49, A52, and A54 to A58, more preferably one of the biallelic markers A1, A4, 16, A30, A31, A42, A50, A51, and A53;

d) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, or 1000 nucleotides of a nucleic acid sequence selected from the group consisting of SEQ ID Nos 2 and 3 or the complements thereof, wherein said contiguous span comprises at least 1, 2, 3, 5, or 10 of nucleotide positions 1 to 4995 of SEQ ID No 2 or 3;

e) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, or 1000 nucleotides of a nucleic acid sequence selected from the group consisting of SEQ ID Nos 2 and 3 or the complements thereof, wherein said contiguous span comprises at least 1, 2, 3, 5, or 10 of nucleotide positions 1 to 2033, 2160 to 2348 and 2676 to 4995 of SEQ ID No 2 or 3;

f) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, or 1000 nucleotides of a nucleic acid sequence selected from the group consisting of SEQ ID Nos 1-3 or the complements thereof, wherein said contiguous span comprises at least 1, 2, 3, 5, or 10 of any one of the following ranges of nucleotide positions of:

(1) SEQ ID No 1: 1-2500, 2501-5000, 5001-7500, 7501-10000, 10001-12500, 12501-15000, 15001-17500, 17501-20000, 20001-22500, 22501-25000, 25001-27500, 27501-30000, 30001-32500, 32501-35000, 35001-37500, 37501-40000, 40001-42500, 42501-45000, 45001-47500, 47501-50000, 50001-50357, 50499-50963, 51257-52147, 52299-53234, 53394-53553, 53689-53837, 53943-54028, 54198-54740, 54896-55753, 55913-57385, 57495-58503, 58828-85946, 59355-85946, 86169-91228, and/or 91852 to 97662;

(2) SEQ ID No 2: 1 to 500, 501 to 1000, 1001 to 1500, 1501 to 2000, 2001 to 2500, 2501 to 3000, 3001 to 3500, 3501 to 4000, 4001 to 4500, 4501 to 4995, 5000 to 5500, 5501 to 6000, 6001 to 6500, and 6501 to 6782; and,

(3) SEQ ID No 3: 1 to 500, 501 to 1000, 1001 to 1500, 1501 to 2000, 2001 to 2500, 2501 to 3000, 3001 to 3500, 3501 to 4000, 4001 to 4500, 4501 to 4995, 5000 to 5500, 5501 to 6000, 6001 to 6500, 6501 to 7000, 7001 to 7500, 7501 to 7932; and

g) a nucleotide sequence selected from the group consisting of SEQ ID Nos 4, and 9-13;
5 and,

h) a nucleotide sequence complementary to any one of the preceding nucleotide sequences.

Homologous sequences refer to a sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, 80%, or 75% homology to these contiguous spans. Homology may be determined using any method described herein, including BLAST2N with the default parameters or with any modified
10 parameters. Homologous sequences also may include RNA sequences in which uridines replace the thymines in the nucleic acid codes of the invention. It will be appreciated that the nucleic acid codes of the invention can be represented in the traditional single character format (See the inside back cover of Stryer, Lubert. *Biochemistry*, 3rd edition. W. H Freeman & Co., New York.) or in any other format or code which records the identity of the nucleotides in a sequence.

As used herein the term "polypeptide codes of the invention" encompass the polypeptide sequences comprising a contiguous span of at least 6, 8, 10, 12, 15, 20, 25, 30, 40, 50, or 100 amino acids of SEQ ID No 5, wherein said contiguous span includes either at least 1, 2, 3, 5 or 10 of the amino acid positions selected from the group consisting of 1 to 1629 of the SEQ ID No 5 or an amino acid selected from the group consisting of an asparagine at the amino acid position 1694 of
20 SEQ ID No 5, a valine at the amino acid position 1854 of SEQ ID No 5, an asparagine at the amino acid position 1967 of SEQ ID No 5, a glutamic acid at the amino acid position 2017 of SEQ ID No 5, and an alanine at the amino acid position 2050 of SEQ ID No 5. It will be appreciated that the polypeptide codes of the invention can be represented in the traditional single character format or three letter format (See the inside back cover of Stryer, Lubert. *Biochemistry*, 3rd edition. W. H Freeman &
25 Co., New York.) or in any other format or code which records the identity of the polypeptides in a sequence.

It will be appreciated by those skilled in the art that the nucleic acid codes of the invention and polypeptide codes of the invention can be stored, recorded, and manipulated on any medium which can be read and accessed by a computer. As used herein, the words "recorded" and "stored" refer to a
30 process for storing information on a computer medium. A skilled artisan can readily adopt any of the presently known methods for recording information on a computer readable medium to generate manufactures comprising one or more of the nucleic acid codes of the invention, or one or more of the polypeptide codes of the invention. Another aspect of the present invention is a computer readable medium having recorded thereon at least 2, 5, 10, 15, 20, 25, 30, or 50 nucleic acid codes of the
35 invention. Another aspect of the present invention is a computer readable medium having recorded thereon at least 2, 5, 10, 15, 20, 25, 30, or 50 polypeptide codes of the invention.

Computer readable media include magnetically readable media, optically readable media, electronically readable media and magnetic/optical media. For example, the computer readable media may be a hard disk, a floppy disk, a magnetic tape, CD-ROM, Digital Versatile Disk (DVD), Random Access Memory (RAM), or Read Only Memory (ROM) as well as other types of other media known to those skilled in the art.

Embodiments of the present invention include systems, particularly computer systems which store and manipulate the sequence information described herein. One example of a computer system 100 is illustrated in block diagram form in Figure 7. As used herein, "a computer system" refers to the hardware components, software components, and data storage components used to analyze the nucleotide sequences of the nucleic acid codes of the invention or the amino acid sequences of the polypeptide codes of the invention. In one embodiment, the computer system 100 is a Sun Enterprise 1000 server (Sun Microsystems, Palo Alto, CA). The computer system 100 preferably includes a processor for processing, accessing and manipulating the sequence data. The processor 105 can be any well-known type of central processing unit, such as the Pentium III from Intel Corporation, or similar processor from Sun, Motorola, Compaq or International Business Machines.

Preferably, the computer system 100 is a general purpose system that comprises the processor 105 and one or more internal data storage components 110 for storing data, and one or more data retrieving devices for retrieving the data stored on the data storage components. A skilled artisan can readily appreciate that any one of the currently available computer systems are suitable.

In one particular embodiment, the computer system 100 includes a processor 105 connected to a bus which is connected to a main memory 115 (preferably implemented as RAM) and one or more internal data storage devices 110, such as a hard drive and/or other computer readable media having data recorded thereon. In some embodiments, the computer system 100 further includes one or more data retrieving device 118 for reading the data stored on the internal data storage devices 110.

The data retrieving device 118 may represent, for example, a floppy disk drive, a compact disk drive, a magnetic tape drive, etc. In some embodiments, the internal data storage device 110 is a removable computer readable medium such as a floppy disk, a compact disk, a magnetic tape, etc. containing control logic and/or data recorded thereon. The computer system 100 may advantageously include or be programmed by appropriate software for reading the control logic and/or the data from the data storage component once inserted in the data retrieving device.

The computer system 100 includes a display 120 which is used to display output to a computer user. It should also be noted that the computer system 100 can be linked to other computer systems 125a-c in a network or wide area network to provide centralized access to the computer system 100.

Software for accessing and processing the nucleotide sequences of the nucleic acid codes of the invention or the amino acid sequences of the polypeptide codes of the invention (such as search tools, compare tools, and modeling tools etc.) may reside in main memory 115 during execution.

In some embodiments, the computer system 100 may further comprise a sequence comparer for comparing the above-described nucleic acid codes of the invention or the polypeptide codes of the invention stored on a computer readable medium to reference nucleotide or polypeptide sequences stored on a computer readable medium. A "sequence comparer" refers to one or more programs which
5 are implemented on the computer system 100 to compare a nucleotide or polypeptide sequence with other nucleotide or polypeptide sequences and/or compounds including but not limited to peptides, peptidomimetics, and chemicals stored within the data storage means. For example, the sequence comparer may compare the nucleotide sequences of nucleic acid codes of the invention or the amino acid sequences of the polypeptide codes of the invention stored on a computer readable medium to
10 reference sequences stored on a computer readable medium to identify homologies, motifs implicated in biological function, or structural motifs. The various sequence comparer programs identified elsewhere in this patent specification are particularly contemplated for use in this aspect of the invention.

Figure 8 is a flow diagram illustrating one embodiment of a process 200 for comparing a new nucleotide or protein sequence with a database of sequences in order to determine the homology levels
15 between the new sequence and the sequences in the database. The database of sequences can be a private database stored within the computer system 100, or a public database such as GENBANK, PIR OR SWISSPROT that is available through the Internet.

The process 200 begins at a start state 201 and then moves to a state 202 wherein the new sequence to be compared is stored to a memory in a computer system 100. As discussed above, the
20 memory could be any type of memory, including RAM or an internal storage device.

The process 200 then moves to a state 204 wherein a database of sequences is opened for analysis and comparison. The process 200 then moves to a state 206 wherein the first sequence stored in the database is read into a memory on the computer. A comparison is then performed at a state 210 to determine if the first sequence is the same as the second sequence. It is important to note that this
25 step is not limited to performing an exact comparison between the new sequence and the first sequence in the database. Well-known methods are known to those of skill in the art for comparing two nucleotide or protein sequences, even if they are not identical. For example, gaps can be introduced into one sequence in order to raise the homology level between the two tested sequences. The parameters that control whether gaps or other features are introduced into a sequence during comparison are
30 normally entered by the user of the computer system.

Once a comparison of the two sequences has been performed at the state 210, a determination is made at a decision state 210 whether the two sequences are the same. Of course, the term "same" is not limited to sequences that are absolutely identical. Sequences that are within the homology parameters entered by the user will be marked as "same" in the process 200.

35 If a determination is made that the two sequences are the same, the process 200 moves to a state 214 wherein the name of the sequence from the database is displayed to the user. This state notifies the user that the sequence with the displayed name fulfills the homology constraints that were entered.

Once the name of the stored sequence is displayed to the user, the process 200 moves to a decision state 218 wherein a determination is made whether more sequences exist in the database. If no more sequences exist in the database, then the process 200 terminates at an end state 220. However, if more sequences do exist in the database, then the process 200 moves to a state 224 wherein a pointer is

- 5 moved to the next sequence in the database so that it can be compared to the new sequence. In this manner, the new sequence is aligned and compared with every sequence in the database.

It should be noted that if a determination had been made at the decision state 212 that the sequences were not homologous, then the process 200 would move immediately to the decision state 218 in order to determine if any other sequences were available in the database for comparison.

- 10 Accordingly, one aspect of the present invention is a computer system comprising a processor, a data storage device having stored thereon a nucleic acid code of the invention or a polypeptide code of the invention, a data storage device having retrievably stored thereon reference nucleotide sequences or polypeptide sequences to be compared to the nucleic acid code of the invention or polypeptide code of the invention and a sequence comparer for conducting the
- 15 comparison. The sequence comparer may indicate a homology level between the sequences compared or identify structural motifs in the nucleic acid code of the invention and polypeptide codes of the invention or it may identify structural motifs in sequences which are compared to these nucleic acid codes and polypeptide codes. In some embodiments, the data storage device may have stored thereon the sequences of at least 2, 5, 10, 15, 20, 25, 30, or 50 of the nucleic acid codes of the
- 20 invention or polypeptide codes of the invention.

- Another aspect of the present invention is a method for determining the level of homology between a nucleic acid code of the invention and a reference nucleotide sequence, comprising the steps of reading the nucleic acid code and the reference nucleotide sequence through the use of a computer program which determines homology levels and determining homology between the nucleic
- 25 acid code and the reference nucleotide sequence with the computer program. The computer program may be any of a number of computer programs for determining homology levels, including those specifically enumerated herein, including BLAST2N with the default parameters or with any modified parameters. The method may be implemented using the computer systems described above. The method may also be performed by reading 2, 5, 10, 15, 20, 25, 30, or 50 of the above described nucleic
- 30 acid codes of the invention through the use of the computer program and determining homology between the nucleic acid codes and reference nucleotide sequences.

- Figure 9 is a flow diagram illustrating one embodiment of a process 250 in a computer for determining whether two sequences are homologous. The process 250 begins at a start state 252 and then moves to a state 254 wherein a first sequence to be compared is stored to a memory. The
- 35 second sequence to be compared is then stored to a memory at a state 256. The process 250 then moves to a state 260 wherein the first character in the first sequence is read and then to a state 262 wherein the first character of the second sequence is read. It should be understood that if the

sequence is a nucleotide sequence, then the character would normally be either A, T, C, G or U. If the sequence is a protein sequence, then it should be in the single letter amino acid code so that the first and sequence sequences can be easily compared.

A determination is then made at a decision state 264 whether the two characters are the same. If they are the same, then the process 250 moves to a state 268 wherein the next characters in the first and second sequences are read. A determination is then made whether the next characters are the same. If they are, then the process 250 continues this loop until two characters are not the same. If a determination is made that the next two characters are not the same, the process 250 moves to a decision state 274 to determine whether there are any more characters either sequence to read.

If there aren't any more characters to read, then the process 250 moves to a state 276 wherein the level of homology between the first and second sequences is displayed to the user. The level of homology is determined by calculating the proportion of characters between the sequences that were the same out of the total number of sequences in the first sequence. Thus, if every character in a first 100 nucleotide sequence aligned with a every character in a second sequence, the homology level would be 100%.

Alternatively, the computer program may be a computer program which compares the nucleotide sequences of the nucleic acid codes of the present invention, to reference nucleotide sequences in order to determine whether the nucleic acid code of the invention differs from a reference nucleic acid sequence at one or more positions. In some embodiments, such a program records the length and identity of inserted, deleted or substituted nucleotides with respect to the sequence of either the reference polynucleotide or the nucleic acid code of the invention. In one embodiment, the computer program may be a program which determines whether the nucleotide sequences of the nucleic acid codes of the invention contain one or more single nucleotide polymorphisms (SNP) with respect to a reference nucleotide sequence. These single nucleotide polymorphisms may each comprise a single base substitution, insertion, or deletion.

Another aspect of the present invention is a method for determining the level of homology between a polypeptide code of the invention and a reference polypeptide sequence, comprising the steps of reading the polypeptide code of the invention and the reference polypeptide sequence through use of a computer program which determines homology levels and determining homology between the polypeptide code and the reference polypeptide sequence using the computer program.

Accordingly, another aspect of the present invention is a method for determining whether a nucleic acid code of the invention differs at one or more nucleotides from a reference nucleotide sequence comprising the steps of reading the nucleic acid code and the reference nucleotide sequence through use of a computer program which identifies differences between nucleic acid sequences and identifying differences between the nucleic acid code and the reference nucleotide sequence with the computer program. In some embodiments, the computer program is a program which identifies single

nucleotide polymorphisms The method may be implemented by the computer systems described above and the method illustrated in Figure 9. The method may also be performed by reading at least 2, 5, 10, 15, 20, 25, 30, or 50 of the nucleic acid codes of the invention and the reference nucleotide sequences through the use of the computer program and identifying differences between the nucleic acid codes and
5 the reference nucleotide sequences with the computer program.

In other embodiments the computer based system may further comprise an identifier for identifying features within the nucleotide sequences of the nucleic acid codes of the invention or the amino acid sequences of the polypeptide codes of the invention.

An "identifier" refers to one or more programs which identifies certain features within the
10 above-described nucleotide sequences of the nucleic acid codes of the invention or the amino acid sequences of the polypeptide codes of the invention. In one embodiment, the identifier may comprise a program which identifies an open reading frame in the cDNAs codes of the invention.

Figure 10 is a flow diagram illustrating one embodiment of an identifier process 300 for detecting the presence of a feature in a sequence. The process 300 begins at a start state 302 and
15 then moves to a state 304 wherein a first sequence that is to be checked for features is stored to a memory 115 in the computer system 100. The process 300 then moves to a state 306 wherein a database of sequence features is opened. Such a database would include a list of each feature's attributes along with the name of the feature. For example, a feature name could be "Initiation Codon" and the attribute would be "ATG". Another example would be the feature name "TAATAA
20 Box" and the feature attribute would be "TAATAA". An example of such a database is produced by the University of Wisconsin Genetics Computer Group (www.gcg.com).

Once the database of features is opened at the state 306, the process 300 moves to a state 308 wherein the first feature is read from the database. A comparison of the attribute of the first feature with the first sequence is then made at a state 310. A determination is then made at a
25 decision state 316 whether the attribute of the feature was found in the first sequence. If the attribute was found, then the process 300 moves to a state 318 wherein the name of the found feature is displayed to the user.

The process 300 then moves to a decision state 320 wherein a determination is made whether more features exist in the database. If no more features do exist, then the process 300
30 terminates at an end state 324. However, if more features do exist in the database, then the process 300 reads the next sequence feature at a state 326 and loops back to the state 310 wherein the attribute of the next feature is compared against the first sequence.

It should be noted, that if the feature attribute is not found in the first sequence at the decision state 316, the process 300 moves directly to the decision state 320 in order to determine if
35 any more features exist in the database.

In another embodiment, the identifier may comprise a molecular modeling program which determines the 3-dimensional structure of the polypeptides codes of the invention. In some

embodiments, the molecular modeling program identifies target sequences that are most compatible with profiles representing the structural environments of the residues in known three-dimensional protein structures. (See, e.g., Eisenberg et al., U.S. Patent No 5,436,850 issued July 25, 1995). In another technique, the known three-dimensional structures of proteins in a given family are
5 superimposed to define the structurally conserved regions in that family. This protein modeling technique also uses the known three-dimensional structure of a homologous protein to approximate the structure of the polypeptide codes of the invention. (See e.g., Srinivasan, et al., U.S. Patent No 5,557,535 issued September 17, 1996). Conventional homology modeling techniques have been used routinely to build models of proteases and antibodies. (Sowdhamini et al., Protein Engineering
10 10:207, 215 (1997)). Comparative approaches can also be used to develop three-dimensional protein models when the protein of interest has poor sequence identity to template proteins. In some cases, proteins fold into similar three-dimensional structures despite having very weak sequence identities. For example, the three-dimensional structures of a number of helical cytokines fold in similar three-dimensional topology in spite of weak sequence homology.

15 The recent development of threading methods now enables the identification of likely folding patterns in a number of situations where the structural relatedness between target and template(s) is not detectable at the sequence level. Hybrid methods, in which fold recognition is performed using Multiple Sequence Threading (MST), structural equivalencies are deduced from the threading output using a distance geometry program DRAGON to construct a low resolution model,
20 and a full-atom representation is constructed using a molecular modeling package such as QUANTA.

According to this 3-step approach, candidate templates are first identified by using the novel fold recognition algorithm MST, which is capable of performing simultaneous threading of multiple aligned sequences onto one or more 3-D structures. In a second step, the structural equivalencies
25 obtained from the MST output are converted into interresidue distance restraints and fed into the distance geometry program DRAGON, together with auxiliary information obtained from secondary structure predictions. The program combines the restraints in an unbiased manner and rapidly generates a large number of low resolution model confirmations. In a third step, these low resolution model confirmations are converted into full-atom models and subjected to energy
30 minimization using the molecular modeling package QUANTA. (See e.g., Aszodi et al., Proteins:Structure, Function, and Genetics, Supplement 1:38-42 (1997)).

The results of the molecular modeling analysis may then be used in rational drug design techniques to identify agents which modulate the activity of the polypeptide codes of the invention.

Accordingly, another aspect of the present invention is a method of identifying a feature
35 within the nucleic acid codes of the invention or the polypeptide codes of the invention comprising reading the nucleic acid code(s) or the polypeptide code(s) through the use of a computer program which identifies features therein and identifying features within the nucleic acid code(s) or

polypeptide code(s) with the computer program. In one embodiment, computer program comprises a computer program which identifies open reading frames. In a further embodiment, the computer program identifies structural motifs in a polypeptide sequence. In another embodiment, the computer program comprises a molecular modeling program. The method may be performed by

5 reading a single sequence or at least 2, 5, 10, 15, 20, 25, 30, or 50 of the nucleic acid codes of the invention or the polypeptide codes of the invention through the use of the computer program and identifying features within the nucleic acid codes or polypeptide codes with the computer program.

The nucleic acid codes of the invention or the polypeptide codes of the invention may be stored and manipulated in a variety of data processor programs in a variety of formats. For example,

10 they may be stored as text in a word processing file, such as MicrosoftWORD or WORDPERFECT or as an ASCII file in a variety of database programs familiar to those of skill in the art, such as DB2, SYBASE, or ORACLE. In addition, many computer programs and databases may be used as sequence comparers, identifiers, or sources of reference nucleotide or polypeptide sequences to be compared to the nucleic acid codes of the invention or the polypeptide codes of the invention. The following list is

15 intended not to limit the invention but to provide guidance to programs and databases which are useful with the nucleic acid codes of the invention or the polypeptide codes of the invention. The programs and databases which may be used include, but are not limited to: MacPattern (EMBL), DiscoveryBase (Molecular Applications Group), GeneMine (Molecular Applications Group), Look (Molecular Applications Group), MacLook (Molecular Applications Group), BLAST and BLAST2 (NCBI),

20 BLASTN and BLASTX (Altschul et al, 1990), FASTA (Pearson and Lipman, 1988), FASTDB (Brutlag et al., 1990), Catalyst (Molecular Simulations Inc.), Catalyst/SHAPE (Molecular Simulations Inc.), Cerius².DBAccess (Molecular Simulations Inc.), HypoGen (Molecular Simulations Inc.), Insight II, (Molecular Simulations Inc.), Discover (Molecular Simulations Inc.), CHARMM (Molecular Simulations Inc.), Felix (Molecular Simulations Inc.), DelPhi, (Molecular Simulations Inc.),

25 QuanteMM, (Molecular Simulations Inc.), Homology (Molecular Simulations Inc.), Modeler (Molecular Simulations Inc.), ISIS (Molecular Simulations Inc.), Quanta/Protein Design (Molecular Simulations Inc.), WebLab (Molecular Simulations Inc.), WebLab Diversity Explorer (Molecular Simulations Inc.), Gene Explorer (Molecular Simulations Inc.), SeqFold (Molecular Simulations Inc.), the EMBL/Swissprotein database, the MDL Available Chemicals Directory database, the MDL Drug

30 Data Report data base, the Comprehensive Medicinal Chemistry database, Derwent's World Drug Index database, the BioByteMasterFile database, the Genbank database, and the Genseqn database. Many other programs and data bases would be apparent to one of skill in the art given the present disclosure.

Motifs which may be detected using the above programs include sequences encoding

35 leucine zippers, helix-turn-helix motifs, glycosylation sites, ubiquitination sites, alpha helices, and beta sheets, signal sequences encoding signal peptides which direct the secretion of the encoded

proteins, sequences implicated in transcription regulation such as homeoboxes, acidic stretches, enzymatic active sites, substrate binding sites, and enzymatic cleavage sites.

Throughout this application, various publications, patents and published patent applications are cited. The disclosures of these publications, patents and published patent specification referenced in this application are hereby incorporated by reference into the present disclosure to more fully describe the state of the art to which this invention pertains.

EXAMPLES

Example 1

10 Identification Of Biallelic Markers - DNA Extraction

Blood donors were from French Caucasian origin. They presented a sufficient diversity for being representative of a French heterogeneous population. The DNA from 100 unrelated and healthy individuals was extracted, pooled and tested for the detection of biallelic markers. The pool was constituted by mixing equivalent quantities of DNA from each individual.

15 30 ml of peripheral venous blood were taken from each donor in the presence of EDTA. Cells (pellet) were collected after centrifugation for 10 minutes at 2000 rpm. Red cells were lysed by a lysis solution (50 ml final volume : 10 mM Tris pH7.6; 5 mM $MgCl_2$; 10 mM NaCl). The solution was centrifuged (10 minutes, 2000 rpm) as many times as necessary to eliminate the residual red cells present in the supernatant, after resuspension of the pellet in the lysis solution.

20 The pellet of white cells was lysed overnight at 42°C with 3.7 ml of lysis solution composed of:

- 3 ml TE 10-2 (Tris-HCl 10 mM, EDTA 2 mM) / NaCl 0.4 M
- 200 μ l SDS 10%
- 500 μ l K-proteinase (2 mg K-proteinase in TE 10-2 / NaCl 0.4 M).

25 For the extraction of proteins, 1 ml saturated NaCl (6M) (1/3.5 v/v) was added. After vigorous agitation, the solution was centrifuged for 20 minutes at 10000 rpm.

For the precipitation of DNA, 2 to 3 volumes of 100% ethanol were added to the previous supernatant, and the solution was centrifuged for 30 minutes at 2000 rpm. The DNA solution was rinsed three times with 70% ethanol to eliminate salts, and centrifuged for 20 minutes at 2000 rpm.

30 The pellet was dried at 37°C, and resuspended in 1 ml TE 10-1 or 1 ml water. The DNA concentration was evaluated by measuring the OD at 260 nm (1 unit OD = 50 μ g/ml DNA).

To determine the presence of proteins in the DNA solution, the OD 260 / OD 280 ratio was determined. Only DNA preparations having a OD 260 / OD 280 ratio between 1.8 and 2 were used in the subsequent examples described below.

Example 2

Identification Of Biallelic Markers: Amplification Of Genomic DNA By PCR

The amplification of specific genomic sequences of the DNA samples of example 1 was carried out on the pool of DNA obtained previously. In addition, 10 individual samples were

5 similarly amplified.

PCR assays were performed using the following protocol:

	Final volume	25 μ l
	DNA	2 ng/ μ l
	MgCl ₂	2 mM
10	dNTP (each)	200 μ M
	primer (each)	2.9 ng/ μ l
	Ampli Taq Gold DNA polymerase	0.05 unit/ μ l
	PCR buffer (10x = 0.1 M TrisHCl pH8.3 0.5M KCl)	1x

Each pair of first primers is designed using the sequence information of the *BAP28* gene
 15 disclosed herein and the OSP software (Hillier & Green, 1991). This first pair of primers were about 20 nucleotides in length.

Table 1

Amplicon	Position range of the amplicon in SEQ ID No 1		Primer name	Position range of amplification primer in SEQ ID No 1		Primer name	Complementary position range of amplification primer in SEQ ID No 1	
5-381	4840	5266	B1	4840	4859	C1	5249	5266
5-382	5307	5729	B2	5307	5324	C2	5710	5729
99-7190	12946	13488	B3	12946	12963	C3	13471	13488
99-7203	23482	23929	B4	23482	23501	C4	23909	23929
5-383	27887	28315	B5	27887	27904	C5	28296	28315
99-7205	29833	30288	B6	29833	29853	C6	30270	30288
5-384	32439	32877	B7	32439	32457	C7	32858	32877
5-379	48110	48460	B8	48110	48127	C8	48441	48460
5-380	49558	49977	B9	49558	49577	C9	49958	49977
5-366	50162	50583	B10	50162	50180	C10	50564	50583
5-370	50937	51359	B11	50937	50955	C11	51341	51359
5-373	53437	53858	B12	53437	53455	C12	53840	53858
5-375	53974	54394	B13	53974	53993	C13	54375	54394
5-376	54602	55021	B14	54602	54619	C14	55002	55021
5-377	55608	56043	B15	55608	55625	C15	56025	56043
5-14	59673	60100	B16	59673	59692	C16	60083	60100
5-11	60718	61137	B17	60718	60737	C17	61119	61137
5-202	66177	66608	B23	66177	66194	C23	66589	66608
99-1605	71723	72170	B21	71723	71743	C21	72150	72170
5-2	71735	72169	B22	71735	71754	C22	72150	72169
5-171	85485	85905	B20	85485	85502	C20	85887	85905
5-169	86184	86600	B19	86184	86203	C19	86581	86600
99-1572	86932	87574	B18	86932	86952	C18	87556	87574
5-403	91068	91417	B24	91068	91085	C24	91398	91417

in SEQ ID No 29								
99-13790	1	454	B25	1	20	C25	434	454
in SEQ ID No 25								
99-13798	1	447	B26	1	20	C26	427	447
in SEQ ID No 27								
99-13808	1	546	B27	1	20	C27	526	546
in SEQ ID No 30								
99-13809	1	444	B28	1	21	C28	424	444
in SEQ ID No 28								
99-13810	1	476	B29	1	18	C29	458	476
in SEQ ID No 23								
99-1585	1	546	B30	1	20	C30	527	546
in SEQ ID No 24								
99-1587	1	396	B31	1	21	C31	377	396
in SEQ ID No 31								
99-1597	1	693	B32	1	19	C32	675	693
in SEQ ID No 26								
99-1601	1	506	B33	1	18	C33	486	506
in SEQ ID No 18								
99-7177	1	504	B34	1	20	C34	484	504
in SEQ ID No 22								
99-7182	1	531	B35	1	20	C35	511	531
in SEQ ID No 21								
99-7186	1	528	B36	1	19	C36	510	528
in SEQ ID No 20								
99-7193	1	542	B37	1	20	C37	522	542
in SEQ ID No 19								
99-7212	1	492	B38	1	20	C38	472	492

Preferably, the primers contained a common oligonucleotide tail upstream of the specific bases targeted for amplification which was useful for sequencing.

Primers PU contain the following additional PU 5' sequence:

- 5 TGTAACGACGCGCCAGT; primers RP contain the following RP 5' sequence:
CAGGAAACAGCTATGACC. The primer containing the additional PU 5' sequence is listed in SEQ ID No 11. The primer containing the additional RP 5' sequence is listed in SEQ ID No 12.

The synthesis of these primers was performed following the phosphoramidite method, on a GENSET UFPS 24.1 synthesizer.

- 10 DNA amplification was performed on a Genius II thermocycler. After heating at 95°C for 10 min, 40 cycles were performed. Each cycle comprised: 30 sec at 95°C, 54°C for 1 min, and 30 sec at 72°C. For final elongation, 10 min at 72°C ended the amplification. The quantities of the amplification products obtained were determined on 96-well microtiter plates, using a fluorometer and Picogreen as intercalant agent (Molecular Probes).

Example 3

**Identification Of Biallelic Markers - Sequencing Of Amplified Genomic DNA And
Identification Of Polymorphisms**

The sequencing of the amplified DNA obtained in example 2 was carried out on ABI 377
5 sequencers. The sequences of the amplification products were determined using automated dideoxy
terminator sequencing reactions with a dye terminator cycle sequencing protocol. The products of
the sequencing reactions were run on sequencing gels and the sequences were determined using gel
image analysis (ABI Prism DNA Sequencing Analysis software (2.1.2 version)).

The sequence data were further evaluated to detect the presence of biallelic markers within
10 the amplified fragments. The polymorphism search was based on the presence of superimposed
peaks in the electrophoresis pattern resulting from different bases occurring at the same position as
described previously.

The localization of the biallelic markers on SEQ ID Nos 1, and 18 to 31 are as shown
above in Table 2.

15 Also encompassed by the present invention are BAP28-related biallelic markers A1 to A58
described below in Table 2.

Table 2

Amplicon	BM	Marker Name	Localization in BAP28 gene	Polymorphism		BM position in SEQ ID No 1	BM position in SEQ ID Nos 2, 3 & 4
				all1	all2		
5-381	A1	5-381-133	5' regulatory region	A	G	4972	
5-382	A2	5-382-162	Exon 2	C	T	5468	178
5-382	A3	5-382-310	Intron 2-3	C	T	5616	
5-382	A4	5-382-316	Intron 2-3	G	C	5622	
99-7190	A5	99-7190-213	Intron 6-7	C	T	13158	
99-7203	A6	99-7203-282	Intron 16-17	A	T	23761	
99-7203	A7	99-7203-286	Intron 16-17	C	T	23765	
5-383	A8	5-383-42	Intron 19-20	A	G	27928	
5-383	A9	5-383-184	Exon 20	G	T	28070	2677
99-7205	A10	99-7205-228	Intron 20-21	A	G	30061	
5-384	A11	5-384-312	Intron 21-22	G	C	32750	
5-379	A12	5-379-80	Intron 32-33	A	C	48189	
5-380	A13	5-380-58	Intron 33-34	G	T	49615	
5-380	A14	5-380-59	Intron 33-34	C	T	49616	
5-366	A15	5-366-143	Intron 34-35	A	G	50304	
5-370	A16	5-370-197	Exon 36	A	G	51133	5193
5-370	A17	5-370-247	Exon 36	C	T	51183	5243
5-373	A18	5-373-98	Intron 38-39	C	T	53534	
5-373	A19	5-373-164	Exon 39	C	T	53600	5673
5-373	A20	5-373-222	Exon 39	A	G	53658	5731
5-375	A21	5-375-200	Exon 41	A	G	54173	6011
5-375	A22	5-375-259	Intron 41-42	C	T	54232	
5-375	A23	5-375-296	Intron 41-42	G	C	54269	
5-375	A24	5-375-399	Intron 41-42	G	C	54372	

5-376	A25	5-376-266	Exon 42	A	G	54867	6162
5-377	A26	5-377-82	Intron 42-43	C	T	55689	
5-377	A27	5-377-227	Exon 43	A	G	55834	6271
5-14	A28	5-14-165	Intron 45-B'	A	G	59937	
5-11	A29	5-11-158	Intron 45-B'	C	T	60980	
5-202	A36	5-202-117	Intron 45-B'	A	T	66492	
5-202	A35	5-202-95	Intron 45-B'	A	C	66514	
99-1605	A33	99-1605-112	Intron 45-B'	A	G	71834	
5-2	A34	5-2-178	Intron 45-B'	A	G	71993	
5-171	A32	5-171-204	Intron 45-B'	A	G	85702	
5-169	A31	5-169-97	Intron B'-A'	G	C	86504	
99-1572	A30	99-1572-440	Intron B'-A'	A	G	87135	
5-403	A37	5-403-325	Intron B'-A'	C	T	91093	
5-403	A38	5-403-294	Intron B'-A'	A	G	91124	
5-403	A39	5-403-209	Intron B'-A'	C	T	91209	
5-403	A40	5-403-156	Exon A'	C	T	91262	7935 in SEQ ID No 3 256 in SEQ ID No 4
Amplicon	BM	Marker Name	Polymorphism		BM position		
			all1	all2			
99-13790	A41	99-13790-129	C	T	127 in SEQ ID No 29		
99-13798	A42	99-13798-284	A	G	283 in SEQ ID No 25		
99-13808	A43	99-13808-80	A	T	79 in SEQ ID No 27		
99-13808	A44	99-13808-268	A	C	266 in SEQ ID No 27		
99-13808	A45	99-13808-425	G	C	419 in SEQ ID No 27		
99-13808	A46	99-13808-455	A	G	453 in SEQ ID No 27		
99-13809	A47	99-13809-153	A	G	153 in SEQ ID No 30		
99-13810	A48	99-13810-214	C	T	212 in SEQ ID No 28		
99-13810	A49	99-13810-170	A	T	168 in SEQ ID No 28		
99-1585	A50	99-1585-373	C	T	372 in SEQ ID No 23		
99-1587	A51	99-1587-281	A	G	278 in SEQ ID No 24		
99-1597	A52	99-1597-162	A	G	162 in SEQ ID No 31		
99-1601	A53	99-1601-402	A	T	402 in SEQ ID No 26		
99-7177	A54	99-7177-81	C	T	81 in SEQ ID No 18		
99-7182	A55	99-7182-49	C	T	49 in SEQ ID No 22		
99-7186	A56	99-7186-212	A	G	212 in SEQ ID No 21		
99-7193	A57	99-7193-228	G	C	226 in SEQ ID No 20		
99-7212	A58	99-7212-346	C	T	345 in SEQ ID No 19		

BM refers to "biallelic marker". All1 and all2 refer respectively to allele 1 and allele 2 of the biallelic marker.

- The biallelic markers A16, A19, A21 and A25 are located in exonic sequence and give 5 amino acid polymorphisms. Indeed, the codon comprising the marker A16 encodes either a serine or an asparagine in position 1694 of the SEQ ID No 5 ; the codon comprising the marker A19 encodes either an alanine or a valine in position 1854 of the SEQ ID No 5 ; the codon comprising the marker A21 encodes either an aspartic acid or an asparagine in position 1967 of the SEQ ID No 5 ; the

codon comprising the marker A25 encodes either a glycine or a glutamic acid in position 2017 of the SEQ ID No 5.

The Table 3 discloses the probes specific of each biallelic markers.

Table 3

BM	Marker Name	Position range of probes in SEQ ID No 1		Probes
A1	5-381-133	4960	4984	P1
A2	5-382-162	5456	5480	P2
A3	5-382-310	5604	5628	P3
A4	5-382-316	5610	5634	P4
A5	99-7190-213	13146	13170	P5
A6	99-7203-282	23749	23773	P6
A7	99-7203-286	23753	23777	P7
A8	5-383-42	27916	27940	P8
A9	5-383-184	28058	28082	P9
A10	99-7205-228	30049	30073	P10
A11	5-384-312	32738	32762	P11
A12	5-379-80	48177	48201	P12
A13	5-380-58	49603	49627	P13
A14	5-380-59	49604	49628	P14
A15	5-366-143	50292	50316	P15
A16	5-370-197	51121	51145	P16
A17	5-370-247	51171	51195	P17
A18	5-373-98	53522	53546	P18
A19	5-373-164	53588	53612	P19
A20	5-373-222	53646	53670	P20
A21	5-375-200	54161	54185	P21
A22	5-375-259	54220	54244	P22
A23	5-375-296	54257	54281	P23
A24	5-375-399	54360	54384	P24
A25	5-376-266	54855	54879	P25
A26	5-377-82	55677	55701	P26
A27	5-377-227	55822	55846	P27
A28	5-14-165	59925	59949	P28
A29	5-11-158	60968	60992	P29
A36	5-202-117	66480	66504	P36
A35	5-202-95	66502	66526	P35
A33	99-1605-112	71822	71846	P33
A34	5-2-178	71981	72005	P34
A32	5-171-204	85690	85714	P32
A31	5-169-97	86492	86516	P31
A30	99-1572-440	87123	87147	P30
A37	5-403-325	91081	91105	P37
A38	5-403-294	91112	91136	P38
A39	5-403-209	91197	91221	P39
A40	5-403-156	91250	91274	P40
BM	Marker Name	Position range of probes		Probes
A41	99-13790-129	115-139 in SEQ ID No 29		P41
A42	99-13798-284	271-295 in SEQ ID No 25		P42
A43	99-13808-80	67-91 in SEQ ID No 27		P43

A44	99-13808-268	254-278 in SEQ ID No 27	P44
A45	99-13808-425	407-431 in SEQ ID No 27	P45
A46	99-13808-455	441-465 in SEQ ID No 27	P46
A47	99-13809-153	141-165 in SEQ ID No 30	P47
A48	99-13810-214	200-224 in SEQ ID No 28	P48
A49	99-13810-170	156-180 in SEQ ID No 28	P49
A50	99-1585-373	360-384 in SEQ ID No 23	P50
A51	99-1587-281	266-290 in SEQ ID No 24	P51
A52	99-1597-162	150-174 in SEQ ID No 31	P52
A53	99-1601-402	390-414 in SEQ ID No 26	P53
A54	99-7177-81	69-93 in SEQ ID No 18	P54
A55	99-7182-49	37-61 in SEQ ID No 22	P55
A56	99-7186-212	200-224 in SEQ ID No 21	P56
A57	99-7193-228	214-238 in SEQ ID No 20	P57
A58	99-7212-346	333-357 in SEQ ID No 19	P58

Example 4**Validation Of The Polymorphisms Through Microsequencing**

The biallelic markers identified in example 3 were further confirmed and their respective frequencies were determined through microsequencing. Microsequencing was carried out for each individual DNA sample described in Example 1.

Amplification from genomic DNA of individuals was performed by PCR as described above for the detection of the biallelic markers with the same set of PCR primers.

The preferred primers used in microsequencing were about 19 nucleotides in length and hybridized just upstream of the considered polymorphic base. According to the invention, the 10 primers used in microsequencing are detailed in Table 4.

Table 4

Marker Name	BM	Mis1	Position range of microsequencing primer mis 1 in SEQ ID No 1		Mis2	Complementary position range of microsequencing primer mis. 2 in SEQ ID No 1	
5-381-133	A1	D1	4953	4971	E1	4973	4991
5-382-162	A2	D2	5449	5467	E2	5469	5487
5-382-310	A3	D3	5597	5615	E3	5617	5635
5-382-316	A4	D4	5603	5621	E4	5623	5641
99-7190-213	A5	D5	13139	13157	E5	13159	13177
99-7203-282	A6	D6	23742	23760	E6	23762	23780
99-7203-286	A7	D7	23746	23764	E7	23766	23784
5-383-42	A8	D8	27909	27927	E8	27929	27947
5-383-184	A9	D9	28051	28069	E9	28071	28089
99-7205-228	A10	D10	30042	30060	E10	30062	30080
5-384-312	A11	D11	32731	32749	E11	32751	32769
5-379-80	A12	D12	48170	48188	E12	48190	48208
5-380-58	A13	D13	49596	49614	E13	49616	49634
5-380-59	A14	D14	49597	49615	E14	49617	49635
5-366-143	A15	D15	50285	50303	E15	50305	50323
5-370-197	A16	D16	51114	51132	E16	51134	51152
5-370-247	A17	D17	51164	51182	E17	51184	51202
5-373-98	A18	D18	53515	53533	E18	53535	53553

5-373-164	A19	D19	53581	53599	E19	53601	53619
5-373-222	A20	D20	53639	53657	E20	53659	53677
5-375-200	A21	D21	54154	54172	E21	54174	54192
5-375-259	A22	D22	54213	54231	E22	54233	54251
5-375-296	A23	D23	54250	54268	E23	54270	54288
5-375-399	A24	D24	54353	54371	E24	54373	54391
5-376-266	A25	D25	54848	54866	E25	54868	54886
5-377-82	A26	D26	55670	55688	E26	55690	55708
5-377-227	A27	D27	55815	55833	E27	55835	55853
5-14-165	A28	D28	59918	59936	E28	59938	59956
5-11-158	A29	D29	60961	60979	E29	60981	60999
5-202-117	A36	D36	66473	66491	E36	66493	66511
5-202-95	A35	D35	66495	66513	E35	66515	66533
99-1605-112	A33	D33	71815	71833	E33	71835	71853
5-2-178	A34	D34	71974	71992	E34	71994	72012
5-171-204	A32	D32	85683	85701	E32	85703	85721
5-169-97	A31	D31	86485	86503	E31	86505	86523
99-1572-440	A30	D30	87116	87134	E30	87136	87154
5-403-325	A37	D37	91074	91092	E37	91094	91112
5-403-294	A38	D38	91105	91123	E38	91125	91143
5-403-209	A39	D39	91190	91208	E39	91210	91228
5-403-156	A40	D40	91243	91261	E40	91263	91281
Marker Name	BM	Mis1	Position range of microsequencing primer mis 1		Mis2	Complementary position range of microsequencing primer mis. 2	
99-13790-129	A41	D41	108-126 in SEQ ID No 29		E41	128-146 in SEQ ID No 29	
99-13798-284	A42	D42	264-282 in SEQ ID No 25		E42	284-302 in SEQ ID No 25	
99-13808-80	A43	D43	60-78 in SEQ ID No 27		E43	80-98 in SEQ ID No 27	
99-13808-268	A44	D44	247-265 in SEQ ID No 27		E44	267-285 in SEQ ID No 27	
99-13808-425	A45	D45	400-418 in SEQ ID No 27		E45	420-438 in SEQ ID No 27	
99-13808-455	A46	D46	434-452 in SEQ ID No 27		E46	454-472 in SEQ ID No 27	
99-13809-153	A47	D47	134-152 in SEQ ID No 30		E47	154-172 in SEQ ID No 30	
99-13810-214	A48	D48	193-211 in SEQ ID No 28		E48	213-231 in SEQ ID No 28	
99-13810-170	A49	D49	149-167 in SEQ ID No 28		E49	169-187 in SEQ ID No 28	
99-1585-373	A50	D50	353-371 in SEQ ID No 23		E50	373-391 in SEQ ID No 23	
99-1587-281	A51	D51	259-277 in SEQ ID No 24		E51	279-297 in SEQ ID No 24	
99-1597-162	A52	D52	143-161 in SEQ ID No 31		E52	163-181 in SEQ ID No 31	
99-1601-402	A53	D53	383-401 in SEQ ID No 26		E53	403-421 in SEQ ID No 26	
99-7177-81	A54	D54	62-80 in SEQ ID No 18		E54	82-100 in SEQ ID No 18	
99-7182-49	A55	D55	30-48 in SEQ ID No 22		E55	50-68 in SEQ ID No 22	
99-7186-212	A56	D56	193-211 in SEQ ID No 21		E56	213-231 in SEQ ID No 21	
99-7193-228	A57	D57	207-225 in SEQ ID No 20		E57	227-245 in SEQ ID No 20	
99-7212-346	A58	D58	326-344 in SEQ ID No 19		E58	346-364 in SEQ ID No 19	

Mis 1 and Mis 2 respectively refer to microsequencing primers which hybridized with the non-coding strand of the *BAP28* gene or with the coding strand of the *BAP28* gene.

The microsequencing reaction was performed as follows :

- 5 After purification of the amplification products, the microsequencing reaction mixture was prepared by adding, in a 20 μ l final volume: 10 pmol microsequencing oligonucleotide, 1 U

Thermosequenease (Amersham E79000G), 1.25 μ l Thermosequenease buffer (260 mM Tris HCl pH 9.5, 65 mM MgCl₂), and the two appropriate fluorescent ddNTPs (Perkin Elmer, Dye Terminator Set 401095) complementary to the nucleotides at the polymorphic site of each biallelic marker tested, following the manufacturer's recommendations. After 4 minutes at 94°C, 20 PCR cycles of 15 sec at 55°C, 5 sec at 72°C, and 10 sec at 94°C were carried out in a Tetrad PTC-225 thermocycler (MJ Research). The unincorporated dye terminators were then removed by ethanol precipitation. Samples were finally resuspended in formamide-EDTA loading buffer and heated for 2 min at 95°C before being loaded on a polyacrylamide sequencing gel. The data were collected by an ABI PRISM 377 DNA sequencer and processed using the GENESCAN software (Perkin Elmer).

Following gel analysis, data were automatically processed with software that allows the determination of the alleles of biallelic markers present in each amplified fragment.

The software evaluates such factors as whether the intensities of the signals resulting from the above microsequencing procedures are weak, normal, or saturated, or whether the signals are ambiguous. In addition, the software identifies significant peaks (according to shape and height criteria). Among the significant peaks, peaks corresponding to the targeted site are identified based on their position. When two significant peaks are detected for the same position, each sample is categorized classification as homozygous or heterozygous type based on the height ratio.

Example 5

Association Study Between Prostate Cancer And The Biallelic Markers Of The *PCTA-1* Gene

Collection Of DNA Samples From Affected And Non-Affected Individuals

Affected population :

The positive trait followed in this association study was prostate cancer. Prostate cancer patients were recruited according to a combination of clinical, histological and biological inclusion criteria. Clinical criteria can include rectal examination and prostate biopsies. Biological criteria can include PSA assays. The affected individuals were recorded as familial forms when at least two persons affected by prostate cancer have been diagnosed in the family. Remaining cases were classified as sporadic cases, and more particularly in informative cases (at least two sibs of the case both aged over 50 years old are unaffected), or sporadic uninformative cases (no information about sibs over 50 years old is available). All affected individuals included in the statistical analysis of this patent were unrelated. Cases were also separated following the criteria of diagnosis age : early onset prostate cancer (under 65 years old) and late onset prostate cancer (65 years old or more).

Unaffected population :

Control individuals included in this study were checked for both the absence of all clinical and biological criteria defining the presence or the risk of prostate cancer (PSA < 4) (WO 96/21042), and for their age (aged 65 years old or more). All unaffected individuals included in the statistical analysis of this patent were unrelated.

The affected group was composed by 491 unrelated individuals, comprising:

- 197 familial cases; and
- 294 sporadic cases, 70 of which are sporadic informative cases.

The unaffected group contained 313 individuals which were 65 years or older.

5 Genotyping Of Affected And Control Individuals

The general strategy to perform the association studies was to individually scan the DNA samples from all individuals in each of the populations described above in order to establish the allele frequencies of the above described biallelic markers in each of these populations. More particularly, the 30 biallelic markers used in the present association study are described in Table 5.

- 10 Allelic frequencies of the biallelic markers of the Table 5 in each population were determined by performing microsequencing reactions on amplified fragments obtained by genomic PCR performed on the DNA samples from each individual. Genomic PCR and microsequencing were performed as detailed above in examples 2 and 4 using the described PCR and microsequencing primers.

Table 5

BM	Marker Name	Position in <i>BAP28</i> gene	Position in <i>PCTA-1</i> gene	Nb of controls	Frequency (allele)
A54	99-7177/81	5' of gene	3' of gene	257	69.07 (C)
A58	99-7212/346	5' of gene	3' of gene	259	66.99 (C)
A57	99-7193/228	5' of gene	3' of gene	250	59.2 (C)
A56	99-7186/212	5' of gene	3' of gene	292	66.1 (A)
A55	99-7182/49	5' of gene	3' of gene	287	63.59 (C)
A1	5-381/133	5' regulatory region	3' of gene	304	65.46 (G)
A4	5-382/316	intron 2-3	3' of gene	304	65.79 (C)
A5	99-7190/213	intron 6-7	3' of gene	297	72.9 (C)
A7	99-7203/286	intron 16-17	3' of gene	257	68.09 (T)
A11	5-384/312	intron 21-22	3' of gene	211	73.22 (G)
A12	5-379/80	intron 32-33	3' of gene	294	73.98 (A)
A16	5-370/197	Exon 36	3' of gene	287	76.31 (G)
A19	5-373/164	Exon 39	3' of gene	298	68.62 (C)
A21	5-375/200	exon 41	3' of gene	307	68.73 (G)
A25	5-376/266	exon 42	3' of gene	298	68.96 (G)
A27	5-377/227	exon 43	3' of gene	307	68.73 (A)
A28	5-14/165	intron 45-B'	3' UTR	307	65.15 (T)
A29	5-11/158	intron 45-B'	3' UTR	303	75.41 (G)
A35	5-202/95	intron 45-B'	Exon 6b	308	95.13 (G)
A33	99-1605/112	intron 45-B'	intron 2	304	68.75 (G)
A34	5-2/178	intron 45-B'	Exon 2	306	68.3 (C)
A32	5-171/204	intron 45-B'	intron B	307	70.85 (T)
A31	5-169/97	intron B'-A'	intron D	305	82.3 (C)
A30	99-1572/440	intron B'-A'	intron D	304	65.79 (T)
A50	99-1585/373	3' of gene	5' of gene	300	78 (C)
A51	99-1587/281	3' of gene	5' of gene	286	67.31 (G)
A42	99-13798/284	3' of gene	5' of gene	278	53.42 (A)
A53	99-1601/402	3' of gene	5' of gene	305	67.21 (A)
A43	99-13808/80	3' of gene	5' of gene	214	59.58 (T)

A48	99-13810/214	3' of gene	5' of gene	289	59.86 (T)
-----	--------------	------------	------------	-----	-----------

Association Study Between Prostate Cancer And The Biallelic Markers Of The BAP28 Gene : Single marker association

Frequencies of biallelic alleles were compared in case-control populations described above. We compare different sub-populations in function of phenotypes (sporadic and familial cases vs controls) to determine the characterisation of association.

The Figure 5 shows the results of allelic association analysis for markers localized in and around *BAP28* gene. This analysis tests the difference of allelic frequency for each marker between population. The statistical significance of this difference is assessed by performing a Pearson chi-square test with one degree of freedom.

The genotyped markers A55 (99-7182/49), A4 (5-382/316), A19 (5-373/164), A28 (5-14/165), A42 (99-13798/284), and A53 (99-1601/402) are significant at the 5% level for allelic test (respectively, $p\text{-value}=4 \times 10^{-2}$, 4×10^{-3} , 4×10^{-2} , 1×10^{-2} , 2×10^{-2} , and 7×10^{-3}) for sporadic cases. The 4 markers A28 (5-14/165), A4 (5-382/316), A1 (5-381/133), and A55 (99-7182/49) present a high significant association for allelic test (respectively, $p\text{-value}=4 \times 10^{-5}$, 8×10^{-6} , 3×10^{-5} , and 1×10^{-4}) between informatif sporadic cases and controls. The marker A30 (99-1572/440) is significant for familial cases (allelic $p\text{-value}=3 \times 10^{-2}$).

Frequencies of the genotypes for one biallelic marker were compared in case-control populations described above. We compare different sub-populations in function of phenotypes (sporadic and familial cases vs controls) to determine the characterisation of association. The Figure 6 shows the results of genotypic association analysis for markers localized in and around *BAP28* gene. This analysis compares the three genotype frequencies between the two studied population. The statistical test used is a Pearson chi-square with 2 degree of freedom.

The genotyped markers A4 (5-382/316), A19 (5-373/164), A28 (5-14/165), A50 (99-1585/373), A42 (99-13798/284), and A53 (99-1601/402) are significant at the 5% level for allelic test (respectively, $p\text{-value}=9 \times 10^{-3}$, 9×10^{-2} , 4×10^{-2} , 4×10^{-2} , 8×10^{-2} , and 3×10^{-2}) for sporadic cases. The 4 markers A28 (5-14/165), A4 (5-382/316), A1 (5-381/133), and A55 (99-7182/49) present a high significant association for allelic test (respectively, $p\text{-value}=1 \times 10^{-5}$, 2×10^{-5} , 3×10^{-6} , and 1×10^{-5}) between informatif sporadic cases and controls. The 2 markers A31 (5-169/97) and A33 (99-1605/112) are significant for familial cases (respectively, $p\text{-value}=3 \times 10^{-2}$ and 2×10^{-2}).

The results of the association studies show that a polymorphism of the *BAP28* gene is related to sporadic and/or familial association. The biallelic markers A55 (99-7182/49), A1 (5-381/133), A4 (5-382/316), A19 (5-373/164), A28 (5-14/165), A50 (99-1585/373), A42 (99-13798/284), A31 (5-169/97), A33 (99-1605/112), and A53 (99-1601/402) can be then used in diagnostics with a test based on these 35 markers.

Haplotype Frequency Analysis

One way of increasing the statistical power of individual markers, is by performing haplotype association analysis.

Haplotype analysis for association of *BAP28* markers and prostate cancer was performed by estimating the frequencies of all possible haplotypes comprising biallelic markers of the Table 5 in the cases and control populations described in Example 5, and comparing these frequencies by means of a chi square statistical test (one degree of freedom). Haplotype estimations were performed by applying the Expectation-Maximization (EM) algorithm (Excoffier L & Slatkin M, 1995), using the EM-HAPLO program (Hawley ME, Pakstis AJ & Kidd KK, 1994). More particularly, two tests were performed, namely a haplo-max test and an Omnibus LR test which compares the profile of haplotype frequencies were also performed.

The haplo-max test, which is based on haplotype frequencies differences, selects the difference showing the maximum positive (maxM) or negative (maxS) test value between cases versus controls (rejecting test values based on rare haplotype frequencies, i.e, with an estimated number of haplotypes carriers inferior to 10) ; for one combination of markers there is therefore one Max-M and one Max-S test values.

For one combination of 2, 3 or 4 markers, the Omnibus Likelihood ratio test allows to compare the profile of haplotype frequency differences between the two populations under study. The null hypothesis is that both cases and controls are samples derived from the same population, i.e., the haplotypes frequencies are close. Using the E-M algorithm, one can calculate the haplotype frequencies in cases, in controls and in the overall population. Once the haplotype frequencies are estimated, a likelihood ratio test (LR test) can be derived. It has to be underlined that for one combination of markers, only one LR test is obtained. If the data at hand would be observed haplotypes frequencies, provided there are no rare haplotypes, the LR test should follows a Chi-square distribution with h-1 degree of freedom, h being the number of possible haplotypes. This is to say: for two markers, a chi-square with 4 degree of freedom; for 3 markers, a chi-square with 7 degree of freedom; and for 4-markers, a chi-square with 15 degree of freedom. As haplotype frequencies are only inferred via the E-M algorithm and that rare haplotypes occur, a permutation procedure is more suitable.

The results of haplotype analysis using all combinations of 2 or 3 biallelic markers from the *BAP28*-related biallelic markers of the Table 5 are represented in the Figures 7 to 11. As above-mentioned, the profile of haplotypes frequencies have been compared by two main approaches: Individual haplotype tests and Omnibus Likelihood ratio tests. A permutation procedure allowed assessment of the significance of the tests. The most significant haplotypes obtained are shown in Figure 12. We analyzed separately the familial cases and sporadic cases, because the singlepoint analyses showed the different significant SNPs pattern.

Haplotype frequency analysis for prostate cancer cases

The most significant haplotypes obtained with the cases of prostate cancer are shown in Figure 7 a and b.

The two-markers haplotypes comprise the biallelic markers A1 (5-381/133), A4 (5-382/316), A19 (5-373/164), A21 (5-375/200), A25 (5-376/266), A27 (5-377/227), A53 (99-1601/402), A42 (99-13798/284), and A55 (99-7182/49).

The preferred two-markers haplotypes are described in Figure 7a as H1 to H8. All these haplotypes comprise either the biallelic marker A53 (99-1601/402) or A42 (99-13798/284). One of the more preferred haplotype is the haplotype H1 and it comprises the biallelic markers A53 (99-1601/402) and A27 (5-377/227), alleles TG respectively. This haplotype presented a p-value for the haplotype frequency test of 3.9×10^{-4} and an odd-ratio of 1.80. Estimated haplotype frequencies were 15.6 % in the cases and 9.3 % in the controls. This haplotype presented a p-value for the likelihood ratio test of 1.7×10^{-2} . The pvalue by permutation test is $<1 \times 10^{-2}$ and the pvalue for this group of markers is 5×10^{-2} by omnibus Lr test.

The three-markers haplotypes comprise the biallelic markers A53 (99-1601/402), A42 (99-13798/284), A51 (99-1587/281), A31 (5-169/97), A34 (5-2/178), A33 (99-1605/112), A28 (5-14/165), A27 (5-377/227), A25 (5-376/266), A21 (5-375/200), A19 (5-373/164), A7 (99-7203/286), A4 (5-382/316), A55 (99-7182/49), A56 (99-7186/212), A57 (99-7193/228), A58 (99-7212/346).

The preferred three-markers haplotypes are described in Figure 7b as H435 to H452. All these haplotypes comprise the biallelic marker A53 (99-1601/402). Most of them comprise the biallelic marker A51 (99-1587/281). The more preferred haplotype is the haplotype H435 and comprises the biallelic markers A53 (99-1601/402), A51 (99-1587/281) and A34 (5-2/178), alleles TAT, respectively. This haplotype presented a p-value for the haplotype frequency test of 3.3×10^{-8} and an odd-ratio of 100. Estimated haplotype frequencies were 5.3 % in the cases and 0 % in the controls. This haplotype presented a p-value for the likelihood ratio test of 7.3×10^{-3} . The pvalue by permutation test is $<1 \times 10^{-2}$ and the pvalue for this group of markers is 1×10^{-2} by omnibus Lr test.

In conclusion, most preferred haplotypes for the cases of prostate cancer comprise the biallelic marker A53 (99-1601/402). Some other preferred haplotypes for the cases of prostate cancer comprise the biallelic markers A42 (99-13798/284) and/or A51 (99-1587/281). These haplotypes can be used in diagnostic, more particularly in diagnostics of prostate cancer susceptibility.

Haplotype frequency analysis for familial cases of prostate cancer

The most significant haplotypes obtained with the familial cases of prostate cancer are shown in Figure 8 a and b.

The two-markers haplotypes comprise the biallelic markers A51 (99-1587/281), A30 (99-1572/440), A32 (5-171/204), A34 (5-2/178), A33 (99-1605/112), A29 (5-11/158), A27 (5-377/227), A19 (5-373/164), A5 (99-7190/213), A56 (99-7186/212), and A54 (99-7177/81).

The preferred two-markers haplotypes are described in Figure 8a as H1 to H10. All these 5 haplotypes comprise either the biallelic marker A51 (99-1587/281) or A30 (99-1572/440). One of the more preferred haplotype is the haplotype H4. The pvalue of haplotype H4 obtained by a chi-square distribution with 2 ddl for this combination of 2 markers with A30 (99-1572/440) and A32 (5-171/204) is 2.4×10^{-3} by omnibus test. These markers are not in disequilibrium linkage. In concerning the individual haplotype test, this haplotype consisting of 2 biallelic markers presented a 10 9.7×10^{-5} p-value of and an odd-ratio of 1.7, for alleles TT respectively. The pvalue by permutation test is $<1 \times 10^{-2}$ and the pvalue for this group of markers is 1×10^{-2} by omnibus Lr test. This haplotype tested on all cases-controls population gives estimated haplotype frequencies for sporadic cases (n=197) of 57.1% and for controls (n=313) of 44.1%. The trend about of estimations of haplotype frequencies are not identic between familial and sporadic cases , but the trend of sporadics 15 are same for controls.

The three-markers haplotypes comprise the biallelic markers A48 (99-13810/214), A53 (99-1601/402), A42 (99-13798/284), A51 (99-1587/281), A30 (99-1572/440), A32 (5-171/204), A34 (5-2/178), A33 (99-1605/112), A29 (5-11/158), A27 (5-377/227), A19 (5-373/164), A7 (99-7203/286), A5 (99-7190/213), A56 (99-7186/212) and A54 (99-7177/81).

The preferred three-markers haplotypes are described in Figure 8b as H436 to H454. Most 20 of them comprise the biallelic marker A30 (99-1572/440), A51 (99-1587/281) and A53 (99-1601/402). One of the more preferred haplotype is the haplotype H437 and comprises the biallelic markers A53 (99-1601/402), A30 (99-1572/440) and A54 (99-7177/81), alleles ATC, respectively. This haplotype presented a p-value for the haplotype frequency test of 3.6×10^{-7} and an odd-ratio of 25 2.13. Estimated haplotype frequencies were 44.8 % in the cases and 27.6 % in the controls. This haplotype presented a p-value for the likelihood ratio test of 2.9×10^{-3} . The pvalue by permutation test is $<1 \times 10^{-2}$ and the pvalue for this group of markers is 1×10^{-2} by omnibus Lr test.

In conclusion, most preferred haplotypes for the familial cases of prostate cancer comprise the biallelic markers A30 (99-1572/440), and A51 (99-1587/281). These haplotypes can be used in 30 diagnostic, more particularly in diagnostics of familial prostate cancer susceptibility.

The most significant haplotypes obtained with the early onset familial cases of prostate cancer are shown in Figure 9 a and b.

The two-markers haplotypes comprise the biallelic markers A42 (99-13798/284), A51 (99-1587/281), A50 (99-1585/373), A30 (99-1572/440), A32 (5-171/204), A34 (5-2/178), A33 (99-1605/112), A29 (5-11/158), A19 (5-373/164), A16 (5-370/197), A12 (5-379/80), A11 (5-384/312), 35 A7 (99-7203/286), A5 (99-7190/213), A4 (5-382/316), and A54 (99-7177/81).

The preferred two-markers haplotypes are described in Figure 7a as H1 to H13. Most of these haplotypes comprise the biallelic marker A30 (99-1572/440). One of the more preferred haplotype is the haplotype H1 and it comprises the biallelic markers A30 (99-1572/440) and A32 (5-171/204), alleles TT respectively. This haplotype presented a p-value for the haplotype frequency test of 2.5×10^{-6} and an odd-ratio of 2.28. Estimated haplotype frequencies were 64.4 % in the cases and 44.2 % in the controls. This haplotype presented a p-value for the likelihood ratio test of 8.3×10^{-5} . The pvalue by permutation test is $<1 \times 10^{-2}$ and the pvalue for this group of markers is 5×10^{-2} by omnibus Lr test.

The three-markers haplotypes comprise the biallelic markers A53 (99-1601/402), A30 (99-1572/440), A32 (5-171/204), A34 (5-2/178), A33 (99-1605/112), A29 (5-11/158), A21 (5-375/200), A19 (5-373/164), A12 (5-379/80), A11 (5-384/312), A7 (99-7203/286), A5 (99-7190/213), A56 (99-7186/212), and A54 (99-7177/81).

The preferred three-markers haplotypes are described in Figure 9b as H421 to H443. All of them comprise the biallelic marker A30 (99-1572/440) and almost all of them comprise the biallelic marker A53 (99-1601/402). One of the more preferred haplotype is the haplotype H421 and comprises the biallelic markers A53 (99-1601/402), A30 (99-1572/440) and A5 (99-7190/213), alleles ATC, respectively. This haplotype presented a p-value for the haplotype frequency test of 2.3×10^{-7} and an odd-ratio of 2.7. Estimated haplotype frequencies were 52.3 % in the cases and 28.8 % in the controls. This haplotype presented a p-value for the likelihood ratio test of 8.6×10^{-4} . The pvalue by permutation test is $<1 \times 10^{-2}$ and the pvalue for this group of markers is 1×10^{-2} by omnibus Lr test.

In conclusion, most preferred haplotypes for the early onset familial cases of prostate cancer comprise the biallelic markers A30 (99-1572/440), and A53 (99-1601/402). These haplotypes can be used in diagnostic, more particularly in diagnostics of early onset familial prostate cancer susceptibility.

Haplotype frequency analysis for sporadic cases of prostate cancer

The most significant haplotypes obtained with the sporadic cases of prostate cancer are shown in Figure 10 a and b.

The two-markers haplotypes comprise the biallelic markers A53 (99-1601/402), A42 (99-13798/284), A32 (5-171/204), A29 (5-11/158), A28 (5-14/165), A27 (5-377/227), A25 (5-376/266), A19 (5-373/164), A16 (5-370/197), A4 (5-382/316), and A55 (99-7182/49).

The preferred two-markers haplotypes are described in Figure 10a as H1 to H12. The more usual biallelic markers in these haplotypes are A4 (5-382/316), A53 (99-1601/402), and A42 (99-13798/284). One of the more preferred haplotype is the haplotype H1 and comprises the biallelic markers A53 (99-1601/402), and A4 (5-382/316), alleles TG respectively. This haplotype presented a p-value for the haplotype frequency test of 1×10^{-5} and an odd-ratio of 2.09. Estimated haplotype

frequencies were 19.9 % in the cases and 10.6 % in the controls. This haplotype presented a p-value for the likelihood ratio test of 4.4×10^{-4} . The pvalue by permutation test is $<1 \times 10^{-2}$ and the pvalue for this group of markers is 1×10^{-2} by omnibus Lr test. The results of allelic association which show that these markers are associated are significant. The haplotype analysis by combining
5 the informativeness of a set of biallelic markers increases the power of the association analysis, allowing false positive and/or negative data that may result from the single marker studies to be eliminated. . The significant trend for singlepoint analysis seems to be identic for multipoint analysis. This haplotype tested on all cases-controls population gives estimated haplotype frequencies for sporadic cases (n=294) of 19.6% and for controls (n=313) of
10 10.6%. For the same haplotype, any significant results for familial cases can be found. Therefore, the association for sporadic cases is differents for familial cases.

The three-markers haplotypes comprise the biallelic markers A53 (99-1601/402), A42 (99-13798/284), A51 (99-1587/281), A31 (5-169/97), A34 (5-2/178), A27 (5-377/227), A25 (5-376/266), A21 (5-375/200), A19 (5-373/164), and A55 (99-7182/49).

15 The preferred three-markers haplotypes are described in Figure 10b as H436 to H444. All the haplotypes comprise the biallelic marker A53 (99-1601/402). The biallelic markers A42 (99-13798/284) and A51 (99-1587/281) are frequently found in these haplotypes. One of the more preferred haplotype is the haplotype H436 and comprises the biallelic markers A53 (99-1601/402), A51 (99-1587/281) and A34 (5-2/178), alleles TAT respectively. This haplotype presented a p-value
20 for the haplotype frequency test of 5.4×10^{-7} and an odd-ratio of 100. Estimated haplotype frequencies were 5.6 % in the cases and 0 % in the controls. This haplotype presented a p-value for the likelihood ratio test of 3.5×10^{-3} . The pvalue by permutation test is $<1 \times 10^{-2}$ and the pvalue for this group of markers is 1×10^{-2} by omnibus Lr test..

In conclusion, most preferred haplotypes for the sporadic cases of prostate cancer comprise
25 the biallelic marker A53 (99-1601/402). The biallelic markers A42 (99-13798/284), A51 (99-1587/281) and A4 (5-382/316) are frequently found in the preferred haplotypes. These haplotypes can be used in diagnostic, more particularly in diagnostics of sporadic prostate cancer susceptibility.

The most significant haplotypes obtained with the informative sporadic cases of prostate
30 cancer are shown in Figure 11 a and b.

The two-markers haplotypes comprise the biallelic markers A53 (99-1601/402), A30 (99-1572/440), A32 (5-171/204), A29 (5-11/158), A16 (5-370/197), A4 (5-382/316), A1 (5-381/133), and A55 (99-7182/49).

The preferred two-markers haplotypes are described in Figure 11a as H1 to H11. The
35 more usual biallelic markers in these haplotypes are A4 (5-382/316), and A1 (5-381/133). One of the more preferred haplotype is the haplotype H1 and comprises the biallelic markers A16 (5-370/197),

and A1 (5-381/133), alleles GA respectively. This haplotype presented a p-value for the haplotype frequency test of 9.4×10^{-8} and an odd-ratio of 3.43. Estimated haplotype frequencies were 28.6 % in the cases and 10.5 % in the controls. This haplotype presented a p-value for the likelihood ratio test of 6.7×10^{-7} . The pvalue by permutation test is $<1 \times 10^{-2}$ and the pvalue for this group of markers is 1×10^{-2} by omnibus Lr test.

The three-markers haplotypes comprise the biallelic markers A53 (99-1601/402), A50 (99-1585/373), A30 (99-1572/440), A31 (5-169/97), A34 (5-2/178), A33 (99-1605/112), A29 (5-11/158), A28 (5-14/165), A27 (5-377/227), A25 (5-376/266), A21 (5-375/200), A16 (5-370/197), A4 (5-382/316), A1 (5-381/133), and A55 (99-7182/49).

The preferred three-markers haplotypes are described in Figure 11b as H415 to H430. Most of the haplotypes comprise the biallelic markers A53 (99-1601/402) and A31 (5-169/97). The biallelic markers A50 (99-1585/373), A16 (5-370/197), A4 (5-382/316), and A1 (5-381/133) are frequently found in these haplotypes. One of the more preferred haplotype is the haplotype H415 and comprises the biallelic markers A50 (99-1585/373), A16 (5-370/197), and A1 (5-381/133), alleles CGA respectively. This haplotype presented a p-value for the haplotype frequency test of 3.8×10^{-9} and an odd-ratio of 4.25. Estimated haplotype frequencies were 26.7 % in the cases and 7.9 % in the controls. This haplotype presented a p-value for the likelihood ratio test of 3.3×10^{-6} . The pvalue by permutation test is $<1 \times 10^{-2}$ and the pvalue for this group of markers is 1×10^{-2} by omnibus Lr test.

In conclusion, most preferred haplotypes for the informative sporadic cases of prostate cancer comprise the biallelic markers A53 (99-1601/402), A31 (5-169/97), A4 (5-382/316), and A1 (5-381/133). The biallelic markers A50 (99-1585/373), A16 (5-370/197) are also frequently found in the preferred haplotypes. These haplotypes can be used in diagnostic, more particularly in diagnostics of informative sporadic prostate cancer susceptibility.

25 Summary of haplotype frequency analysis

The most preferred two- biallelic markers haplotypes for the familial and sporadic prostate cancer are summarized in Figure 12. This haplotype can be used in diagnostic of prostate cancer susceptibility.

The statistical significance of the results obtained for the haplotype analysis was evaluated by a phenotypic permutation test reiterated 1000 times on a computer. For this computer simulation, data from the cases and control individuals were pooled and randomly allocated to two groups which contained the same number of individuals as the case-control populations used to produce the haplotype frequency analysis data. A haplotype analysis was then run on these artificial groups for the preferred haplotypes which presented a strong association with prostate cancer. This experiment was reiterated 1000 times and the results are shown in Figure 12.

Figure 12A shows the association results the preferred haplotype with A30 (99-1572/440) and A32 (5-171/204), alleles TT, for each population and with 1000 permutations. This haplotype is specific of familial prostate cancer, and more particularly of early onset prostate cancer. This haplotype is highly significant and could be used in diagnostic.

Figure 12B shows the association results the preferred haplotype with A16 (5-370/197), and A1 (5-381/133), alleles GA, for each population and with 1000 permutations. This haplotype is specific of sporadic prostate cancer. This haplotype is highly significant and could be used in diagnostic.

Figure 12C shows the association results the preferred haplotype with A53 (99-1601/402), and A4 (5-382/316), alleles TG, for each population and with 1000 permutations. This haplotype is specific of prostate cancer, and more particularly of sporadic prostate cancer. This haplotype is highly significant and could be used in diagnostic.

Example 6

Preparation of Antibody Compositions to the BAP28 protein

Substantially pure protein or polypeptide is isolated from transfected or transformed cells containing an expression vector encoding the BAP28 protein or a portion thereof. The concentration of protein in the final preparation is adjusted, for example, by concentration on an Amicon filter device, to the level of a few micrograms/ml. Monoclonal or polyclonal antibody to the protein can then be prepared as follows:

A. Monoclonal Antibody Production by Hybridoma Fusion

Monoclonal antibody to epitopes in the BAP28 protein or a portion thereof can be prepared from murine hybridomas according to the classical method of Kohler, G. and Milstein, C., Nature 256:495 (1975) or derivative methods thereof. Also see Harlow, E., and D. Lane. 1988. Antibodies A Laboratory Manual. Cold Spring Harbor Laboratory. pp. 53-242.

Briefly, a mouse is repetitively inoculated with a few micrograms of the BAP28 protein or a portion thereof over a period of a few weeks. The mouse is then sacrificed, and the antibody producing cells of the spleen isolated. The spleen cells are fused by means of polyethylene glycol with mouse myeloma cells, and the excess unfused cells destroyed by growth of the system on selective media comprising aminopterin (HAT media). The successfully fused cells are diluted and aliquots of the dilution placed in wells of a microtiter plate where growth of the culture is continued. Antibody-producing clones are identified by detection of antibody in the supernatant fluid of the wells by immunoassay procedures, such as ELISA, as originally described by Engvall, (1980), and derivative methods thereof. Selected positive clones can be expanded and their monoclonal antibody product harvested for use. Detailed procedures for monoclonal antibody production are described in Davis, L. et al. Basic Methods in Molecular Biology Elsevier, New York. Section 21-2.

B. Polyclonal Antibody Production by Immunization

Polyclonal antiserum containing antibodies to heterogeneous epitopes in the BAP28 protein or a portion thereof can be prepared by immunizing suitable non-human animal with the BAP28 protein or a portion thereof, which can be unmodified or modified to enhance immunogenicity. A suitable non-human animal is preferably a non-human mammal is selected, usually a mouse, rat, rabbit, goat, or horse. Alternatively, a crude preparation which has been enriched for BAP28 concentration can be used to generate antibodies. Such proteins, fragments or preparations are introduced into the non-human mammal in the presence of an appropriate adjuvant (e.g. aluminum hydroxide, RIBI, etc.) which is known in the art. In addition the protein, fragment or preparation can be pretreated with an agent which will increase antigenicity, such agents are known in the art and include, for example, methylated bovine serum albumin (mBSA), bovine serum albumin (BSA), Hepatitis B surface antigen, and keyhole limpet hemocyanin (KLH). Serum from the immunized animal is collected, treated and tested according to known procedures. If the serum contains polyclonal antibodies to undesired epitopes, the polyclonal antibodies can be purified by immunoaffinity chromatography.

Effective polyclonal antibody production is affected by many factors related both to the antigen and the host species. Also, host animals vary in response to site of inoculations and dose, with both inadequate or excessive doses of antigen resulting in low titer antisera. Small doses (ng level) of antigen administered at multiple intradermal sites appears to be most reliable. Techniques for producing and processing polyclonal antisera are known in the art, see for example, Mayer and Walker (1987). An effective immunization protocol for rabbits can be found in Vaitukaitis, J. et al. J. Clin. Endocrinol. Metab. 33:988-991 (1971).

Booster injections can be given at regular intervals, and antiserum harvested when antibody titer thereof, as determined semi-quantitatively, for example, by double immunodiffusion in agar against known concentrations of the antigen, begins to fall. See, for example, Ouchterlony, O. et al., (1973). Plateau concentration of antibody is usually in the range of 0.1 to 0.2 mg/ml of serum (about 12 μ M). Affinity of the antisera for the antigen is determined by preparing competitive binding curves, as described, for example, by Fisher, D., Chap. 42 in: Manual of Clinical Immunology, 2d Ed. (Rose and Friedman, Eds.) Amer. Soc. For Microbiol., Washington, D.C. (1980).

Antibody preparations prepared according to either the monoclonal or the polyclonal protocol are useful in quantitative immunoassays which determine concentrations of antigen-bearing substances in biological samples; they are also used semi-quantitatively or qualitatively to identify the presence of antigen in a biological sample. The antibodies may also be used in therapeutic compositions for killing cells expressing the protein or reducing the levels of the protein in the body.

Example 7

Tissular specificity of the BAP28 expression.

Synthesis of the cDNA

The mRNA used are human RNA from CLONTECH.

11.5 μ L water treated with DEPC (diethyl pyrocarbonate) with 1 μ L of human RNA (1 μ g/ μ L) and 1 μ L of oligo dT primer random (oligo dT hexamer) (20pmol/ μ L) were heated at 74°C for 2 min 30 s. Then the enzymatic mixture was added. The enzymatic mixture comprised 4 μ L 5X Reaction Buffer, 1 μ L dNTP 10mM each, 0.5 μ L Recombinant RNase Inhibitor 40U/ μ L and 1 μ L MMLV Reverse Transcriptase 200U/ μ L. The sample was heated 1 h at 42°C, and 5 min at 94°C. Then 80 μ L of water treated with DEPC were added. (kit Advantage RT-for-PCR.CLONTECH K1402-2) The synthesized cDNAs were stocked at -20°C.

Amplification of the BAP28 amplicon

The cDNAs used in this experiment come from the cDNA preparation described above and from Marathon Ready cDNA from CLONTECH.

For each tissue, the following PCR reactions were done.

* First PCR reaction : The couple of primers used in this PCR was PCTAexALF12 (SEQ ID No 36)/ BAP283Ra6283 (SEQ ID No 32). There were located in exon A' and exon 43 of the BAP28 gene, respectively.

The PCR assay was performed using the following protocol :

	Final volume	50 μ L
	Water	19.8 μ L
	Buffer 3.3X	15 μ L
	Mix dNTP (25mM each)	4 μ L
20	rttHXL PERKIN ELMER (2U/ μ L)	1 μ L
	Primer PCTAexALF12 (20pmol/ μ L)	1 μ L
	Primer BAP283Ra6283 (20pmol/ μ L)	1 μ L
	cDNA	6 μ L

After 3 min of denaturation, 2.2 μ L of Mg(OAc)₂ 25 mM were added. The PCR was proceeded with 10 min at 94°C; 34 cycles of 30 sec at 94°C, and 3 min at 67°C; and 10 min at 72°C.

* Second PCR reaction (Nested PCR) : The couple of primers used in this PCR was PCTAexALF13n (SEQ ID No 37)/ BAP283Ra6324n (SEQ ID No 33). There were also located in exon A' and exon 43 of the BAP28 gene, respectively, and they were more downstream than the first couple of primers.

The PCR assay was performed using the following protocol :

	Final volume	50 μ L
	Water	20.8 μ L
	Buffer 3.3X	15 μ L
	Mix dNTP (25mM each)	4 μ L
35	rttHXL PERKIN ELMER (2U/ μ L)	1 μ L
	Primer PCTAexALF13n (20pmol/ μ L)	1 μ L
	Primer BAP283Ra6324n (20pmol/ μ L)	1 μ L

Product of PCR N°1

5 µL

After 3 min of denaturation, 2.2 µl of Mg(OAc)₂ 25 mM were added. The PCR was proceeded with 10 min at 94°C; 34 cycles of 30 sec at 94°C, and 3 min at 67°C; and 10 min at 72°C.

The PCR products of the second PCR were analyzed on a 1% TAE1X gel.

- 5 The results are shown in Figure 13. The segment comprising the exons 43 to A has been observed in the following tissues : Marathon testis, Marathon hippocampus, Marathon leukemia (chronic myelogenous K-562), cDNA cerebellum, cDNA substantia nigra, cDNA thalamus, cDNA caudate nucleus, cDNA spinal cord, cDNA pituitary gland and cDNA mammary gland.

- In contract, this cDNA segment has not been observed in Marathon Brain, Marathon
10 Cerebellum, Marathon Cerebral Cortex, Marathon Hypothalamus, Marathon Fetal Kidney, Marathon Thyroid, Marathon Bone Marrow, Marathon HL60, Marathon MOLT4, Marathon Fetal Liver, Marathon Stomach, Marathon Prostate, cDNA Testis, cDNA Corpus Callosum, cDNA Amygdala, cDNA Fetal Brain, cDNA Skeletal Muscle, cDNA Lung, cDNA Kidney, cDNA Placenta, cDNA Spleen, cDNA Fetal Liver, cDNA Thyroid Gland, cDNA MOLT4, cDNA Adrenal Gland, cDNA
15 Trachea, cDNA Salivary Gland, cDNA HL60, cDNA Small Intestine, cDNA Pancreas, cDNA Stomach, cDNA Bone Marrow, cDNA Thymus, and cDNA Prostate.

An additional analysis of the expression pattern in the tissue has been done by the search of ESTs in Genbank database which show homology with the BAP28 cDNA. The results are shown in Table 6.

20

Table 6

Tissue	Accession number in Genbank
placenta	AK001857 ; AI277866
colon	AW858897 ; AW858960
colon tumor metastasis	AW962967
HeLa cell	AA098827
Adipose tissue white	AA320776
LNCAP cells	AA357743
Total fetus	AA424101 ; AA460031 ; AA992680
germinal center B cell	AA814857 ; AA814859
testis	AI023607 ; AL040338 ; AA437086
Fetal liver spleen	AI033328
Fetal liver	AI114709
Fetal heart	AI150773
lung	AI348668 ; AW450486
kidney	AI582623
colon tumor	AI738790
pooled fetal lung testis B-cell	AI827817
stomach	AW389900
Multiple sclerosis	N77431
fetal liver spleen	T85649
anaplastic oligodendroglioma	AI356180
Organ: brain	
breast	AI905672

Example 8

Cloning of a BAP28 cDNA.

We cloned the BAP28 cDNA consisting to the exons 1 to 45.

Synthesis of cDNAs

5 mRNAs were total human prostate RNA from CLONTECH (Lot N°8040072 – Ref
Cat:64038).

11.5 μ L water treated with DEPC with 1 μ L Total Human Prostate RNA (1 μ g/ μ L) and 1 μ L primer oligodT BAP20polyTcourt (20pmol/ μ L) (ttttttttttttgtata : SEQ ID No 57) were heated 2 min 30 sec at 74°C. Then the enzymatic mixture was added. The enzymatic mixture comprised 4 μ L 10 5X Reaction Buffer, 1 μ L mix dNTP10mM each, 0.5 μ L Recombinant RNase Inhibitor 40U/ μ L and 1 μ L MMLV Reverse Transcriptase 200U/ μ L. The sample was heated 1 h at 42°C and 5 min at 94°C. Then, 80 μ L water treated with DEPC was added. The obtained cDNAs were stocked -20°C.

Amplification of the BAP28 segment to be cloned : (Double PCR Reaction)

A first PCR with a couple of primer BAP281LF12.1 (SEQ ID No 58) / BAP28LR6726.1

15 (SEQ ID No 59) was performed using the following protocol :

20	Final volume	50 μ l
	Water	19.8 μ L
	Buffer 3.3X	15 μ L
	Mix dNTP (25mM each)	4 μ L
	rtHXL PERKIN ELMER (2U/ μ L)	1 μ L
	Primer BAP281LF12.1 (20pmol/ μ L)	1 μ L
	Primer BAP28LR6726.1 (20pmol/ μ L)	1 μ L
	Preparation of cDNA	6 μ L

As soon as the end of PCR, the phenol/chloform extraction was performed in order to avoid in degradation. Finally, the PCR product was precipitated with NaCl and ethanol.

The PCR product and the cloning vector pGEM11Zf(+) were both digested by the restriction endonuclease SalI. The digested vector was then dephosphorylated. The digested PCR
5 product was ligated with the digested and dephosphorylated pGEM11Zf(+) vector. E.coli DH10B was transformed by the obtained vector and the bacteria containing the recombinant vector were selected. The positive clones contained an 6.8 kb insert which is the expected size for the entire BAP28 cDNA. The sequencing of the insert showed a cDNA consisting of the exons 1 to 45 of BAP28.

10

Example 9

Natural antisense structure.

The natural antisense structure observed in the BAP28 gene related to the PCTA-1 gene is conserved in the Drosophila. Indeed, the new CDS generated from the Genbank sequence AE00315 (gene CG10805) is located between the positions 97601 and 104127 of the sequence. Another CDS
15 is described on the opposite strand as the gene CG10806. This CDS is located between the positions 107695 and 104389 of the sequence. Then, the distance between the two CDS is about 262 bp. Therefore, as the 3'UTR of the 2 genes are likely overlapping, the new gene gene CG10805 is a natural antisense of the gene CG10806 and the natural antisense organization of BAP28 is conserved in Drosophila.

20

While the preferred embodiment of the invention has been illustrated and described, it will be appreciated that various changes can be made therein by the one skilled in the art without departing from the spirit and scope of the invention.

25

REFERENCES

The following references cited herein are incorporated herein by reference in their entireties

- Abbondanzo SJ et al., 1993, Methods in Enzymology, Academic Press, New York, pp. 803-823 / Ajioka R.S. et al., *Am. J. Hum. Genet.*, 60:1439-1447, 1997 / Altschul et al.,
30 1990, *J. Mol. Biol.* 215(3):403-410 / Altschul et al., 1993, *Nature Genetics* 3:266-272 / Altschul et al., 1997, *Nuc. Acids Res.* 25:3389-3402 / Anton M. et al., 1995, *J. Virol.*, 69 : 4600-4606 / Araki K et al. (1995) *Proc. Natl. Acad. Sci. U.S.A.* 92(1):160-4. / Ausubel et al. (1989) *Current Protocols in Molecular Biology*, Green Publishing Associates and Wiley Interscience, N.Y. / Baubonis W. (1993) *Nucleic Acids Res.* 21(9):2025-9. /
35 Beaucage et al., *Tetrahedron Lett* 1981, 22: 1859-1862 / Bowcock et al., 1998, International Patent Publication No WO98/12327 / Bradley A., 1987, Production and

- analysis of chimaeric mice. *In*: E.J. Robertson (Ed.), *Teratocarcinomas and embryonic stem cells: A practical approach*. IRL Press, Oxford, pp.113. / Bram RJ et al., 1993, *Mol. Cell Biol.*, **13** : 4760-4769 / Brown EL, Belagaje R, Ryan MJ, Khorana HG, *Methods Enzymol* 1979;68:109-151 / Brutlag et al. *Comp. App. Biosci.* 6:237-245, 1990 / Bush et al., 1997, *J. Chromatogr.*, **777** : 311-328. / Capecchi, M.R. (1989a) *Science*, 244:1288-1292 / Capecchi, M.R. (1989b) *Trends Genet.*, 5:70-76 / Chai H. et al. (1993) *Biotechnol. Appl. Biochem.* 18:259-273. / Chee et al. (1996) *Science*. 274:610-614. / Chen et al. (1987) *Mol. Cell. Biol.* 7:2745-2752. / Chen et al. *Proc. Natl. Acad. Sci. USA* 94/20 10756-10761, 1997 / Chen and Kwok *Nucleic Acids Research* 25:347-353 1997 / Chen and Kwok *Nucleic Acids Research* 25:347-353 1997 / Cho RJ et al., 1998, *Proc. Natl. Acad. Sci. USA*, **95**(7) : 3752-3757. / Chou J.Y., 1989, *Mol. Endocrinol.*, **3**: 1511-1514. / Clark A.G. (1990) *Mol. Biol. Evol.* 7:111-122. / Coles R, Caswell R, Rubinstein DC, *Hum Mol Genet* 1998;7:791-800 / Compton J. (1991) *Nature*. 350(6313):91-92. / Davis L.G., M.D. Dibner, and J.F. Battey, *Basic Methods in Molecular Biology*, ed., Elsevier Press, NY, 1986 / Dempster et al., (1977) *J. R. Stat. Soc.*, 39B:1-38. / Dent DS & Latchman DS (1993) *The DNA mobility shift assay*. In: *Transcription Factors: A Practical Approach* (Latchman DS, ed.) pp1-26. Oxford: IRL Press / Eckner R. et al. (1991) *EMBO J.* 10:3513-3522. / Edwards et Leatherbarrow, *Analytical Biochemistry*, 246, 1-6 (1997) / Engvall, E., *Meth. Enzymol.* 70:419 (1980) / Excoffier L. and Slatkin M. (1995) *Mol. Biol. Evol.*, 12(5): 921-927. / Feldman and Steg, 1996, *Medecine/Sciences, synthese*, 12:47-55 / Felici F., 1991, *J. Mol. Biol.*, Vol. 222:301-310 / Fields and Song, 1989, *Nature*, **340** : 245-246 / Fisher, D., Chap. 42 in: *Manual of Clinical Immunology*, 2d Ed. (Rose and Friedman, Eds.) Amer. Soc. For Microbiol., Washington, D.C. (1980) / Flotte et al. (1992) *Am. J. Respir. Cell Mol. Biol.* 7:349-356. / Fodor et al. (1991) *Science* 251:767-777. / Fraley et al. (1979) *Proc. Natl. Acad. Sci. USA*. 76:3348-3352. / Fried M, Crothers DM, *Nucleic Acids Res* 1981;9:6505-6525 / Fromont-Racine M. et al., 1997, *Nature Genetics*, **16**(3) : 277-282. / Fuller S. A. et al. (1996) *Immunology in Current Protocols in Molecular Biology*, Ausubel et al. Eds, John Wiley & Sons, Inc., USA. / Furth P.A. et al. (1994) *Proc. Natl. Acad. Sci USA*. 91:9302-9306. / Garner MM, Revzin A, *Nucleic Acids Res* 1981;9:3047-3060 / Geysen H. Mario et al. 1984. *Proc. Natl. Acad. Sci. U.S.A.* **81**:3998-4002 / Ghosh and Bacchawat, 1991, *Targeting of liposomes to hepatocytes*, IN: *Liver Diseases, Targeted diagnosis and therapy using specific receptors and ligands*. Wu et al. Eds., Marcel Dekker, New York, pp. 87-104. / Gonnet et al., 1992, *Science* 256:1443-1445 / Gopal (1985) *Mol. Cell. Biol.*, 5:1188-1190. / Gossen M. et al. (1992) *Proc. Natl. Acad. Sci. USA*. 89:5547-5551. / Gossen M. et al. (1995) *Science*. 268:1766-1769. / Graham et al. (1973) *Virology* 52:456-457. / Green et al., *Ann. Rev. Biochem.* 55:569-597 (1986) / Grompe, M. (1993) *Nature Genetics*. 5:111-117. / Grompe, M. et al. (1989)

- / Newton et al. (1989) *Nucleic Acids Res.* 17:2503-2516. / Nickerson D.A. et al. (1990) *Proc. Natl. Acad. Sci. U.S.A.* 87:8923-8927. / Nicolau C. et al., 1987, *Methods Enzymol.*, 149:157-76. / Nicolau et al. (1982) *Biochim. Biophys. Acta.* 721:185-190. / Nyrén P, Pettersson B, Uhlen M, *Anal Biochem* 1993;208(1):171-175 / O'Reilly et al.
- 5 (1992) *Baculovirus Expression Vectors: A Laboratory Manual.* W. H. Freeman and Co., New York. / Ohno et al. (1994) *Science.* 265:781-784. / Oldenburg K.R. et al., 1992, *Proc. Natl. Acad. Sci.*, 89:5393-5397. / Orita et al. (1989) *Proc. Natl. Acad. Sci. U.S.A.* 86: 2776-2770. / Ott J., *Analysis of Human Genetic Linkage*, John Hopkins University Press, Baltimore, 1991 / Ouchterlony, O. et al., Chap. 19 in: *Handbook of*
- 10 *Experimental Immunology* D. Wier (ed) Blackwell (1973) / Parmley and Smith, Gene, 1988, 73:305-318 / Pastinen et al., *Genome Research* 1997; 7:606-614 / Pearson and Lipman, 1988, *Proc. Natl. Acad. Sci. USA* 85(8):2444-2448 / Pease S. and William R.S., 1990, *Exp. Cell. Res.*, 190: 209-211. / Perlin et al. (1994) *Am. J. Hum. Genet.* 55:777-787. / Peterson et al., 1993, *Proc. Natl. Acad. Sci. USA*, 90 : 7593-7597. / Pietu et al. *Genome Research* 6:492-503, 1996 / Potter et al. (1984) *Proc. Natl. Acad. Sci. U.S.A.*
- 15 81(22):7161-7165. / Ramunsen et al., 1997, *Electrophoresis*, 18 : 588-598. / Reid L.H. et al. (1990) *Proc. Natl. Acad. Sci. U.S.A.* 87:4299-4303. / Risch, N. and Merikangas, K. (*Science*, 273:1516-1517, 1996 / Robertson E., 1987, *Embryo-derived stem cell lines.* In: E.J. Robertson Ed. *Teratocarcinomas and embryonic stem cells: a practical approach.* IRL Press, Oxford, pp. 71. / Rossi et al., *Pharmacol. Ther.* 50:245-254, (1991) / Roth J.A. et al.
- 20 (1996) *Nature Medicine.* 2(9):985-991. / Roux et al. (1989) *Proc. Natl. Acad. Sci. U.S.A.* 86:9079-9083. / Ruano et al. (1990) *Proc. Natl. Acad. Sci. U.S.A.* 87:6296-6300. / Sambrook, J., Fritsch, E.F., and T. Maniatis. (1989) *Molecular Cloning: A Laboratory Manual.* 2ed. Cold Spring Harbor Laboratory, Cold Spring Harbor, New York.
- 25 / Samson M. et al. (1996) *Nature*, 382(6593):722-725. / Samulski et al. (1989) *J. Virol.* 63:3822-3828. / Sanchez-Pescador R. (1988) *J. Clin. Microbiol.* 26(10):1934-1938. / Sarkar, G. and Sommer S.S. (1991) *Biotechniques.* / Sauer B. et al. (1988) *Proc. Natl. Acad. Sci. U.S.A.* 85:5166-5170. / Schaid D.J. et al., *Genet. Epidemiol.*, 13:423-450, 1996 / Schedl A. et al., 1993a, *Nature*, 362: 258-261. / Schedl et al., 1993b, *Nucleic Acids Res.*, 21: 4783-4787. / Schena et al. *Science* 270:467-470, 1995 / Schena et al., 1996, *Proc Natl Acad Sci U S A*, 93(20):10614-10619. / Schneider et al. (1997) *Arlequin: A Software For Population Genetics Data Analysis.* University of Geneva. / Schwartz and Dayhoff, eds., 1978, *Matrices for Detecting Distance Relationships: Atlas of Protein Sequence and Structure*, Washington: National Biomedical Research Foundation / Sczakiel G. et al.
- 30 (1995) *Trends Microbiol.* 3(6):213-217. / Shay J.W. et al., 1991, *Biochem. Biophys. Acta*, 1072: 1-7. / Sheffield, V.C. et al. (1991) *Proc. Natl. Acad. Sci. U.S.A.* 49:699-706. / Shizuya et al. (1992) *Proc. Natl. Acad. Sci. U.S.A.* 89:8794-8797. / Shoemaker

- [illegible]

What is claimed is:

1. A purified or isolated *BAP28* nucleic acid comprising at least 12 contiguous nucleotides of the nucleotide sequence of SEQ ID No 1, or the complements thereof, wherein said contiguous span comprises at least one of the following nucleotide positions of SEQ ID No 1: 1-50357, 50499-50963, 51257-52147, 52299-53234, 53394-53553, 53689-53837, 53943-54028, 54198-54740, 54896-55753, 55913-57385, 57495-58503, 58828-85946, 59355-85946, 86169-91228, and/or 91852 to 97662.
2. A purified or isolated nucleic acid encoding a *BAP28* protein comprising at least 12 consecutive nucleotides of a nucleotide sequence selected from the group consisting of SEQ ID Nos 2 and 3 or the complement thereof, wherein said contiguous span comprises at least 1 of nucleotide positions 1 to 4995 of SEQ ID No 2 or 3.
3. An isolated, purified or recombinant polynucleotide consisting essentially of a contiguous span of 8 to 50 nucleotides of SEQ ID No 1 or the complement thereof, wherein a span includes a *BAP28*-related biallelic marker.
4. A purified or isolated nucleic acid according to claim 3, wherein said contiguous span comprises a *BAP28*-related biallelic marker selected from the group consisting of A1 to A58, and the complements thereof.
5. A purified or isolated nucleic acid according to claim 3, wherein said contiguous span comprises a *BAP28*-related biallelic marker selected from the group consisting of A1 to A27, A34, A37 to A41, A43 to A49, A52, and A54 to A58, and the complements thereof.
6. A polynucleotide according to claim 3, wherein said contiguous span is 18 to 35 nucleotides in length and said biallelic marker is within 4 nucleotides of the center of said polynucleotide.
7. A polynucleotide according to claim 6, wherein said polynucleotide consists of said contiguous span and said contiguous span is 25 nucleotides in length and said biallelic marker is at the center of said polynucleotide.

8. A polynucleotide according to claim 7, wherein said polynucleotide consists essentially of a sequence selected from the following sequences: P1 to P58, and the complementary sequences thereto.

5 9. A polynucleotide according to claim 3, wherein the 3' end of said contiguous span is located at the 3' end of said polynucleotide and said biallelic marker is present at the 3' end of said polynucleotide.

10 10. An isolated, purified, or recombinant polynucleotide consisting essentially of a contiguous span of 8 to 50 nucleotides of anyone of SEQ ID Nos 1, 2, or 3 or the complement thereof, wherein the 3' end of said contiguous span is located at the 3' end of said polynucleotide, and wherein the 3' end of said polynucleotide is located within 20 nucleotides upstream of a *BAP28*-related biallelic marker in said sequence.

15 11. A polynucleotide according to claim 10, wherein the 3' end of said polynucleotide is located 1 nucleotide upstream of a *BAP28*-related biallelic marker in said sequence.

20 12. A polynucleotide according to claim 11, wherein said polynucleotide consists essentially of a sequence selected from the following sequences: D1 to D58, and E1 to E58.

13. An isolated, purified, or recombinant polynucleotide consisting essentially of a sequence selected from the following sequences: B1 to B38 and C1 to C38.

25 14. An isolated, purified, or recombinant polynucleotide which encodes a polypeptide comprising a contiguous span of at least 6 amino acids of SEQ ID No 5, wherein said contiguous span includes:

- at least 1 of the amino acid positions 1 to 1629 of the SEQ ID No 5; or,
- an amino acid selected from the group consisting of an asparagine at the amino acid position 1694 of SEQ ID No 5, a valine at the amino acid position 1854 of SEQ ID No 5,
- 30 an asparagine at the amino acid position 1967 of SEQ ID No 5, a glutamic acid at the amino acid position 2017 of SEQ ID No 5, and an alanine at the amino acid position 2050 of SEQ ID No 5.

35 15. An isolated, purified, or recombinant polynucleotide comprising a sequence selected from the group consisting of SEQ ID Nos 4, and 9-13 and the complementary sequence thereto.

16. A polynucleotide according to any one of claims 1-3, 10, 13-15 attached to a solid support.

5 16. 17. An array of polynucleotides comprising at least one polynucleotide according to claim

18. An array according to claim 17, wherein said array is addressable.

10 19. A polynucleotide according to any one of claims 1-3, 10, 13-15 further comprising a label.

20. A recombinant vector comprising a polynucleotide according to any one of claims 1-3, 10, 13-15.

15 21. A host cell comprising a recombinant vector according to claim 20.

22. A non-human host animal or mammal comprising a recombinant vector according to claim 20.

20 23. A mammalian host cell comprising a *BAP28* gene disrupted by homologous recombination with a knock out vector, comprising a polynucleotide according to any one of claims 1-3 and 14.

24. A non-human host mammal comprising a *BAP28* gene disrupted by homologous recombination with a knock out vector, comprising a polynucleotide according to any one of claims 1-3 and 14.

25. A method of genotyping comprising determining the identity of a nucleotide at a *BAP28* -related biallelic marker or the complement thereof in a biological sample.

30 26. A method according to claim 25, wherein said biological sample is derived from a single subject.

27. A method according to claim 26, wherein the identity of the nucleotides at said biallelic marker is determined for both copies of said biallelic marker present in said individual's genome.

28. A method according to claim 25, wherein said biological sample is derived from multiple subjects.

29. A method according to claim 25, further comprising amplifying a portion of said
5 sequence comprising the biallelic marker prior to said determining step.

30. A method according to claim 29, wherein said amplifying is performed by PCR.

31. A method according to claim 25, wherein said determining is performed by an assay
10 selected from the group consisting of hybridization assay, a sequencing assay, a microsequencing assay, and an enzyme-based mismatch detection assay.

32. A method of estimating the frequency of an allele of a *BAP28*-related biallelic marker in a population comprising:
15 a) genotyping individuals from said population for said biallelic marker according to the method of claim 25; and
b) determining the proportional representation of said biallelic marker in said population..

33. A method of detecting an association between a genotype and a trait, comprising the
20 steps of:
a) determining the frequency of at least one *BAP28*-related biallelic marker in trait positive population according to the method of claim 32;
b) determining the frequency of at least one *BAP28*-related biallelic marker in a control population according to the method of claim 32; and
25 c) determining whether a statistically significant association exists between said genotype and said trait.

34. A method of estimating the frequency of a haplotype for a set of biallelic markers in a population, comprising:
30 a) genotyping at least one *BAP28*-related biallelic marker according to claim 27 for each individual in said population;
b) genotyping a second biallelic marker by determining the identity of the nucleotides at said second biallelic marker for both copies of said second biallelic marker present in the genome of each individual in said population; and
35 c) applying a haplotype determination method to the identities of the nucleotides determined in steps a) and b) to obtain an estimate of said frequency.

35. A method according to claim 34, wherein said haplotype determination method is selected from the group consisting of asymmetric PCR amplification, double PCR amplification of specific alleles, the Clark algorithm, or an expectation-maximization algorithm.

5 36. A method of detecting an association between a haplotype and a trait, comprising the steps of:

a) estimating the frequency of at least one haplotype in a trait positive population according to the method of claim 34;

b) estimating the frequency of said haplotype in a control population according to the
10 method of claim 34; and

c) determining whether a statistically significant association exists between said haplotype and said trait.

37. A method according to claim 33, wherein said genotyping steps a) and b) are
15 performed on a single pooled biological sample derived from each of said populations.

38. A method according to claim 33, wherein said genotyping steps a) and b) performed separately on biological samples derived from each individual in said populations.

20 39. A method according to either claim 33 or 36, wherein said trait is cancer.

40. A method according to either claim 33 or 36, wherein said control population is a trait negative population.

25 41. A method according to either claim 33 or 36, wherein said case control population is a random population.

42. A method of determining whether an individual is at risk of developing prostate cancer, comprising:

30 a) genotyping at least one *BAP28*-related biallelic marker according to the method of claim 27; and

b) correlating the result of step a) with a risk of developing prostate cancer.

43. A method according to any one of claims 25, 32, 33, 34, 36, and 42 wherein said
35 *BAP28*-related biallelic marker is selected from the group consisting of A1 to A58 and the complements thereof.

44. A method according to claim 42, wherein said *BAP28*-related biallelic marker is selected from the following list of biallelic markers: A1, A4, 16, A30, A31, A42, A50, A51, and A53, and the complements thereof.

5 45. A diagnostic kit comprising a polynucleotide according to any one of claims 3-13 and 16-19.

46. An isolated, purified, or recombinant polypeptide comprising a contiguous span of at least 6 amino acids of SEQ ID No 5, wherein said contiguous span includes:

- 10 - at least 1 of the amino acid positions 1 to 1629 of the SEQ ID No 5; or,
 - an amino acid selected from the group consisting of an asparagine at the amino acid position 1694 of SEQ ID No 5, a valine at the amino acid position 1854 of SEQ ID No 5, an asparagine at the amino acid position 1967 of SEQ ID No 5, a glutamic acid at the amino acid position 2017 of SEQ ID No 5, and an alanine at the amino acid position 2050 of SEQ ID No 5.
- 15

47. An isolated or purified antibody composition are capable of selectively binding to an epitope-containing fragment of a polypeptide according to claim 46, wherein said epitope comprises:

- 20 - at least 1 of the amino acid positions 1 to 1629 of the SEQ ID No 5; or,
 - an amino acid selected from the group consisting of an asparagine at the amino acid position 1694 of SEQ ID No 5, a valine at the amino acid position 1854 of SEQ ID No 5, an asparagine at the amino acid position 1967 of SEQ ID No 5, a glutamic acid at the amino acid position 2017 of SEQ ID No 5, and an alanine at the amino acid position 2050 of SEQ ID No 5.
- 25

48. A method for the screening of a candidate substance interacting with a *BAP28* polypeptide comprising the following steps :

- a) providing a polypeptide according to claim 46;
 b) obtaining a candidate substance;
30 c) bringing into contact said polypeptide with said candidate substance; and
 d) detecting the complexes formed between said polypeptide and said candidate substance.

49. A method for screening of a candidate substance that modulated the expression of the *BAP28* gene comprising the following steps:

- 35 a) providing a recombinant cell host containing a nucleic acid, wherein said nucleic acid comprises a nucleotide sequence of the 5' regulatory region (2996 -4996 of SEQ ID No 1) or a

biologically active fragment or variant thereof located upstream a polynucleotide encoding a detectable protein;

- obtaining a candidate substance; and
- determining the ability of the candidate substance to modulate the expression levels of

5 the polynucleotide encoding the detectable protein.

50. A computer readable medium having stored thereon a sequence selected from the group consisting of a nucleic acid code comprising one of the following:

- a) a contiguous span of at least 12 nucleotides of SEQ ID No 1, wherein said contiguous
 - 10 span comprises at least 1 of the following nucleotide positions of SEQ ID No 1: 1-50357, 50499-50963, 51257-52147, 52299-53234, 53394-53553, 53689-53837, 53943-54028, 54198-54740, 54896-55753, 55913-57385, 57495-58503, 58828-85946, 59355-85946, 86169-91228, and/or 91852 to 97662;
 - b) a contiguous span of at least 12 nucleotides of SEQ ID No 1 or the complement thereof,
 - 15 wherein said contiguous span comprises at least 1 nucleotides selected from the group consisting of the following nucleotide positions of SEQ ID No 1: 4997-5076, 5371-5544, 6121-6337, 9877-10018, 11522-11623, 12521-12661, 13453-13664, 13824-13957, 15376-15478, 16855-16965, 17378-17495, 18535-18642, 21446-21541, 21999-22087, 23036-23247, 23546-23667, 24270-24461, 26287-26470, 26611-26747, 28068-28260, 32540-32709, 33112-33270, 34586-34828,
 - 20 35156-35287, 36660-36763, 36934-37077, 37803-37921, 38017-38138, 40365-40493, 42618-42848, 43452-43578, 44836-44999, 48223-48269, and 49656-49779;
 - c) a contiguous span of at least 12 nucleotides of SEQ ID No 1 or the complements thereof, wherein said contiguous span comprises at least one BAP28-related biallelic marker selected from the group consisting of A1 to A58;
 - 25 d) a contiguous span of at least 12 nucleotides of a nucleic acid sequence selected from the group consisting of SEQ ID Nos 2 and 3 or the complements thereof, wherein said contiguous span comprises at least 1 of nucleotide positions 1 to 4995 of SEQ ID No 2 or 3;
 - e) a contiguous span of at least 12 nucleotides of a nucleic acid sequence selected from the group consisting of SEQ ID Nos 2 and 3 or the complements thereof, wherein said contiguous span
 - 30 comprises at least 1 of nucleotide positions 1 to 2033, 2160 to 2348 and 2676 to 4995 of SEQ ID No 2 or 3;
 - f) a contiguous span of at least 12 nucleotides of a nucleic acid sequence selected from the group consisting of SEQ ID Nos 1-3 or the complements thereof, wherein said contiguous span comprises at least 1 of any one of the following ranges of nucleotide positions of:
 - 35 (1) SEQ ID No 1: 1-2500, 2501-5000, 5001-7500, 7501-10000, 10001-12500, 12501-15000, 15001-17500, 17501-20000, 20001-22500, 22501-25000, 25001-27500, 27501-30000, 30001-32500, 32501-35000, 35001-37500, 37501-40000, 40001-42500, 42501-45000, 45001-

47500, 47501-50000, 50001-50357, 50499-50963, 51257-52147, 52299-53234, 53394-53553, 53689-53837, 53943-54028, 54198-54740, 54896-55753, 55913-57385, 57495-58503, 58828-85946, 59355-85946, 86169-91228, and/or 91852 to 97662;

(2) SEQ ID No 2: 1 to 500, 501 to 1000, 1001 to 1500, 1501 to 2000, 2001 to 2500, 2501 to 3000, 3001 to 3500, 3501 to 4000, 4001 to 4500, 4501 to 4995, 5000 to 5500, 5501 to 6000, 6001 to 6500, and 6501 to 6782; and,

(3) SEQ ID No 3: 1 to 500, 501 to 1000, 1001 to 1500, 1501 to 2000, 2001 to 2500, 2501 to 3000, 3001 to 3500, 3501 to 4000, 4001 to 4500, 4501 to 4995, 5000 to 5500, 5501 to 6000, 6001 to 6500, 6501 to 7000, 7001 to 7500, 7501 to 7932; and

10 g) a nucleotide sequence selected from the group consisting of SEQ ID Nos 4, and 9-13; and,

h) a nucleotide sequence complementary to any one of the preceding nucleotide sequences.

51. A computer readable medium having stored thereon a sequence consisting of a
15 polypeptide code comprising a contiguous span of at least 6 amino acids of SEQ ID No 5, wherein said contiguous span includes:

- at least 1 of the amino acid positions 1 to 1629 of the SEQ ID No 5; or,
- an amino acid selected from the group consisting of an asparagine at the amino acid position 1694 of SEQ ID No 5, a valine at the amino acid position 1854 of SEQ ID No 5,
20 an asparagine at the amino acid position 1967 of SEQ ID No 5, a glutamic acid at the amino acid position 2017 of SEQ ID No 5, and an alanine at the amino acid position 2050 of SEQ ID No 5.

52. A computer system comprising a processor and a data storage device wherein said data
25 storage device a computer readable medium according to with claim 50 or 51.

53. A computer system according to claim 52, further comprising a sequence comparer and a data storage device having reference sequences stored thereon.

30 54. A computer system of Claim 53 wherein said sequence comparer comprises a computer program which indicates polymorphisms.

55. A computer system of Claim 52 further comprising an identifier which identifies features in said sequence.

35

56. A method for comparing a first sequence to a reference sequence, comprising the steps of:

reading said first sequence and said reference sequence through use of a computer program which compares sequences; and

determining differences between said first sequence and said reference sequence with said computer program,

5 wherein said first sequence is selected from the group consisting of a nucleic acid code comprising one of the following:

a) a contiguous span of at least 12 nucleotides of SEQ ID No 1, wherein said contiguous span comprises at least 1 of the following nucleotide positions of SEQ ID No 1: 1-50357, 50499-50963, 51257-52147, 52299-53234, 53394-53553, 53689-53837, 53943-54028, 54198-54740, 10 54896-55753, 55913-57385, 57495-58503, 58828-85946, 59355-85946, 86169-91228, and/or 91852 to 97662;

b) a contiguous span of at least 12 nucleotides of SEQ ID No 1 or the complement thereof, wherein said contiguous span comprises at least 1 nucleotides selected from the group consisting of the following nucleotide positions of SEQ ID No 1: 4997-5076, 5371-5544, 6121-6337, 9877-10018, 11522-11623, 12521-12661, 13453-13664, 13824-13957, 15376-15478, 16855-16965, 17378-17495, 18535-18642, 21446-21541, 21999-22087, 23036-23247, 23546-23667, 24270-24461, 26287-26470, 26611-26747, 28068-28260, 32540-32709, 33112-33270, 34586-34828, 35156-35287, 36660-36763, 36934-37077, 37803-37921, 38017-38138, 40365-40493, 42618-42848, 43452-43578, 44836-44999, 48223-48269, and 49656-49779;

20 c) a contiguous span of at least 12 nucleotides of SEQ ID No 1 or the complements thereof, wherein said contiguous span comprises at least one BAP28-related biallelic marker selected from the group consisting of A1 to A58;

d) a contiguous span of at least 12 nucleotides of a nucleic acid sequence selected from the group consisting of SEQ ID Nos 2 and 3 or the complements thereof, wherein said contiguous span 25 comprises at least 1 of nucleotide positions 1 to 4995 of SEQ ID No 2 or 3;

e) a contiguous span of at least 12 nucleotides of a nucleic acid sequence selected from the group consisting of SEQ ID Nos 2 and 3 or the complements thereof, wherein said contiguous span comprises at least 1 of nucleotide positions 1 to 2033, 2160 to 2348 and 2676 to 4995 of SEQ ID No 2 or 3;

30 f) a contiguous span of at least 12 nucleotides of a nucleic acid sequence selected from the group consisting of SEQ ID Nos 1-3 or the complements thereof, wherein said contiguous span comprises at least 1 of any one of the following ranges of nucleotide positions of:

(1) SEQ ID No 1: 1-2500, 2501-5000, 5001-7500, 7501-10000, 10001-12500, 12501-15000, 15001-17500, 17501-20000, 20001-22500, 22501-25000, 25001-27500, 27501-30000, 30001-32500, 32501-35000, 35001-37500, 37501-40000, 40001-42500, 42501-45000, 45001-47500, 47501-50000, 50001-50357, 50499-50963, 51257-52147, 52299-53234, 53394-53553, 35

53689-53837, 53943-54028, 54198-54740, 54896-55753, 55913-57385, 57495-58503, 58828-85946, 59355-85946, 86169-91228, and/or 91852 to 97662;

(2) SEQ ID No 2: 1 to 500, 501 to 1000, 1001 to 1500, 1501 to 2000, 2001 to 2500, 2501 to 3000, 3001 to 3500, 3501 to 4000, 4001 to 4500, 4501 to 4995, 5000 to 5500, 5501 to 6000, 6001 to 6500, and 6501 to 6782; and,

(3) SEQ ID No 3: 1 to 500, 501 to 1000, 1001 to 1500, 1501 to 2000, 2001 to 2500, 2501 to 3000, 3001 to 3500, 3501 to 4000, 4001 to 4500, 4501 to 4995, 5000 to 5500, 5501 to 6000, 6001 to 6500, 6501 to 7000, 7001 to 7500, 7501 to 7932; and

g) a nucleotide sequence selected from the group consisting of SEQ ID Nos 4, and 9-13;

10 and,

h) a nucleotide sequence complementary to any one of the preceding nucleotide sequences; and a polypeptide code comprising a contiguous span of at least 6 amino acids of SEQ ID No 5, wherein said contiguous span includes:

- at least 1 of the amino acid positions 1 to 1629 of the SEQ ID No 5; or,
- 15 - an amino acid selected from the group consisting of an asparagine at the amino acid position 1694 of SEQ ID No 5, a valine at the amino acid position 1854 of SEQ ID No 5, an asparagine at the amino acid position 1967 of SEQ ID No 5, a glutamic acid at the amino acid position 2017 of SEQ ID No 5, and an alanine at the amino acid position 2050 of SEQ ID No 5.

20

57. Use of a polynucleotide comprising a contiguous span of at least 12 nucleotides of the SEQ ID No 1 or the complementary sequence thereto for determining the identity of the nucleotide at a BAP28-related biallelic marker

25

58. Use according to claim 57 in a microsequencing assay, wherein the 3' end of said contiguous span is located at the 3' end of said polynucleotide and wherein the 3' end of said polynucleotide is located 1 nucleotide upstream of said BAP28-related biallelic marker in said sequence.

30

59. Use of according to claim 57 in a hybridization assay, wherein said span includes said PG1-related biallelic marker.

35

60. Use according to claim 57 in a specific amplification assay, wherein the 3' end of said contiguous span is located at the 3' end of said polynucleotide and said biallelic marker is present at the 3' end of said polynucleotide.


ABSTRACT

The present invention is directed to BAP28 polypeptides, BAP28 cDNA sequences encoding BAP28 polypeptides, to the genomic DNA sequence of the BAP28 gene as well as to regulatory regions located at the 5'- and 3'-ends of the BAP28 coding region. The invention also
5 deals with antibodies directed specifically against such polypeptides that are useful as diagnostic reagents. The invention further encompasses biallelic markers of the *BAP28* gene useful in genetic analysis. The invention concerns an association of the *BAP28*-related biallelic markers with prostate cancer. Therefore, the invention contemplates the diagnostic and treatment methods of prostate cancer.

10

S:\DOCS\DOH\DOH-4557.DOC
062300




062300 062300 062300



1/30

FIGURE 1

0	1	2	3	4	5	6	7	8	9
---	---	---	---	---	---	---	---	---	---



C	A	...
---	---	-----





FIGURE 2

Figure 3

H -MTSLAQQLQRLALPQSDASLLSRD---EVASLLFDPKKAATIDRDTAFAIGCTGLEEL
 D MSTALAQQLQKLAAPQSSVTLADAR---SRASILFDPKKAATKDRRSIYEIGLTGLQEL
 A MSSSIYVSQLQALKSVLQADTEPSKRP--FTRPSILFSPKEAADFDIESIYELGLKGLEVL
 S MASSLQKQLKNVQSQSNVVLKINKIRR---APSLLYDPKVAADMDEEIVTAVSAGEHEL
 Y -MSSLSQQLNAQVSNATVALDRKRRQKLHSASLTYNKSKTADQDYDFIFENASKALEEL
 C MATSLTSQLENLRTSAAARHLTVEKR----HVSLLFDRKEANKLSNETAHRIGVAGLEQM
 : : . * * : * : : . * * . : : . !

H LGIDPSFE-QFEAPLFSQLAKTLERSVQTKAVNKQLDENISLFLIHLSPYFLLKPAQKCL
 D TDFNPAFK-EFQTLTDEATLTLERSVELPEINKMLDAAIAKFLRLLSPYLLLRPAHMAF
 A GNKDERFK-NYMNDLFSHKSEIDRELLGKEENARIDSSISSYLRLSSGYLQFRASLETL
 S AVHEPRLL-YFEKTLGEGSQVQVDRVLLNRTENEKI DLECVQILRLAPFTEKNALKVL
 Y SQIEPKFA-IFSRTLFSESSISLDRNVQKEIKDLDNAINAYLLASSKWYLAFTLHAT
 C KRIDPVDTEFANDLFSEBRVDFVRSMLKEGANEELNKQIEKLLLELSPYLQHFACQOVL
 : : : * : . * : : : * : :

H EWLHHRFHIHLNYQDSLIACVLPYHETRI FVRVIQLLKINNKKHR-WFWLLPVKQSGVPL
 D EWLRLRFQVHEYNRSEVMALILPYHETMIFVQIVKTMRLRSSDGD-WYWLRLPQRPQVPL
 A EYLIRRYKIHINLEDOVVLCAFPYHDTAFVRIQVLLSTGNSK--WKFLDGVKNSSGAPP
 S EWLIRRFSIHEYVSEDEFILSFLPFHDHPPFARILGCSKSPKSRP--LLFLENAIKMPVTL
 Y EWLVRRFQIHVKNTTEMLLLSTLNYYQTPVFKRILSI IKLPLF----NCLSNFVRSEKPP
 C EFLHTYQIYSFNAETLLLTFLFPHETKVYSRLLRILDFDKWRSKEWQMQPFTKETPTPI
 * : * : : : : * : : : : : : : : : : :

H AKGTLITHCYK-DLGFMDFICSLVTKSVKVFAYEPGSSAQLRVLLAFYASTIVSALVAAE
 D AKTAIINRAAS-NPAFLGPGICQSTOKAVKELGFR---AHQLQAQINFYATVVVGALQTAK
 A FRSVIVQQCIR-DKQVLEALCDYASR-TKKYQFS-----KPV-VSPSTAVVVGVLGSPV
 S SRADIVHALSR-DKEFFAMFAQFVQNTAESHNMY-----FELARFWAGTMMMEVLVAWH
 Y TALTMIKLFN--DMDFLKYTSYLDQCQIKHNATY-----TNQLLFTTCFCFINVVAFNS
 C PFTSIARATLSSKHSIITCIDHIRHAVEIVGSD-YLEIKHPILFNHAKILLSMFTDPE
 . : . : . : . : . : * : . : .

H D-VSDNIIAKLFPYIYQKGLKS---SIPDYRAATYMIICQISVKVMTMENTFVNSLASQIIK
 D P-LQDWHITLILESLLRGLIS--DNIDFMAAAVIVIAQLVSRTKLKSKVCNALLERVAN
 A T-VGDGIVKTIILFPVDSGLQSGVGKGLDQQAAGALMVVGMLANRAVLNTNLIKRLMRSIID
 S SNEDPVLVLDREFLRVSYAVSVSSIDFQIAGFMLLSSIASLPLSPSIIIPPLVSAIID
 Y N-NDEKINQIVPILLLEISAKLLASKSKDCQIAAHTLLVVFATALLPKKTIILAAMETILS
 C K-VDEMMLAKLMPFIEINGIKS---PMKSFYSAMVVISQLVLTVKLKDEVLSMCKLLIT
 : : : : : : : : : : : : : : : :

H T-LTKIPSLIKDGLSCLIVLLQROKQFESLGKKPFPFHLNCNVPDLITILHGISE-TYDVSP
 D CPFERLHSESLLLLVCIYKQQAALP-HFKPETILNLVGKKWLITSLSSLAGKNIAIQSI
 A I--GREHAKE-----SSDP-HSLRLSLMALINFVQLQSVDLIPRK-----
 S R--LSFDN-----IKP-----ALICVGHLLQFCSSEFFDHEQLE-----
 Y NLDAKEAKHS-----ALLTICKLFOTLKGQGNVDQLPSKIFKLF-----
 C K---MRSDT-----AASLSLTMVVVFQQQNVQSLSKN-----
 : : : : : : : : : : : : : : :

H LRYMLPLHVSVIIHHVTG---EETEGMDGQIYKRHLEAILTKISLKNNDHLLAS-LFEE
 D CMPLMTGAVAAIRDDASSNSCKLFLDNLSEVPMKPPTAQQLINCFLDTYVETIDAPE
 A ----ALDLFNEISSDDK-----CCVEIASIETVP-----VSNLVDHLISK-VFSLC
 S K-----LESFGASSLLIELS-----QEHRLDEFFVSYW-----VS-----LIK-SRKQKD
 Y -----SKFDTVSLITFLDK--EDKPVCDKFIITSYT-----RS-----IARYDRS--KLNI
 C -----TLKKLLRHEEG--IDVWKILKELSER-----DT-----TKFNVWLKE
 : : : : : : : : : : : : : : :

Figure 3 (following)

H YISYSSQEE-----MDSN-KVSLLENEQFLPLIRLLESK-YPRTLDOVVEEHLKEIAD--I
D PMETNSNEDDDTIVIDSDDEIETEKTTFAQWYSTYLEK-LERRYPEAFDVSVEALR--S
A MTQYQKNSD-----FRSS-----TSGSWAKKFLVVVSXK-YPAELRAAVPKFLEATEVQ-S
S KKRILISLLD-----TSIS-QIRVTHEQAKFLLSVIPVN-QQFKALQSYRRILDSVIQP-E
Y ILSLLKIR-----LERY-EVRLIITDLIYLSEILEDKSQVELFEYFISINEDVLVK-C
C LIVLSKDAES-----EDNTLAIQVLIETIETDASILTGDQ-AGTILKLIQEGMDGNIQFDNK

H KQQLFHOQFVSLSTSGGKYQFLADSDTSLMLSLNLHPLAVRILAMNHLKKIMKTSKEG-V
D KSSTSNRQKALKLALGFRLNTTDEKAKHAYEKLYHSADWRLSAVQKLLQNLVNTKKRER
A KKEDLKLEMLSCMLDGNSDMSHPFVDSKLWFLRHHPRAAVRCAALSSINGVLKDDSSKAE
S RKEGKLDNLIQLQKKKSSTFSKKDREVLLKKIS-----EIDSQTSFEQCLAYADSAAD
Y KLSGLTGELFEIRLTSTLTNADVNTDIVKQLSDPVETTKKDTASQTFLDKHSELINT
C KKLKSNIRAIMGRFAKQFDIAHAEKAKDKKTLKNVLKEYQIEDIVQFASEAVAATQSEE

H DESFIKEAVLARLGDNDIDVLSAISA-FEIKHEFSSEVTISNLLNLFQRAELSKNGEW
D SVKLLQECLEPDRINDDSGAVVSTLSPTEBLAELMGLPLAQTLCHILLYRAQSEKDEEN
A NLVTIQDAILRQLWDDDLAVVQAALSF--DKLPNTITSSGGLLDALLHVVKRCVGIIVSGV
S LDSSVFIISLKSFG-DKIPFLFLFCIAN-----GSERIIILSLIELRKTIEENKDVYD
Y TNVSMILTETGERYK-KVLSLFTBAIGK-----G--YKASSFLTSTFTTLESRLVFLKRVTI
C SIEIIEEAPSSKK-IKLTASEKAQKL--AQ--SSEFAKREVTFSGDPINKKATEWNLNGEKW

H YEVLKIAADILIKEEILSENDQLSNQVVVCLLPFVVINDDTESAEMKIAIYLSKSGICS
D QPVVPLAVRHLSALVSGSYD--TNLVLLALMPLLPGEALAEHQHAKLRILLG-SDFVS
A SHNVQLAVDVVALSLKIAVSSFGNQTDSTEKVTSAMFPFLIOPKTNWNLNLLVFLKLGKDV
S QIILPVVLYLSQSKDTEVRSR-----ALNLLITFLELRN-----ENLEFSIIYG-----
Y SPAAPTALKLISLNNIAKYIN--S--IEKEVNIFTLVPLCLALRDSAIKVRTG-----
C DKVEWALNEMAQRGEKYPYSRK-----VEDDVEQFVLEIVKVVG--VGVVKQIDG-----

H LHPLFLRGEEALENVIKSTKPGKLGIVGANQKMIELLAD-NINLGDPF-SMLKMVEDLISV
D KVPFLA--ELKVSNNKFSDFN-----VGEHRQFMDIASSNQELSSQERALLQSVEDHG--
A NWPLFK--NLAADDGMMKLP-----DIMSTNLSSISMDIINDLG-----EALSLDPDER--
S --MD-----DNDNKNLR--WLSPEVETKYICSD--LLLD-----
Y --VK-----KILSLIAKRP-----STKHVFLSKLYGENVTIP-----MLN-----
C --GS-----VKAALAGAN-----LNPQFVADLLTK-PDGVF-----

H GEEESFNLIKQKVTPHVILSVLVSCSS-LKETHFPFAIRVPSLLQKKIKKLESVITAVEI
D GELYIQKASQLTHLLLLLITAYAKRELQPRESLHMLEKIGLYSRLQFRVNGSSQNTQVCA
A RIELIERACNYKLESEVLETCSENIKCE--QDRNKLQKGLLIRESVSALNIDVNIKVEA
S RSSEIGLDGTYLFSYIPERLFTTEKKPK-----NASKEIAVTSFLSSHAACSKLNSNVRLV
Y PKDSEAWLSGFLNEYVTENYDISRLT-----PKRNEKVFVLMFWANQALLIPSPYAKTVL
C EIAPKRTKGAQKKNLVEKTFGTESWE-----AFNQRVVFLDLLNARQIIPSEKVLAA

H PSEWHIELMDRGI PVELWAHYVEELNSTQRVAVEDSVFLVFLSK-KFIYALKAPKSFPPK
D FLQYIVYDFLLT-LVKNTKWT-----ALASTFWNQMTDELRLCLRL--EIIQAVQVSEKADQ
A -----FMMH-PADYQWL-----TTEWELEVEVDVSLKELSKSNCOELLYQLLDT
S -----LEILTRV-----HGKVEDAKMOILLPRL--EQLSEFNESEKFT
Y -----LDNLNKS-----PTYASSYSSEFEFISHYLENRRSSWEKSCIANK
C -----LFAVVQVQN-----SKSDVESSSYQQLHAVN-AIRKILEHPEKTKI

00000000-00000000

Figure 3 (following)

H GDIWNPEQKEDSRDYLHLLIGLFEMMLNGADAVHFRVLMKLFIKVHLEDVQLFKFCS
 D -----PERQ-EWTRALQQSILILPEAQ-----D-----RLEVLSNFYVFERLP
 A -----SDFTALNSKDVKAAAINCIEALFN-----LRAA---IYGSSFDE
 S -----VSKREVEALVNCENHTS-----FTSLLSFSSNI
 Y -----INFEHFERSLVNLVSPKE-----KQSFMDIFVLNALNS
 C -----GASEVDMDCVIETM-----RSTHNNH

H VLWTYGSSLSNPLNCSVKTVLTQALYVGCAMLSSQKTQCKHQALSISSPVVTSLLINLG
 D ELWPRDSYA-----VFRLQGFIIIEAVLSNPKSQIDCGLVHVLR-----VANACC
 A LLG-----MIVOQRRLILSDNKKFFA---SYLTSLSSTTN---DLLVPVG
 S VLS-----QAICRRIVEIQSHLKD---PQRLFEVKAVIS-----QDEQ
 Y DYEQ-LA-----NIAAERLISI FASLNN---AQKLKIVQNIVD---SSSNVES
 C LLR-----DCLRLIVAAAKHTP---NSVVKHVMVSFT---FMGNG

H SPVKEVRRAAIQCLQALSG---VASPFYLIIDHLSKAEIETSD---AAYVIQDLATLFEELQ
 D SPLQTLRVQAINILQISNRKLVSHVEQLVRSILQKSELMDEHQVALIYLTILEPEKA
 A LQKRFPQSTKENILSVILCAEDLPAYGKLRVLSLLKDLGIMLMRDEIVKLLSQLLDK--
 S PHYVVDVLDISKIPDVFVK---KLIGSVRLVKEKNPAIAKR---KRIDSHIFDG--
 Y SYDTVGVLQSLPLDSDFVS---ILNQNSISNEMDQDFSKRR---RRSSSTSNAFLKEEV
 C MLRKDNELTSLIVEKTVES-----LFSTIINSSGQAVLTQKQ-QTEKLTELARLFAASA

H REKKLKSHOKLSETLKNLLSCVYSCPSYIAKDLMKVLQGVNGEMVLSQLLPMAEQLLEKI
 D TAKERVLVSLKKRSVLALASDFKQSP-ICTASLLAALKHVNDENFLNELPLGLDLSKTI
 A RSQYYKLDKTSQPLSDTEVDLLCLLLECSMMRTSSFKQS---LDDHILSALNVDCMA
 S -----DVQRLTRILELLETKNAASYPKLASPLFEVLNSVIA---LKEDIVSSNYLLQLL
 Y SQAELHLRKLITIIIEALDKVRNVGSEKLLFTLLSLSDLET---LDQDGGFLPVLYAQET
 C IDIPAHRRARIAQAIARAVQAENAST--VVLVLVSSFCARWQ---RSSDAAAEAMKRGS

H QK-EPTAVLKDEAMVLHLTLGKYNE-FSVSLNEDPKSLDIFIKAVHTTKELY-AGMPTI
 D TAGEDNQNIKQLFWPHSEIYKSVIERFEGRVALLNLLKDLAWKLFEDSPAQY-DTVQL
 A SE-RPAVISPLCTILEKLSNRFYDE---LQT-----DVQIRFFHKLVSFMFSSNGSI
 S LG-----LLYEMIGASPITELSP-----SIRIDTLVGCIRST---NNPQI
 Y LI---SCTLNTITYLKEHGCTELTN-----VRADILVSAINRS---ASPOV
 C DQ-----DAYDDLAEIELSALNP-----FEQLSSVLEMCEYVVARLGGDK

H QITALEKITKPPFFAASIDEKVQKKLLRMLFDLLVNCNKNSHCAQTVSSVFKGIS-VNAEOV
 D EQ-KLQPLFCVLLNSLTPEFQMHAKHKIALIKLIVESATNSDNDISFFLASH-RLKRC
 A QNGAKEAVLRKLKSSSTVVALDRITQQDTIVIGLSLKKKKQKKNKSCPEED-INSEEF
 S QN---KALLLVSAANAAPEAVLHGVMPIFTFMGSTVLSRDDAFSIVHIEQTVKTVISALI
 Y QN---KLLLVIGSLATLSESEVILHSVMPIFTFMGAHSIRQDDEFTTKVVERTILTVVPALI
 C PA---KSTTTKKDLDTMIPDRTAQTLERIRHFRYVVVTLISIRIFSNRVLIERLAAYDDEEL

H RIELEPP-DKAKPLGTVOOKRRQK-MQKKSQDLESVQEVGGS-Y-QQWVTLILELLQHK
 D RLDCQP---LVPIILEMANTKVEK-KOPVKRRSVQATQLDLTSPY-WKQGMTLELLESHK
 A RSGEKA-LFIAASLLDMLLKKDLTHRESLIRPLFKILQRSMSKE-WVKIAFSIEETSLO
 S RLGDKF---DSSLLVSCFVNAFFHPQHRRRLRLYRLVLTIGS---NRFLSVVLIOFAE
 Y KNSKGNEKEEMFLLSFTTALQHVPRHRVKKLFTLTKTLDPVKALGSFLFLIAQOYSS
 C LKNALP---LGKRLIECSVELDEFANKEANDQDGSDDPAQRYWVAFASRTEVVSEKRLHL

00003665-062300

Figure 3 (following)

H XKLRSFQILVPTLFNLLSRCLEPLPQEQQNMEYTKQLILSCLLNICQKLSPDGGKIPKDI
 D KQLVGAELIIPPLFELLQACLT--MEEHSAAEYKQLILSLLHCCQTAQSGVQLVKAM
 A PPQ-DVRETTPTPFISSIQOTLL-----LILKDI FDSLNMMN-PLKAEVANEI
 S KML--LAKSTNVVAIHDFCLT-----L--VQSF--SVADRI
 Y ALVNFKIGEARLIEFIKALLV-----D-----LHVNEELS--G--LNDLL
 C LPG--GVAARIADVLQECVN-----DKK-----MSYKM

H LDEEKNFVELIQCIRLSEMPQTHHALLLLGTVAGIFPDKVLHNIMSIFTFMGANVMRL
 D P-ESSFRIELVVQSLRNTRNPQTQHALLFLTHCAGMYPQQVLHKIVEIPTFVGSTVARH
 A N-----VKMLVELAHSSNDGVTRNHFSLFTAIVKFVPDKVLDHIISILT LVGESTVQT
 S G-----SIN-QCSRFLKSLSEQSNDSNGKAVSLIKLDELPMVDVLATLGSLRVKVL
 Y D-----IKLLTSSKSSSEKKKSLSESVLFSNGVLNFSESEFTFMNNTFEFIN-KITEE
 C C-----EKVQLANIKLG-----HDRYLFA-DSGINEKELITLAQALNKFI VAETKSE

H DDTSYFQVINKTVKMVIPALIQSDSGDSIEVSRNVEEIVVKIISVFDALPHVPEHRRLP
 D DDAFSLHIHNVVESIIPILLN-TG-----HNELVIPVLKVFADICTDVPVHRRLP
 A IDSHSKSIFEGFISMVIFFWLSK-----TKSEQLLIQIFVKVLPDIVEHRRRS
 S ELISLVSKAKNPAFDLAKIMENS-----VDSFVEIQAGLFES--IK
 Y TDQYYDVKRNRLKLVYSVLLDETSD-----KKLIRNIREEGFTLLEGVLFF-INS
 C EKMRMCQNSAYTLKLI AKNLPQ-----SESLVADTMQR-CVS

H ILVQLVDTLGAEKFLWILLIILFEQYVTKTVLAAAYGEKDAILEADTEFWFVSCCEFSVQ
 D LYATLFRVLEPKHELWQFLCIIFES---QVLEQVPQKVSTDKSRLDFARELTLMFEEDP
 A IWAYLLGVVTS-----LLQQ-----ADKSD-----KLLHDERA
 S LLITLSQQSSNE-----MELG-----
 Y VELTFSCITSOE-----NEEAS-----
 C IVSQQYKLDEN-----

H -HQIQSLMNLQYLLKPEEKETIPKAVSFNKSSESQEMLOQFNVETHTSKQLRHFKFL
 D TVAIQTCIRLLDYAKLPATKSSLSGGSGSVLSTEQ-----QLFDVTRTFKQLRHYYKL
 A ---QTDYNGTKKVLGLISERAKDTS--SS-----KMKHKRRI
 S -HVYVALRSVHLLPNELFCTVLG-----KLLHDERA
 Y ---DSETSLSDHTTEIKEILFKVLGN-----VLQILPVDEFV
 C -----LTGNVLLLAGELIRS-----HNMR

H SVSFMSQLSSNNFLKVVESGGPEILKGLEERLLETVLGYISAVAQSMERNADKLTVK-
 D IDPFLSGISSCNEWKMKRDPDPNELLPPYQEFILKT-LAYVGVNLGALEAASETPSLEK
 A S-----N--OK-----GRN-----S-----
 S LLR-----RK-----ALS-----IVQ-----
 Y NAVLPLLTSTSTNEDIR-----YHLT-----LVIGS-----
 C T-----I-----

H FWRALLSKAYDILLDKVNALLPTETFIPVIRGLVGNPLPSVRRKALDLLNNKLQONISWKK
 D FWRVLNHAHDVLDNAIGLLAPQHFI SVITELLKHDHVYVRIKVMDDLVTLKSPSSDYFQ
 A -WLNLDDEVADDSFGKMCCEIIV--HLINATDDSGVPVKRAAISTLEVLAGRFP-----SGH
 D -QRVQOGSKSVALTALIPDVT--YINISYSD--ETTQLAMDCLAVMKRRFS-----
 Y KFELEGEALPIVNNVMKVLL--DRMPLESKS--VVISQVILNTMTALVSKYG-----
 C -----H-HATSLKTKLATVQ--ECIARFSKP--QYDASAASPGSSVAGGRGN-----

00603665-062300

Figure 3 (following)

H -TIVTRFLKIVPDLIAIVO--RKKKEGESEEQAINRQTALYTLKLLCKNFGAENPDPEVPV
 D QSNAERFGVLFPALQEIINGILEGSSNSAQKALQQTALHALOLLALRHGRDYIEECRSL
 A -PIFRKCLAAVAECIS-----SKNLGVS--SCLRT
 S ----ASPFLFISPIEVVS-----GPYGLKN-SARDVQ
 Y ----KKLEGSILRQALTAT-----EKVSSD--MTEVK
 C ----RG-HRIRQQSLGG-----NKFGSD----TLL

H LSTAVKLIAPERKEEKNVLGSALLCIAEVTSTLEALAIQPLPSLMPSLTMMKN----TS
 D LATLTKITKRANVPKAVGVNVLTLEICASLKAHALAQLEKFPALTELLKEQVHQMA
 A TGA LINVLG----PKALIELPCIMKNLVKQSLVSVFASQS--G--RN--
 S VSAIVCITV--LTNTLAARILPYLADIVNYSLSILDDAR-----KD--
 Y ISSLALITN--CVQVLGVKSIAFYPKIVPPSIKLPDASLADS-----SN--
 C ICSLTICIR--VYDQFASFVVESTGDVVIIRYCRLIARFG-----D-----
 : : : : :

H ELVSSEVYLLSALA-ALQKVETLPHFISPYLEGILS----QVIHLEKITSEMGSASQAN
 D SLKGGPYVVCSTLVTLHLKLFKALPLFLGPYLVDIIGGLARLSVQLENPQLQDKRTQVL
 A ATAEQILLMLSVLV-LEAVIDKLGFLNPHLGDMK-----IMVLHPEVSVDFDKNLK
 S --PEGDLLELACFS--MMIDFFKVLPEFPSSSYVEPTIK-----CALASDRAFEHDAI
 Y --PLKEQLQVAILL-LFAGLIKRI PSFLMSNILDLVLH-----VIYFSREVVDSSIR
 C ----PSELLALNQPS--SSTTAAFQGGSSQTSFGSGKTG-----IHRLSLIRRSLLS

H IR-LTSLKKTATTLAPRVLLPAIKKTYK-QIEKNWNHMGPFMS-ILQEHIGAMKKEEL
 D KQKLADVWSAVAQGVVIRILVPSKAKAFSSLLSEQQAYDELGHLMQQLLQSVRHNSAAQL
 A SK-ANAIARRLLTKIPVRLTLQPLLRIVNEAVSSGNASLVIAFNM--LEDLVVMDRSSI
 S GE-----LLFETIANFIPTRLMKSIFAAWPECARLGSTAAALRLEL--LEALQNSSRSIAI
 Y LS-----VISLIIENIDLKEVLKVLFRIWSTELATSNDTVAVSLFLSTLESTVENIDKSA
 C IE----LRVLPAHIVKTVGELKTEKKALS--ALFNLLTGYIETQH--Q-QKPEILRKSVI
 : : : : :

H TSHQSQLTAFLEALDFRAQHSN--DLEEVGKTENCII DCLVAMVVKLSEVTFRPLFFK
 D QPVQDDISELFLQALNFRILQVRGLGLQRLVSDVEASITETFTVWILKSTSEFRPMYSR
 A VSSHGKIFDQCCLVALDIRRLNPA--IQNIDDAERSVTSAMVALTKKLTESEFRPLFIR
 S GTVYKSFIFKFFLDSFDSRRSLFA--EDVDNVETQAVNVFLKFMVKLSDTTFRPLFLH
 Y TSQSPIFFKLLLSLFEFRSISFD--N-NTISRIEASVHEISNSYVLMKMDKVRFPFLVI
 C QLRRTFVSDVITITLIVRSQERQSD-QFENVKLEHTVFNVISIASILSEVTFVNVNE
 : * : : * : : *

H LFDWAKTEDAP---K---DRLLTFYNLADCIAEKLKGLFT---LFAGHLVVPFADTL
 D VHKWALESTSR---E---TRLTYFL-LTNRIAEALKSLFV---LFASDFVEDSSRL
 A SIDWAEISDVVDGSGENKSIDRAISFYGLVDRLCESHRSIFVYFKYVLDGIVAHLLTAE
 S LHSWALELDYETD--PSGIVSRQTFYFNFLTIFLDTLKSIVT-----N-YYAVLDDT
 Y LVRWAFDGEVGTN-AGITETERLLAFAFKFENKQLQENLRGIIT----SYFTYLLFEPVMDLL
 C LVAWAEPGLEAKA--DLAARLRVLSLLHFANDLYTSFNSLALP--YFGRIEISALV
 ** * : : *

H DQVNI SKTDEAFFDSENDPE--KCCLLLQFILNCLYKIFLFD--QHFISKERAGALMMP
 D TEHNSIRPEFEVEEREDD-----VDLLMAILNTLHHVFLYCS--EDFINDHRFNVMMP
 A ASVSTRKKKKAKIQOTSDSIQPKSWHLRALVLSCLKNCFLEHDTGSLKFLDTNNFQVLLP
 S IELSSK-D-----TNS-----EVR--HLVNSSLSVAFENDT--EEFMMVPAFPGKISPV
 Y KRFLSKD-----MEN-----VNLRLRVINSLSLTKFDR-DEYMKSTSRFELTSVS
 C KKC NATLLLTGDELLLSGKRGSI EALETDLALT LAIDVISNAARHRDFFTVDRCQLVSDV
 : : : : :

[illegible][illegible]

```

H      VLGE--FLQSYF---
D      ILGE--SVQKYL---
A      MSGE--SLAEYL---
S      RLGENESLQDYLT--
Y      VLGE--PFDRYLD--
C      KFGE--TFWSGGSSA

```

HEAT REPEAT


```

BAP28      MTSLAQQLQRLALPQSDASLLSRDEVASILLFOPKCAATIDRDRTAFAGICTGLEELLGIDP
BAP28      SFEQFEAPLSFQSLAKTLERSVQTKAVNKQLDENISFLFIHLSPYFLKLPAQKCLEWLIHR
BAP28      FHIHLYNQDSLACVLPYHETRIFVRVIQQLKINNKSHRWFVLLPVKQSGVPLAKGLTIT
BAP28      HCYDKQGFMDFTICSLVTSKVFAEYPGSSAQVRLVAFYASTIVSALVAEDSDNITIA
BAP28      KLFPYIQKGLKSSMLPYRAATYMIICQISVQVTMENTFVNSLASQIKTLTKIPSLIKDG
BAP28      LSLCLIVLQKQKPEISLGKFFPHCLNPVDLITLHGISETVDVSPLLRYMLPHLVVSIIH
BAP28      HVTGEETEGMDGQIKYRHLBAITTKILKNNNDIHLHLFEIYTSYSSSQEEMSNKVSIL
BAP28      LNEQFLPLIRLLESQKYPTLDDVLEHLKKEIADLKQKLEFHQFVSLSTSGGKYQFLOLSD
BAP28      TSLMLSLNHPLAPVRILAMHKLKMKTKMSEKGVDESFIKEAVLARLGDDNDVLSAISAI
BAP28      FEIPEKHFSEVTTISNLLNLQFRAELSKSGEYVVLKIAADILIKEEILSENDQLSNQV
BAP28      VCLLFFVIVNNDTSEAMKIAITLSYSGKSCGSHWPLRLRGWEEALENVIKSPKGLIGVA
BAP28      NCKMTELLADNINLGDPSMLMKVEDLISVGEESFNLKQKVTFHVILSVLVSCSSSKLE
BAP28      THVDFAIRVLSLQKKFKKLESVITAVEIPSEWHIELMDRGIPVELWAHVVEELNSQR
BAP28      VAVEDSVLFVLSLKKFIYALKAPKSPFKGDIWWNPQLKQEDSRDYLHLIGLFEMMLNGA
BAP28      DAVHFRVIMKLFIFKVHLEDVQFLFKFCSVLWTVYSSLSNPLNCSVKTVLQTQALYVGCAM

BAP28      LSSQKTQCKHQLASISSPVVTTSLNLINGSPVKEVRRAAIQCLQALS-GVASFPFYLIIDHL
Tetraodon1 -----FPSLLCSLSPQEVRRVSLGALQSLSRARASFPFWIMEKL
          .*.***.***:..*.*:..*.*:..*.*:..*.*:..*.*:..*.*:..*.*:

BAP28      ISKAEIITSDAAVYIQDLATLFEELQREKKLQSHQKLSSETLKNLLSCVYSCPSYIAKDLM
Tetraodon1 LRTTDELLADPSSYLSQVRRSSPAGDLRFWLLTPSVCVCCLG----YRPSRRRPLGLVLI
          :.:::.*.*:.*.*:..*.*:..*.*:..*.*:..*.*:..*.*:..*.*:..*.*:

BAP28      KVLQGVNGEMVLSQLLPMAEQLEKTIQKEPTAVLKDEAMVHLITLQKYNFVSLLNEDP
Tetraodon1 PVVV-VFQCSILSALLPLLERLLEQSSPDTPNQLRDEAQLALLISKYNEASAPILLAKE
          :..*.*:..*.*:..*.*:..*.*:..*.*:..*.*:..*.*:..*.*:..*.*:..*.*:

BAP28      KSLDIFIKAVHTTKELYAGMPTTIQITALEKITKPFFAAISDEKVQOKLLRMLFDLLVNCK
Tetraodon1 NCLDLFIRALNRNSQQHLDIPSQIQIFALEQITKSFSAISETETVQOKLLSVMFDDLLAENX
          :.***:..*.*:..*.*:..*.*:..*.*:..*.*:..*.*:..*.*:..*.*:..*.*:

BAP28      NSHCAQTVSSVFEGKISVNAEQVRIELEPPDKAKPLGTVQOKRRQKMQKQKSDLESQEV
Tetraodon1 XPLVAITIGSVFKRITVDAQVLVNAELAPADKASISMTVQSSRRSRMIL-----
          *.***.***.*.*:..*.*:..*.*:..*.*:..*.*:..*.*:..*.*:..*.*:

BAP28      GGSYQWRVTLILELLOKHLKRSFQIVLPTFNLLSRLCLEPLPQEQNNMEYTKOLISCLL
BAP28      NICQKLSPDGKIKPKDLDXKLEPNVLIQVCRILSEMPQTHHALLHLGTAGIFPDKVL
BAP28      HNIMSIFFMGANVMRLDDTYSFQVINKTVKMVLPALIQSDSGDSIEVSRNVEETVVKII

BAP28      SVFVDALPHVPEHRRLLPILVQLVDTLGAEKFLVILLILFLEQYVHTTVLAAAYGEKDAL
Tetraodon2 -----LPVLVQLVTEIPARFLVWMLLILFKLHATANTASE--KDAV
          :..*.*:..*.*:..*.*:..*.*:..*.*:..*.*:..*.*:..*.*:..*.*:..*.*:

BAP28      EADTEFWFSVCCEFSVQHOIQSLMNLQYLLKLPEEKEETIPKAVSFNKSQEE---
Tetraodon2 EKDVDFWISLCSQFKVGEQLASLNHLIGFLQLQEPDKDEAASKHATGRRITQKKEKEEQ
          :..*.*:..*.*:..*.*:..*.*:..*.*:..*.*:..*.*:..*.*:..*.*:..*.*:

BAP28      ---MLQVFNVEHTSKQLRHFKFLSVSFMQSLLSSNNFLKKVSVESGGP-EILKGLERLL
Tetraodon2 DKMEELISFVEAHSKELRHHFKFTSVSFMALQLGSASFIGKVS EITTSNLLSLKRMILL
          :..*.*:..*.*:..*.*:..*.*:..*.*:..*.*:..*.*:..*.*:..*.*:..*.*:

BAP28      ETVLGYISAVAQSMERNADKLTVKFWRALLSKAYDLLDKVNALLPTETFIPVIRGLVGNP
Tetraodon2 EDLLRYHISARIASVEENAMKPTAKFWRVLLNKAYDVLDDKVNSLPTDTFIVMKGLMGND
          :..*.*:..*.*:..*.*:..*.*:..*.*:..*.*:..*.*:..*.*:..*.*:..*.*:

```

Figure 1 (Continued)

BAP28	LPSVRRKALDLLNNKLQQNISWKKTIVTRFLKLVDPDLLAIVQRKKKEGEEEQAINRQTAL
Tetraodon2	LPSVRRKAMELLNNKL-----
	*****.*****

```

BAP28      YTTLLCKNFGAENPDFFVPLSTAVKLIAPERKEEKNVLGSGALLCIAEVTSTLEALAIQPLPSLMFSL
BAP28      LTTMKNTSELVSSEVILLSALAALQKVETPLPHFISPYLEGLISQVILHEKITSEMGSAS
BAP28      QANIRLTSLKKTLLATIAPRVLLPAIKKTKYQTEKNWKNHMGFMSILQEHIGAMKKEEL
BAP28      TSHSQSLTAFLEALDFRAQHSSENDLEEVGKTENCII DCLVAMVVKLSEVTRFRLPFFKFLF

BAP28      DWAKTEDAPKDRLLTTFYNLADCIAEKLGLFTLFAGHLVKPFADTLDOQVNISKTEAEFFD
Tetraodon3 -----EVLFE
                        *.:*.:

BAP28      SENDPEKCCLLQFILNCLYKIFLFDTQHFSKERAGALMMPDVDQLENRLGGEKQFQER
Tetraodon3 SSHAADQKVALKQVVLVCLHKIIFLYDTQRFLSKERADTLMNPLDQLENFAGGPQTYYQQR
                        *.: *.: *.: *.: *.: *.: *.: *.: *.: *.: *.: *.: *.: *.:

BAP28      VTKHLIPICIAQFSVAMADDSLWKPLNYQILLKTRDSSPKVRFALITVLALAEKLKENYI
Tetraodon3 VTQHLVPCLGQFAVALADDQTKWLTNXXLKSRRHSDAKVRFSSLLMLMXLTSKLKENYM
                        **.:**.:**.:**.:**.:**.:**.:**.:**.:**.:**.:**.:

BAP28      VLLPESIPFLAELMEDECEEVEHQCKQTIIQOLETVLGEPLQSYF
Tetraodon3 VLLPETIPFLAELME-----
                        *****

```

SINGLE LOCUS: ALLELIC ASSOCIATION ANALYSIS




Figure 5

BAP28



Figure 6

[illegible]

HAPLOTYPE ANALYSIS SORTED BY INDIVIDUAL HAPLOTYPE TEST (2 markers)
491 CASES vs 313 CONTROLS

[illegible]

Figure 7A

HAPLOTYPE ANALYSIS SORTED BY INDIVIDUAL HAPLOTYPE TEST (2 markers) 197 FAMILY CASES VS 313 CONTROLS

MARKERS											HAPLOTYPE FREQUENCY TEST											OMNIBUS LR TEST										
POLYMORPHISM																																
cases / controls																																
99-1567/281											99-1572/440											5-171/204										
5-2/178											99-1605/112											5-11/158										
5-377/227											6-373/164											99-7190/213										
99-7188/212											99-7177/81																					
frequency%(case/controls)											Estimation frequency of haplotype											Statistical test										
diff freq all case - controls																																
pvalue											cases(%)											controls(%)										
Odds ratio											differency											Odds ratio										
Test											pvalue(1df)											Nb of permut										
Hardy Weinberg											LR Test											Pvalue (3 df)										
											Pvalue (100 permu)																					
Haplotype 1											Haplotype 2											Haplotype 3										
Haplotype 2											Haplotype 4											Haplotype 5										
Haplotype 3											Haplotype 6											Haplotype 7										
Haplotype 4											Haplotype 8											Haplotype 9										
Haplotype 5											Haplotype 10											Haplotype 11										
Haplotype 6											Haplotype 12											Haplotype 13										
Haplotype 7											Haplotype 14											Haplotype 15										
Haplotype 8											Haplotype 16											Haplotype 17										
Haplotype 9											Haplotype 18											Haplotype 19										
Haplotype 10											Haplotype 20											Haplotype 21										

Figure 8A

**HAPLOTYPE ANALYSIS SORTED BY INDIVIDUAL HAPLOTYPE TEST (3 markers)
197 FAMILY CASES vs 313 CONTROLS**

[illegible]

Figure 8B

HAPLOTYPE FREQUENCY TEST				OMNIBUS LRT TEST	
cases(%)	controls(%)	difference	Estimation frequency of haplo type	Statistical test	Likelihood Ratio
Odds ratio	pvalue(1df)	Nb of permut			
L.R Test	Pvalue (7 df)	Pvalue (100 permut)	omnibus test		

17/30

[illegible]

91 FAMILY CASES having less than 65 years old vs 313 CONTROLS

MARKERS										HAPLOTYPE FREQUENCY TEST										ONIBUS LR TEST									
POLYMORPHISM										HAPLOTYPE FREQUENCY TEST										ONIBUS LR TEST									
cases / controls										HAPLOTYPE FREQUENCY TEST										ONIBUS LR TEST									
frequency (%), case:control										HAPLOTYPE FREQUENCY TEST										ONIBUS LR TEST									
diff freq (cases-controls)										HAPLOTYPE FREQUENCY TEST										ONIBUS LR TEST									
pvalue										HAPLOTYPE FREQUENCY TEST										ONIBUS LR TEST									
Odds ratio										HAPLOTYPE FREQUENCY TEST										ONIBUS LR TEST									
Test										HAPLOTYPE FREQUENCY TEST										ONIBUS LR TEST									
Haplotype										HAPLOTYPE FREQUENCY TEST										ONIBUS LR TEST									
153 vs 263	A	T	A	T	A	T	A	T	A	52.92	22.80	22.51	2.23	5.0E-07	0.00	24.62	8.80E-4	1.00E-02	5	66.40	27.50	22.51	2.65	5.4E-07	0.00	23.00	1.30E-4	1.00E-02	5
153 vs 263	A	T	A	T	A	T	A	T	A	50.20	27.50	22.51	2.65	5.4E-07	0.00	23.00	1.30E-4	1.00E-02	5	66.40	27.50	22.51	2.65	5.4E-07	0.00	23.00	1.30E-4	1.00E-02	5
153 vs 263	A	T	A	T	A	T	A	T	A	50.20	27.50	22.51	2.65	5.4E-07	0.00	23.00	1.30E-4	1.00E-02	5	66.40	27.50	22.51	2.65	5.4E-07	0.00	23.00	1.30E-4	1.00E-02	5
153 vs 263	A	T	A	T	A	T	A	T	A	50.20	27.50	22.51	2.65	5.4E-07	0.00	23.00	1.30E-4	1.00E-02	5	66.40	27.50	22.51	2.65	5.4E-07	0.00	23.00	1.30E-4	1.00E-02	5
153 vs 263	A	T	A	T	A	T	A	T	A	50.20	27.50	22.51	2.65	5.4E-07	0.00	23.00	1.30E-4	1.00E-02	5	66.40	27.50	22.51	2.65	5.4E-07	0.00	23.00	1.30E-4	1.00E-02	5
153 vs 263	A	T	A	T	A	T	A	T	A	50.20	27.50	22.51	2.65	5.4E-07	0.00	23.00	1.30E-4	1.00E-02	5	66.40	27.50	22.51	2.65	5.4E-07	0.00	23.00	1.30E-4	1.00E-02	5
153 vs 263	A	T	A	T	A	T	A	T	A	50.20	27.50	22.51	2.65	5.4E-07	0.00	23.00	1.30E-4	1.00E-02	5	66.40	27.50	22.51	2.65	5.4E-07	0.00	23.00	1.30E-4	1.00E-02	5
153 vs 263	A	T	A	T	A	T	A	T	A	50.20	27.50	22.51	2.65	5.4E-07	0.00	23.00	1.30E-4	1.00E-02	5	66.40	27.50	22.51	2.65	5.4E-07	0.00	23.00	1.30E-4	1.00E-02	5
153 vs 263	A	T	A	T	A	T	A	T	A	50.20	27.50	22.51	2.65	5.4E-07	0.00	23.00	1.30E-4	1.00E-02	5	66.40	27.50	22.51	2.65	5.4E-07	0.00	23.00	1.30E-4	1.00E-02	5
153 vs 263	A	T	A	T	A	T	A	T	A	50.20	27.50	22.51	2.65	5.4E-07	0.00	23.00	1.30E-4	1.00E-02	5	66.40	27.50	22.51	2.65	5.4E-07	0.00	23.00	1.30E-4	1.00E-02	5
153 vs 263	A	T	A	T	A	T	A	T	A	50.20	27.50	22.51	2.65	5.4E-07	0.00	23.00	1.30E-4	1.00E-02	5	66.40	27.50	22.51	2.65	5.4E-07	0.00	23.00	1.30E-4	1.00E-02	5
153 vs 263	A	T	A	T	A	T	A	T	A	50.20	27.50	22.51	2.65	5.4E-07	0.00	23.00	1.30E-4	1.00E-02	5	66.40	27.50	22.51	2.65	5.4E-07	0.00	23.00	1.30E-4	1.00E-02	5
153 vs 263	A	T	A	T	A																								

**HAPLOTYPE ANALYSIS SORTED BY INDIVIDUAL HAPLOTYPE TEST (2 markers)
294 SPORADICS CASES vs 313 CONTROLS**

MARKERS		HAPLOTYPE FREQUENCY TEST												OMNIBUS LR TEST	
POLYMERPHISM															
cases / controls															
frequency, % (cases/controls)															
Hfr all, cases - controls															
pvalue															
Odds ratio															
Test															
Hardy-Weinberg															
controls															
cases vs controls															
D1															
D2															
D3															
D4															
D5															
D6															
D7															
D8															
D9															
D10															
D11															
D12															
D13															
D14															
D15															
D16															
D17															
D18															
D19															
D20															
D21															
D22															
D23															
D24															
D25															
D26															
D27															
D28															
D29															
D30															
D31															
D32															
D33															
D34															
D35															
D36															
D37															
D38															
D39															
D40															
D41															
D42															
D43															
D44															
D45															
D46															
D47															
D48															
D49															
D50															
D51															
D52															
D53															
D54															
D55															
D56															
D57															
D58															
D59															
D60															
D61															
D62															
D63															
D64															
D65															
D66															
D67															
D68															
D69															
D70															
D71															
D72															
D73															
D74															
D75															
D76															
D77															
D78															
D79															
D80															
D81															
D82															
D83															
D84															
D85															
D86															
D87															
D88															
D89															
D90															
D91															
D92															
D93															
D94															
D95															
D96															
D97															
D98															
D99															
D100															
D101															
D102															

Figure 10A

HAPLOTYPE ANALYSIS SORTED BY INDIVIDUAL HAPLOTYPE TEST (3 markers) 294 SPORADICS CASES VS 313 CONTROLS

MARKERS	HAPLOTYPE FREQUENCY TEST										OMNIBUS LR TEST						
POLYMORPHISM	A/T	AG	AG	C/G	C/T	AG	AG	AG	C/T	C/T	Estimation frequency of haplotype	Statistical test	Likelihood Ratio	omnibus test			
	256	281	274	285	285	285	290	280	275	287							
cases / controls	VS	VS	VS	VS	VS	VS	VS	VS	VS	VS							
	305	278	268	305	305	307	299	307	298	297							
frequency % (cases/controls)	40.32	69.63	67.67	82.62	35.61	35.31	35.31	35.31	36.31	42.36							
	(T)	(A)	(G)	(C)	(T)	(G)	(A)	(A)	(T)	(T)							
diff freq all(cases-controls)	7.4	8.5	0.2	0.3	3.9	4.5	4.5	4.4	5.5	5.7							
pvalue																	
	7.70E-03	2.70E-02	7.50E-01	7.50E-01	1.50E-01	9.40E-02	1.00E-01	1.00E-01	4.50E-02	4.80E-02							
Odds ratio	1.40	1.30	1.00	1.00	1.20	1.20	1.20	1.20	1.30	1.30							
	0.07	0.07	-0.02	-0.07	-0.03	0.00	0.00	0.00	-0.03	0.02							
Hardy Weinberg controls	0.07	0.00	0.07	-0.07	-0.02	-0.02	-0.02	-0.02	-0.07	0.07							
Haplotype 436	284	VS	278	T	A	A	T	T	T	T							
	259	VS	283	T	A	A	T	T	T	T							
Haplotype 437	272	VS	285	T	A	A	T	T	T	T							
	283	VS	274	T	A	A	T	T	T	T							
Haplotype 439	246	VS	268	T	A	A	T	T	T	T							
	277	VS	285	T	A	A	T	T	T	T							
Haplotype 441	273	VS	284	T	A	A	T	T	T	T							
	271	VS	272	T	A	A	T	T	T	T							
Haplotype 442	271	VS	272	T	A	A	T	T	T	T							
	273	VS	284	T	A	A	T	T	T	T							
Haplotype 443	271	VS	272	T	A	A	T	T	T	T							
	273	VS	272	T	A	A	T	T	T	T							
Haplotype 444	273	VS	272	T	A	A	T	T	T	T							
	271	VS	272	T	A	A	T	T	T	T							

Figure 10 B

22/30

[illegible]

MARKERS		99-1572440	5-171224
HAPLOTYPE 1		T	T
pvalue (1df)		1.10E-02	5.40E-02
% frequency difference (sample sizes)	Familial cases vs controls (2 screening)	10.1 (89 vs 304)	7.2 (89 vs 307)

HAPLOTYPE FREQUENCY TEST					OMNIBUS LR TEST	
estimation frequency of haplotype		Statistical test			Likelihood Ratio	omnibus test
sample sizes cases vs controls	cases(%)	controls(%)	difference (%)	Odds ratio	Pvalue (1000 permurt)	Likelihood Ratio Test
				pvalue(1df)	Pvalue (1000 permurt)	Pvalue (3 df)
						Pvalue (1000 permurt)

HAPLOTYPE 1											
cases vs controls	464 vs 300	50.1	44.2	5.9	1.26	2.50E-02	2.1E-02	4.81	1.80E-01	1.80E-01	NS
cases (<65 years) vs controls	177 vs 300	54.5	44.2	10.3	1.51	2.10E-03	3.1E-03	4.62	3.40E-02	4.60E-02	S
cases (>65 years) vs controls	283 vs 300	46.7	44.2	2.5	1.11	3.70E-01	2.1E-01	1.11	7.50E-01	7.60E-01	NS
sporadic cases vs controls	280 vs 300	45.5	44.2	1.3	1.05	6.50E-01	5.1E-01	1.32	7.10E-01	7.40E-01	NS
sporadic cases (<65 years) vs controls	89 vs 300	45.4	44.2	1.2	1.05	7.50E-01	7.1E-01	1.19	7.50E-01	7.30E-01	NS
sporadic cases (>65 years) vs controls	187 vs 300	45.0	44.2	0.8	1.03	7.50E-01	7.1E-01	0.85	8.30E-01	8.40E-01	NS
sporadic informative vs controls	67 vs 300	43.4	44.2	0.8	0.87	7.50E-01	7.1E-01	3.29	3.30E-01	3.30E-01	NS
familial cases vs controls	184 vs 300	57.1	44.2	12.9	1.63	9.70E-05	<1.0E-03	14.30	2.40E-03	4.00E-03	S
familial cases (<65 years) vs controls	88 vs 300	64.4	44.2	20.2	2.23	2.50E-06	<1.0E-03	21.42	8.30E-05	1.00E-03	S
familial cases (>65 years) vs controls	96 vs 300	60.1	44.2	5.9	1.26	1.50E-01	9.1E-02	2.04	5.50E-01	5.50E-01	NS
familial cases (>3cap) vs controls	83 vs 300	58.6	44.2	14.4	1.79	1.90E-04	1.1E-03	10.89	1.20E-02	1.00E-02	S

Figure 12A

Figure 13A

1 2 3 4 5 6 7 8 9 10 11 12 13



Figure 13B

1 2 3 4 5 6 7



Figure 13C

1 2 3 4 5 6 7 8 9 10 11 12 13



Figure 13D

1 2 3 4 5 6 7 8 9 10 11 12 13



Figure 13E

1 2 3 4 5 6 7 8 9 10 11 12 13







FIGURE 14

**FIGURE 15**




FIGURE 16




FIGURE 17

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Barry, et al
Appl. No. : To be assigned
Filed : Herewith
For : A Novel BAP28 Gene and Protein



SEQUENCE SUBMISSION STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

A copy of the Sequence Listing in computer readable form as required by 37 C.F.R. § 1.821(e) is submitted herewith.

As required by 37 C.F.R. § 1.821(f), the data on the enclosed disk is identical to the Sequence Listing in the application filed herewith.

Respectfully submitted,

Dated: 6/22/00

By: Tia de Langen

Tia de Langen
Legal Assistant
Genset Corporation
875 Prospect Street
Suite #206
La Jolla, CA 92037
(858) 551-3000

SEQUENCE LISTING

<110> Barry, Caroline
 Bougueleret, Lydie
 Chumakov, Ilya
 Cohen-Akenine, Annick

 <120> A NOVEL BAP28 GENE AND PROTEIN

 <130> GENSET.063AUS

 <141> 2000-06-23

 <150> US 60/141,323
 <151> 1999-06-25

 <150> US 60/176,880
 <151> 2000-01-18

 <160> 63

 <170> Patent.pm

 <210> 1
 <211> 97662
 <212> DNA
 <213> Homo sapiens

 <220>
 <221> misc_feature
 <222> 2996..4996
 <223> 5'regulatory region BAP28

 <220>
 <221> exon
 <222> 4997..5076
 <223> exon 01 BAP28

 <220>
 <221> exon
 <222> 5371..5544
 <223> exon 02 BAP28

 <220>
 <221> exon
 <222> 6121..6337
 <223> exon 03 BAP28

 <220>
 <221> exon
 <222> 9877..10018
 <223> exon 04 BAP28

 <220>
 <221> exon
 <222> 11522..11623
 <223> exon 05 BAP28

 <220>
 <221> exon

<222> 12521..12661
<223> exon 06 BAP28

<220>
<221> exon
<222> 13453..13664
<223> exon 07 BAP28

<220>
<221> exon
<222> 13824..13957
<223> exon 08 BAP28

<220>
<221> exon
<222> 15376..15478
<223> exon 09 BAP28

<220>
<221> exon
<222> 16855..16965
<223> exon 10 BAP28

<220>
<221> exon
<222> 17378..17495
<223> exon 11 BAP28

<220>
<221> exon
<222> 18535..18642
<223> exon 12 BAP28

<220>
<221> exon
<222> 21446..21541
<223> exon 13 BAP28

<220>
<221> exon
<222> 21999..22087
<223> exon 14 BAP28

<220>
<221> exon
<222> 23036..23247
<223> exon 15 BAP28

<220>
<221> exon
<222> 23546..23667
<223> exon 16 BAP28

<220>
<221> exon
<222> 24270..24461
<223> exon 17 BAP28

<220>
<221> exon
<222> 26287..26470
<223> exon 18 BAP28

<220>
<221> exon
<222> 26611..26747
<223> exon 19 BAP28

<220>
<221> exon
<222> 28068..28260
<223> exon 20 BAP28

<220>
<221> exon
<222> 32540..32709
<223> exon 21 BAP28

<220>
<221> exon
<222> 33112..33270
<223> exon 22 BAP28

<220>
<221> exon
<222> 34586..34828
<223> exon 23 BAP28

<220>
<221> exon
<222> 35156..35287
<223> exon 24 BAP28

<220>
<221> exon
<222> 36660..36763
<223> exon 25 BAP28

<220>
<221> exon
<222> 36934..37077
<223> exon 26 BAP28

<220>
<221> exon
<222> 37803..37921
<223> exon 27 BAP28

<220>
<221> exon
<222> 38017..38138
<223> exon 28 BAP28

<220>
<221> exon
<222> 40365..40493
<223> exon 29 BAP28

<220>
<221> exon
<222> 42618..42848
<223> exon 30 BAP28

<220>

```

<221> exon
<222> 43452..43578
<223> exon 31 BAP28

<220>
<221> exon
<222> 44836..44999
<223> exon 32 BAP28

<220>
<221> exon
<222> 48223..48269
<223> exon 33 BAP28

<220>
<221> exon
<222> 49656..49779
<223> exon 34 BAP28

<220>
<221> exon
<222> 50358..50498
<223> exon 35 BAP28

<220>
<221> exon
<222> 50964..51256
<223> exon 36 BAP28

<220>
<221> exon
<222> 52148..52298
<223> exon 37 BAP28

<220>
<221> exon
<222> 53235..53393
<223> exon 38 BAP28

<220>
<221> exon
<222> 53554..53688
<223> exon 39 BAP28

<220>
<221> exon
<222> 53838..53942
<223> exon 40 BAP28

<220>
<221> exon
<222> 54029..54197
<223> exon 41 BAP28

<220>
<221> exon
<222> 54741..54895
<223> exon 42 BAP28

<220>
<221> exon
<222> 55754..55912

```

```

<223> exon 43 BAP28

<220>
<221> exon
<222> 57386..57494
<223> exon 44 BAP28

<220>
<221> exon
<222> 58504..58827
<223> exon 45 BAP28

<220>
<221> exon
<222> 58504..59354
<223> exon 45b BAP28

<220>
<221> exon
<222> 85947..86168
<223> exon B' BAP28

<220>
<221> exon
<222> 91229..91851
<223> exon A' BAP28

<220>
<221> misc_feature
<222> 91852..97662
<223> 3'regulatory region BAP28

<220>
<221> misc_feature
<222> 55071..57071
<223> 3'regulatory region PCTA

<220>
<221> exon
<222> 57072..58406
<223> exon 9ter PCTA complement

<220>
<221> exon
<222> 57072..61478
<223> exon 9 PCTA complement

<220>
<221> exon
<222> 61344..61478
<223> exon 9bis PCTA complement

<220>
<221> exon
<222> 64578..64743
<223> exon 8 PCTA complement

<220>
<221> exon
<222> 65844..65932
<223> exon 7 PCTA complement

```

<220>		
<221>	exon	
<222>	66452..66577	
<223>	exon 6b PCTA	complement
<220>		
<221>	exon	
<222>	66705..66731	
<223>	exon 6 PCTA	complement
<220>		
<221>	exon	
<222>	67782..67838	
<223>	exon 5 PCTA	complement
<220>		
<221>	exon	
<222>	68810..68929	
<223>	exon 4 PCTA	complement
<220>		
<221>	exon	
<222>	70404..70614	
<223>	exon 3 PCTA	complement
<220>		
<221>	exon	
<222>	71931..72019	
<223>	exon 2 PCTA	complement
<220>		
<221>	exon	
<222>	83433..83580	
<223>	exon 1 PCTA	complement
<220>		
<221>	exon	
<222>	85486..85577	
<223>	exon 0 PCTA	complement
<220>		
<221>	exon	
<222>	85923..86108	
<223>	exon B PCTA	complement
<220>		
<221>	exon	
<222>	91043..91119	
<223>	exon D PCTA	complement
<220>		
<221>	exon	
<222>	91259..91325	
<223>	exon A PCTA	complement
<220>		
<221>	exon	
<222>	92449..92662	
<223>	exon C PCTA	complement
<220>		
<221>	misc_feature	

<222> 92663..94662
 <223> 5'regulatory region PCTA

 <220>
 <221> allele
 <222> 4972
 <223> 5-381-133 : polymorphic base A or G

 <220>
 <221> allele
 <222> 5468
 <223> 5-382-162 : polymorphic base C or T

 <220>
 <221> allele
 <222> 5616
 <223> 5-382-310 : polymorphic base C or T

 <220>
 <221> allele
 <222> 5622
 <223> 5-382-316 : polymorphic base G or C

 <220>
 <221> allele
 <222> 13158
 <223> 99-7190-213 : polymorphic base C or T

 <220>
 <221> allele
 <222> 23761
 <223> 99-7203-282 : polymorphic base A or T

 <220>
 <221> allele
 <222> 23765
 <223> 99-7203-286 : polymorphic base C or T

 <220>
 <221> allele
 <222> 27928
 <223> 5-383-42 : polymorphic base A or G

 <220>
 <221> allele
 <222> 28070
 <223> 5-383-184 : polymorphic base G or T

 <220>
 <221> allele
 <222> 30061
 <223> 99-7205-228 : polymorphic base A or G

 <220>
 <221> allele
 <222> 32750
 <223> 5-384-312 : polymorphic base G or C

 <220>
 <221> allele
 <222> 48189
 <223> 5-379-80 : polymorphic base A or C

<220>
 <221> allele
 <222> 49615
 <223> 5-380-58 : polymorphic base G or T

<220>
 <221> allele
 <222> 49616
 <223> 5-380-59 : polymorphic base C or T

<220>
 <221> allele
 <222> 50304
 <223> 5-366-143 : polymorphic base A or G

<220>
 <221> allele
 <222> 51133
 <223> 5-370-197 : polymorphic base A or G

<220>
 <221> allele
 <222> 51183
 <223> 5-370-247 : polymorphic base C or T

<220>
 <221> allele
 <222> 53534
 <223> 5-373-98 : polymorphic base C or T

<220>
 <221> allele
 <222> 53600
 <223> 5-373-164 : polymorphic base C or T

<220>
 <221> allele
 <222> 53658
 <223> 5-373-222 : polymorphic base A or G

<220>
 <221> allele
 <222> 54173
 <223> 5-375-200 : polymorphic base A or G

<220>
 <221> allele
 <222> 54232
 <223> 5-375-259 : polymorphic base C or T

<220>
 <221> allele
 <222> 54269
 <223> 5-375-296 : polymorphic base G or C

<220>
 <221> allele
 <222> 54372
 <223> 5-375-399 : polymorphic base G or C

<220>

<221> allele
 <222> 54867
 <223> 5-376-266 : polymorphic base A or G

 <220>
 <221> allele
 <222> 55689
 <223> 5-377-82 : polymorphic base C or T

 <220>
 <221> allele
 <222> 55834
 <223> 5-377-227 : polymorphic base A or G

 <220>
 <221> allele
 <222> 59937
 <223> 5-14-165 : polymorphic base A or G

 <220>
 <221> allele
 <222> 60980
 <223> 5-11-158 : polymorphic base C or T

 <220>
 <221> allele
 <222> 66492
 <223> 5-202-117 : polymorphic base A or T

 <220>
 <221> allele
 <222> 66514
 <223> 5-202-95 : polymorphic base A or C

 <220>
 <221> allele
 <222> 71834
 <223> 99-1605-112 : polymorphic base A or G

 <220>
 <221> allele
 <222> 71993
 <223> 5-2-178 : polymorphic base A or G

 <220>
 <221> allele
 <222> 85702
 <223> 5-171-204 : polymorphic base A or G

 <220>
 <221> allele
 <222> 86504
 <223> 5-169-97 : polymorphic base G or C

 <220>
 <221> allele
 <222> 87135
 <223> 99-1572-440 : polymorphic base A or G

 <220>
 <221> allele
 <222> 91093

<223> 5-403-325 : polymorphic base C or T
 <220>
 <221> allele
 <222> 91124
 <223> 5-403-294 : polymorphic base A or G
 <220>
 <221> allele
 <222> 91209
 <223> 5-403-209 : polymorphic base C or T
 <220>
 <221> allele
 <222> 91262
 <223> 5-403-156 : polymorphic base C or T
 <220>
 <221> primer_bind
 <222> 4840..4859
 <223> 5-381.pu
 <220>
 <221> primer_bind
 <222> 5249..5266
 <223> 5-381.rp complement
 <220>
 <221> primer_bind
 <222> 5307..5324
 <223> 5-382.pu
 <220>
 <221> primer_bind
 <222> 5710..5729
 <223> 5-382.rp complement
 <220>
 <221> primer_bind
 <222> 12946..12963
 <223> 99-7190.pu
 <220>
 <221> primer_bind
 <222> 13471..13488
 <223> 99-7190.rp complement
 <220>
 <221> primer_bind
 <222> 23482..23501
 <223> 99-7203.pu
 <220>
 <221> primer_bind
 <222> 23909..23929
 <223> 99-7203.rp complement
 <220>
 <221> primer_bind
 <222> 27887..27904
 <223> 5-383.pu

```

<220>
<221> primer_bind
<222> 28296..28315
<223> 5-383.rp complement

<220>
<221> primer_bind
<222> 29833..29853
<223> 99-7205.rp

<220>
<221> primer_bind
<222> 30270..30288
<223> 99-7205.pu complement

<220>
<221> primer_bind
<222> 32439..32457
<223> 5-384.pu

<220>
<221> primer_bind
<222> 32858..32877
<223> 5-384.rp complement

<220>
<221> primer_bind
<222> 48110..48127
<223> 5-379.pu

<220>
<221> primer_bind
<222> 48441..48460
<223> 5-379.rp complement

<220>
<221> primer_bind
<222> 49558..49577
<223> 5-380.pu

<220>
<221> primer_bind
<222> 49958..49977
<223> 5-380.rp complement

<220>
<221> primer_bind
<222> 50162..50180
<223> 5-366.pu

<220>
<221> primer_bind
<222> 50564..50583
<223> 5-366.rp complement

<220>
<221> primer_bind
<222> 50937..50955
<223> 5-370.pu

<220>
<221> primer_bind

```

```
<222> 51341..51359
<223> 5-370.rp complement

<220>
<221> primer_bind
<222> 53437..53455
<223> 5-373.pu

<220>
<221> primer_bind
<222> 53840..53858
<223> 5-373.rp complement

<220>
<221> primer_bind
<222> 53974..53993
<223> 5-375.pu

<220>
<221> primer_bind
<222> 54375..54394
<223> 5-375.rp complement

<220>
<221> primer_bind
<222> 54602..54619
<223> 5-376.pu

<220>
<221> primer_bind
<222> 55002..55021
<223> 5-376.rp complement

<220>
<221> primer_bind
<222> 55608..55625
<223> 5-377.pu

<220>
<221> primer_bind
<222> 56025..56043
<223> 5-377.rp complement

<220>
<221> primer_bind
<222> 59673..59692
<223> 5-14.rp

<220>
<221> primer_bind
<222> 60083..60100
<223> 5-14.pu complement

<220>
<221> primer_bind
<222> 60718..60737
<223> 5-11.rp

<220>
<221> primer_bind
<222> 61119..61137
<223> 5-11.pu complement
```



```

<221> primer_bind
<222> 91068..91085
<223> 5-403.rp

<220>
<221> primer_bind
<222> 91398..91417
<223> 5-403.pu complement

<220>
<221> primer_bind
<222> 4953..4971
<223> 5-381-133.mis

<220>
<221> primer_bind
<222> 4973..4991
<223> 5-381-133.mis complement

<220>
<221> primer_bind
<222> 5449..5467
<223> 5-382-162.mis

<220>
<221> primer_bind
<222> 5469..5487
<223> 5-382-162.mis complement

<220>
<221> primer_bind
<222> 5597..5615
<223> 5-382-310.mis

<220>
<221> primer_bind
<222> 5603..5621
<223> 5-382-316.mis

<220>
<221> primer_bind
<222> 5617..5635
<223> 5-382-310.mis complement

<220>
<221> primer_bind
<222> 5623..5641
<223> 5-382-316.mis complement

<220>
<221> primer_bind
<222> 13139..13157
<223> 99-7190-213.mis

<220>
<221> primer_bind
<222> 13159..13177
<223> 99-7190-213.mis complement

<220>
<221> primer_bind
<222> 23742..23760

```

050696

<221> primer bind

<223> 99-7203-286.mis

<221> primer bind

<223> 99-7203-282.mis complement

<221> primer bind

<223> 99-7203-286.mis complement

<221> primer bind

<223> 5-383-42.mis

<221> primer bind

<223> 5-383-42.mis complement

<221> primer bind

<223> 5-383-184.mis

<221> primer bind

<223> 5-383-184.mis complement

<221> primer bind

<223> 99-7205-228.mis

<221> primer bind

<223> 99-7205-228.mis complement

<221> primer bind

<223> 5-384-312.mis

<221> primer bind

<223> 5-384-312.mis complement

<221> primer bind

<223> 5-379-80.mis

```

<220>
<221> primer_bind
<222> 48190..48208
<223> 5-379-80.mis complement

<220>
<221> primer_bind
<222> 49596..49614
<223> 5-380-58.mis

<220>
<221> primer_bind
<222> 49597..49615
<223> 5-380-59.mis

<220>
<221> primer_bind
<222> 49616..49634
<223> 5-380-58.mis complement

<220>
<221> primer_bind
<222> 49617..49635
<223> 5-380-59.mis complement

<220>
<221> primer_bind
<222> 50285..50303
<223> 5-366-143.mis

<220>
<221> primer_bind
<222> 50305..50323
<223> 5-366-143.mis complement

<220>
<221> primer_bind
<222> 51114..51132
<223> 5-370-197.mis

<220>
<221> primer_bind
<222> 51134..51152
<223> 5-370-197.mis complement

<220>
<221> primer_bind
<222> 51164..51182
<223> 5-370-247.mis

<220>
<221> primer_bind
<222> 51184..51202
<223> 5-370-247.mis complement

<220>
<221> primer_bind
<222> 53515..53533
<223> 5-373-98.mis

<220>
<221> primer_bind

```

```

<222> 53535..53553
<223> 5-373-98.mis complement

<220>
<221> primer_bind
<222> 53581..53599
<223> 5-373-164.mis

<220>
<221> primer_bind
<222> 53601..53619
<223> 5-373-164.mis complement

<220>
<221> primer_bind
<222> 53639..53657
<223> 5-373-222.mis

<220>
<221> primer_bind
<222> 53659..53677
<223> 5-373-222.mis complement

<220>
<221> primer_bind
<222> 54154..54172
<223> 5-375-200.mis

<220>
<221> primer_bind
<222> 54174..54192
<223> 5-375-200.mis complement

<220>
<221> primer_bind
<222> 54213..54231
<223> 5-375-259.mis

<220>
<221> primer_bind
<222> 54233..54251
<223> 5-375-259.mis complement

<220>
<221> primer_bind
<222> 54250..54268
<223> 5-375-296.mis

<220>
<221> primer_bind
<222> 54270..54288
<223> 5-375-296.mis complement

<220>
<221> primer_bind
<222> 54353..54371
<223> 5-375-399.mis

<220>
<221> primer_bind
<222> 54373..54391
<223> 5-375-399.mis complement

```



```

<220>
<221> primer_bind
<222> 54848..54866
<223> 5-376-266.mis

<220>
<221> primer_bind
<222> 54868..54886
<223> 5-376-266.mis complement

<220>
<221> primer_bind
<222> 55670..55688
<223> 5-377-82.mis

<220>
<221> primer_bind
<222> 55690..55708
<223> 5-377-82.mis complement

<220>
<221> primer_bind
<222> 55815..55833
<223> 5-377-227.mis

<220>
<221> primer_bind
<222> 55835..55853
<223> 5-377-227.mis complement

<220>
<221> primer_bind
<222> 59918..59936
<223> 5-14-165.mis

<220>
<221> primer_bind
<222> 59938..59956
<223> 5-14-165.mis complement

<220>
<221> primer_bind
<222> 60961..60979
<223> 5-11-158.mis

<220>
<221> primer_bind
<222> 60981..60999
<223> 5-11-158.mis complement

<220>
<221> primer_bind
<222> 66473..66491
<223> 5-202-117.mis

<220>
<221> primer_bind
<222> 66493..66511
<223> 5-202-117.mis complement

<220>

```

```

<221> primer_bind
<222> 66495..66513
<223> 5-202-95.mis

<220>
<221> primer_bind
<222> 66515..66533
<223> 5-202-95.mis complement

<220>
<221> primer_bind
<222> 71815..71833
<223> 99-1605-112.mis

<220>
<221> primer_bind
<222> 71835..71853
<223> 99-1605-112.mis complement

<220>
<221> primer_bind
<222> 71974..71992
<223> 5-2-178.mis

<220>
<221> primer_bind
<222> 71994..72012
<223> 5-2-178.mis complement

<220>
<221> primer_bind
<222> 85683..85701
<223> 5-171-204.mis

<220>
<221> primer_bind
<222> 85703..85721
<223> 5-171-204.mis complement

<220>
<221> primer_bind
<222> 86485..86503
<223> 5-169-97.mis

<220>
<221> primer_bind
<222> 86505..86523
<223> 5-169-97.mis complement

<220>
<221> primer_bind
<222> 87116..87134
<223> 99-1572-440.mis

<220>
<221> primer_bind
<222> 87136..87154
<223> 99-1572-440.mis complement

<220>
<221> primer_bind
<222> 91074..91092

```


<220>
<221> misc_binding
<222> 23749..23773
<223> 99-7203-282.probe

<220>
<221> misc_binding
<222> 23753..23777
<223> 99-7203-286.probe

<220>
<221> misc_binding
<222> 27916..27940
<223> 5-383-42.probe

<220>
<221> misc_binding
<222> 28058..28082
<223> 5-383-184.probe

<220>
<221> misc_binding
<222> 30049..30073
<223> 99-7205-228.probe

<220>
<221> misc_binding
<222> 32738..32762
<223> 5-384-312.probe

<220>
<221> misc_binding
<222> 48177..48201
<223> 5-379-80.probe

<220>
<221> misc_binding
<222> 49603..49627
<223> 5-380-58.probe

<220>
<221> misc_binding
<222> 49604..49628
<223> 5-380-59.probe

<220>
<221> misc_binding
<222> 50292..50316
<223> 5-366-143.probe

<220>
<221> misc_binding
<222> 51121..51145
<223> 5-370-197.probe

<220>
<221> misc_binding
<222> 51171..51195
<223> 5-370-247.probe

<220>
<221> misc_binding

```
<222> 53522..53546
<223> 5-373-98.probe

<220>
<221> misc_binding
<222> 53588..53612
<223> 5-373-164.probe

<220>
<221> misc_binding
<222> 53646..53670
<223> 5-373-222.probe

<220>
<221> misc_binding
<222> 54161..54185
<223> 5-375-200.probe

<220>
<221> misc_binding
<222> 54220..54244
<223> 5-375-259.probe

<220>
<221> misc_binding
<222> 54257..54281
<223> 5-375-296.probe

<220>
<221> misc_binding
<222> 54360..54384
<223> 5-375-399.probe

<220>
<221> misc_binding
<222> 54855..54879
<223> 5-376-266.probe

<220>
<221> misc_binding
<222> 55677..55701
<223> 5-377-82.probe

<220>
<221> misc_binding
<222> 55822..55846
<223> 5-377-227.probe

<220>
<221> misc_binding
<222> 59925..59949
<223> 5-14-165.probe

<220>
<221> misc_binding
<222> 60968..60992
<223> 5-11-158.probe

<220>
<221> misc_binding
<222> 66480..66504
<223> 5-202-117.probe
```

0960-894X(200705)27:5;1-B

0960-894X(200705)27:5;1-B

0960-894X(200705)27:5;1-B

0960-894X(200705)27:5;1-B

0960-894X(200705)27:5;1-B

[illegible][illegible][illegible]

0960-894X(200705)27:5;1-B

0960-894X(200705)27:5;1-B

0960-894X(200705)27:5;1-B

ggctcaaatg	atcctccagc	gctcaactga	tctcccaatt	ttcagcctcc	caggggcgtgc	660
taccatgccc	ggctaatttt	tgtgtctcatt	gcagaggtgg	agtttccccc	tggtgtctcag	720
actgggtctg	aattcctggg	ctcaagcgat	atgccagcct	tggtcctctca	accttgctgg	780
gtttacaagc	gtgagccact	gagcccgagc	acagatatat	tttcaatgtg	atggtatccc	840
atcagttgtg	atatatgatg	taaacactct	actaataatt	aaactttgaa	gtttgtgaaa	900
attttacttt	tattatagtt	agaataattc	taagtatttc	ctataataat	gctacactta	960
ttcacttgaa	ttctgataca	cattttctga	acaggaagga	gatacagata	cagcttatgc	1020
accatttatat	tcatttcattc	attcgataaa	taaatatgta	ttgttaacca	cggtccaggt	1080
actttttatg	gtagtttagga	tttagtagta	aaacagagaa	agttcttaac	atcatcctta	1140
gatcgtgttg	ttgtcatatc	acaaatcata	caaaataaat	ttgtttaaaa	attgtgggaac	1200
ctgcctttca	aaacctgcca	tttagcacta	ctgtggcata	acctataaac	ctaaacatag	1260
acctcattga	tttatgcatt	taagttttgt	ggaataaggt	ctcttgtccc	ttgtcctgaa	1320
agtaaaagac	aacctgtctc	gaatacactg	aatatcctgt	gattgtactg	ttcccgagc	1380
ctgcctaaga	gcataaggag	aattttgttt	ttgtttgttt	ttttgtttcg	ttttattttt	1440
gagacggagt	ttcgctcttt	ttgccaggc	ttgagtgcaa	acggcgcgat	ctcggtccac	1500
tgcaacctct	acctcccggt	tcaagagatt	ctcctgcctc	agcctcccta	gtagctggga	1560
ttacagcgct	gcgccaccac	gcccgcccaa	ttttttttta	gtagagctag	gattagttat	1620
attagtagtag	atggggtttc	accatgttgg	ccaggctggg	ctcaaacctc	tgacctcagg	1680
tgagccgcc	ctccagcgtc	ccaaagtgtc	gggtttacag	catgagccac	gcactctggc	1740
cgggaccgga	ccaggatgct	gaatacagaa	atgcttaggt	aagagaaaag	aaaagttaat	1800
ttgtcacact	tttctcttca	aactacatga	acataatttt	gcattataaa	gtattatate	1860
tgaatagttc	caaacactga	attcttattt	tctttttttt	ccccccataa	tattgtctgt	1920
gataatactca	ggaatttagt	tagaattctc	aaacatcaga	tatggtgtct	gaggacattt	1980
taacaattat	aaacaattca	catgactctg	aaatttgaaa	ataggtatga	acagacataa	2040
catgaacaaa	gggtgatacc	aattctttac	actggcaact	aggtggacat	gtaatgatac	2100
ctgttggagt	aatttctatt	aatgaacaat	ttcatttagt	aatattttac	aaaaaaacaa	2160
atacaacttt	agattttatt	aaattatttt	acttaaaatt	ttgtcactaa	ttaaaccccc	2220
ttctctactaa	aaatacaaaa	attagctggg	tgtgttgcca	ggcactgtta	attccagcta	2280
cttgagaagc	tgaggcagag	gattgtctga	acctggggag	cggaggtgtc	agtgagctga	2340
gatcacgcga	ccacactcga	gcctggggcg	cacagacaaga	ctccactcca	aaacaaaaaa	2400
aaaattattg	cactaatttt	actttacatc	tttaagaaga	ggtaaatctt	ttgaaaaaag	2460
tgaaaaagat	ttaatgtatt	gctttttta	tttaattata	ttttttatga	aacattccaa	2520
ctatatgttt	tgaatatatt	taaaatttat	ttttaactct	ttttgatcat	tattcttgat	2580
agaacacaa	tacatgaaaa	tcttgatcaa	acagcatata	tggttaattt	gctgaaatga	2640
aggtgaaatt	tcatgggtct	aatatatagg	aaatgtatta	actatagatg	ttctttatcc	2700
tcatccaaaa	taatcagcca	atcaatagga	caccgggaca	ggaatgatatt	aataaaatgc	2760
aatcagattt	tgctgatttt	catctatgta	aaaaacattt	tattttgcca	ttataaatgt	2820
ttactcacc	atatttgagc	ttatagcata	tcttagttta	taattgtgta	agtttaattt	2880
taacttttt	aattttacag	ctacagcagt	gagtcactct	gtactctttc	tcaggctcca	2940
taagtcttag	ggatgggctt	tatgcacaag	tgctgaagcc	aatatttatg	tgagggaata	3000
caagaataaa	acagggtaaa	aaacagacaa	atcagggtcat	ttcaagtagt	gataattggc	3060
atgaagaaaa	taccagctgt	gtacatctgt	ccgtcagata	aaaataataa	attcaagatt	3120
attacatttt	tttttaaaac	aaagcttttt	ttaaaaaaaa	aattcacattt	atgaacattc	3180
gacttgtttt	cttttttact	ttccaaagta	aaattcgcca	ttgcatcata	accacacata	3240
gctgacatag	gaaggcctga	gtcaaatctt	ttgtagcatt	tttcaagttt	ctcttaataa	3300
aagcttttt	aaaaatatata	gggtattttt	taagcaaaaa	aagcaaaatt	tacataagga	3360
gaacacagac	tggtgttcat	ttctttttaa	gtaccgaaag	ctgattgtct	ctgtaaaagt	3420
aaaactctgt	tgacatgtta	gaaagaaaaa	aaaaattcct	ttgagagata	ttgttgtaag	3480
aatgaaatag	gtactactag	aattttcatg	ttattctctg	caaggcactc	aacaccacat	3540
gtaaaagaaga	tatttaacag	tcagtagaaa	tactaataac	tgaagaaaaa	atttggttgt	3600
tttaaatgct	tttaaaagcaa	accaacaaca	aaagattctg	tttgtaaatg	ggagagaatc	3660
tgcatgaggt	atagacaaac	agggccctcca	aatttgttagc	ttgtgtttct	acattctcca	3720
gggaagacgg	ttacagaaga	acttgacccc	ctggccccc	agagctcttc	agagaataat	3780
ttgcattccag	aaagacagaa	gcatacagtc	tcatcctctc	gtctgggaag	ctgcagtgtca	3840
ctctagttct	agccgcatacc	gggtttttgg	aaacagatga	gctatatatca	tacataagga	3900
tactcttccg	caacactatc	tgtagtgagg	ccaagaccag	tggttgccgg	aatctttcgca	3960
aacaggcga	agacaatttt	tagggcgcga	gaaacactgt	attttgactg	ggggaggtcat	4020
tacacctata	catgcattct	ctaaaagtca	tcaaacctct	ccactgcagc	gggtgtaacc	4080
attgttttga	aattataacct	caacaggatt	cgattaaatt	atttatgttg	acagctctgc	4140
tctgtggagt	gcagtggtgc	aatcttggcc	cactgcaacc	ttccagctcc	gggttcacag	4200
gattcttctt	tctcagcttt	cctagtagtc	gggattacag	gcgccgcgca	ccagctccgg	4260
taattttctt	taatttttagt	agagacgggg	tttctgatag	ttggccaggc	tggtcccgaa	4320

gcttgccag	catggtaata	cctgtctgtg	tgaataatc	aaaaattagc	tgggtgcagt	8100
ggcgagcact	tgtatattcta	gctactctggg	aggctgaggg	aggagaaattg	cttgaattcca	8160
ggagacagat	tttgcagtgta	gctgagatgca	gcgccactgca	ctccagccgtg	ggtaacagggg	8220
agacgcgcgt	tcaaaaaaaa	aaacacaaaa	atgggagacgt	ggggataaac	taattttttt	8280
tcaagaagca	agtgagtcac	caagaaaaaca	tgaatttaac	tgggtgtctc	tgattgtcag	8340
aacattaggg	caatcagaca	agaattattt	aaaaagtctgt	aaatttttcca	cttgttttct	8400
agcacctaac	tttaccacca	aatagatcat	taattgtaagg	aatacttttt	gcatttgtatt	8460
tttctatttta	tgtctctcaga	taactttatt	attcagcaaa	tactaagtctc	agtaacataga	8520
taagtgtattt	gccgtgtgatt	actgtttttga	aataaaatgcc	ataataaaagg	attaaagcaga	8580
gtttttgtgga	tatagttctcg	cctggaaatag	tgaagaaaag	cttcacgtgaa	aaagttaacct	8640
ctaaaaacgt	atgtcaaacct	aagaggctgg	gttcagtgcc	tcacgcctgt	aatcccagca	8700
cttttgagagg	ctgaggcagg	ccagtcactt	gagatcagga	gtttgagacg	agcctgacca	8760
acatggtgaa	tcctctgtctc	tactagaaat	acaaaaaaa	attagctggg	tgtggtgctg	8820
gtcacctgta	attccagcta	cttgggaggc	tagggcatga	gaatcgcttg	aacttggggg	8880
gcgaaggttg	tcctctgtctc	agatcacacc	actgcactcc	agcctgggtg	accaagttaga	8940
ctctggaaaa	aaaaaaaaaa	ctaataaaag	gcaatgtatg	gtactgttta	aaaaaagtag	9000
ccgatttaggg	aggaatggag	agttttcaca	gaagagggag	caagttggcag	taattgaaaa	9060
aaacattctag	ccaggcatgg	tggctcacac	ctgtagtcct	agcaacttgg	gaggctgagg	9120
caggtagattg	gcctgagctc	aggagttgga	gaccagcctg	ggcaacccca	agtaacccca	9180
tctctactaa	agtaaaaaaa	aaaaatttag	tgggcatgtg	ggtagcggtt	tgtagtccca	9240
gctacttggg	agggcgaggc	aggagaactt	tttaacttgg	gaggtggagg	tgcagtgag	9300
ccgagattgt	gccactgcac	tcacgcctgg	gcaacagcaa	gactccctct	caaaaaaaa	9360
aaaaaaaaaa	aaaaaaaaaa	aattgtgaca	gaccagcctg	ggcaacacag	ggagacctag	9420
ctctcacaca	gaataaaaaa	attagccagc	tgtgatgttg	ctccctgtgtg	gtccagccta	9480
ctcaggagac	ctaggtggga	ggatcatttg	agcctgggag	gttgaggctg	cagtgaccgg	9540
tgatctgtcc	actgcactcc	agcctcagtg	gcagagcaag	actctattca	aaaaatttaa	9600
taaaaattgt	aaagctgaga	gaaggttaat	gggatgtata	ttttgatgta	gaattgtcaa	9660
agatatgcca	taggaatttg	ctggaccact	ttgaggggat	tgtgaatgca	aaatctggga	9720
cttttttaatt	gctctgtatc	ttataatttt	gtgattttta	ctgtactctg	ttttaggttg	9780
tttttagctta	ttataataat	agtttgggga	gttgaggaaa	taggtgtcta	ttattagttt	9840
tgtgtttcag	tgtgaactgt	tgtctttttt	ccccagggtc	catatacatc	tctataatca	9900
agatagcctc	attgtctgtg	ttctgccata	ccacagagca	agaattattg	tcgcagtcac	9960
acagctttcta	aaaatttaata	attcaaaagca	cagatgggtc	tgtgtgtgtc	gacttagaagg	10020
ataattgtctg	aatgacatatt	gtctgtaatc	attacagatc	ttgattaaagg	gattttaata	10080
ggaaaaataa	agtcatttgt	cctgggggata	gtccagataa	ctacctccat	catttttatt	10140
tctctgacttc	caattgaaac	tattattaat	gttaataaat	tttagctttt	atttagtatt	10200
tgacatcagg	ctaggcaatt	tacattatat	tattcttgga	tatcacaaaa	cttacttttt	10260
acagatagtg	acaggctact	tgccaaaagt	cacataacta	taaaagtggc	gagtttgagat	10320
ttgaaccccaa	attctgatttc	agagtcctgt	cctttgtatc	gtacctgcc	gtttggcatt	10380
ttaaaatttgg	aactgagaac	ttaaaaaaaa	gttgaagggt	aagaaaaggc	gaaaataact	10440
acaaaaataa	aaaggataag	gataacttta	gggggtttca	gaattttacta	aagttgtgag	10500
gaagatgcta	ggagtttaatt	tacagactaa	gaaaaggagt	cttgtgtaac	aggaagggtc	10560
tgggttaagaa	aagacagcat	gctattgtag	gaaaaccaac	tgactaacctg	ttagcacttt	10620
ttgtgtcaaca	tgtgtgtggag	gaaagtagat	gtattgttgt	agcaggaact	tgactgcagt	10680
ttgggcatgg	tctccagggg	taggggggga	ggcaaatggg	gatgaaggta	agctaacaga	10740
tcacagagct	gtgcacatta	ggcgtgatgt	ggtagtgggg	tcagttgttca	gaattagttaa	10800
gatagagagta	atgaggacttt	tttaattaga	aggagaattt	aagaattctga	acgttaagca	10860
cttgaacttaa	agaacgttgg	atgaggccag	cctttgataa	agctcattaa	ctgctcttcc	10920
caacattcaac	tctgcccata	gcatcaaaat	tattcttctc	ctaactctac	ctggattctg	10980
tgctctcccta	ggcactctcta	ttccaggtag	ccaaactcca	ctcacactact	aaagttcact	11040
taaaaattctc	ctttcatttta	tttaactcagt	atttatggag	catctattac	ataccatgta	11100
caacgctaga	tgggtgggaat	agtggtataa	gttggtgcagt	ttcttagtct	atttctgttc	11160
ttagtgttat	tgtaaagcaa	tgacagaagc	gtatcatagt	ggctcagaaa	ccaaatcgaa	11220
ccagttaagt	tactaagaatt	ctagagaatc	cagattttga	taaaactcct	tcaaaattgtg	11280
acatacgata	agcaaacatc	tttcaactaa	tacctctgcc	ctcattgttc	tccttctctt	11340
tgaattttct	aagttttacat	gatttttatg	gttaatttca	tcacacaccac	cagttataag	11400
ggagagattat	atttttttatt	tatgaattgt	agcagataga	agacattact	agggtaaatg	11460
ctttaaataa	aggaatcagtt	gatgaattgt	gctagtagtt	tgtttctttcc	atcaataaca	11520
gcaatctgga	gtgccgttgt	ctaaaggaaac	ttgttactac	cactgtcaca	agaacttggg	11580
attacttgat	attttttgca	gtttggtgac	aaaactctgt	aaggtgagca	gctctgttca	11640
tgtagtataa	ttttttatgaa	agaattgact	gctttgaaat	aagaaaaaat	actaaaacat	11700
tccttaataa	caatgataat	tgtgataaatt	ttattttgtt	aaatggctcg	gtgttttgaa	11760

aagctattat	ttttgacatg	cttttgattt	acatttttgc	gactcagtat	aattttcaag	15540
attgggttaga	aatttccocag	tatttcccttt	taatgtatat	cttgttttgc	ctgtatcatt	15600
tcattaaacta	taagtatctta	atccagtaaac	tgccagcatt	aaaagcaaaa	gtaatttttc	15660
ttgactgtgt	ttagtgtcta	tagatgaaa	tggaaggtta	gtggttaaga	caaatttggg	15720
taataactaa	atgcagctttg	tgccgcgtttg	aagtttttctc	ttagttaaatg	gaccataata	15780
ctgaaataa	cacatcacaa	ttaaaacgca	gtaaatgtca	tttagaataa	tatttgaagg	15840
taagcataga	tgaaggattta	ttcttttaaa	gataaattcag	tctttttttt	tttttttttt	15900
ttttctctta	atggggcaact	cgatacagtg	aaaagatgta	ggcggtgtgg	tcagacatag	15960
gtgtaaattc	tgccgcctacc	acttccaggg	ctatagtaag	ttttggagggt	tagtctggat	16020
gtacgtttgc	cattttgttag	gatcaagaga	gtgcctgtgt	gttgggtgtgc	atattctatg	16080
cccttttgtc	cagagggtttg	gttttgtgaat	taaaaggagag	tatacacagt	tagtaattgt	16140
gagaaacatag	gctctagaat	cagactgggg	cttaaaatgt	gaaacccac	tctgtggcac	16200
agaagggctt	gctctttatt	gctgttctca	tgagcaaat	gggaagactta	gactctgaac	16260
cactctagtt	tcttttctct	tttttttttt	ctttaagatg	gagttttcgt	cttattgccc	16320
aggctggagt	gcagttggcac	aatctcggtc	cactgcaacc	tcgcgcctccc	agggtcaagc	16380
gattctcctg	cctcagcctc	ctgtgtagct	gggattacag	gcattgtgcc	ccatgcccgag	16440
ctaattttgt	atatttgtta	gagacaagtg	ttaccatgt	ttgtcaggct	gactctgaac	16500
ctctgctctc	aggtgtatccg	cccactctcg	ctcccaaaag	tactgggatt	acagggctga	16560
gcacagacca	tttaagatag	caatgtagtc	ttgctgtgtt	gttcagacag	gtctcgaaact	16620
cctgacctta	agcagctctc	ctgcgccggc	ctccgaaagt	gctgggatta	taatgccagt	16680
aggtgtgaac	actcacacagc	gctctagtt	tctttattctg	taaaataggt	atlaaaactat	16740
actttgtata	agctatgacaa	ttagagataa	tattttctaaa	gcatttagaa	taagttaggt	16800
actcaataaa	tatataactct	tatgtatgct	gatatttctg	tttttttttt	acagcctctt	16860
atttgaagag	ttgttttctat	atagtttcaa	ggagaataatg	gatttctaata	aagtgtctctt	16920
gcttaattgaa	caattttcttc	cactcattag	acttttagaa	agcaagtaag	ttatgtgtgt	16980
atgttttatgc	ttcttctctag	tacttctctg	tctataaagg	tattgatcac	aagtcacatc	17040
taataatact	gaatttgtaca	gagactgtcc	tttttaaat	tggttctcaa	gaaggggtga	17100
gtatcggagt	caaaaataatt	tgaataataa	gaggaaatag	tggttgtgtg	ggggctatgg	17160
agagttaaat	ttttttataga	gagactattt	tggttatgga	gtagtcatag	taacacacct	17220
gaccaatgtc	attttggtttt	acctacaaca	tttgttaaaa	tttaagtcac	agttctagta	17280
attttttaaga	tttttatgtct	ttcctttata	tgtgtatggt	gtatgagatt	ataaaattta	17340
tttaagaataa	tgaatttcaat	cttttaattgc	ttccagagata	ccccagacata	ttagatgtgt	17400
tatttagagga	acactttaaag	gaaatttgcag	atctgaaaaaa	acaaagacct	ttccatcagt	17460
ttgttctctc	ttctacaagt	ggaggaaaagt	atcagggtatg	ttgttctcca	aaggaaattat	17520
gacaaatttgg	ggtaactattg	tatgggtatg	tgaagagctc	cagaagacata	tttgcaactt	17580
ttttcccttg	tgtggaataat	tttacagaga	taaccttata	cagtttgctc	agttgcctga	17640
agtcaggctc	tagggcaggga	atagaataat	tgggaagagg	tacaataaac	tgatcataaac	17700
tatgaacgtg	atactttatg	caggaaaagt	attgtttgag	aattttttta	tggttatctc	17760
attaagggaat	catacagagga	cgccctcatg	taggtttcta	gcatctctctg	tctttcatct	17820
aggtctatgc	tttccagttg	accagccaca	gatggctata	tatttagatta	gcaagggggga	17880
gatgggttct	atttcatgat	cacattaaaa	cttgagaatat	tttgtgtgta	ttcaagcccta	17940
aagctttata	ctagagggtta	gacattttaag	caggagttct	tataattagc	cttaaaaaaa	18000
gataaattatg	aagagaaata	tgattgtttt	atatttctct	tccaataata	cttttctttt	18060
tatttggtgt	gcatttccaa	atcttaggtt	tagggataag	actttctttt	tgatctcaatt	18120
gcgttaagtga	actaagttgt	cacgaatttt	agtgctacata	tttgttatat	catgtagatg	18180
agttgcatc	tgctctctgg	aagggtgctaa	aacagggtatt	tatcttaggt	gatttattcag	18240
atacgcatac	aaaaatacaaa	attactttgt	agaattactt	gactaaaatt	aacctacaca	18300
tagacacaag	tatacatgaa	atcataccat	taacataaca	aattttttta	tctattggcaa	18360
ctcatgtgat	gtctcatgaaa	caaagatttt	gcattttttt	gtttgttttc	tgtagttaga	18420
tggttgtttac	tgaataatttg	gggcaatttg	gggtgttttt	ctctgggttt	tattcttgat	18480
catagactgt	tcagatttaag	tgaatacatt	gtgataactat	gttgaaacct	gtagttttta	18540
cgagattctg	atacttcttt	gatgctcagc	ctgaactatc	acttgtctcc	tgtgagaatt	18600
ctggccatga	atcattttgaa	aaagatcatg	aaaacatcaa	aggtttgttt	cagatcgctt	18660
ttttataagg	ttttttttt	ttatgatgag	cagtgtaatt	ctgaataaga	tattgaagtt	18720
accacctaag	tggtgtaata	tacagatgag	ttgaataaac	ctcatgagag	taacctagac	18780
taattatttag	gactgtgtat	gccagtcgtc	ccccattttaa	caataaaccta	ataaacacta	18840
cttttatgtt	ttccacattga	cagttgtttta	tttttagtgt	ttttcaaat	ggaattttga	18900
gatttaattca	ctgtaggttca	ttaatattat	gagaaatttt	ttagttttga	aatttttgtt	18960
tgggccggtc	acagcagctc	atgctcataa	tccagcactc	ctgtgagaag	gactcattga	19020
gcccaaaagt	ttgagaccaa	ctctgggcaac	ataggggagac	ccccctctct	gtcaaaaaagt	19080
tcaaaaaata	aaaaattagc	caagtttggg	ggcacacgct	ttgggtccag	ctacttgaga	19140
ggctgaggta	ggaggaatctc	ttgggtgtga	gaggttgagg	ctgcagcgag	ccatgatcac	19200

aagaagacag	cagggactat	ctgcacttgc	tcatgggctt	gtttgagatg	atgctcaatg	26700
gtgccctcag	tgtctacttc	agagttctga	tgaactcttt	cataaagta	caagcctctt	26760
ccctttcagg	cgctactctc	ctctaaagaa	tgataggctg	gcctgcacat	ccagcactctt	26820
ggggagccga	ggcaggcgga	tcaacttgcg	tccaggagttc	aaatccacat	tggcccaact	26880
agtgaaactc	ctattctcga	taaaatagaa	aaattagcca	ggcatgggtg	tggggccctgt	26940
aatcccgacc	actctgggag	caggagcgag	agaattcgct	tgaaccttgg	aggcagaggtt	27000
tcagatgagc	cgagatcac	ccacgcagct	ccagctgggg	tgaacagatg	agactctgtc	27060
tccaaaaaaa	aagatagcct	ggggcgagta	gtccacgcct	ataatccgag	caacttggga	27120
ggccagagtg	gggtgatcat	gaggtcgatc	gagtcagacc	actctgtgta	acatgggtga	27180
acgcgctctc	tacgaaaaat	acaaaaaaaa	ttagctgggt	gtggtggcgg	gctctgtaag	27240
tccgcagctc	tccggaggct	gaggcaggag	aatggcatga	actctggggg	tggagcattg	27300
agtgagcgga	gatcgctcca	ctgcactcca	gcctggcgga	cagcagcaga	ctccacttca	27360
aaaaaaataa	taataaata	aaaagatact	gtgggtttat	tgggttatga	cagttttata	27420
gttaaaacaa	agtagactgt	taaacagttc	agagtatata	atagacgggg	ccctgtataa	27480
gagtaacaat	acaaacttaa	tcgtagagtt	gaatagaaac	taacattgct	acactctcac	27540
taatatgtta	cgccattacc	tattattaaa	ataaacacaa	ggccagctgt	tttgattggg	27600
taataccatt	taaaaattgt	aatacttggt	ttcagagagg	ttatttagca	cacgtgaagt	27660
tactcaggaa	atttcatccc	cagccagctc	gacctcgatg	ttgccagggc	gttcgggtcag	27720
ttctgtttct	tgcctgactt	gttctctcta	cagcatttga	ctcgaagttg	gcattgtcta	27780
gcactattgt	gaagtatttt	cttaattag	cgctccagat	actcgtcttg	tcttggttct	27840
gtgttttcaa	gtcgaaggtt	atagtagggc	ttctgaatat	cactcttcat	tgcactcttc	27900
ccagtttgtt	aaaaacatga	atatggarta	atttgaagat	atagaacaaa	gcaaaacttt	27960
gccttaattt	attttgtctt	ttataattgt	acctagatga	gtagaggatt	tgggaaccag	28020
ttatttgtag	aagaattaaa	agtttgtctt	ttttttttt	taattaggtk	cacttagaag	28080
atgtttttca	gtttatcagg	ttctgttctg	ttttttgac	ctatggctct	ccctgttcaa	28140
actcactaaa	ctgcagctgt	aaaaacatga	tcgacatcta	agctctttat	tgtggctgtg	28200
caatgctttc	ctctcagaag	acacagtgta	aacaccaact	ggcatccata	ttctctccag	28260
gtattaaaag	tagcatttgt	atgttttttc	atgaccaact	gttcagctgt	tctctatatg	28320
gtttatgtag	tttggaaaat	tataacttaa	aaaaaaaata	gacagggcca	ggccgggtat	28380
ctcacgcctg	taatcccag	actttgggaag	gccgaagcag	gcagatagat	aggtcaggag	28440
atcaagacca	tctctgggca	catgttgaaa	cccctctctt	actaaaaata	caaaaattag	28500
ctggggcggt	tggcgctgtg	ctgtataact	agcctacttg	gaggtctgag	ctggagaatt	28560
gcttgaacca	gggagtgatg	ggttgctagtg	agccgagatt	gtgccaaatg	actccagcct	28620
ggtggaacga	cagagactcca	tctcaaaaaa	aaaaaaaata	actcgataat	gccaggcgagg	28680
tggcttacac	ctatagcttc	agcactttgg	ggggcttaagg	caggaggactc	acttgaggcc	28740
aagagttcaa	gcagagcttg	gcacacgtga	taggatcttg	ccctacaaaa	aaatacaaaa	28800
attagctgtg	cgtagtggtt	cgctgcgtga	gtccagcatc	ctcagttgg	tggagtaggc	28860
agatggcttg	tgcctgggaag	ctcaagctgt	catgtagctg	tgatgtca	ctgcaatcca	28920
aactgggcaa	cagagcaaga	ccctcggtca	aaaaaaaata	aaaaaaaata	gggctgtaca	28980
ctgtacata	tttctgtgta	cctctaagta	ttgtctttta	gttactggca	ctgcagaaat	29040
ctcaccaaac	acaaaattgt	ataataagaa	atggcaggtg	atatatagat	ttcttaata	29100
tcagctattc	taattctcag	ctgtagcagc	aatgggttag	atatggaagt	cagcatcatc	29160
taatacaatt	taataatgag	ctaacaaaaa	caaaacgtc	ctgcatttat	ttcattttat	29220
gggcatcaaat	catattcagg	ttcggcttat	tctaattgaa	taactgaaag	taagtttttt	29280
ttataatagt	gaattgcaaa	ttttgcaaaa	gatgcagaat	ttctatgaag	aatgaattgc	29340
atattgaaaa	gtgggttgag	ttacagagct	atgtgacatg	ggggatgtgg	cagaattaga	29400
tcagagaaga	atggttggaag	atgaaaaaat	tgattagaat	aatggacatg	attaatgctt	29460
caaacgttaa	tgttattaat	atcagagcca	taggaggggc	ccctggggaaa	tttgaagatg	29520
tctctgggtt	tttttttgtt	tgttttctgt	ttttttttt	atccaaaaat	tactctttgt	29580
aaatgcttgt	tggagcaag	ttagatgatc	gtatacttt	ccctgaacaa	ttctcagtg	29640
ttattttttt	gttagttctt	tgaagagcca	cataattaca	tttgttaacca	aattttgtta	29700
catttaaagt	agtttatgaa	tttcaagttt	tattttctaa	ataaaatct	acaaaagtaa	29760
ttttttatc	gtctcaaaaa	tttcggtctt	tttttaggtg	gagttttactg	ttaaggtttt	29820
tctagttata	tttggaataag	aaacaactca	ttcatttttt	aaactttaat	tttcaattaa	29880
tttgagcatc	tttccaatat	atcaaaaatga	aaaattttat	tttttcaaac	tgctcgca	29940
gtattccatt	gtatggagat	agcaaatatt	taaaatagtt	attttctcag	aaacttgtgg	30000
gttttcaaaa	aggtcatcat	attttttata	gagataacata	ttctcttgtt	ccaaatttgt	30060
trtaaatg						

atattggaat	ttttggatca	aggttgetca	acctgtatga	acttcttagg	caggttttgaa	30420
acctgtgcaa	gctttatctt	agtatttccag	aaatggaaag	tataatggaa	aatttctagc	30480
aaaatataaa	tgaccgtagt	ttgtctgcagt	agatatgaaa	taaaagcttaa	ataactaat	30540
actgtaaaag	gaattttagat	atctctttgt	tccaaagaca	tctttttaaa	aacctagagc	30600
cagttgtgct	ccacagatgca	ttcctactag	atcttttgaag	cagatttttt	caatgtgtgt	30660
gaactgggca	gggcataagag	aagggaagct	tccagatctc	ttatttataa	ctggcataac	30720
atgtgaaatt	ggaaaagcct	acagacaaaa	actataggtc	atgtgtcttt	gaataaatt	30780
atgtgaaatt	ctgaaaagaa	atattcgcaa	ataggctcta	gcagcatatt	tataaaaatc	30840
atttacotag	ctagagttca	tgcccagaat	ataaaattgg	ttcagtaaag	ggaactatgt	30900
taataataat	gactgtatca	gtgaaggaca	aaacccataa	agtgctccaa	gatttgaaaa	30960
ggcattagcc	aaaaatcagt	aatcctgatt	gacagcagaa	taggagtaac	atgatcaaaa	31020
atctctcaaa	tcaaaagcta	gcgttttcac	ttcataattg	ggaaaacaaa	ggcattccctg	31080
ctgaaatcat	cactctcatt	gaacatgatt	ctagaagtac	tagccggcag	aaatagacaa	31140
gtttcaataa	cttatggaa	gtatgaatat	aaataaagca	aaatcaagaa	ctgtgtgagt	31200
ggttatgtgg	attgttaaat	gggacatctg	gctatccatt	tggaaacatt	aggaagtgtt	31260
actccaacct	cattctctag	atagaaattt	catgtgaact	aaagatttaa	cataaaccta	31320
gctctggcat	tgaagaaag	catgagggtac	atatgatctc	tcctctaaa	tatatagaga	31380
ggactttctc	aaacttcaatt	agagtggagga	gggcctttct	aagcacaaga	aaaaaagtag	31440
aagaaaattc	tgactctaac	atttctctat	caaaaaagta	aatcaaaaac	ccacgactgt	31500
ggaccacaaa	tttgtagatg	acgatgcaca	gggtggtaat	ttccctgtca	cgcttgtaca	31560
aggtgtgatg	tgacgcgggt	tttgtgtgag	catgtgtttg	atgacaaaaa	aatagaaaaa	31620
accttaactt	taccagttaag	gtaccggttt	ttaaaaatag	gaaaatacat	tggtgatatc	31680
aattaaaaaa	taatatgttt	gcgcgggttt	atggctcaca	ccataatacc	cagcactttg	31740
ggagggcgag	gtggggcgat	cacctgaggt	tgggagttcg	agaccggcct	gaccaacatg	31800
aagaaaaccc	gtctctacta	aaaatacaaa	attagccgga	tgtgtgtgtg	cgctgctgta	31860
ctcccgacta	cttggggaggc	tgaggcagga	gaatcgcttg	aatccaggag	gcagaggttg	31920
cagtgagccg	agatcgtgcc	attgcactcc	agcctgggca	acaagaggaa	aactccatct	31980
gaaaaaaaaa	aaaaagaaatg	atgtaatttg	gatattgatg	tacttatgta	aaactttcgc	32040
aagagtttag	atgtgtctgt	aatcccagca	ctttgggagg	ccaaggtggg	tggtctcaact	32100
gaggtcagga	gtctgaagaa	agcctggcca	acatgtgtga	accagctctc	tactaacat	32160
accaaaatta	gccaggcggt	tggcgtgcac	ctgtaatccc	agctgctcaa	gaggctgagg	32220
caggagaatt	gcttgaaccc	agggagtgga	gggtgcagtg	agccgagatt	gcacacttga	32280
gcaatgtcca	gctcatatgt	gatagcagtt	gggtgtagaac	agagtttata	tgcactgctt	32340
atttgtgtat	tttcaaaaaga	atgcaccagg	taacatatgc	ctaacccttc	tttgtgaatat	32400
taaatattca	aacagtgagc	agagaaggag	tttgaattcg	aagggaaact	cttctacaag	32460
taccttttgt	actatgtaaa	ttttgtactg	tttcagtttt	taaaatttgt	ttttaaattt	32520
ttttttcctt	tgatttttag	gggtgacatc	ttactcata	acctgggaag	ccccgtaaaa	32580
gaagttctga	gggctgccat	tcagtgtctc	caggccctca	gtggagtggc	atccccgttt	32640
tatctctgta	tagatcatct	gatttctaaa	gcagaggaga	tcacttcaga	tgtgcctcat	32700
gtttactcag	taagctcgtt	agcaaaagag	attgagtgtg	ttcatgcctt	tgtgtactgt	32760
agcaattttc	ttcattctctg	acatttcact	gtgtagggat	tttgatggac	taagtcattg	32820
gtttagtgaa	ctgataggtc	aatatctgta	catctgtgtc	ccctcatgtt	tgaaaagata	32880
gcaatgtcat	atttcaattt	tgttcttttc	attggataaa	ggattagtgt	tgactgtttc	32940
atagtaagcc	agctgtgtgt	ttttaataac	gtttcttatt	aaaggtttta	ggagaaatgg	33000
aaaattataa	acaatgtcac	atcattttgg	taagagtctt	ccgttaattaa	tatatattagc	33060
ttctgtagtt	ttttaaacct	tttttatcca	attttctttt	tgttatctta	ggattttggct	33120
actttatttg	aggaactaca	gagagaaaaa	aaactgaaat	ctcatcagaa	gttgtctgaa	33180
actttgaaag	acttacttag	ttgtgtgtat	agttgccaat	cttatatagc	aaaagatttt	33240
atgaaagtac	ttcagggaggt	caacgggtgag	gtatgtgcca	tttaagtggg	ttgtacattc	33300
ctgtgatgtt	actaaagatt	tgttgaatat	gcttgtgggt	gaagaagaca	attgttaagag	33360
ttcgtatgtg	gcactcagaa	gagataaatg	taatatataat	ttgagagggg	gatgagttga	33420
ggtagagaaa	accagataca	agatacaaa	acaagtagc	tgtgattctc	ttttatttta	33480
caatttaagt	tgttctccct	gtctaatcat	taagtttatt	ttaaatgca	ttaacagctc	33540
gggttctcat	ggggctgcac	tgtcgaagaa	agcttgtgct	ttctctcagt	ttttcaagtg	33600
aaaattctat	acaaaggaat	atatttggac	acgagtctat	gaaaattcca	aaatcatttg	33660
ctcgtttatt	atataattt	agagctttca	tttgtttttc	gaagaagctt	gtgttcaaaa	33720
agaaagcagt	tgtgaaacac	ttgtgtatgt	gatggcatgt	gctgaccaac	atcaaaaagg	33780
ttctttctat	ccagttgtac	agaaaagcct	gtgtgcttca	tcagtcttag	actgactgtg	33840
ggcttagaga	actaaaaatg	gccaaaatgg	ttgaagacca	tttgatttaa	ctttcttggt	33900
aggaacaaac	aggtgtcatt	cagcccttag	tgttccctgg	tatagtttaa	atataaatt	33960
gcaaaatttc	ttgggttaag	gaccagatag	gaaataattt	atgctttcgg	ggccaacag	34020
tctctgttgc	agctactcat	ctctgcagtt	gtatcaggaa	agcagccaca	gacaggtgtg	34080

ttttatcaac	aactatat	tgatcaccaa	tacctggagt	aaaatgggtc	aaactttatt	41580
ctgaagacag	caggaagctg	ttggcccttt	ctgtgctctg	cttatctctca	ttctctctga	41640
ggcacaaacc	aaatcctgtg	tgattttgtc	agcctctcca	ggcagctctaa	gcagactctgc	41700
ttacagtgtg	acatatcttg	catctgccat	tactgcctcc	tgttatctctt	tcacacatgt	41760
attgtttctt	ttgttttgtt	gtttgagaca	gagttttgtc	cttgttgccc	aggctagagtg	41820
ccaatggcat	gctctgggtg	cactgcaacc	tctgcctcct	gttttcaagt	gattctctctg	41880
cctcagcctc	ctgagtacct	gggactcacg	gcacgcacca	ccacgcccg	ctaattttgtg	41940
atttttatga	gagatgggtt	taaccatggt	ggcctgggtg	gtcttgaact	gcctgaactta	42000
ggatgatctg	ccagcttggtc	ctcccaaa	gttgggatta	caggcgtag	ccactgccc	42060
gcacgatctg	tctctgttcca	tacagaaaat	aaatctcctt	tggggcagg	ctcatctcgt	42120
acacttttga	ttccctctgg	ggctaagtag	cgcttggga	atgacagtag	cttactgaat	42180
attttattgt	aggcctttga	ttattaaaa	tcttctggct	gagtggtggt	gcactgcacct	42240
gtaacaccag	cactttggga	ggctgaggtg	ggattatttg	aggccaggag	tttgagaaca	42300
ccttggtcaa	catagcaaaa	ccccatctct	acaaaaaatt	ttaaaaagtg	gtgtgtgggt	42360
cctgggatgt	cccagctctt	tccggaggctg	gggcaggagg	atctctttga	gctcaggaga	42420
cctggcgctc	agtggagatg	gatcacatca	ctgcacttca	gcctgggcc	cggagaaaa	42480
ttctgtctct	aaaaaaataa	ataaaaattct	tctggcaatt	tcttggggcc	catgtaaaag	42540
cottattcttg	ttccactaaa	cttgtttttg	ggaagattac	ttgcacctac	ctattgtctc	42600
tgcttctgtg	tttgcagtct	gatagtggag	attctataga	agtttcaaga	aacgtttgaag	42660
agatttgggt	aaaaatcatt	agtgattattg	tggatgcgtg	gccacacgtc	coggagcaca	42720
ggcgccctgc	catcctctct	caacttctgt	atcacactggg	tgcagagaaa	ttcctcttga	42780
ttctctctat	cttctgtttt	gaacagtatg	tcacaaaaac	agtgtctggc	gtgcctctatg	42840
gcgaaaagtg	cagaacctag	ggtgggaaga	taaggaaaaat	gggtgattct	cacacagatt	42900
ttatgatatt	ctccagttta	aacatgaggg	tgatgatgcc	taagtgtgtg	tatttgagaac	42960
ctttttgtct	agaacctctt	tcaaaaaggt	ttttggcatt	ttaaaaaatt	gcatttcagag	43020
cccatagcac	ctcgaataat	ctcagtttga	gcacaaaatc	ttctgaaggc	gaattaaact	43080
ttctgagaaa	cagtttctgt	gccacgcaag	tggttctctt	ttaaagccag	cagagtagtg	43140
ctgaagagta	atgaaaacgt	gtctcttcaa	agcggttttg	aaggcagatt	gtggggaatt	43200
agagggagct	ccgtgtccct	gaagtcagta	agacacaaa	acaggtgatt	gtttggataa	43260
agccctgttt	ggataagctg	aggaccattt	ttaaatgact	ttctagactt	gggattctggg	43320
agtagatctc	gaccactgtg	aaataaagta	gtatactctg	ttctgctaga	aaactcaacg	43380
cacattatcc	tgaattatg	ctctcacaat	tcctaagta	agatttgtta	ctctttctct	43440
ttctctacaa	ggatgctatt	ttagaagcag	acactgaatt	gttttttcca	gtctgtgtgtg	43500
agttctagtg	ccagcatcag	atacaaagct	tgatgaatat	cctccagta	ttactaaaagc	43560
gtccagagga	aaagagaagt	aagcgtagat	cgggtgtcac	ttactgttca	atctgaaagc	43620
taaagagaaa	cagaagagaa	tgcaggttat	ccttagtaca	tcttcagaag	gatttttaaa	43680
gtaagttaat	cattttaatt	tgatttgtga	gtttcttgaa	tccttatgga	aaatagtctg	43740
aattccattt	gccattctct	acacattgtc	ttttataact	ctgtgctctg	cgctgacgtc	43800
ttggctgtgg	aattgttgtg	gtatccagga	tgagttagtg	tcacatgaca	gtaaatgac	43860
aggacctcat	tagtctctct	tcagcttctc	attaaaaat	ctgaagacat	ttacatgaaa	43920
agaaaaaaag	taggtaccac	aggagtgcca	gcacaaaat	aaaattgtac	tcagcagcag	43980
agcccttgaag	aaaaatccac	gaactgcagc	accactgagg	ctggcttagg	aaagggttga	44040
tgaagccagg	tgtagtggtg	ttagcctgtg	gtcccagcta	cccaggagaa	tgaagacaga	44100
ggatcacttt	agcgcaggtc	aagaaccagc	tgagcaacat	agtaagacgc	catctctaaa	44160
aaaaactttt	tttcatgaa	aaagggttga	cggtgtgata	gtctttagtt	ctctacaaat	44220
cgaagcagaa	cgacaaggca	cgttagaagg	aagtgactct	aagagctccg	cagagactgt	44280
tttctcgctg	gcacgccatt	ggccctgtca	tcactgtttg	gcgagccgag	aaactgtccc	44340
atcctgcagt	cagctcaggt	ttggcaggga	cagacaggag	agtgccctgt	acagtatgtg	44400
gtgtattgtg	tatatgtggg	gatgtgggtg	aggaagtgct	tttagcagtaa	gtcatctcat	44460
aggatagttg	tttttaaac	tgcaactgcca	acccatatta	cttagacaga	attgaaataa	44520
gaaatctaca	cctgcagttg	gaagttcaga	gaactctctc	gtgatgtgtg	ttcttccatt	44580
tgatgtctca	gttctccctg	tttgtttttt	gtcttaaaaa	ctgcttctct	agggcgactg	44640
gtgactctct	tgggcaaatc	actcactgtt	ttcactaatt	tagaagagga	gaaactggat	44700
gtaatatgtg	aacacatttc	tctgggaaaa	tgttattccg	tttaattgtc	ttacttgaaa	44760
aggttatatc	tgtttaattc	gtatgaagga	ttcaggtgaa	aatgagtag	gtcaacttgt	44820
ttattgtctg	ttcagaaaa	attccaaa	cagtgctcatt	taataagagt	gaatcacaa	44880
aagaaatcgt	acaggttttt	aatgtagaga	ctcacactag	caagcaactg	cggcatttta	44940
aatttttgtc	agtgctctct	atgtctcagc	tcctgtcttc	caatataatt	ctgaaaaagg	45000
taattgtgtc	tttaaatgtg	tttataaaaa	ggatattctg	tgcttccaa	gaactgtctg	45060
caacagtaga	aagtagctgt	gtaaaatggc	catgaaaatg	ggaggacacg	cttttaagat	45120
aatagaaaca	gaaagtagct	ttcccatatg	aaagccgttc	gtcatgtgct	actagatagg	45180
aacataatgt	aaactctgtg	actcagtggt	ttcattctta	agtgttgtgt	accatcaga	45240

atctcatgctt	ttagtaacgg	gttttgatga	gtcctcaaga	accacacatg	tccagacaa	63900
gtgtcagttt	aaaatgctgt	agaatgataa	cctaaaccaa	tgaccctaa	tgactgtgtg	63960
aggcagtgcc	acctgacgtg	gtgatgtagg	ctggcccaaa	accocggcat	cacatcacaa	64020
ggagactatt	ctctgctcag	catcccgaa	acataatttc	ggaaagggtat	gtgttacaat	64080
attccatcat	ctggggagcat	aggactgcac	gcctttttag	tccaaggagac	tgtgttatatt	64140
ttccttgaa	acataataac	aagactaac	ccttagggaga	aaggactcgc	acctaccctt	64200
atggggagatg	atggccagtg	caagcaagca	gttttaggtg	ctccagtcct	caagtctcgt	64260
tatatgatta	aatgtgtgac	tccagtcctg	agacaagctt	cctggttaaa	ttcctatcaa	64320
tatggggcta	cacagggaatt	ttaatatgat	gacaaatgtc	aattccaatg	tgcataatatt	64380
gacactctac	tggctttgccc	attatactat	attgcccacg	ttataaaaaa	gaaggggcaa	64440
attacaactc	ccaaagtaaac	aaaaaacata	cacacactcc	acataactag	ttaggactctg	64500
atttaaatgg	accacttatc	ccaccctctg	tcccaggatt	cttatttgctg	tcccatatttc	64560
aaaaactgga	acctcacctc	aaagtacatc	ccaggactaa	atgggaaaga	ggtaatatatt	64620
ctctctctct	ctccccagga	ctcctgaaga	aaagaatttc	ttacaaatgc	tttaatatatt	64680
aggcgtgggt	tcaagtgtag	agcaaatatcc	tttgatttcc	ctgctagtag	gtcaacatta	64740
agacgtttga	gaagacaaga	aaaaaaaac	cttaattaac	caagttaggac	agagttagtgg	64800
caatttcagc	aatgtgttag	accagacttg	aactatgatt	ctaactctat	gacacacacg	64860
tatccacatg	gacatgggaa	tgacagtgaa	gttgaaattt	taaacccagt	cagcatocca	64920
ctaattctgt	atttgcaaaa	taaaaatac	aaaaaaaata	ccctttttaa	atgacagtgt	64980
aggctgagat	gtgggtggac	agaaatggaa	gggttaacgc	taaaactgaat	gactacttca	65040
ggctgcagga	gctctgggac	ctctcaagca	ggatattctc	ttctatcatc	taccctgtgtt	65100
ctctctctct	tgaagatgat	ccactttcta	ggaaatagct	ctaatttcaa	gtcttcagaa	65160
gctgtgaact	ctgttgaaaa	agttgtttaa	gcagaaattt	tctaaatcac	atgcacagag	65220
gggccctaaa	aaatgttgtcc	tgggctgggc	ctggcgactc	acacctgtaa	tccagcaact	65280
ggggggggca	agtggtggcga	tcaacttgag	tcaggagctc	cagaccagccg	tgggccaacat	65340
gggtgaacccc	tgctctctac	aaaaatacaa	aaattcaaaa	atagctggcc	gctgggtgggt	65400
gcctgttaat	ccagctactc	ccagaggtcg	aggttaggaa	atggctgtga	accacaggaa	65460
goggaggttg	tggtgtgtctg	ggattgtgac	actgcactcc	agcctgggtg	acacagtgag	65520
gctccatctc	aaaaaaaaaa	agaaaaagat	ttgcctgtat	ttacggggct	gctctggagt	65580
tctacaagcg	aggagttagc	ctcgtggaca	aaatgctcac	ctcttgtct	ggccagaaaa	65640
agccgaggtg	agaaacacgc	cttagctggc	tctgctgcc	actggctgtt	cacaactcaa	65700
ccacactctg	cttgaatact	ctcactttgg	aaatgaagat	tctgacacta	ggcctacttc	65760
cagctcacag	gaccgttcac	gggtagaagg	cggttaacagg	acgggaagta	tctgactctg	65820
gactgtgtacc	gaaggatact	gaccttttgg	cattttgcatt	cacttctcct	ttaacgacga	65880
cagttctgtc	agggccatg	gggtgtttca	accttgcagc	gaatggcagc	ctctgaaaaa	65940
aagccacagt	caggaccaag	aggcctgcag	aaagcgatct	ccaggggaaa	ctcgtgtcca	66000
aagaacacta	cagaattgttt	cagagccatg	acctgtataa	tcccaggagg	ggagagacag	66060
tctgctcttg	tcccagctgg	gtcccttgca	gcagcactgt	ccctggctcg	aagcaaacac	66120
tcatgattac	atttttagac	atgaaatgag	tgacagggtg	ggaccctgag	ccctctgtat	66180
gagtgaaaca	gcgcaggaag	gcgccctgtg	cctggggctc	gaggcgacta	tgctgtctgc	66240
ctgaaggagg	agcagccaag	cagggaggtg	ctgaggaaat	acacaggaat	ggctcagagag	66300
caggcctgtg	tgaactctga	atccatccag	ggacggcaca	caaatgcaga	gggggtgctct	66360
tggggctctc	attgtggata	caggttactc	gtaacagctc	attacaactc	aaattttata	66420
cagagttaag	aaaatttggg	gctcttcaaa	cctttgacac	atagttcata	ggtggatatt	66480
gtgtgcaagt	cwaagtgtga	ttgacagctg	aattmttgct	cttgggttag	acagtctctgg	66540
tgcgagtttt	agaaattctc	ctctctctat	tactaggctg	tgggaaaaaa	gtttcacagt	66600
aaggaaatgga	atgaatgaag	ctgcctccca	cggtttaaac	tgttcaattt	ctatgcaact	66660
tataaaatac	ttccacatga	ataaacccag	gcaaaaatac	tacaaagctg	gggcgtgccca	66720
gacttttgaa	cttatgtgaa	aagaaacaaa	acacaacact	gttagaaggg	gaagaattat	66780
agtttataat	ctgaagtcct	ggttgtgctg	agctgagcct	ctggcggagcc	tggtatgttc	66840
ctgctccact	ctgggtgac	ctccaggcag	ctggtgcttt	atgacggaa	ggatagctgt	66900
tgtgaagggc	tacacgggtg	gagaagagag	tctgatatcc	gtgttcactc	tgactcttta	66960
tctctaccac	taaaattata	atttttcata	gaactatatt	aaattttttt	aagagacagc	67020
gtcttactct	ctgtccacac	ctgggatgca	gtggctcaat	ctatgcctac	tgacgtctcg	67080
acctctctgg	ctcaagtctc	ccgcctactt	cagccaccca	aagctgggat	ccagaccatg	67140
cgccaccatg	cccagataat	tttttaattt	tttgtagaga	tggggttctc	ctatgtggcc	67200
caggctgat	ctcaaaatcc	taggcctcaag	caatccccc	acctcagcca	aacgcctggg	67260
tgacagggcc	tgagccaccca	cttcaaccca	gcactacact	aaactcaaac	gtgtcttagt	67320
gtctctttcc	aggggtgcctc	cagaatgcac	agattctat	ctgtctgtga	gggtggaagc	67380
tggcagctgg	taagacactca	ctttctccat	taataacagc	gcatttttaa	attgcagtta	67440
ttctccagg	ggttgaagat	acacatggaa	gttcatgtgc	cagtgccact	gctgatgttc	67500
aatatttga	aatccccag	aacagtacta	ctcagcagtt	aagagtga	gagtgtcttt	67560

tacataagaa	cagtgagtgg	cagttacaga	aactgacagg	tgaatcatca	gcaaaaaactt	67620
actgcgtggc	tgccaccaca	agtgatgtatc	tcaatttttca	agtgattactt	tgctgtcttaa	67680
aagcataaatt	ttcaaaaaact	cagcctctctt	gccattttcat	taacataggca	gctaataacaa	67740
caatttttaa	ccagtggtctc	attaaaaagat	ttaatatttta	cattttctctt	acttactctct	67800
gtcagttcca	gacttagatga	ttgggttactt	tgtaagtctt	gagaaaaagtt	aataaagatt	67860
aatttgtaac	atccagtagca	aaatatatttc	tatatataaac	ctgttttgaca	tataaaaaaa	67920
ttcataaatg	tactaaaaaat	atgcttgaaa	actatgatcc	aaaaatatat	ttgacactgg	67980
ggctctcttc	gccccccatc	agatttgccaa	acattacaga	gaataaagat	taagtctcaac	68040
aagaagtggt	gagcatggct	gttgagagtg	caaactgttt	ttacccttgt	gaagggcgag	68100
ttagatctta	tcaaaaatttt	caatgcaaa	acagtcagt	gttgcttaac	gaagggggta	68160
tggtctgaga	aatgtgtcct	tacatgactt	ttgtcatcgt	gcaaactatca	cagaatatta	68220
cttaacaacc	ttagatggta	ctggccaacta	cacactagg	ctgtgaggtg	taagcctggt	68280
ctcctggcca	gtgaatctgt	acagcaggca	ctgtaccaaa	tactgttaggc	aaccagagca	68340
ggatgggtaag	tatttgtgca	tataaaactta	cctaacaata	gaaaagggtat	ggtaaaaaata	68400
cagtatatga	caatcttatg	ggaccacggt	tgatatgag	gttcatcttt	gactgaactg	68460
tccttatgca	acacatgact	gtgctcttg	actcagacac	ttccagccta	ggaactctgt	68520
ttacagaaat	actcctattt	atgcccagtc	aaaggaaata	gtgtctaccc	agctaataaac	68580
tgtgtgtgtt	ttattaaaaa	cacactaggt	ttgagatctt	acagacaagt	aagcctctggc	68640
tgataaacag	ctctctgtcta	gtgtgaaac	ttcactttcca	aaaaattaat	actcagctga	68700
gggagtagac	tcctttttat	gtcaatagaa	gtgttatttg	aagatttttt	ctaccactct	68760
atcagaaaacc	atcctcataa	aagaccceaa	gtgtgggaag	gtcactcacc	gaagctgaag	68820
taaaaccaa	tgagtgaata	ttcacttttg	cataaatgcc	cagagtgtct	ttattctctg	68880
ggccgatctct	gtggccatag	agcagagtat	gttttccatt	tacagccacc	tagagagata	68940
cagaagaagc	agcccccccg	ccaccaaaaa	aaaaacagtta	ataaattaac	ttattatcca	69000
aattttaaatg	tttctctgcy	ttcaatttta	tacctgttcc	cacaggtctc	cacacaagct	69060
accaaattgg	aaccggaaag	acccaaaaaa	ccagcagtg	ttccgaactt	cttttgagtt	69120
ctgatttga	tttaagcaca	ggaaactgtc	ctcccagac	aaacagggag	tcataagtat	69180
atgtgcgtgt	gtttgtgtgc	gcctctgcac	acatgtggga	catctgggt	cgaaggtcgc	69240
ctggaaagccc	agggcacaggt	cccctggaga	ttgtgaacc	aggttaaaag	ttcgtctgct	69300
agctccccc	aaacactgtc	ctggagacac	cccatgtggc	agacactcaa	aatctgtgtg	69360
atttgtctaaa	taaaatttaaa	tggaacaagtt	accacaacta	tttgaattgc	gtttttctat	69420
ttcgaagtga	gaacaactct	tacctcaaca	gactcacagta	agatgacag	aaagtacgtt	69480
ctcgaggtct	tcggcacgct	acgagcctcc	ttcctctctc	ctctcaaat	gccaggtacc	69540
acgttatagtt	ataggcagaa	aacgcgagca	gcatacaata	tagtctctga	ctcaaggagc	69600
ttttaaattccc	attgtggagg	caaaaataaac	acataaaagc	aaagcacaac	tgttaaaaaa	69660
tggtgaaaag	aatgatacag	acacgggctc	aaaaggccag	agaaggggga	gggtgaatgga	69720
gtttgggaga	ttcagaaga	ctttcgggca	ggagcagtat	cccgaagatc	agaaaggatc	69780
tgtgccagag	gcattgtgagt	cttctctcac	gttggtacaa	acctctactg	tgggaaaagct	69840
ccacagggcca	gaggggcagc	aggtgtaaga	gcttctggga	ccaaattcaa	ccatacacac	69900
ggcgctcag	tataagacac	ttcatgaagc	cagagatgga	actgacatca	aggaattcta	69960
ggatgtctct	tggtgtctaaa	aatctcatga	ttctctggga	ctgtcttggt	cgaaagctgt	70020
aatttacaaa	accctcttga	ttctctatgt	gggattgccc	ttgttagttc	ttcaggtgtg	70080
gacgtttata	ttataactta	ccctcccatc	atgaacataa	tactgtgtca	actcagaact	70140
gcgacctgtc	aggagaaata	ggatctaaata	aaaagatcta	gtcacagtg	accatattat	70200
tgcatggcaa	caactggctg	gagagttagt	gtgccacccc	ctcatattta	gggtgcttcc	70260
ttgtctcttt	atgggaaag	actcaaaaag	caaatctat	ctcaggttga	ggaaatacaa	70320
ggctgggctc	acaaattgta	aaggcccccc	tgctcactcc	tgctcactaa	tgaggactca	70380
acctgtccct	ctccaaaact	tacctggaa	ttgtccttta	gcaccataat	cagactctca	70440
aaagactttt	ctcttttgaa	agggctgtca	taggtgatct	cttcccgctc	ccatttttca	70500
tttatcaaa	tattgcaaac	gcttctggga	gccccttttg	aacgaggtat	gaaatgaaag	70560
ggcacatcgg	ctcaggggtt	cacactgctg	ccattctgca	gatccacctg	gaattctaat	70620
gggggaaagc	acaggggctt	catgagtgtc	cagaaaggga	agcccaccag	aaagggccag	70680
caggcactac	actccaggcc	cagtgaacag	ggactgacca	attccctctc	attcattcac	70740
tatgaggctc	aaagagctga	ctgtctaatc	ttttctgtct	ttctcagtaa	aatagccctc	70800
gagtttgaa	tggtgttgaa	cttgcccaaga	ataaaaacct	ttctttccca	gctccctctg	70860
cagctaggcc	tgctctgtga	gctaaaagctc	tgctgataag	atggaaagtg	agtgctcagg	70920
gaaggctact	gaaaactgct	ttaaaagtca	gcaagcactg	gctctttgtc	cagctcttgt	70980
ttcccgcmaa	caccacatgc	accatccag	ctacccaaag	cacagaagtg	agggctggaa	71040
atcatagctg	caaggataat	gggaaaaggg	accctacact	accctcaaga	tacagagtg	71100
gtcagctgga	aggagtctac	ttctctaacg	acttgaaagga	gttaactgaa	aaggcctggg	71160
ctgtctctct	gagacttaac	ttctacatct	taaacacctg	ctcttcaggt	gttagctaca	71220
ccagagctgag	cccaaacacta	atgataccac	agcttgatct	caaagcaagt	attcagtaaa	71280

accatctgaa	ctagatctgt	gatgctgtgg	gaatgtcaga	ctaaaactag	actctccctg	71340
tcacatcgacc	acaattccct	tctttaatga	catacctaata	tctttttctt	tctttttttt	71400
tttttttttt	tttttttttt	tttgtcaccc	aggctatagt	cgagtggctc	ctcacaagct	71460
cactgcaacc	tcaaaactcc	gggctcaagg	gatccctcta	cctcagccccc	ctgagtagct	71520
acaactacag	gcgcacacca	ccaagccccc	ttaatttttta	tttttttttt	tttttttaac	71580
agatgggggg	gggtctcacta	tggtggccag	gctgtgtctcg	aactcctggc	ctcaacaact	71640
cctcccgccgt	tggtcctccca	aaagtgtcga	aaagtatgtg	taagtccaca	catccagctg	71700
atagtttctaa	ttttttttata	ctgaaatcag	actttacagca	atgaaataaa	ctccacaatc	71760
ctttattttag	tcattctcttc	caatctcttc	agccactctg	ccaggggctgc	tgatgaaagc	71820
taattggggc	tcaragtatc	aaatgggtct	tcccgcttta	ctctgtttatc	atctccaat	71880
cacaaaaaga	cagcctattc	atgctccttc	ctttagcaca	gtgattttac	ctgtctcgct	71940
cactaggaac	atgccacatc	atccacaatc	aaagtccagg	atccagctga	tcrggaatgg	72000
tgccaacata	cgggattacc	taagaaaaaa	aatttaacaa	atgtacgttt	acataaacaa	72060
aattacttct	taagcaatta	caaccacac	tcattattga	tagagaaaaa	ctacactttt	72120
taaggctgca	cataaatctc	agaatccagc	attttccaag	tcacttttcc	tattcaacaa	72180
gctataaaaa	ggaactcggg	cgggctcgcc	tggtccacgc	ctgtaatccc	agcactttgg	72240
gaggcggggg	caggaggatc	acgaggtcag	gagatcgaga	ccatccatga	taaacagggtg	72300
aaaccccgct	tctactaaaa	atacaaaaat	tagccgggtg	tggtggcggg	cgctctgagt	72360
ccagctact	cgggaggctg	aggcaggaga	atggcacgaa	cccgggaggc	ggagcttgca	72420
gtgagccgag	atcgccgccac	tatgctccag	cctggggcag	agagcaaggc	tcgcctctaa	72480
aaaaaaaaaa	aaaaacaaaa	aaaggaaccg	cataccgcac	gacacaagg	gtcgcaatag	72540
ctgcaaacca	ctatgagttc	tttggaagaa	gacacaagg	aaatactatt	catagatttt	72600
tgtattttggc	tgaagatttg	tgaagcaaaa	cttctgctta	atatgataat	ctgaacagaa	72660
aaaaaaaaaa	agactttgtg	caatgccatc	tctactcatt	ctttttctta	tgtctccact	72720
gctgatccca	acagaaagtt	cgaggccaca	ctaggcccaa	agccaatgct	cgaggagaca	72780
atgacaagag	ctcactcgct	ctgaaggaaa	ctccagctta	agccacgccc	ccacacactg	72840
gattccaggg	cctgcctctc	ctctgctggc	tcccagctga	caaccccagc	tgcatctgta	72900
gaaacccagag	aactcgatga	tcatgaggat	gagtggtgtc	ctgtgtgtct	ctcaagacatg	72960
gcacccacct	gccgtggacc	agtcacgtct	gcaggccgtg	actctgacac	ctggctccac	73020
ccagtattca	gggtctcaact	tgcacctcta	ctgcaccgaa	ccagccctct	ttttctggg	73080
acctgccaca	ctgccagatc	tgtcattctc	ccttccccag	agatgactac	actgtctccc	73140
cagtcacctg	ctggggggac	tgtgctatgt	gggtgctctc	ctcgtcatcc	aaccatctgc	73200
ctccacttgg	agcatctgac	caggatgtac	agccccacaa	cogtataagc	tcacatctag	73260
ctcactcaaa	ttacagatgt	catggtaaaa	cctaccccaa	gtactcttga	ttgtcaagaa	73320
ataagaataa	aaataagacg	ggccacagaa	aaagtgttat	aaattgggtg	ctcctaatac	73380
gaaatcgctc	tgaggcacag	cctcctctgt	ggagcctctc	tcaagctccc	tgggctgctg	73440
agtcagagccc	ctcagagagg	ttcatgatag	caactttggat	ctgtgttgtt	tgcatgtagc	73500
tttgctcaga	ctgtgagctc	catggggcag	aactgggtct	tcacctttac	ctccccagga	73560
cacaggtcaa	gagacgatcg	gttaactgcat	ggtagaatga	tgaactctca	ctgtctgga	73620
aagtgggctc	tggcaggcct	cacacataca	gaggagaggc	aacaaggcac	ctgtcgaaac	73680
gcaagctgag	ccccaaagct	ctctgttgcc	taggacaata	agatgagaaa	ttacggagaac	73740
caattatcta	tttgttttca	tggaacttgc	taggagcagg	gtgggaggca	cgtgacacca	73800
gaaacacaaa	aatacaacag	acaggttga	ctggggctac	actgacatc	cacagatctc	73860
gaattttgtg	gtagagaaatg	gggaaggacc	tacatcccta	catgtactct	ttgggtcaca	73920
gctgggttcca	agaatatata	cgacgaggtt	ctatagcgtt	aactccttaa	taaataggaa	73980
agtttttata	acatacaaat	tcacttttaa	attatcttta	tgcagaatct	tttaatacac	74040
aaatgcttag	aatataaagag	aaagttaact	atagagccat	atatagtatt	atctcaacta	74100
aataaataat	aacatttaaaa	agaaaaacct	gctaatacac	actgtatcct	gtatcaaaa	74160
atgccatata	ccccataaat	agatatatac	actacatact	caaaaaaatt	aaaaatttaa	74220
aaaagaaaaa	gagaaacact	aaagaaatca	gacaaaaaat	atacaaatag	ttttcatggg	74280
ggatgatggc	atttttaatt	ttttcttcat	ataattttcat	acttttgcca	tgctataaat	74340
aagcatcgat	attttttatg	ccagaaaaat	attttttaat	tatatgtttta	ttttagtgtt	74400
ggaaagagct	ttttgagaca	aaacaatcta	ttccccatcc	tttttttttt	tttttttttt	74460
ttttgagacag	agactcaact	tgtccccag	gctagatgtc	agtggtggtg	cttcagctca	74520
ctgcaacctc	tgctcccgcc	ttcaagcgat	ctctctgcct	cagccatcca	agtagctggg	74580
actacagcca	tgtgcaccca	tgcccagcta	attttttgta	gttttagaga	gatgggggtt	74640
tgccatgttg	gcggggctgc	cttggaactc	ctgggctcaa	agtgatcctc	ccaaagtact	74700
tgctgtgtct	tgggaggttaa	tgagcttttg	gagaagctac	cgaccccgcc	ccccatcact	74760
tctaatactc	tgttcaacaa	tgtttatagg	tttgaaacaa	tttgagaacaa	ctctcgttaa	74820
gaacgggtgg	cacttgctgc	tttagttttc	tggtgtctat	atgccttcta	cttcagaaaa	74880
gatcctgcac	tactctcagta	atactttttt	ttttttttta	ctatgagaca	cagtgccctg	74940
cogctgacct	attttaaccca	cgactatgtg	gcttctgtga	aaacggagga	catacattgt	75000

aaatgatttg	cacatatatt	ctttaaattt	ttttaaaagg	aaaagccact	ggtttggaca	78780
taaatgtagt	ttaaaatttg	gaagacagac	tatcttccaa	ctattgggtg	ctaggaaaaca	78840
aggaggagag	caaaagttaa	acagcagaga	gacatctgct	cagaaaaactg	caaggagaaa	78900
gctggtttgg	gaaggagaagt	ccaagtttgg	tgttaacttc	ctagctctga	agggcttgctt	78960
gagaaactga	gagttggggg	gtccatttag	gtgaaagggt	ggaacttgat	acatatggaa	79020
gaaaaaattt	atagatgtatc	ggtaaaagaca	taaaaagaag	agacatttaa	gacaaaattt	79080
ccactgataa	accaaaaaag	aaaaagagat	gaaaaactag	agggcgagagc	cttatgtagg	79140
aaatccactc	tcagtccagga	agggcggcag	caaaaaaaga	agaaaaacag	cacaaaggct	79200
agaagatcac	tcacaggtta	caaaaagaag	actgtactgt	ttgtgttttt	aagactataa	79260
tgtaaggtaa	aaaaaggtga	cttagaataa	taagcagaaa	aggtataaca	tgaagcaag	79320
gttctccaag	aaactgggta	ccaggttaga	tttatgttga	caagcaactt	attaacttgg	79380
agtaaacaca	aattctcttt	catcttcata	gtattcttca	accagctagc	atttaactat	79440
atcttaagaa	ctctataaac	aatgacataa	ttaatatata	aggtatagaa	tgaacttgca	79500
aacagaataa	ttcactggca	gcattccccg	taataagtaa	actactgtct	ttccaaattc	79560
ttcatctaaa	ttcaatagaa	agaaaagtta	gtggccagcc	acggtgtgtc	acgcctataa	79620
tcctcatgct	ttggggagcc	gagggccggcg	gattgcctga	ctgcaggagt	tcgagccacg	79680
ctgtggccaa	ctgtgtgaac	cccgctctca	ctaaaaatac	agaacacaat	tacggggggc	79740
tgccggtgtg	cgcgctgtag	cccagctact	cgggagggct	agggcagaga	atgtctagaa	79800
cccagggagc	aaaggtggca	gtgagccagt	attgcaccac	gtcactccgc	catgggcaat	79860
agagcaagcc	ttcatctctt	aaaaaaaaaa	aaaaaaaag	agaaaaagag	aaaaaaaaaa	79920
cagaaaaagg	agcctaactt	tttttttttt	tttttttttt	tgaagtgaag	tatcaactct	79980
tcgccacagg	tgcagtcgag	tttgtcaact	ttgtgctatt	acacactctc	ctctccgggt	80040
tcaagtgttt	ctctgccttc	aaacctccat	gtagctggga	ttcacggcca	cgcgcacact	80100
cgccggctaa	tttttgtatt	ttttagttag	acggggtttc	actgtgttag	tcagggtggt	80160
ctgcgaactc	tgacctcaag	tgactctctc	gcctcgggct	cccaaaagtct	tgggattctc	80220
ggcatcagcc	gagccaccgc	ctgactgact	ttttattttt	tttttgaac	atggtttctg	80280
ctctgtcaac	cagaaatgaag	cacagtgtca	aaactcacgc	ctactcgagc	ctcaaccttc	80340
tgggctcaag	caatctccaa	actcactact	tcctcatagc	tgggatacga	gacatcgccc	80400
acaatcccca	gttaattttt	gtatttttat	agagagacaa	tggtctcata	tgttctcaaa	80460
ctcggtcttg	aaactctctg	ctcaagttag	ccactagcct	ggctctccca	catgctgtcg	80520
attacaggca	tgagcctctg	gaccacgctt	tagagcctga	cttttttaag	ctttggaaat	80580
ctcatagttg	aactagttcaa	agaaattata	taaataggga	aaaaaataca	tgtgccagtt	80640
gcaatattta	ctctactctt	ttccaagata	cttaagtgtg	acagttgtgc	taacaccaat	80700
gtgagccaaa	atatatagaa	tagggccagg	atgtgtgctc	atgctctgca	ttcccaacct	80760
ttggggaggg	gagggcggag	gagtgtctga	ccagactgag	aaactgttaa	aaactctgtc	80820
tttaccaaaa	aaaaatacaa	aatttagcag	gcagtgtggt	gcactgcgtg	agttccagct	80880
atttacaagg	ctgacggcag	gaggtggagg	ttgcagttgt	gtgaagactg	accactccac	80940
tcacagcttg	atgacagatg	gagcctctgt	cttcaaaaaa	aaaaaaaaaa	aaaaaaaaat	81000
ggaaaacata	atagaataaa	aattaaaaag	ttgcggtgtg	tttataatgc	ctaataaaga	81060
atacacagaa	caataaataa	atttacttat	tgaacctata	agtaacaaaa	caacctatgat	81120
atacagaaga	aggttttgtg	ttgtgggggg	gttttttttt	ttttgagatg	cgctctcgct	81180
ctgtcaccca	tggttgagtg	cagtggcacc	ctatcggctc	actgcgaact	cgcctcccca	81240
gggttcaagt	attctctctg	ctcagccttc	cgagatagtg	ggattacagg	agggctgccat	81300
cacgcctggc	taagttttgt	atttttaagt	agagacggag	tttgcgccat	tgtggccagg	81360
gggttttgaa	ctctactgct	cggtgatcac	ctgcctcggc	ctcccaaaag	ctgtgggata	81420
caggtgtgag	ccccatgctc	cagctgaaaa	gactttttct	aagctctagct	tataaaatat	81480
actaatgtat	tatcttttaa	taactaagtt	gccagggcat	ctgtgcctcac	gctgttaact	81540
ccagcacttt	ttgtggctcaa	ggtgggcaca	ctcactgagg	tgcaggatttt	gagactaggc	81600
tgggccaacac	tggtgaaccc	catatctact	aaaaaacaca	aaattagccg	ggcatgtggg	81660
cacgtgtcct	cagctccagc	tactcaggag	gcttgaggac	tagaattgct	tgaaccgggt	81720
aggcagaagt	tcagtagtaa	cgagatgtga	tcatttctact	ccagcctggg	tgaaccaggg	81780
gaaactatat	cttcaaaaat	ttaaaaattg	aaatttaatt	ataataaatt	ataagatttat	81840
tacagccttt	tttttgaac	attgaaaggg	caactagcta	caaatagaga	aaattcagtg	81900
caatacagct	ccctttatac	ataaattatt	tacagcagtg	gaagcttaag	agagcggaaa	81960
ctgtttttgc	acttcagttg	agctcactcc	taacctttcc	gaactcttgc	tgaagactga	82020
taataaaaaca	gagaattttg	aaaaaagctc	aaaaaagctc	atttgccaaa	aatatctccc	82080
ttggaaatgc	attatctcca	cagacagcat	cagccactag	ccaaagactg	aaggcatttt	82140

gtatgcaggt	gaaacgggtg	gggaagggtt	cagtagcgtg	gactgtgccc	agcccaagct	86220
ccccatccgt	tagtgataac	ttggactcgc	agccactccg	cgctcaatcgc	cggttatcct	86280
gcgtgtgggt	gtttttccca	aattggacac	ttagggaaca	gtttaagcac	tatgaagcac	86340
aattctgtgc	ctattagatg	ctcttaaaaa	cccgacttct	caggggcccta	caactgactga	86400
tagtttgacc	tattggcgat	aaacacacca	gccagaaata	caaataaagt	taaaaagaat	86460
catgtcagcg	acttggaaag	gctggctgct	tactgtttat	tttstgttag	ggacctcaaa	86520
gtttctcatct	gtctctactg	gcttttatcc	acatttggtt	ggaaagatat	attttagtgt	86580
cattaaacgtg	ggctttctoc	tcctcgggtt	ttgttttcat	tattttttgt	tttaattgag	86640
gaattcatta	caagtcoccat	aactcgggaac	tcagtgtctg	attcactgtt	gcttttctct	86700
cctccttacc	cattttccaa	gctgtgatga	cttctcaaga	tcctaatctga	atagcttgaat	86760
ttacccctga	catacactgc	cttggattta	tagctgtctt	ttggtatgtg	ttgtgtgttt	86820
tatctatcca	actcgactgt	agttttgaaa	aaggaaactg	ttctatacac	tctccagtgc	86880
atagtgtaat	gctttgcata	aaatagatat	caatgttagg	ttgaaatgtt	agattattga	86940
taaagtcagg	agcaattgaa	tatcttcaca	attctgcctg	agtcctccccc	cagccccgcg	87000
actttgagac	agggtttccc	tcaagtgatc	ctcccaacct	agccccaggga	gtagctgggga	87060
ctatagacgt	acaccactat	gccacgctaa	tttaaaaatt	tttttttgtga	gagacaggggt	87120
ccactgtggt	cgccrggtgc	gtctcaaaact	cctgggctca	caatatctct	ctgccttggc	87180
ctcccaacaat	gctgaaattt	caggcatgag	acaccaagct	gggcccgtgag	tcaaccttgt	87240
acttctttac	aaagcttaag	taagtgtgaa	taagtacaca	taaatgtctgt	gtttctttttg	87300
taagtcatat	taggttgcaa	acggggctga	gtgaaagggt	cagagagcac	agtttaacaaa	87360
gaaaatctgg	attaaaaatg	tcataaaatc	taagaactta	ttctagaaaa	tatctccctc	87420
atttggcaact	gttgttcaat	tagcccaagt	tgatttttta	ataaagcaaa	tattcaactga	87480
atgctcatca	tggccaggga	cagcagtaaa	gaatactagc	atgcaaaagg	cctcatgggc	87540
ctttctagat	agagttccac	atctcttaca	ttattactgc	agtatccata	tcggctctccc	87600
tatatattgcc	cttgcacctc	tgaactgtag	tctcaacaca	acagccagag	aagtcagtac	87660
aaaaactaat	tcagatcatg	ttaactccct	actaaaaact	actttttttt	ttttttttag	87720
gcagctctcac	tcgtgtgccc	aggttggagt	ggagtacagt	gttaccattct	cagctcaactg	87780
cagcctctgc	ctaccggtgt	caagtgatc	atgtgcctca	gcctctctgag	tagctggggac	87840
tacagggtgc	cgccaccatg	cccagctaa	ttttgtattt	ttagttagaga	tgaagtttca	87900
ccatgttgcc	caggctagtc	ttgaactcct	gacctcaagt	gatccggccc	cctcggcctc	87960
ctgtaacctg	ggattgcagg	tgtgagccac	tgcatccggc	caaccgtcta	ctaattttttg	88020
ctcattcttt	gagtaaaagt	ccagtttcta	cacagcactc	tcctgatctc	ccgaactcct	88080
cacacactgt	gatttcaact	cctactactt	tcctttctac	ttttttctga	gcagccacag	88140
cgactttgct	atttctcctg	caggcctgtc	acactcccat	cctaaaaatct	ttactcaata	88200
tttctctttc	ccttttcaag	tctactcaaa	tgtcagttct	cagtgggggc	cttctctgac	88260
accaatattt	aaaattgcga	acactctccc	aaaaacacact	catcacacact	ccctagcaac	88320
tcttctcttg	tttatttctg	gctaacaatt	gtcatgctaa	tatactatat	aaggtgcctt	88380
tttattttat	gttaactcac	ccatcataag	actataaact	ccatgagggc	agaaggtttt	88440
gattgtttct	gtttcgagga	agcttatact	ctagttgagg	acacatacac	ttagtgtttt	88500
tagagaagat	taaaattggga	gcacctgagt	ggcaacctta	gttgggtgac	aaggaaaagtc	88560
tctcagaggga	gtcctaaagt	aaagctgtgg	tgagtgaagg	aaaggaacaa	gccatagtga	88620
gatgtgtggg	aagagcattc	cagccttagc	gagcagctgc	tgcaaaagtcc	ctgagggtct	88680
tgagaaatga	ttaaattgtg	tcaggaaaca	aaggccacca	accagtatgg	ctgaagcatg	88740
aggggaagaa	gatattgaact	catgagatgt	gatggaccaca	cctaggagga	ctgtgggaga	88800
aaatcacctc	ggacagccct	ggggagataa	gacaaaccca	ataaatgaga	ctgagaaggg	88860
acaaacaggg	gaatttgcgt	agagtgggtg	cacagatgcc	aaagaagaag	aaacagcctg	88920
tgtgcacagt	gtgctgactga	gccaaaggag	acggaagtaa	gcaattgggt	taggacacatg	88980
gatgtctcgt	ctctgactga	ctctgaagtg	tgttgagaaa	tgggaggtga	agaactcgtg	89040
gaaaaccatga	ctataaaagt	ttcagaaaag	tttgctgtga	ggaggaatgg	agaagcagca	89100
ttatagctga	ggaaaggagt	gagcaaaagg	cagattcagg	ttttctcctg	ttgttttttt	89160
ttttttttta	agagaagata	ctacattgggt	gacttttaga	cttctttttt	ttcaagtgaac	89220
ctgccataag	aatttaccatt	ccattgagac	ttactacaca	catacttaaa	ataacgaaaa	89280
caaaaaattt	gaccagccac	gttggctcac	tcctgtaatc	ccagcacttt	gggaagccga	89340
ggcagctgga	tcacttgagg	tcaggagttt	gagaccagcc	tgggccaatat	ggttgaacccc	89400
tggtttctact	aaaaattacaa	taattagctg	ggccttgttg	cgcatgctga	taattttcagc	89460
tactcgggag	gctcgagcat	gagaatcgct	tgaacccaga	agggcagagt	tgcagtggag	89520
tgagatttga	ccactgtact	ccagcctgtc	caacagagtg	aaactgtgtc	taaaaaaaag	89580
aaaaaaaaaa	aaaaatttga	caaaaacata	ctcctgttat	gtgtaaaaaa	atctactttt	89640
tcatttttaa	aaaaactgct	ttatagctca	ctaaaattgt	tgcgaagccc	actaactggc	89700
tgtagctgga	agtttgaaga	acactgggta	gtatgttggt	gttagctctac	actgggtctg	89760
gacagccatt	tttgtacata	acttccatgt	tgatacctgt	aagttatcca	gggcacgtgc	89820
tagaaccttag	gaactttttc	ccccaaagaa	caagatctta	aacattttacc	agcacgtcac	89880

tgactttact	catgtgaatg	atccgtggag	aggagaaact	gatcatgcag	gagaggggat	89940
gggtgtccca	ataaaagtgt	cgaaaaaccg	tttcagaaac	atagatatgt	ccaattattt	90000
ggccacaact	cctgagaggtt	atgcagataa	aaggatccat	tctgttagga	tcaatttctt	90060
ttctctctat	atgtctctct	ttccttgcct	aagaagccac	atttatatgg	tataatatag	90120
ccacacattt	agaaatagtc	tttttttttt	tttgagacag	agtctcaact	tattaccagg	90180
gctggaggtg	tgtgtgtacaa	taatggctca	ctgcagcagt	gacctctctg	gctcaagtgga	90240
tcctcccccac	tcagctctccc	aagttagctgg	gactacaagt	gcacaccacc	atgctctgaat	90300
aaatttttttt	tttttttggtg	gtgatggggg	cccactgtgt	tgcccaggct	ggtctgtgaac	90360
tcctgggggtc	aagcagtcct	cctgcctcaa	cctcctgaag	tgctaggatt	acaggcatga	90420
gccaccatca	ccaggccaaaa	ttaagtccta	caagcaaaat	gttaaattat	atataatagag	90480
cccacattttt	ttaaaaaaat	agtaaaaaaa	tcagtatttt	agacatgaat	tgtaagctct	90540
tgctacttagt	cagggttaac	tgattaaaca	gaaatagatg	ccatatttcta	tcgatgtgaa	90600
ccgtatttgtt	tcaagctaa	gaatactctg	gcagtgattt	tgcttattgt	tttgttgctg	90660
tgctacttttt	gttaacataa	ttgtaaaatt	tttggacccc	ctctccaacc	atccatgaaa	90720
tagcgtgtgt	aagtgtctggg	aaaatgtgct	caaactcaat	aatttttgaa	tacaagttag	90780
atatgtataaa	agagtataca	gaactttaaa	gaactgcctt	ggtagctgtg	gaaattagaa	90840
accgaactc	cgctcacagaa	cctgtgacaa	taatgataaa	aaaaaaggct	gttaaagcaaa	90900
aatgtggccac	aatggattat	acattttgtga	gcgcccagaa	cacataccct	gctattctca	90960
tgagaaaatt	aatcaaaaat	tgtaggtttt	aaattatgca	acatctctgc	gaatgctatc	91020
tttcaaaaaa	cacaatactc	acatccttat	acatacatct	gcttcccag	gaatgtctat	91080
ggagcgtgtgc	tttactctct	tcagattatc	ttcccacatc	taarggaatt	cattttctct	91140
ttgaactcttc	ttgtctttgac	ctaactctcc	ctacacccca	atactagccc	catctcatgag	91200
caccaaacyc	tttttttttca	ccctccagac	ccctcatgat	ctgattcacc	aggtcttaact	91260
cygaagttct	acaggtacat	gtcccaaatc	cagctttttc	agctggggaga	acaaagcttc	91320
tagaactctat	gttttgtcat	aaaaataaa	aatcttagtg	acgagaggga	tcttaggagg	91380
agataaaatt	aatctcatctc	aatagctcaa	aggatgagat	agcctatttt	gttcaaataca	91440
ttttttgaaat	ggcttcagaa	ctatgatgtt	agtactaaaa	aatgttgaaat	tttttgatga	91500
gagggaaaatg	tatctgacaa	tatgtaaaaa	gtaaaaagcaa	aatgatataca	aaaatgtata	91560
aatagataac	atggggccggg	cgccgtggct	tatgctgtga	atcccagcac	tttggggagg	91620
cgaggcgagat	ggatcacgag	gtcaggaggt	cgagaccagg	ctgggacaaca	tagtgaaaacc	91680
ctgtctccatg	tataaaataca	aaaattagoc	aggagcgctg	gcagcgccgt	gagtgtccag	91740
ctactcttggg	ggctgagaca	ggagaatcgc	ttgaacctgg	gagggcggaga	tgcgagtgag	91800
ctgagactctg	gcgactgcctc	tcgagcctag	gtgacagagc	aagctctgtga	aaaaaataaa	91860
aaaaaaaaaa	aaaaaaaaaa	acagtaaaaa	aagtgcatac	gtatatgtctg	tatatatcca	91920
gtaacagctca	gcagctataat	tacatacaca	tatttagcaaa	agtgcaaaaag	ataatgatgtt	91980
aatgtagtggt	tcattgttat	cttttctctt	gcaaaattac	tgagattcat	taaaaggctt	92040
ccctcagcaaa	ggcagttctca	atattttaacc	aacccttcca	gcgcataagct	gatctcttcc	92100
agotgtgtgtt	tacacagtttc	atgtgaaagc	aacaagtaaa	acctcaggaa	tttctatggc	92160
acgttagagag	aagcaaaaaa	attgagggtga	tttttttaaa	ttaaaaaaaa	gctgttgaaat	92220
ccaaacctagt	actcttccaa	aaatatttta	tctggggagta	ttttaaaaaa	tacacaagag	92280
gacctctctct	tcggcgtttg	gagcccccct	cctctgtctc	tgtagcgggg	agcgtcttcc	92340
ttcagccttc	tcttttcttt	cttgccattt	agactctctg	ctccttaaaa	ccaaaaccac	92400
aaacaaaaaa	aaaaaacacac	aaaagttagag	agatggtgtg	ataaataact	gtgctttcat	92460
cgccacagctc	cagcaattat	cgagctggcc	aatcttgttt	caactacacc	tccaccactt	92520
ctctcccccac	actggtttcat	tttgaagcaa	atctcagact	tcatttaact	tgtaaaagct	92580
tcaaaaactaa	ttgttagatt	taaaagttta	ataaggtccg	gctggggtta	attttttggc	92640
cagaagacttt	tacaggtgat	atgtagctcc	aattgcaact	catcaggaga	cagaaaaat	92700
ctgggtgtttt	ttctttttat	gacatcaaaa	ccagtttagtg	gtttcagatg	ttgttgacct	92760
gagcatctctg	ttacgaagtt	cccatcagtg	tttgatcaaga	tgatttttag	atctagctat	92820
tgatgtctcat	tgcttagata	cggtatttca	ttaggaattg	aaaatgtgtga	tatttcaatt	92880
ctatcatcttc	tctctcatctt	attagtaaga	attctttttc	tctcttctct	ttctttttct	92940
ttcttttttct	ttctttttctt	tctcttcttc	ttcttttttc	ttctttcttc	ttcttctctt	93000
ctctttctctc	ctttcttctct	ttctttctct	tctctctctc	tctctctctc	tttgacaggg	93060
tctcaactctg	tcacccaggc	tgaggtgcag	tggtgcgcat	ttggtctcat	gcaacctgtg	93120
cctccaggc	tcagccgagc	ctcccacctc	agcctctcga	gtagctggga	ctcacaggtgc	93180
atgccaccat	gcccgggtcaa	tttttgtatt	tttgttagag	atgggggttt	ctcaggttat	93240
atccgctggt	ctgaaactcc	agagctcaag	ccatctgcct	tctccagctt	gccagggtgc	93300
tggggattaca	ggcctgagcc	attgcgcctg	acctaagaat	tattttatga	ggaaatagtg	93360
cttgataaaat	aatgctctctt	tttgtatatt	tgccacagtg	tatttttaga	tagatctcta	93420
gaagctgcac	tttttgtctg	aaagggttaa	tgccatgtaa	ttttgtcaga	tatgactcca	93480
agcaactctct	gagaattcat	ttaattctgt	acctgtctct	acatgagctg	aaggtccggg	93540
ctgtctctgat	gggaagaagg	tattggagg	gaggcccaag	aggctgtagt	gggaaacctc	93600

aaccttgaaa	tgacaggaga	atccaaattc	agggagcgtg	tgggatcagg	agccacatga	93660
aaataccgaag	gccaggagcc	aggaaggaaa	tctggggatg	tccaatagg	gccacagatc	93720
gaatctggaag	ctctccatca	ggacatacaa	tgtgtggaag	atgatacaac	aaacaggctg	93780
ggacacaattt	ggggagggtc	caaggtctct	accccaacaa	cgagctgctc	ttttacaact	93840
atttttctgt	gctgtctgga	catataagca	aaggcagaca	cgctgttcga	ctgtattctg	93900
tcacgcccag	gctgagctaac	tgaaggagga	tgtgtgatgt	gaacctagt	ctgtacttta	93960
gccactggcc	ctccaccccc	aaaaggatga	gagtgaaagg	atgaagacca	ctctttttca	94020
atttgaccaa	agatgcattt	ggcttaacaa	aatggggcag	aattatccca	aatctctctc	94080
catcttttgc	gttatattca	tatttttctt	cataatttgg	ctataccagt	gcacttttaa	94140
actcgatagt	tagtaggaag	gttaggctaa	atgttatggg	cctttgcatt	ttgatccgta	94200
agcaaacagt	tgtgttttat	ttttagaaaa	tgtgtttccg	gtgtaactcg	caactctcga	94260
aaacttaggg	ttatgtgagg	tgaggcgatg	tgtatcttta	gtttattcgt	agatggggga	94320
agcaggaaaa	agcagcaaac	ttgtcagtat	ctggaaattg	tatggattct	tgtgtttaag	94380
acaggggact	gaagcctggc	tgtacataca	atacttttaa	catttatgtc	ttgtgaactg	94440
ctaagtgaat	tttgaaaaac	tatataactt	ttcacaaatt	tacaaaggat	gtttagtggt	94500
aatgatctga	aaagatatca	atttcagaa	tttgaaatta	tgacatttta	aataaaaaat	94560
gttcacacac	ctcttttaaa	gtggcgaagt	ggggccgtag	cagtgagctc	caactctaat	94620
cccgacagct	tgggaggctg	aggcaggagg	atctgttgag	gccaggagct	tgcacccagg	94680
cttgaccaca	tagtgagatc	ccacctctac	agcaaatatt	aaaattaatg	tattaatgat	94740
aatattgaca	ccaaagtgat	tgtatatctc	cgatactcca	atggaaaaaa	agaaaaaac	94800
tgcaagaact	ttctttaaaa	gaaaaaccca	aggacaacca	gcagagggat	tttcatctct	94860
cattttcaat	tgctctcttc	tctcttgaaa	atgtatttcc	atcccattcc	cgcaaaaaat	94920
tttatctagt	tgaaatatatt	tttaacgtct	aaaagccttt	cgtgtgatac	tatttatgtc	94980
tgtcacaaca	aaatatattat	ataaattaat	aattctctgg	ttctcaattc	ctacagttct	95040
aaggctctaa	tgtctcaaga	tttcttcaat	tagttatttt	tacaaagttt	ttttatttgt	95100
acaatgttca	ttcacaaatc	aaaaataata	attttttatc	tttttgagac	catgtgtaaa	95160
caaaatttgc	tgtcaaaagta	cttttttaat	gagagattgt	ttttcagaac	ctttgtttaa	95220
gaaggtctct	caggcatcag	tgtgaatttc	cttactcttg	gaaggtgggt	tttttatagt	95280
tctcagggca	ctgcataata	ttaaaataaa	ggatggggcc	gtgcagtggt	ttcacactgt	95340
aatcccgaca	ttttgggaag	tcgaggtgga	aaagcgttgt	agcccaggag	ttcgagacca	95400
gcccgtggca	tacagtgaag	cccacatctc	tacgaaaaat	aaaataacta	actggggtgt	95460
gtgacacacg	ctctctagtc	cagccattca	ggaagctgag	gtggagaagt	cactgtgagc	95520
ggggaggtgc	tgcagctgtc	atagcccacc	gaacttcagc	ctggggcgca	gagtgagatg	95580
ctgtctcaaa	aaatatgtat	atactatata	tatatacaca	cacacatgca	aacacatata	95640
tatcacacac	cacactttat	atatatatac	cacatatagc	tatttgcta	catatacaca	95700
tatatagaca	caccctatac	tacatatata	gacacacata	tatgatgtat	atagtgtcac	95760
acacacgtgt	atatatacac	atatcacac	atatacatat	acacacatg	atatcacac	95820
tatatattgt	tacatagcat	atagtgtat	atcatatcat	catacatata	tatgatgtgt	95880
gtgcatgtat	atgtagggtg	tgttatatata	gaatatcatg	gggaatatat	atatatgatg	95940
gggggtgcaa	gattttggtg	aagcaggaga	agggcaatta	tgaaatgaga	aataaaaaaa	96000
gagccagctt	aatgctctaa	tctcaggag	ttctctgtct	agaccaatgt	tcagaaaaag	96060
gtacaaatgt	aggtgtatgg	ttcccactat	aaagaccctg	cgagggtctc	caactacccc	96120
ttgggttgtg	cataccocaa	ctgggaagac	actggcccat	gtaattatg	gtgagatcct	96180
tattctagaa	atggagagta	ataaaaccca	cctgtcagag	tgtgtaggag	taaacagatg	96240
aatctctctg	ctcagctctg	tgttatatg	ctgtgttaac	acagggttaa	tgaaactatg	96300
tgtctgagtt	gggcatttat	tgttatttgt	atcttctatg	gtgttgataa	tgttatgaat	96360
aattaagata	agggatgagg	ataatttgtt	cgaaagtctc	atgtatctct	tattctcaag	96420
gttagatgtg	aatgtctctg	ttctctgtct	gtctctatct	ccggaattgt	tggctctctg	96480
gtgtgggatt	tcagaggttg	ctatgttatg	cccgaaagtc	acaaaggggc	ctgaactacg	96540
gaagtgtcca	tgaatgtttg	gttgtagtga	ttaatgtgat	ttctctatct	agtgctctat	96600
tacaattaaa	acgagaacaa	cgactcatct	aaaaggagta	gaagccacta	ggccaaacct	96660
atccctcttc	aaaaattctc	cccttttgac	tgatctgtgt	cttttcagag	accocataat	96720
agaaaaagaa	ccaattcttg	ccacttattt	ctcttttgga	aagaaaaagt	ggtttcataa	96780
ttgttttgtg	tgtcaactat	gccaaactgg	gcatttgcaa	agctcagggt	gagtggttac	96840
atagacgtaa	ggtatacttt	agccttgggg	gcactataaa	gacatgttgt	tgtcttgata	96900
aaaaagaaag	aaagggcagg	tacggtggct	catgcttata	atcccagcac	ttcggggagc	96960
ctagggcagc	ggagaaatg	ctcaggagat	cagagcattc	ctggccacaa	tgttaaaaac	97020
ccgtctctag	aaaaataaaa	aaattagctg	cgctgggtgc	acacacctgt		

gaggattact	tgagccgggg	aggtagaggc	tgcaagtgaac	tatgatgacg	tcactgcact	97380
tcggcctgga	cgacagcaag	accctatctc	aaaaaaaaaa	aaaagaaaga	aagaaaaatta	97440
acaagcaaa	gaagaattct	ttttaaaaag	tttgagagtt	aatactctaa	tcggttaacta	97500
tgcttatctt	aagtttagtt	agtcaaat	tatcgaatcg	aaactgaagc	tggttaggttt	97560
ctgcatgtgt	aaaacctggc	tcctaaagaa	ctccagattt	ccttcagtt	ctaaaattaa	97620
gtttatgcat	caatttacgt	ttatgcatag	cacatgcatg	cc		97662

<210> 2
 <211> 6782
 <212> DNA
 <213> Homo sapiens

<220>
 <221> 5'UTR
 <222> 1..112

<220>
 <221> CDS
 <222> 113..6547

<220>
 <221> 3'UTR
 <222> 6548..6782

<220>
 <221> allele
 <222> 178
 <223> 5-382-162 : polymorphic base C or T

<220>
 <221> allele
 <222> 2677
 <223> 5-383-184 : polymorphic base G or T

<220>
 <221> allele
 <222> 5193
 <223> 5-370-197 : polymorphic base A or G

<220>
 <221> allele
 <222> 5243
 <223> 5-370-247 : polymorphic base C or T

<220>
 <221> allele
 <222> 5673
 <223> 5-373-164 : polymorphic base C or T

<220>
 <221> allele
 <222> 5731
 <223> 5-373-222 : polymorphic base A or G

<220>
 <221> allele
 <222> 6011
 <223> 5-375-200 : polymorphic base A or G

<220>
 <221> allele
 <222> 6162

<223> 5-376-266 : polymorphic base A or G

<220>

<221> allele

<222> 6271

<223> 5-377-227 : polymorphic base A or G

<400> 2

```

ggttgggctc cttggtacca tgtgggaagc gctgtgaaga gttgttcct tccaagatat      60
acccaaattc ccaggtccag cccgtgtcat taaaactccg ctggcgtgaa ag atg acg      118
Met Thr
1
tcc tta gcc cag cag ctg caa cga ctc gcc ctc cct caa agt gat gcc      166
Ser Leu Ala Gln Gln Leu Gln Arg Leu Ala Leu Pro Gln Ser Asp Ala
5 10 15
agc ctc tta tcy aga gat gaa gtt gct tct ttg tta ttt gac cct aag      214
Ser Leu Leu Ser Arg Asp Glu Val Ala Ser Leu Leu Phe Asp Pro Lys
20 25 30
gaa gcg gcc aca atc gac agg gac acc gcc ttc gcc att gga tgt act      262
Glu Ala Ala Thr Ile Asp Arg Asp Thr Ala Phe Ala Ile Gly Cys Thr
35 40 45 50
ggc ctg gaa gag ttg ctt gga att gat cct tcc ttt gag cag ttt gaa      310
Gly Leu Glu Glu Leu Leu Gly Ile Asp Pro Ser Phe Glu Gln Phe Glu
55 60 65
gca ccg ttg ttc agt cag cta gca aaa acc ttg gag cga agt gtt cag      358
Ala Pro Leu Phe Ser Gln Leu Ala Lys Thr Leu Glu Arg Ser Val Gln
70 75 80
acc aaa gca gta aac aaa cag ttg gat gaa aac att tca tta ttc ctt      406
Thr Lys Ala Val Asn Lys Gln Leu Asp Glu Asn Ile Ser Leu Phe Leu
85 90 95
att cac ttg tcy cct tac ttc ctg ctt aag cca gca cag aag tgt ctg      454
Ile His Leu Ser Pro Tyr Phe Leu Leu Lys Pro Ala Gln Lys Cys Leu
100 105 110
gag tgg ttg att cac agg ttc cat ata cat ctc tat aat caa gat agc      502
Glu Trp Leu Thr Ile His Arg Phe His Ile His Leu Tyr Asn Gln Asp Ser
115 120 125 130
ctc att gct tgt gtt ctg cca tac cac gag aca aga ata ttt gtg cga      550
Leu Ile Ala Cys Val Leu Pro Tyr His Glu Thr Arg Ile Phe Val Arg
135 140 145
gtc ata cag ctt cta aaa att aat aat tca aag cac aga tgg ttc tgg      598
Val Ile Gln Leu Leu Lys Ile Asn Asn Ser Lys His Arg Trp Phe Trp
150 155 160
ttg ttg cca gtt aag caa tct gga gtg ccg tta gct aaa gga act ttg      646
Leu Leu Pro Val Lys Gln Ser Gly Val Pro Leu Ala Lys Gly Thr Leu
165 170 175
att acc cac tgc tac aaa gat ctt gga ttc atg gat ttc att tgc agt      694
Ile Thr His Cys Tyr Lys Asp Leu Gly Phe Met Asp Phe Ile Cys Ser
180 185 190
ttg gtg aca aaa tct gtg aag gtt ttt gct gag tac ccg gcc agc tca      742
Leu Val Thr Lys Ser Val Lys Val Phe Ala Glu Tyr Pro Gly Ser Ser
195 200 205 210
gct cag ttg agg gtg ctc ttg gct ttc tat gct tct acc ata gtg tcy      790
Ala Gln Leu Arg Val Leu Leu Ala Phe Tyr Ala Ser Thr Ile Val Ser
215 220 225
gcg ctg gta gct gca gag gac gta tca gac aat atc atc gcc aaa cta      838
Ala Leu Val Ala Ala Glu Asp Val Ser Asp Asn Ile Ile Ala Lys Leu
230 235 240
ttt ccc tat atc caa aag gga ttg aaa tca tct tta cca gat tac aga      886
Phe Pro Tyr Ile Gln Lys Gly Leu Lys Ser Ser Leu Pro Asp Tyr Arg
245 250 255
gct gca aca tac atg ata tga tgt cag att tct gtg aaa gtg acc atg      934
Ala Ala Thr Tyr Met Ile Ile Cys Gln Ile Ser Val Lys Val Thr Met

```

260	gaa aat acc ttt gtg aat	265	tgt tca ttg gca tca cag atc	270	atc aaa aca ttg	982
	Glu Asn Thr Phe Val Asn Ser		Leu Ala Ser Gln Ile Ile Lys Thr		Leu	
275	acc aag att ccc tct ttg atc aag gat ggg tta agt tgc ttg ata gtg	280	Thr Lys Ile Pro Ser Leu Ile Lys Asp	285	Gly Leu Ser Cys Leu Ile Val	1030
	295		300		305	
	ctc ctg cag aga cag aag cca gag agc ctt ggg aaa aag cca ttc cct		Leu Leu Gln Arg Gln Lys Pro Glu Ser Leu Gly Lys Lys Pro Phe Pro			1078
	310		315		320	
	cac tta tgt aat gtt cct gat ctt att aca ata ctt cat ggg att tct		His Leu Cys Asn Val Pro Asp Leu Ile Thr Ile Leu His Gly Ile Ser			1126
	325		330		335	
	gaa act tac gat gtc agt cct ctt ctg cgt tac atg ctt ccc cat ctg		Glu Thr Tyr Asp Val Ser Pro Leu Leu Arg Tyr Met Leu Pro His Leu			1174
	340		345		350	
	gtc gtc tcc atc att cat cat gtt aca gga gaa aac act gaa gga atg		Val Val Ser Ile Ile His His Val Thr Gly Glu Glu Thr Glu Gly Met			1222
	355		360		365	
	gat ggt caa atc tac aag aga cac tta gaa gct ata ctt aca aaa ata		Asp Gly Gln Ile Tyr Lys Arg His Leu Glu Ala Ile Leu Thr Lys Ile			1270
	375		380		385	
	tca ctg aag aac aac tta gac cat ttg ttg gct agc ctt cta ttt gaa		Ser Leu Lys Asn Asn Leu Asp His Leu Leu Ala Ser Leu Leu Phe Glu			1318
	390		395		400	
	gag tat att tca tat agt tca cag gaa gaa atg gat tct aat aaa gtg		Glu Tyr Ile Ser Tyr Ser Ser Gln Glu Glu Met Asp Ser Asn Lys Val			1366
	405		410		415	
	tct ttg ctt aat gaa caa ttt ctt cca ctc att aga ctt tta gaa agc		Ser Leu Leu Asn Glu Gln Phe Leu Pro Leu Ile Arg Leu Leu Glu Ser			1414
	420		425		430	
	aaa tac ccc aga aca tta gat gtt gta tta gag gaa cac tta aag gaa		Leu Tyr Pro Arg Thr Leu Asp Val Val Leu Glu Glu His Leu Lys Glu			1462
	435		440		445	
	att gca gat ctg aaa aaa caa gag ctt ttc cat cag ttt gtt tct ctt		Ile Ala Asp Leu Lys Lys Gln Glu Leu Phe His Gln Phe Val Ser Leu			1510
	455		460		465	
	tct aca agt gga gga aag tat cag ttt tta gca gat tct gat act tct		Ser Thr Ser Ser Gly Gly Lys Tyr Gln Phe Leu Ala Asp Ser Asp Thr Ser			1558
	470		475		480	
	ttg atg ctc agc ctg aat cat cca ctt gct cct gtg aga att ctg gcc		Leu Met Leu Ser Leu Asn His Pro Leu Ala Pro Val Arg Ile Leu Ala			1606
	485		490		495	
	atg aat cat ttg aaa aag atc atg aaa aca tca aag gag ggt gtt gat		Met Asn His Leu Lys Lys Ile Met Lys Thr Ser Lys Glu Gly Val Asp			1654
	500		505		510	
	gaa tct ttc ata aaa gaa gct gtt tta gcc cga tta ggt gat gat aat		Glu Ser Phe Ile Lys Glu Ala Val Leu Ala Arg Leu Gly Asp Asp Asn			1702
	515		520		525	
	ata gat gtt gtt ttg tcg gct ata agt gct ttt gag att ttc aaa gaa		Ile Asp Val Val Leu Ser Ala Ile Ser Ala Phe Glu Ile Phe Lys Glu			1750
	535		540		545	
	cac ttc agt tca gaa gtg acg att tca aat ctt ctg aat ctc ttt caa		His Phe Ser Ser Glu Val Thr Ile Ser Asn Leu Leu Asn Leu Phe Gln			1798
	550		555		560	
	aga gca gaa ctt tca aag aat gga gaa tgg tac gag gta ctt aag ata		Arg Ala Glu Leu Ser Lys Asn Gly Glu Trp Tyr Glu Val Leu Lys Ile			1846
	565		570		575	
	gcc gct gac ata tta att aaa gaa gag ata ctg agt gaa aat gat cag		Ala Ala Asp Ile Leu Ile Lys Glu Glu Ile Leu Ser Glu Asn Asp Gln			1894
	580		585		590	
	ttg tca aat cag gtg gtt gta tgt ttg ctg cca ttt gtg gtt atc aat					1942

Leu	Ser	Asn	Gln	Val	Val	Val	Cys	Leu	Leu	Pro	Phe	Val	Val	Ile	Asn	
595				600					605						610	
aat	gat	gat	acg	gaa	tct	gct	gag	atg	aaa	att	gct	ata	tat	tta	tca	1990
Asn	Asp	Asp	Thr	Glu	Ser	Ala	Glu	Met	Lys	Ile	Ala	Ile	Tyr	Leu	Ser	
			615						620					625		
aaa	tca	gga	atc	tgc	tcc	cac	cct	cta	tta	aga	ggc	tgg	gaa	gaa		2038
Lys	Ser	Gly	Ile	Cys	Ser	Leu	His	Pro	Leu	Leu	Arg	Gly	Trp	Glu	Glu	
			630					635				640				
gct	ctt	gaa	aat	gta	att	aaa	agc	aca	aag	cca	agg	aaa	cta	atc	ggg	
Ala	Leu	Glu	Asn	Val	Ile	Lys	Ser	Thr	Lys	Pro	Gly	Lys	Leu	Ile	Gly	2086
			645					650				655				
gta	gca	aat	cag	aag	atg	att	gag	ttg	ttg	gct	gat	aat	ata	aat	tta	
Val	Ala	Asn	Gln	Lys	Met	Ile	Glu	Leu	Leu	Ala	Asp	Asn	Ile	Asn	Leu	2134
			660				665					670				
gga	gat	cct	tct	tca	atg	tta	aag	atg	gtg	gag	gat	ttg	ata	agc	gtg	
Gly	Asp	Pro	Gag	gag	tcc	ttt	aac	ctg	aat	aaa	gta	acg	ttt	cat	gtg	2182
			675				680			685					690	
ggg	gat	gag	gag	gag	tcc	ttt	aac	ctg	aag	cag	aaa	gta	acg	ttt	cat	gtg
Gly	Glu	Glu	Glu	Ser	Phe	Asn	Leu	Lys	Gln	Lys	Val	Thr	Phe	His	Val	2230
					695				700					705		
atc	ctg	tct	gtg	ctc	gtc	tct	tgt	tgt	tca	tct	tta	aaa	gaa	acc	cac	
Ile	Leu	Ser	Val	Leu	Val	Ser	Cys	Cys	Ser	Ser	Leu	Lys	Glu	Thr	His	2278
			710					715					720			
ttt	cca	ttt	gcg	ata	aga	gtc	ttc	agt	ttg	ttg	cag	aaa	aaa	ata	aag	
Phe	Pro	Phe	Ala	Ile	Arg	Val	Phe	Ser	Leu	Leu	Lys	Gln	Lys	Ile	Lys	2326
			725				730					735				
aag	ctt	gaa	agt	gtc	att	act	gca	gtg	gaa	atc	ccc	tca	gaa	tgg	cac	
Lys	Leu	Glu	Ser	Val	Ile	Thr	Ala	Val	Glu	Ile	Pro	Ser	Glu	Trp	His	2374
			740				745				750					
att	gaa	ctg	atg	tta	gac	aga	ggg	atc	cca	gta	gag	ctg	tgg	gca	cat	
Ile	Glu	Leu	Met	Leu	Asp	Arg	Gly	Ile	Pro	Val	Glu	Leu	Trp	Ala	His	2422
			755				760			765					770	
tat	gta	gaa	gag	ctc	aac	agc	act	cag	agg	gtg	gcc	gtg	gag	gac	tcg	
Tyr	Val	Glu	Glu	Leu	Asn	Ser	Thr	Gln	Arg	Val	Ala	Val	Glu	Asp	Ser	2470
					775				780					785		
gtt	ttt	ctt	gta	ttt	tcc	ttg	aaa	aaa	ttt	att	tat	gca	ctg	aaa	gct	
Val	Phe	Leu	Val	Phe	Ser	Leu	Lys	Lys	Phe	Ile	Tyr	Ala	Leu	Lys	Ala	2518
			790					795					800			
cct	aaa	tct	ttt	cct	aaa	ggg	gat	ata	tgg	tgg	aat	cct	gaa	caa	ctg	
Pro	Lys	Ser	Phe	Pro	Lys	Gly	Asp	Ile	Trp	Tr						

Leu Leu Asp Lys Val Asn Ala Leu Leu Pro Thr Glu Thr Phe Ile Pro
 1590 1595 1600
 gtg atc aga ggg ctg gtg ggc aat ccc ctg cca tct gtt cgc cgc aaa 4966
 Val Ile Arg Gly Leu Val Gly Asn Pro Leu Pro Ser Val Arg Arg Lys
 1605 1610 1615
 gcg ctg gac ctt ttg aat aac aag ctg cag caa aat ata tcc tgg aag 5014
 Ala Leu Asp Leu Leu Asn Asn Lys Leu Gln Gln Asn Ile Ser Trp Lys
 1620 1625 1630
 aag aca ata gtt acc cgt ttc cta aaa ctg gtt cca gac ctt ttg gcc 5062
 Lys Thr Ile Val Thr Arg Phe Leu Lys Leu Val Pro Asp Leu Leu Ala
 1635 1640 1645 1650
 att gtg cag cgt aag aaa aag gaa ggg gaa gaa gaa gln Ala Ile Asn 5110
 Ile Val Gln Arg Lys Lys Lys Glu Gly Glu Glu Glu Gln Ala Ile Asn
 1655 1660 1665
 aga cag aca gcg ttg tat acc tta aag ctt tta tgc aag aat ttt ggt 5158
 Arg Gln Thr Ala Leu Tyr Thr Leu Lys Leu Cys Lys Asn Phe Gly
 1670 1675 1680
 gca gaa aat cca gat cct ttt gtc cca gtg ctg arc act gct gtg aaa 5206
 Ala Glu Asn Pro Asp Pro Phe Val Pro Val Leu Xaa Thr Ala Val Lys
 1685 1690 1695
 ctg att gct cca gag aga aag gag gag aag aat gtc ytg gga agc gcg 5254
 Leu Ile Ala Pro Glu Arg Lys Glu Glu Lys Asn Val Leu Gly Ser Ala
 1700 1705 1710
 ctg ctg tgc ata gca gag gtg acc tcc acc ctg gag cgc ctg gcc atc 5302
 Leu Leu Cys Ile Ala Glu Val Thr Ser Thr Leu Glu Ala Leu Ala Ile
 1715 1720 1725 1730
 ccc cag ctt ccc agc ctg atg cca tgc ttg ctg aca aca atg aag aac 5350
 Pro Gln Leu Pro Ser Leu Met Pro Ser Leu Thr Thr Met Lys Asn
 1735 1740 1745
 acc agc gag ctg gtc tcc agc gag gtc tac ctg ctc agt gcc ttg gct 5398
 Thr Ser Glu Leu Val Ser Ser Glu Val Tyr Leu Leu Ser Ala Leu Ala
 1750 1755 1760
 gct ctg cag aag gtt gtg gag act ctc ccg cac ttc atc agc ccc tat 5446
 Ala Leu Gln Lys Val Val Glu Thr Leu Pro His Phe Ile Ser Pro Tyr
 1765 1770 1775
 ctg gaa ggc att ctc tcc cag gtg att cat ctg gag aaa atc act agt 5494
 Leu Glu Gly Ile Leu Ser Gln Val Ile His Leu Glu Lys Ile Thr Ser
 1780 1785 1790
 gaa atg ggt tct gcg tca cag gct aat atc cgt ctc aca tct ctt aaa 5542
 Glu Met Gly Ser Ala Ser Gln Ala Asn Ile Arg Leu Thr Ser Leu Lys
 1795 1800 1805 1810
 aag aca ctg gct acc aca ctt gca ccc cga gtc ctg ttg ccc gcc atc 5590
 Lys Thr Leu Ala Thr Thr Leu Ala Pro Arg Val Leu Leu Pro Ala Ile
 1815 1820 1825
 aaa aaa act tac aag cag att gag aag aac tgg aag aat cac atg ggt 5638
 Lys Lys Thr Tyr Lys Gln Ile Glu Lys Asn Trp Lys Asn His Met Gly
 1830 1835 1840
 cgg ttt atg agc atc ttg caa gag cat att ggg gyg atg aag aag gaa 5686
 Pro Phe Met Ser Ile Leu Gln Glu His Ile Gly Xaa Met Lys Lys Glu
 1845 1850 1855
 gag ctc acc tcc cat cag tct cag cta acc gcc ttt ttc ctg gar gcc 5734
 Glu Leu Thr Ser His Gln Ser Gln Leu Thr Ala Phe Phe Leu Glu Ala
 1860 1865 1870
 ctg gac ttc cga gcc cag cac tct gag aac gat ctg gag gaa gtt gga 5782
 Leu Asp Phe Arg Ala Gln His Ser Glu Asn Asp Leu Glu Glu Val Gly
 1875 1880 1885 1890
 aaa acg gaa aat tgt atc att gac tgt cta gta gcc atg gtt gtc aaa 5830
 Lys Thr Glu Asn Cys Ile Ile Asp Cys Leu Val Ala Met Val Val Lys
 1895 1900 1905
 ctt tcc gag gtc aca ttc agg ccc ctg ttc ttc aag ctg ttt gat tgg 5878
 Leu Ser Glu Val Thr Phe Arg Pro Leu Phe Phe Lys Leu Phe Asp Trp
 1910 1915 1920

gct aaa aca gaa gat gcc cca aag gac agg ttg ttg aca ttt tac aac	5926
Ala Lys Thr Glu Asp Ala Pro Lys Asp Arg Leu Leu Thr Phe Tyr Asn	
1925 1930 1935	
ttg gca gat tgc att gct gaa aag ctg aaa ggg ctt ttt act ctg ttt	5974
Leu Ala Asp Cys Lys Ile Ala Glu Lys Cys Gly Leu Phe Thr Leu Phe	
1940 1945 1950	
gcc ggc cac tta gtg aag cct ttt gct gac acc ttg rac cag gtg aac	6022
Ala Gly His Leu Val Lys Pro Phe Ala Asp Thr Leu Xaa Gln Val Asn	
1955 1960 1965 1970	
atc tcc aaa aca gat gaa gca ttt ttt gac tct gaa aat gac cct gaa	6070
Ile Ser Lys Thr Asp Glu Ala Phe Phe Asp Ser Glu Asn Asp Pro Glu	
1975 1980 1985	
aag tgc tgc ttg ctg ttg cag ttt att ttg aac tgt tta tac aaa atc	6118
Lys Cys Cys Leu Leu Leu Gln Phe Ile Leu Asn Cys Leu Tyr Lys Ile	
1990 1995 2000	
ttc ctt ttt gat acc cct ttt ata aac gag aga gca gra gcc	6166
Phe Leu Phe Asp Thr Gln His Phe Ile Ser Lys Glu Arg Ala Xaa Ala	
2005 2010 2015	
ttg atg atg cct ctg gtg gat cag ctg gaa aac agg ctt ggg gga gaa	6214
Leu Met Met Pro Leu Val Asp Gln Leu Glu Asn Arg Leu Gly Gly Glu	
2020 2025 2030	
gag aaa tct cag gaa cgg gtg aca aag cac ctg ata cca tgc atc gca	6262
Glu Lys Phe Gln Glu Arg Val Thr Lys His Leu Ile Pro Cys Ile Ala	
2035 2040 2045 2050	
cag ttt tcr gtg gcc atg cct gat gac tct ctt tgg aaa cca ctg aac	6310
Gln Phe Ser Val Ala Met Ala Asp Asp Ser Leu Trp Lys Pro Leu Asn	
2055 2060 2065	
tac cag att ctg cta aag acg aga gac tcc tgc cct aag gtt cga ttt	6358
Tyr Gln Ile Leu Lys Lys Thr Arg Asp Ser Ser Lys Val Arg Phe	
2070 2075 2080	
gct gct ttg att act gtg tta gca ctg gct gaa aaa cta aag gag aat	6406
Ala Ala Lys Ile Thr Val Leu Ala Leu Ala Glu Lys Leu Lys Glu Asn	
2085 2090 2095	
tat att gtc ttg cta cca gaa tcc att cct ttc tta gca gag ttg atg	6454
Tyr Ile Val Leu Leu Pro Glu Ser Ile Pro Phe Leu Ala Glu Leu Met	
2100 2105 2110	
gaa gat gaa tgt gaa gaa gta gaa gaa cat cag tgc caa aag act act cag	6502
Glu Asp Glu Cys Glu Glu Val Glu His Gln Cys Gln Lys Thr Ile Gln	
2115 2120 2125 2130	
caa ctg gaa act gtc ctg gga gag cca ctc cag agc tat ttc taa	6547
Gln Leu Glu Thr Val Leu Gly Glu Pro Leu Gln Ser Tyr Phe *	
2135 2140 2145	
gactttctgt ggtgtttcat actctactca gaggttcacac tcatatttca tattttttat	6607
tttggtgtgt ggggtccatg ttacttttgg tgcccttaata caccctactt gattactttac	6667
aaatggtttta tcaacttgtt acaaaatccc cactgggctt gtgctgccac atagaacctt	6727
ctcgcctact qtatagagct gcagaaagag taatagtatac acggtatttt tatac	6782

```
<210> 3
<211> 7932
<212> DNA
<213> Homo sapiens
```


0960365 = 062300

[illegible]

20					25					30						
gaa	gag	gcc	aca	atc	gac	agg	gac	acc	gcc	ttc	gcc	att	gga	tgt	act	262
Glu	Ala	Gla	Thr	Ile	Asp	Arg	Asp	Thr	Ala	Phe	Ala	Ile	Gly	Cys		
35				40					45					50		
ggc	ctg	gaa	gag	ttg	ctt	gga	att	gat	cct	tcc	ttt	gag	cag	ttt	gaa	310
Gly	Leu	Glu	Glu	Leu	Leu	Gly	Ile	Asp	Pro	Ser	Phe	Glu	Gln	Phe	Glu	
				55					60					65		
gca	ccg	ttg	ttc	agt	cag	cta	gca	aaa	acc	ttg	gag	cga	agt	gtt	cag	358
Ala	Pro	Leu	Phe	Ser	Gln	Leu	Ala	Lys	Thr	Leu	Arg	Ser	Val	Gln		
			70					75					80			
acc	aaa	gca	gta	aac	aaa	cag	ttg	gat	gaa	aac	att	tca	tta	ctt	ctt	406
Thr	Lys	Ala	Val	Asn	Lys	Gln	Leu	Asp	Glu	Asn	Ile	Ser	Leu	Phe	Leu	
			85				90				95					
att	cac	ttg	tcg	cct	tac	ttc	ctg	ctt	aag	cca	gca	cag	aag	tgt	ctg	454
Ile	His	Leu	Ser	Pro	Tyr	Phe	Leu	Leu	Lys	Pro	Ala	Gln	Lys	Cys	Leu	
			100				105				110					
gag	tgg	ttg	att	cac	agg	ttc	cat	ata	cat	ctc	tat	aat	caa	gat	agc	502
Glu	Trp	Leu	Ile	His	Arg	Phe	His	Ile	His	Leu	Tyr	Asn	Gln	Asp	Ser	
115				120					125						130	
ctc	att	gct	tgt	gtt	ctg	cca	tac	cac	gag	aca	aga	ata	ttt	gtg	cga	550
Leu	Ile	Ala	Cys	Val	Leu	Pro	Tyr	His	Glu	Thr	Arg	Ile	Phe	Val	Arg	
				135					140				145			
gtc	ata	cag	ctt	cta	aaa	att	aat	aat	tca	aag	cac	aga	tgg	tct	tggt	598
Val	Ile	Gln	Leu	Leu	Lys	Ile	Asn	Asn	Ser	Lys	His	Arg	Trp	Phe	Trp	
			150					155					160			
ttg	ttg	cca	gtt	aag	caa	tct	gga	gtg	ccg	tta	gct	aaa	gga	act	ttg	646
Leu	Leu	Pro	Val	Lys	Gln	Ser	Gly	Val	Pro	Leu	Ala	Lys	Gly	Thr	Leu	
			165				170				175					
att	acc	cac	tcg	tac	aaa	gat	ctt	gga	ttc	atg	gat	ttc	att	tcg	agt	694
Ile	Thr	His	Cys	Tyr	Lys	Asp	Leu	Gly	Phe	Met	Asp	Phe	Ile	Cys	Ser	
			180				185				190					
ttg	gtg	aca	aaa	tct	gtg	aag	gtt	ttt	gct	gac	ccg	ggc	agc	tca		742
Leu	Val	Thr	Lys	Ser	Val	Lys	Val	Phe	Ala	Glu	Tyr	Pro	Gly	Ser	Ser	
195				200					205					210		
gct	cag	ttg	agg	gtg	ctc	ttg	gct	ttc	tat	gct	tct	acc	ata	gtg	tcg	790
Ala	Gln	Leu	Arg	Val	Leu	Ala	Phe	Tyr	Ala	Ser	Thr	Ile	Val	Ser		
				215				220					225			
gcg	ctg	gta	gct	gca	gag	gac	gta	tca	gac	aat	atc	atc	gcc	aaa	cta	838
Ala	Leu	Val	Ala	Ala	Glu	Asp	Val	Ser	Asp	Asn	Ile	Ile	Ala	Lys	Leu	
			230					235					240			
ttt	ccc	tat	atc	caa	aag	gga	ttg	aaa	tca	tct	tta	cca	gat	tac	aga	886
Phe	Pro	Tyr	Ile	Gln	Lys	Gly	Leu	Lys	Ser	Ser	Leu	Pro	Asp	Tyr	Arg	
			245				250					255				
gct	gca	aca	tac	atg	ata	ata	tgt	cag	att	tct	gtg	aaa	gtg	acc	atg	934
Ala	Ala	Thr	Tyr	Met	Ile	Ile	Cys	Gln	Ile	Ser	Val	Lys	Val	Thr	Met	
			260				265				270					
gaa	aat	acc	ttt	gtg	aat	tca	ttg	gca	tca	cag	atc	atc	aaa	aca	ttg	982
Glu	Asn	Thr	Phe	Val	Asn	Ser	Leu	Ala	Ser	Gln	Ile	Ile	Lys	Thr	Leu	
275				280					285					290		
acc	aag	att	ccc	tot	ttg	atc	aag	gat	ggg	tta	agt	tcg	ttg	ata	gtg	1030
Thr	Lys	Ile	Pro	Ser	Leu	Ile	Lys	Asp	Gly	Leu	Ser	Cys	Leu	Ile	Val	
				295					300					305		
ctc	ctg	cag	aga	cag	aag	cca	gag	agc	ctt	ggg	aaa	aag	cca	tct	cct	1078
Leu	Leu	Gln	Arg	Gln	Lys	Pro	Glu	Ser	Leu	Gly	Lys	Lys	Pro	Phe	Pro	
			310					315					320			
cac	tta	tgt	aat	gtt	cct	gat	ctt	att	aca	ata	ctt	cat	ggg	att	tct	1126
His	Leu	Cys	Asn	Val	Pro	Asp	Leu	Ile	Thr	Ile	Leu	His	Gly	Ile	Ser	
			325				330					335				
gaa	act	tac	gat	gtc	agt	cct	ctt	ctg	cgt	tac	atg	ctt	ccc	cat	ctg	1174
Glu	Thr	Tyr	Asp	Val	Ser	Pro	Leu	Leu	Arg	Tyr	Met	Leu	Pro	His	Leu	
			340				345				350					
gtc	gtc	tcc	atc	att	cat	cat	gtt	aca	gga	gaa	gaa	act	gaa	gga	atg	1222

Val	Val	Ser	Ile	Ile	His	His	Val	Thr	Gly	Glu	Glu	Thr	Glu	Gly	Met	
355				360					365						370	
gat	ggt	caa	atc	tac	aag	aga	cac	tta	gaa	gct	ata	ctt	aca	aaa	ata	1270
Asp	Gly	Gln	Ile	Tyr	Lys	Arg	His	Leu	Glu	Ala	Ile	Leu	Thr	Lys	Ile	
				375					380					385		
tca	ctg	aag	aac	aac	tta	gac	cat	tgt	ttg	gct	agc	ctt	cta	ttt	gaa	1318
Ser	Leu	Lys	Asn	Asn	Leu	Asp	His	Leu	Leu	Ala	Ala	Ser	Leu	Phe	Glu	
				390					395				400			
gag	tat	att	tca	tat	agt	tca	cag	gaa	gaa	atg	gat	tct	aat	aaa	gtg	1366
Glu	Tyr	Ile	Ser	Tyr	Ser	Ser	Gln	Glu	Glu	Met	Asp	Ser	Asn	Lys	Val	
				405				410				415				
tct	tgt	ctt	aat	gaa	caa	ttt	ctt	cca	ctc	att	aga	ctt	tta	gaa	agc	1414
Ser	Leu	Leu	Asn	Glu	Gln	Phe	Leu	Pro	Leu	Ile	Arg	Leu	Leu	Glu	Ser	
				420				425				430				
aaa	tac	ccc	aga	aca	tta	gat	gtt	gta	tta	gag	gaa	cac	tta	aag	gaa	1462
Lys	Tyr	Arg	Arg	Thr	Leu	Asp	Val	Val	Glu	Glu	Glu	His	Lys	Glu	Val	
435				440					445					450		
att	gca	gat	ctg	aaa	aaa	caa	gag	ctt	ttc	cat	cag	ttt	gtt	tct	ctt	1510
Ile	Ala	Asp	Leu	Lys	Lys	Gln	Glu	Leu	Phe	His	Gln	Phe	Val	Ser	Leu	
				455					460					465		
tct	aca	agt	gga	gga	aag	tat	cag	ttt	tta	gca	gat	tct	gat	act	tct	1558
Ser	Thr	Ser	Gly	Gly	Lys	Tyr	Gln	Phe	Leu	Ala	Asp	Ser	Asp	Thr	Ser	
				470				475					480			
ttg	atg	ctc	agc	ctg	aat	cat	cca	ctt	gct	cct	gtg	aga	att	ctg	gcc	1606
Leu	Met	Leu	Ser	Leu	Asn	His	Pro	Leu	Ala	Pro	Val	Arg	Ile	Leu	Ala	
				485				490				495				
atg	aat	cat	ttg	aaa	aag	atc	atg	aaa	aca	tca	aag	gag	ggt	gtt	gat	1654
Met	Asn	His	Leu	Lys	Lys	Ile	Met	Lys	Thr	Ser	Lys	Glu	Gly	Val	Asp	
				500				505				510				
gaa	tct	ttc	ata	aaa	gaa	gct	gtt	tta	gcc	cga	tta	ggt	gat	gat	aat	1702
Glu	Ser	Phe	Ile	Lys	Glu	Ala	Val	Leu	Ala	Arg	Leu	Gly	Asp	Asp	Asn	
515				520					525					530		
ata	gat	gtt	gtt	ttg	tcg	gct	ata	agt	gct	ttt	gag	att	ttc	aaa	gaa	1750
Ile	Asp	Val	Val	Leu	Ser	Ala	Ile	Ser	Ala	Phe	Glu	Ile	Phe	Lys	Lys	
				535					540					545		
cac	ttc	agt	tca	gaa	gtg	acg	att	tca	aat	ctt	ctg	aat	ctc	ttt	caa	1798
His	Phe	Ser	Ser	Glu	Val	Thr	Ile	Ser	Asn	Leu	Leu	Asn	Leu	Phe	Gln	
				550				555					560			
aga	gca	gaa	ctt	tca	aag	aat	gga	gaa	tgg	tac	gag	gta	ctt	aag	ata	1846
Arg	Ala	Glu	Leu	Ser	Asn	Gly	Glu	Trp	Tyr	Glu</						

ggt gag gag gag tcc ttt aac ctg aag cag aaa gta acg ttt cat gtg Gly Glu Glu Glu Ser Phe Asn Leu Lys Gln Lys Val Thr Phe His Val	2230
695 700	
atc ctg tct gtg ctc gtc tct tgt tct tca tct tta aaa gaa acc ccc Ile Leu Ser Val Leu Val Ser Cys Cys Ser Ser Lys Glu Lys Thr His	2278
710 715	
ttt cca ttt gcg ata aga gtc ttc agt ttg ttg cag aaa aaa ata aag Pro Phe Pro Ala Ile Arg Val Phe Ser Leu Leu Gln Lys Lys Ile Lys	2326
725 730	
aag ctt gaa agt gtc att act gca gtg gaa atc ccc tca gaa tgg cac Lys Leu Glu Ser Val Ile Thr Ala Val Glu Ile Pro Ser Glu Trp His	2374
740 745	
att gaa ctg atg tta gac aga ggg atc cca gta gag ctg tgg gca cat Ile Glu Leu Met Leu Asp Arg Gly Ile Pro Val Glu Leu Trp Ala His	2422
755 760	
tat gta gaa gag ctc aac agc act cag agg gtg gcc ctg gag gac tgc Tyr Val Glu Glu Leu Asn Ser Thr Cln Arg Val Ala Val Glu Asp Ser	2470
775 780	
gtt ttt ctt gta ttt tcc ttg aaa aaa ttt att tat gca ctg aaa gct Val Phe Leu Val Phe Ser Leu Lys Lys Phe Ile Tyr Ala Leu Lys Ala	2518
790 795	
cct aaa tct ttt cct aaa ggt gat ata tgg tgg aat cct gaa caa ctg Pro Lys Ser Phe Pro Lys Gly Asp Ile Trp Trp Asn Pro Glu Gln Leu	2566
805 810	
aaa gaa gac agc agg gac tat ctg cac ttg ctc att ggg ctg ttt gag Lys Glu Asp Ser Arg Asp Tyr Leu His Leu Leu Ile Gly Leu Phe Glu	2614
820 825	
atg atg ctc aat ggt gcc gat gct gtt cat ttc aga gtt ctg atg aaa Met Met Leu Asn Gly Ala Asp Ala Val His Phe Arg Val Leu Met Lys	2662
835 840	
ctt ttc ata aag gtc cat cta gaa gat gtt ttt cag tta ttc aag ttc Leu Phe Ile Lys Val His Leu Glu Asp Val Phe Gln Leu Phe Lys Phe	2710
855 860	
tgt tct gtt tta tgg acc tat ggt tct agc ctt tca aat cca cta aac Cys Ser Val Leu Trp Thr Tyr Glu Ser Ser Lys Ser Asn Pro Leu Asn	2758
870 875	
tgc agt gtg aaa aca gtg ctg cag act caa gct ctt tat gtg ggc tgt Cys Ser Val Lys Thr Val Leu Gln Thr Gln Ala Leu Tyr Val Gly Cys	2806
885 890	
gca atg ctt tct tct cag aag aca cag tgt aaa cac caa ctg gca tcc Ala Met Leu Ser Ser Gln Lys Thr Gln Cys Lys His Gln Leu Ala Ser	2854
900 905	
ata tct tct cca gtg gtg aca tct tta ctc att aac ctg gga agc ccc Ile Ser Pro Val Val Thr Ser Asp Ala Ala Tyr Val Ile Asn Leu Gly Ser Pro	2902
915 920	
gta aaa gaa gtt cgt agg gct gcc att cag tgt ctc cag gcc ctc agt Val Lys Glu Val Arg Arg Ala Ala Ile Gln Cys Leu Gln Ala Leu Ser	2950
935 940	
gga gtg gca tcc ccg ttt tat ctg ata ata gat cat ttg att tct aaa Gly Val Ala Ser Pro Phe Tyr Leu Ile Ile Asp His Leu Ile Ser Lys	2998
950 955	
gca gag gag atc act tca gat gct gcc tct gtt att cag gat ttg gct Ala Glu Glu Ile Thr Ser Asp Ala Ala Tyr Val Ile Gln Asp Leu Ala	3046
965 970	
act tta ttt gag gaa cta cag aga gaa aag aaa ctg aaa tct cat cag Thr Leu Phe Glu Glu Leu Gln Arg Glu Lys Lys Leu Lys Ser His Gln	3094
980 985	
aag ttg tct gaa act ttg aaa aac tta ctt agt tgt gtg tat agt tgc Lys Leu Ser Glu Thr Leu Lys Asn Leu Leu Ser Cys Val Tyr Ser Cys	3142
995 1000	
cca tct tat ata gca aaa gat ttg atg aaa gta ctt cag gga gtc aac Pro Ser Tyr Ile Ala Lys Asp Leu Met Lys Gln Glu Gly Val Asn	3190
1005	

										1015											1020											1025											3238											
ggt	gag	atg	gtg	ctt	tct	cag	cta	ttg	cct	atg	gct	gaa	caa	ctg	cta	Gly	Glu	Met	Val	Leu	Ser	Gln	Leu	Tyr	Pro	Met	Ala	Glu	Leu	Leu																								
										1030											1035											1040											3286											
gaa	aag	atc	cag	aag	gag	ccc	aca	gct	gtg	ctg	aaa	gat	gag	gcc	atg	Glu	Lys	Ile	Gln	Lys	Glu	Pro	Thr	Ala	Val	Leu	Lys	Asp	Glu	Ala	Met																							
										1045											1050											1055											3334											
ggt	ctg	cat	ctc	act	ctg	gga	aag	tat	aat	gaa	ttt	tca	gtt	tcc	ctt	Val	Leu	His	Leu	Thr	Leu	Gly	Lys	Tyr	Asn	Glu	Pro	Ser	Val	Ser	Leu																							
										1060											1065											1070											3382											
tta	aat	gag	gat	ccg	aag	agt	cta	gat	ata	ttt	ata	aaa	gct	gtg	cac	Leu	Asn	Glu	Asp	Pro	Lys	Ser	Leu	Asp	Ile	Phe	Ile	Lys	Ala	Val	His																							
										1075											1080											1085											1090											3430
aca	aca	aag	gaa	ctt	tac	gcg	gga	atg	cca	acc	att	cag	atc	aca	gcc	Thr	Thr	Lys	Glu	Leu	Tyr	Ala	Gly	Met	Pro	Thr	Ile	Gln	Ile	Thr	Ala																							
										1095											1100											1105											3478											
ctt	gaa	aag	att	aca	aaa	cca	ttt	ttt	gca	gcc	ata	tca	gat	gaa	aaa	Leu	Glu	Lys	Thr	Lys	Pro	Phe	Gln	Ala	Ile	Ser	Asp	Glu	Lys	Ile	Thr																							
										1110											1115											1120											3526											
ggt	cag	cag	aag	ctt	tta	aga	att	ttg	ttt	gag	ttt	tta	ttg	gtg	aac	tgt	Val	Gln	Gln	Lys	Leu	Leu	Arg	Met	Leu	Phe	Asp	Leu	Leu	Val	Asn	Cys																						
										1125											1130											1135											3574											
aaa	aac	tca	cat	tgt	gct	cag	act	gtc	agc	agt	ggt	ttt	aaa	ggg	att	Lys	Asn	Ser	His	Cys	Ala	Gln	Thr	Val	Ser	Ser	Val	Phe	Lys	Gly	Ile																							
										1140											1145											1150											3622											
tcc	gtt	aat	gct	gaa	caa	gtc	cga	ata	gaa	ctg	gag	cca	cca	gat	aaa	Ser	Val	Asn	Glu	Glu	Val	Arg	Ile	Glu	Ala	Gly	Glu	Pro	Pro	Asp	Lys																							
										1155											1160											1165											1170											3670
gct	aaa	ccc	ttg	ggc	aca	gtt	cag	caa	aaa	aga	agg	caa	aaa	atg	cag	Ala	Lys	Pro	Leu	Gly	Thr	Val	Gln	Gln	Lys	Arg	Arg	Gln	Lys	Met	Gln																							
										1175											1180											1185											3718											
cag	aaa	aaa	tca	caa	gat	cta	gaa	tct	ggt	cag	gaa	ggt	gga	ggt	tct	Gln	Lys	Lys	Ser	Gln	Asp	Leu	Glu	Ser	Val	Gln	Glu	Val	Gly	Gly	Ser																							
										1190											1195											1200											3766											
tac	tgg	caa	aga	gta	act	ctc	act	ctg	gaa	tta	ctg	cag	cac	aaa	aag	Tyr	Trp	Gln	Arg	Val	Thr	Leu	Ile	Leu	Gly	Leu	Lys	Gln	His	Lys	Leu																							
										1205											1210											1215											3814											
aag	ctc	aga	agt	cct	cag	ata	ttg	gtg	cca	act	ctt	ttt	aac	tga	cta	Lys	Leu	Arg	Ser	Pro	Gln	Ile	Leu	Val	Pro	Thr	Leu	Phe	Asn	Leu	Leu																							
										1220											1225											1230											3862											
tca	aga	tgt	tta	gaa	ccc	ttg	cca	caa	gag	cag	gga	aat	atg	gaa	tac	Ser	Arg	Cys	Leu	Glu	Pro	Leu	Pro	Gln	Glu	Gln	Gly	Asn	Met	Glu	Tyr																							
										1235											1240											1245											1250											3910
acc	aaa	caa	tta	att	ctt	agt	tgt	ctg	ctc	aac	att	tgc	caa	aaa	cta	Thr	Lys	Gln	Lys	Ile	Leu	Ser	Cys	Leu	Leu	Leu	Asn	Ile	Cys	Gln	Lys	Leu																						
										1255											1260											1265											3958											
tct	cca	gat	ggt	ggc	aaa	ata	ccc	aaa	gat	att	tta	gat	gag	gag	aag	Ser	Pro	Asp	Gly	Gly	Lys	Ile	Pro	Lys	Asp	Ile	Leu	Asp	Glu	Glu	Lys																							
										1270											1275											1280											4006											
ttc	aac	gtg	gag	ttg	ata	gtt	cag	tgc	atc	cgc	ctt	ctg	gat	atg	ccg	Phe	Asn	Val	Glu	Ile	Val	Gln	Cys	Ile	Arg	Leu	Ser	Ser	Glu	Met	Pro																							
										1285											1290											1295											4054											
cag	acc	cat	cac	cat	gcc	ctt	tta	ctt	ttg	ggc	act	ggt	gct	gga	ata	Gln	Thr	His	His	Ala	Leu	Leu	Leu	Leu	Gly	Thr	Val	Ala	Gly	Ile																								
										1300											1305											1310											4102											
ttt	ccg	gat	aaa	gtt	tta	caa	aat	atc	atg	tct	att	ttt	aca	ttt	atg	Phe	Pro	Asp	Lys	Val	Leu	His	Asn	Ile	Met	Ser	Ile	Phe	Thr	Phe	Met																							
										1315											1320											1325											1330											4150
gga	gcc	aat	gtc	atg	cgc	cta	gat	gat	act	tac	agt	ttt	caa	gtt	att	Gly	Ala	Asn	Val	Met	Arg	Leu	Asp	Asp	Thr	Tyr	Ser	Phe	Gln	Val	Ile																							
										1335											1340											1345											4198											
aac	aaq	aca	atg	aaa	atq	qtt	att	ccc	qca	ctt	att	cag	tct	gat	agt																																							

Asn	Lys	Thr	Val	Lys	Met	Val	Ile	Pro	Ala	Leu	Ile	Gln	Ser	Asp	Ser		
1350																	
gga	gat	tct	ata	gaa	gtt	tca	aga	aac	ggt	gaa	gag	att	gtg	gta	aaa	4246	
Gly	Asp	Ser	Ile	Glu	Val	Ser	Arg	Asn	Val	Glu	Glu	Ile	Val	Val	Lys		
1365																	
atc	att	agt	gta	ttt	gtg	gat	gcg	ctg	cca	cac	gtc	ccg	gag	cac	agg	4294	
Ile	Ile	Ser	Val	Phe	Val	Asp	Ala	Leu	Pro	His	Val	Pro	Glu	His	Arg		
1380																	
cgc	ctg	ccc	atc	ctt	gtt	caa	ctt	gtt	gat	aca	ctg	ggg	gca	gag	aaa	4342	
Arg	Leu	Pro	Ile	Leu	Val	Gln	Leu	Val	Asp	Thr	Leu	Gly	Ala	Glu	Lys		
1395																	
ttc	ctc	tggt	att	ctc	ctc	atc	ttg	ctt	ttt	gaa	cag	tat	gtc	aca	aaa	4390	
Phe	Leu	Trp	Ile	Leu	Leu	Ile	Leu	Leu	Phe	Glu	Gln	Tyr	Val	Thr	Lys		
1410																	
aca	gtg	ctg	gcg	gct	gcc	tat	ggc	gaa	aag	gat	gct	att	tta	gaa	gca	4438	
Thr	Val	Leu	Ala	Ala	Ala	Tyr	Ile	Glu	Gly	Asp	Ala	Ile	Leu	Glu	Ala		
1430																	
gac	act	gaa	ttt	tggt	ttt	tca	gtc	tgt	tgt	gag	ttt	agt	gtc	cag	cat	4486	
Asp	Thr	Glu	Phe	Trp	Phe	Ser	Val	Cys	Cys	Glu	Phe	Ser	Val	Gln	His		
1445																	
cag	ata	caa	agc	ttg	atg	aat	atc	ctc	cag	tac	tta	cta	aag	ctg	cca	4534	
Gln	Ile	Gln	Ser	Leu	Met	Asn	Ile	Leu	Gln	Tyr	Leu	Leu	Lys	Leu	Pro		
1460																	
gag	gaa	aaa	gaa	gaa	acc	att	ccc	aaa	gca	gtg	tca	ttt	aat	aag	agt	4582	
Glu	Glu	Lys	Glu	Glu	Thr	Ile	Pro	Ile	Ala	Val	Ser	Phe	Asn	Lys	Glu		
1475																	
gaa	tca	caa	gaa	gaa	atg	cta	cag	gtt	ttt	aat	gta	gag	act	cac	act	4630	
Glu	Ser	Gln	Glu	Glu	Met	Leu	Gln	Val	Phe	Asn	Val	Glu	Thr	His	Thr		
1490																	
agc	aag	caa	ctg	cgg	cat	ttt	aaa	ttt	ttg	tca	gtg	tcc	ttc	atg	tct	4678	
Ser	Lys	Gln	Leu	Arg	His	Phe	Lys	Phe	Leu	Ser	Val	Ser	Phe	Met	Ser		
1510																	
cag	ctc	ctg	tct	tcc	aat	aat	ttt	ctg	aaa	aag	gta	gtt	gag	agt	ggg	4726	
Gln	Leu	Ser	Ser	Ser	Asn	Ser	Phe	Leu	Lys	Val	Glu	Val	Glu	Ser	Gly		
1525																	
ggg	cct	gag	gatt	tta	aaa	ggc	ctt	gaa	agg	ttg	ctg	gag	acc	gtt		4774	
Gly	Pro	Glu	Ile	Leu	Lys	Gly	Leu	Glu	Glu	Arg	Leu	Leu	Glu	Thr	Val		
1540																	
ctc	ggc	tat	atc	agt	gca	gtt	gca	cag	tcc	att	gaa	agg	aac	gca	gac	4822	
Leu	Gly	Tyr	Ile	Ser	Ala	Val	Ala	Gln	Ser	Met	Glu	Arg	Asn	Ala	Asp		
1555																	
aaa	ctc	acc	gtg	aag	ttc	tggt	cgc	gcg	ctc	ctt	agt	aaa	gct	tac	gac	4870	
Lys	Leu	Thr	Val	Lys	Phe	Tyr	Arg	Ala	Leu	Leu	Ser	Lys	Ala	Tyr	Asp		
1575																	
ctg	tta	gat	aag	gtc	aat	gcc	tty	ctg	ccc	aca	gag	aca	ttc	att	ctt	4918	
Leu	Leu	Asp	Lys	Val	Asn	Ala	Leu	Leu	Pro	Thr	Glu	Thr	Phe	Ile	Pro		
1590																	
gtg	atc	aga	ggg	ctg	gtg	ggc	aat	ccc	ctg	cca	tct	gtt	cgc	cgc	aaa	4966	
Val	Ile	Arg	Gly	Leu	Val	Gly	Asn	Pro	Leu	Pro	Ser	Val					


```

ccgcctgcct ggaccaagcg ctggccttc cggggcgccc aggtccacgg ggtcaacgcc 120
aggggtttct cagcttcttc gtctgcctcg gatccaagtc cagacagtgc cagaagagac 180
ttggaggcgc tgctttttga cagtacacac ctctgtatgc agacccctta tgatctgatt 240
caccaggcct acctcgyaag ttctacagga tcattgtccca aatccagttct tttcagtggt 300
gagaaacaag cttctagaac tatggttttg tcataaaata aaagaatctt agtgacgaga 360
gggatcttag gaggagtata aattaattca tctcaatagc tcaaaggatg agatagccta 420
ttttgtgaaa tacatttttt gaatggctta cagactatga tgtagtact aaaaaatgct 480
gaattattttg atataggaa aatgtatctg aaattatgta aaatgtaaag acaaaatgat 540
actaaaaatg tataaatagt atacatgggc cgggcccggg ggcttatgcc tgtaatccca 600
gcactttggg aggccgaggg agatggatca cgaggtcagg agttcgagac cagcctggac 660
aacatagtga aacctgtct ctactaaaaa tacaaaaatt agccaggagc ggtggcaggc 720
gcctgtatgc ccagctactt tggaggctga gacaggagaa tcgcttgaa cgtggaggcg 780
gagattgcag tgagctgaga ctgcgccact gccctccagg ctaggtgaca gagcaagctc 840
tgtaa

```

```

<210> 5
<211> 2144
<212> PRT
<213> Homo sapiens

<220>
<221> VARIANT
<222> 1694
<223> Xaa=Ser or Asn

<220>
<221> VARIANT
<222> 1854
<223> Xaa=Ala or Val

<220>
<221> VARIANT
<222> 1967
<223> Xaa=Asp or Asn

<220>
<221> VARIANT
<222> 2017
<223> Xaa=Gly or Glu

```

```

<400> 5
Met Thr Ser Leu Ala Gln Gln Leu Gln Arg Leu Ala Leu Pro Gln Ser
1 5 10 15
Asp Ala Ser Leu Leu Ser Arg Asp Glu Val Ala Ser Leu Leu Phe Asp
20 25 30
Pro Lys Glu Ala Ala Thr Ile Asp Arg Asp Thr Ala Phe Ala Ile Gly
35 40 45
Cys Thr Gly Leu Glu Glu Leu Leu Gly Ile Asp Pro Ser Phe Glu Gln
50 55 60
Phe Glu Ala Pro Leu Phe Ser Gln Leu Ala Lys Thr Leu Glu Arg Ser
65 70 75 80
Val Gln Thr Lys Ala Val Asn Lys Gln Leu Asp Glu Asn Ile Ser Leu
85 90 95
Phe Leu Ile His Leu Ser Pro Tyr Phe Leu Leu Lys Pro Ala Gln Lys
100 105 110
Cys Leu Glu Trp Leu Ile His Arg Phe His Ile His Leu Tyr Asn Gln
115 120 125
Asp Ser Leu Ile Ala Cys Val Leu Pro Tyr His Glu Thr Arg Ile Phe
130 135 140
Val Arg Val Ile Gln Leu Leu Lys Ile Asn Asn Ser Lys His Arg Trp
145 150 155 160
Phe Trp Leu Leu Pro Val Lys Gln Ser Gly Val Pro Leu Ala Lys Gly

```

Thr	Leu	Ile	Thr	His	Cys	Tyr	Lys	Asp	Leu	Gly	Phe	Met	Asp	Phe	Ile
Cys	Ser	Leu	Val	Thr	Lys	Ser	Val	Lys	Val	Phe	Ala	Glu	Tyr	Pro	Gly
Ser	Ser	Ala	Gln	Leu	Arg	Val	Leu	Leu	Ala	Phe	Tyr	Ala	Ser	Thr	Ile
Val	Ser	Ala	Leu	Val	Ala	Ala	Glu	Asp	Val	Ser	Asp	Asn	Ile	Ile	Ala
Lys	Leu	Phe	Pro	Tyr	Ile	Gln	Lys	Gly	Leu	Lys	Ser	Ser	Leu	Pro	Asp
Tyr	Arg	Ala	Ala	Thr	Tyr	Met	Ile	Ile	Cys	Gln	Ile	Ser	Val	Lys	Val
Thr	Met	Glu	Asn	Thr	Phe	Val	Asn	Ser	Leu	Ala	Ser	Gln	Ile	Ile	Lys
Thr	Leu	Thr	Lys	Ile	Pro	Ser	Leu	Ile	Lys	Asp	Gly	Leu	Ser	Cys	Leu
Ile	Val	Leu	Leu	Gln	Arg	Gln	Lys	Pro	Glu	Ser	Leu	Gly	Lys	Lys	Pro
Phe	Pro	His	Leu	Cys	Asn	Val	Pro	Asp	Leu	Ile	Thr	Ile	Leu	His	Gly
Ile	Ser	Glu	Thr	Tyr	Asp	Val	Ser	Pro	Leu	Leu	Arg	Tyr	Met	Leu	Pro
His	Leu	Val	Val	Ser	Ile	Ile	His	His	Val	Thr	Gly	Glu	Glu	Thr	Glu
Gly	Met	Asp	Gly	Gln	Ile	Tyr	Lys	Arg	His	Leu	Glu	Ala	Ile	Leu	Thr
Lys	Ile	Ser	Leu	Lys	Asn	Asn	Leu	Asp	His	Leu	Leu	Ala	Ser	Leu	Leu
Phe	Glu	Glu	Tyr	Ile	Ser	Tyr	Ser	Ser	Gln	Glu	Glu	Met	Asp	Ser	Asn
Lys	Val	Ser	Leu	Leu	Asn	Glu	Gln	Phe	Leu	Pro	Leu	Ile	Arg	Leu	Leu
Glu	Ser	Lys	Tyr	Pro	Arg	Thr	Leu	Asp	Val	Val	Leu	Glu	Glu	His	Leu
Lys	Glu	Ile	Ala	Asp	Leu	Lys	Lys	Gln	Glu	Leu	Phe	His	Gln	Phe	Val
Ser	Leu	Ser	Thr	Ser	Gly	Gly	Lys	Tyr	Gln	Phe	Leu	Ala	Asp	Ser	Asp
Thr	Ser	Leu	Met	Leu	Ser	Leu	Asn	His	Pro	Leu	Ala	Pro	Val	Arg	Ile
Leu	Ala	Met	Asn	His	Leu	Lys	Lys	Ile	Met	Lys	Thr	Ser	Lys	Glu	Gly
Val	Asp	Glu	Ser	Phe	Ile	Lys	Glu	Ala	Val	Leu	Ala	Arg	Leu	Gly	Asp
Asp	Asn	Ile	Asp	Val	Val	Leu	Ser	Ala	Ile	Ser	Ala	Phe	Glu	Ile	Phe
Lys	Glu	His	Phe	Ser	Ser	Glu	Val	Thr	Ile	Ser	Asn	Leu	Leu	Asn	Leu
Phe	Gln	Arg	Ala	Glu	Leu	Ser	Lys	Asn	Gly	Gly	Trp	Tyr	Glu	Val	Leu
Lys	Ile	Ala	Ala	Asp	Ile	Leu	Ile	Lys	Glu	Glu	Ile	Leu	Ser	Glu	Asn
Asp	Gln	Leu	Ser	Asn	Gln	Val	Val	Val	Cys	Leu	Leu	Pro	Phe	Val	Val
Ile	Asn	Asn	Asp	Asp	Thr	Glu	Ser	Ala	Glu	Met	Lys	Ile	Ala	Ile	Tyr
Leu	Ser	Lys	Ser	Gly	Ile	Cys	Ser	Leu	His	Pro	Leu	Leu	Arg	Gly	Trp
Glu	Glu	Ala	Leu	Glu	Asn	Val	Ile	Lys	Ser	Thr	Lys	Pro	Gly	Lys	Leu
Ile	Gly	Val	Ala	Asn	Gln	Lys	Met	Ile	Glu	Leu	Leu	Ala	Asp	Asn	Ile

1155 1160 1165
 Asp Lys Ala Lys Pro Leu Gly Thr Val Gln Gln Lys Arg Arg Gln Lys
 1170 1175 1180
 Met Gln Gln Lys Lys Ser Gln Asp Leu Glu Ser Val Gln Glu Val Gly
 1185 1190 1195 1200
 Gly Ser Tyr Trp Gln Arg Val Thr Leu Ile Leu Glu Leu Leu Gln His
 1205 1210 1215
 Lys Lys Lys Leu Arg Ser Pro Gln Ile Leu Val Pro Thr Leu Phe Asn
 1220 1225 1230
 Leu Leu Ser Arg Cys Leu Glu Pro Leu Pro Gln Glu Gln Gly Asn Met
 1235 1240 1245
 Glu Tyr Thr Lys Gln Leu Ile Leu Ser Cys Leu Leu Asn Ile Cys Gln
 1250 1255 1260
 Lys Leu Ser Pro Asp Gly Gly Lys Ile Pro Lys Asp Ile Leu Asp Glu
 1265 1270 1275 1280
 Glu Lys Phe Asn Val Glu Leu Ile Val Gln Cys Ile Arg Leu Ser Glu
 1285 1290 1295
 Met Pro Gln Thr His His His Ala Leu Leu Leu Leu Gly Thr Val Ala
 1300 1305 1310
 Gly Ile Phe Pro Asp Lys Val Leu His Asn Ile Met Ser Ile Phe Thr
 1315 1320 1325
 Phe Met Gly Ala Asn Val Met Arg Leu Asp Asp Thr Tyr Ser Phe Gln
 1330 1335 1340
 Val Ile Asn Lys Thr Val Lys Met Val Ile Pro Ala Leu Ile Gln Ser
 1345 1350 1355 1360
 Asp Ser Gly Asp Ser Ile Glu Val Ser Arg Asn Val Glu Glu Ile Val
 1365 1370 1375
 Val Lys Ile Ile Ser Val Phe Val Asp Ala Leu Pro His Val Pro Glu
 1380 1385 1390
 His Arg Arg Leu Pro Ile Leu Val Gln Leu Val Asp Thr Leu Gly Ala
 1395 1400 1405
 Glu Lys Phe Leu Trp Ile Leu Leu Ile Leu Leu Phe Glu Gln Tyr Val
 1410 1415 1420
 Thr Lys Thr Val Leu Ala Ala Tyr Gly Glu Lys Asp Ala Ile Leu
 1425 1430 1435 1440
 Glu Ala Asp Thr Glu Phe Trp Phe Ser Val Cys Cys Glu Phe Ser Val
 1445 1450 1455
 Gln His Gln Ile Gln Ser Leu Met Asn Ile Leu Gln Tyr Leu Leu Lys
 1460 1465 1470
 Leu Pro Glu Glu Lys Glu Glu Thr Ile Pro Lys Ala Val Ser Phe Asn
 1475 1480 1485
 Lys Ser Glu Ser Gln Glu Glu Met Leu Gln Val Phe Asn Val Glu Thr
 1490 1495 1500
 His Thr Ser Lys Gln Leu Arg His Phe Lys Phe Leu Ser Val Ser Phe
 1505 1510 1515 1520
 Met Ser Gln Leu Leu Ser Ser Asn Asn Phe Leu Lys Lys Val Val Glu
 1525 1530 1535
 Ser Gly Gly Pro Glu Ile Leu Lys Gly Leu Glu Glu Arg Leu Leu Glu
 1540 1545 1550
 Thr Val Leu Gly Tyr Ile Ser Ala Val Ala Gln Ser Met Glu Arg Asn
 1555 1560 1565
 Ala Asp Lys Leu Thr Val Lys Phe Trp Arg Ala Leu Leu Ser Lys Ala
 1570 1575 1580
 Tyr Asp Leu Leu Asp Lys Val Asn Ala Leu Leu Pro Thr Glu Thr Phe
 1585 1590 1595 1600
 Ile Pro Val Ile Arg Gly Leu Val Gly Asn Pro Leu Pro Ser Val Arg
 1605 1610 1615
 Arg Lys Ala Leu Asp Leu Leu Asn Asn Lys Leu Gln Gln Asn Ile Ser
 1620 1625 1630
 Trp Lys Lys Thr Ile Val Thr Arg Phe Leu Lys Leu Val Pro Asp Leu
 1635 1640 1645
 Leu Ala Ile Val Gln Arg Lys Lys Lys Glu Gly Glu Glu Gln Ala

	1650				1655				1660						
Ile	Asn	Arg	Gln	Thr	Ala	Leu	Tyr	Thr	Leu	Lys	Leu	Leu	Cys	Lys	Asn
1665					1670				1675						1680
Phe	Gly	Ala	Glu	Asn	Pro	Asp	Pro	Phe	Val	Pro	Val	Leu	Xaa	Thr	Ala
				1685					1690					1695	
Val	Lys	Leu	Ile	Ala	Pro	Glu	Arg	Lys	Glu	Glu	Lys	Asn	Val	Leu	Gly
			1700					1705					1710		
Ser	Ala	Leu	Leu	Cys	Ile	Ala	Glu	Val	Thr	Ser	Thr	Leu	Glu	Ala	Leu
		1715					1720					1725			
Ala	Ile	Pro	Gln	Leu	Pro	Ser	Leu	Met	Pro	Ser	Leu	Leu	Thr	Thr	Met
		1730				1735					1740				
Lys	Asn	Thr	Ser	Glu	Leu	Val	Ser	Ser	Glu	Val	Tyr	Leu	Leu	Ser	Ala
1745					1750					1755					1760
Leu	Ala	Ala	Leu	Gln	Lys	Val	Val	Glu	Thr	Leu	Pro	His	Phe	Ile	Ser
				1765					1770					1775	
Pro	Tyr	Leu	Glu	Gly	Ile	Leu	Ser	Gln	Val	Ile	His	Leu	Glu	Lys	Ile
			1780					1785					1790		
Thr	Ser	Glu	Met	Gly	Ser	Ala	Ser	Gln	Ala	Asn	Ile	Arg	Leu	Thr	Ser
		1795					1800					1805			
Leu	Lys	Lys	Thr	Leu	Ala	Thr	Thr	Leu	Ala	Pro	Arg	Val	Leu	Leu	Pro
		1810				1815					1820				
Ala	Ile	Lys	Lys	Thr	Tyr	Lys	Gln	Ile	Glu	Lys	Asn	Trp	Lys	Asn	His
1825					1830					1835					1840
Met	Gly	Pro	Phe	Met	Ser	Ile	Leu	Gln	Glu	His	Ile	Gly	Xaa	Met	Lys
				1845					1850					1855	
Lys	Glu	Glu	Leu	Thr	Ser	His	Gln	Ser	Gln	Leu	Thr	Ala	Phe	Phe	Leu
			1860					1865					1870		
Glu	Ala	Leu	Asp	Phe	Arg	Ala	Gln	His	Ser	Glu	Asn	Asp	Leu	Glu	Glu
		1875					1880					1885			
Val	Gly	Lys	Thr	Glu	Asn	Cys	Ile	Ile	Asp	Cys	Leu	Val	Ala	Met	Val
		1890				1895					1900				
Val	Lys	Leu	Ser	Glu	Val	Thr	Phe	Arg	Pro	Leu	Phe	Phe	Lys	Leu	Phe
1905					1910					1915					1920
Asp	Trp	Ala	Lys	Thr	Glu	Asp	Ala	Pro	Lys	Asp	Arg	Leu	Leu	Thr	Phe
				1925					1930					1935	
Tyr	Asn	Leu	Ala	Asp	Cys	Ile	Ala	Glu	Lys	Leu	Lys	Gly	Leu	Phe	Thr
		1940					1945						1950		
Leu	Phe	Ala	Gly	His	Leu	Val	Lys	Pro	Phe	Ala	Asp	Thr	Leu	Xaa	Gln
		1955					1960					1965			
Val	Asn	Ile	Ser	Lys	Thr	Asp	Glu	Ala	Phe	Phe	Asp	Ser	Glu	Asn	Asp
		1970				1975					1980				
Pro	Glu	Lys	Cys	Cys	Leu	Leu	Leu	Gln	Phe	Ile	Leu	Asn	Cys	Leu	Tyr
1985					1990					1995					2000
Lys	Ile	Phe	Leu	Phe	Asp	Thr	Gln	His	Phe	Ile					

<210> 6
 <211> 5406
 <212> DNA
 <213> Homo sapiens

<220>
 <221> 5'UTR
 <222> 1..198

<220>
 <221> CDS
 <222> 199..1149

<220>
 <221> 3'UTR
 <222> 1150..5406

<220>
 <221> polyA_signal
 <222> 5384..5389

```

<400> 6
ccgccccagg acgcccagagc cgggaaaccct gacggcactt agctgctgac aaacaacctg      60
ctccgtggag cgcctgaaac accagtccttt gggggccagt cctcagtttc aatccaggta      120
acctttaaat gaaacttgcc taaaatctta ggtcatacac agaagagact ccaatcgaca      180
agaagctgga aaagaatg atg ttg tcc tta aac aac cta cag aat atc atc      231
                Met Leu Ser Leu Asn Asn Leu Gln Asn Ile Ile
                1             5             10
tat aac ccg gta atc ccg tat gtt ggc acc att ccc gat cag ctg gat      279
Tyr Asn Pro Val Ile Pro Tyr Val Gly Thr Ile Pro Asp Gln Leu Asp
                15             20             25
cct gga act ttg att gtg ata tgt ggg cat gtt cct agt gac gca gac      327
Pro Gly Thr Leu Ile Val Ile Cys Gly His Val Pro Ser Asp Ala Asp
                30             35             40
aga ttc cag gtg gat ctg cag aat ggc agc agt gtg aaa cct cga gcc      375
Arg Phe Gln Val Asp Leu Gln Asn Gly Ser Ser Val Lys Pro Arg Ala
                45             50             55
gat gtg gcc ttt cat ttc aat cct cgt ttc aaa agg gcc ggc tgc att      423
Asp Val Ala Phe His Phe Asn Pro Arg Phe Lys Arg Ala Gly Cys Ile
                60             65             70             75
gtt tgc aat act ttg ata aat gaa aas tgg gga cgg gaa gag atc acc      471
Val Cys Asn Thr Leu Ile Asn Glu Lys Trp Gly Arg Glu Glu Ile Thr
                80             85             90
tat gac acg cct ttc aaa aga gaa aag tct ttt gag atc gtg att atg      519
Tyr Asp Thr Pro Phe Lys Arg Glu Lys Ser Phe Glu Ile Val Ile Met
                95             100             105
gtg cta aag gac aaa ttc cag gtg gct gta aat gga aaa cat act ctg      567
Val Leu Lys Asp Lys Phe Gln Val Ala Val Asn Gly Lys His Thr Leu
                110             115             120
ctc tat ggc cac agg atc ggc cca gag aaa ata gac act ctg ggc att      615
Leu Tyr Gly His Arg Ile Gly Pro Glu Lys Ile Asp Thr Leu Gly Ile
                125             130             135
tat ggc aaa gtg aat att cac tca att ggt ttt agc ttc agc tgc gac      663
Tyr Gly Lys Val Asn Ile His Ser Ile Gly Phe Ser Phe Ser Ser Asp
                140             145             150             155
tta caa agt acc caa gca tct agt ctg gaa ctg aca gag ata agt aga      711
Leu Gln Ser Thr Gln Ala Ser Ser Leu Glu Leu Thr Glu Ile Ser Arg
                160             165             170
gaa aat gtt cca aag tct ggc acg ccc cag ctt agc ctg cca ttc gct      759
Glu Asn Val Pro Lys Ser Gly Thr Pro Gln Leu Ser Leu Pro Phe Ala
                175             180             185
gca agg ttg aac acc ccc atg ggc cct gga cga act gtc gtc gtt aaa      807

```

Ala	Arg	Leu	Asn	Thr	Pro	Met	Gly	Pro	Gly	Arg	Thr	Val	Val	Val	Lys	
		190					195					200				
gga	gaa	gtg	aat	gca	aat	gcc	aaa	agc	ttt	aat	gtt	gac	cta	cta	gca	855
Gly	Glu	Val	Asn	Ala	Asn	Ala	Lys	Ser	Phe	Asn	Val	Asp	Leu	Leu	Ala	
		205					210					215				
gga	aaa	tca	aag	gat	att	gct	cta	cac	ttg	aac	cga	cgc	ctg	aat	att	903
Gly	Lys	Leu	Ser	Gly	Asp	Ile	Ala	His	Leu	Asn	Pro	Arg	Leu	Asn	Ile	
		220					225					230				
aaa	gca	ttt	gta	aga	aat	tct	ttt	ctt	cag	gag	tcc	tggt	gga	gaa	gaa	951
Lys	Ala	Phe	Val	Arg	Asn	Ser	Phe	Leu	Gln	Glu	Ser	Trp	Gly	Glu	Glu	
gag	aga	aat	att	acc	tct	ttc	cca	ttt	agt	oct	ggg	agt	tac	ttt	gag	999
Glu	Arg	Asn	Ile	Thr	Ser	Phe	Pro	Phe	Ser	Pro	Gly	Met	Tyr	Phe	Glu	
atg	ata	att	tac	tgt	gat	gtt	arg	gaa	tto	aag	gtt	gca	gta	aat	ggc	1047
Met	Ile	Ile	Tyr	Cys	Asp	Val	Arg	Glu	Phe	Lys	Glu	Ala	Val	Asn	Gly	
gta	cac	agc	ctg	gag	tac	aaa	cac	aga	ttt	aaa	gag	ctc	agc	agt	att	1095
Val	His	Ser	Leu	Glu	Tyr	Lys	His	Arg	Phe	Lys	Glu	Leu	Ser	Ser	Ile	
gac	acg	ctg	gga	aat	aat	gga	cac	atc	cac	tta	ctg	gaa	gta	agg	agc	1143
Asp	Thr	Leu	Glu	Ile	Asn	Gly	Asp	Ile	His	Leu	Leu	Glu	Val	Arg	Ser	
tggt	gat	ctc	act	cata	cag	ctg	ctac	aaaa	acccaaa	ata	caga	gaatg	gctt	ctgtg	ta	1199
Trp	*															
tactgtgacct	gctga	aaacgc				atctcactgt			cattctattg		tttatattgt				taaaatgagc	1259
ttctggccct	ttgatgctgt					ctgggtgttc			tcagtctctg		ctcagaatga				tggtgggtgtc	1319
tagcattgaa	ctgggaaact					ggggggcaca			acactattag		ccagttaaag				ctcaactgtcc	1379
ctctctctcta	tttctgtgtga					ctctctcaaga			atgcccattca		acaagtattt				atggtagtacc	1439
tactataata	cagtagctaa					catgtataga			gcacagattt		tttttggtaa				aactgtgtgag	1499
agctaggata	tatacttggt					ggaacataacc			agttatgttc		ctgttctctt				gagctctgac	1559
ctctctgtgc	tctattgtgt					cgcaactgctt			tttctacagg		tactatcata				actcttaagg	1619
ggctctctgt	gattagttaa					gcagcttatta			aatcaccgca		agacactaat				ttacagaaga	1679
cacaactct	tcccacgtga					tcaactgtcat			acaccagtctg		ctaccgtcat				ccatcaactga	1739
ggagctgatgt	ctagctgacat					cattttatgc			taataaaacat		gtggctctat				tagctgtcgaag	1799
ctttaccaag	taattggcat					gcacatctgc			cacagaattat		aaggccataaa				accagaagcaa	1859
acacaataac	tggtgtctgaa					attaactctga			tgccaagcctc		aaggcagctgt				atttctgtgt	1919
atttgaaact	agggcaaatc					agagctgtaca			cgagacgctca		cagaaagtat				caggaagaggt	1979
caagatgcat	tcaatttgaa					agatatattat			gggcaacaaa		gtaagtgagc					

```

cagtcacaaag  tactctctggt  gattgctaaa  taacttcatt  ttcttgaagt  agagcaactt  3479
tgagtgaaat  ctgcaacatg  gataccatgt  atataagata  ctgctgtaca  gaagagttaa  3539
ggcttcacagt  gcaaatgagg  cgctcagctt  ggggtgctaaa  attaacaagt  ctaattattt  3599
taccatcaat  cattttactct  ttctgcagct  ctatacgata  ggcaggagag  gcttatgttg  3659
cagcacaaag  caggtgggga  ttttgtaacg  aagtgataaa  acatttgtaa  gtaattccaa  3719
taggtgtatt  aaggcaccaa  aagttaacatg  gaccccaaca  cccaaaaata  aaaatatgaa  3779
atatgagtgt  gaactctgag  tagagtatga  aacaccacag  aaagtcttag  aaatagctct  3839
ggagtggtct  tcccgaggca  gtttccagtt  gctgaatagt  cttttggcac  tgatgtttct  3899
cttcttcaca  ttcatctaaa  aaaaaaaaaa  aaaaaaatca  aaattaaaat  ctgagtcagt  4019
ctgcttgctt  cgggttctcat  tagtttaatt  cttaatgcct  tgcactttcc  agcaatcatt  4079
caatcaaaag  agtgaaatga  agcacattaa  caaagcagga  ggcgcacagg  accgcctccc  4139
tccacaccgc  tccttccgct  ttcattcctt  gccacacagg  ttgcactgga  agctgaataa  4199
gaatccccaa  aactcaaaact  tcctagggat  gccaccctct  tagtagctca  caccctcccc  4259
ctccaagagc  taagaaacaa  aggagaatgt  acttttgtag  cttagataag  caatgaatca  4319
gtaaaggagt  gatctacttg  ctccaccacc  cctcccttaa  taataacatt  tactgttatt  4379
tcctggcctt  aagacttatg  ttccagaact  gtcacagctc  cccatgtcac  acccactagc  4439
ttgtgatctt  tgtcacaata  ctgaaatctt  ttaagcctct  agttttctcc  tttgtaaaaa  4499
agagataaaa  tgttgtgggt  ttttaagtga  ataatccaag  taaagcaccct  aacatggagt  4559
agtgaaatga  catcggtgtg  tactaaaagt  ggacatccta  ccgcacacct  aatgccacta  4619
ggcatttcca  tacaatctgg  ggacccaaac  ttcaatcata  taaatgtatg  aggttaatta  4679
aaaaacactac  tgtaactctg  tctaatctgc  acaaaaccac  acaaaagaaa  agatcgtgaa  4739
gattacactg  taaacggact  ctcaaatgat  caggagggtg  tcacttcgca  acttgctccc  4799
tcaccccaac  tcaaaacagg  agctcgagcc  tgccgtgatt  tgagactgga  gctgcctgta  4859
tgaggactgg  atcaactgct  agtcacgtta  tatccaaatc  tgcattatca  ttggggcacat  4919
ttttcacaga  tttttactga  ttattcctta  attgtttaat  ggttgggaa  agtttgggaa  4979
ttacctttca  tcaactctgc  taagaaagga  atggattctg  gttagcaagc  aatataaatt  5039
tcctcttagt  tttcagccag  tgctaacaca  gtaatcaaa  cagcaaatcg  aacctgaaag  5099
ggataaaaag  gcaaaagaat  aaaaagtgt  gttactgtat  ttattatctt  aagagctgta  5159
ctgacttgag  acaagctcta  actttttaaa  cattagtcca  cagctgttta  ttcaactcat  5219
ttggttcatt  aagctttcat  cttagaatac  cagttttacc  atttggggag  tgtttgtaat  5279
atgtgcaacc  ttataaatag  tgttttccaa  actgtgtccc  aggactgcaa  atcttttaag  5339
tgaaatgtct  ttattataat  tcttccttta  aaaaaaacca  ataaaaataa  atgccacatg  5399
caaaactc  5406

```

<210> 7
 <211> 5532
 <212> DNA
 <213> Homo sapiens

<220>
 <221> 5'UTR
 <222> 1..198

<220>
 <221> CDS
 <222> 199..1275

<220>
 <221> 3'UTR
 <222> 1276..5532

<220>
 <221> polyA_signal
 <222> 5510..5515

<400> 7
 ccgccacagg acggcagagc cggaacccct gacggcactt agctgtgtac aaacaacctg 60
 ctccgtggag cgcttgaagc accagctctt gggggcagtg cctcagtttc aatccaggta 120
 accttttaaa gaaacttgcc taaaattctta ggtcatcac agaagagact ccaatcgaca 180
 agaagctgga aaagaatg atg ttg tcc tta aac aac cta cag aat atc atc 231
 Met Leu Ser Leu Asn Asn Leu Gln Asn Ile Ile

										1											5											10							
tat	aac	ccg	gta	atc	ccg	gta	gtt	ggc	acc	att	ccc	gat	cag	ctg	gat	279																							
Tyr	Asn	Pro	Val	Leu	Pro	Tyr	Val	Gly	Thr	Ile	Pro	Asp	Gln	Leu	Asp																								
																15											20											25	
cct	gga	act	ttg	att	gtg	ata	tgt	ggg	cat	gtt	cct	agt	gac	gca	gac	327																							
Pro	Gly	Thr	Leu	Ile	Val	Ile	Cys	Gly	His	Val	Pro	Ser	Asp	Ala	Asp																								
																30											35											40	
aga	ttc	cag	gtg	gat	ctg	cag	aat	ggc	agc	agt	gtg	aaa	cct	cga	gcc	375																							
Arg	Phe	Gln	Val	Asp	Leu	Gln	Asn	Gly	Ser	Ser	Val	Lys	Pro	Arg	Ala																								
																45											50											55	
gat	gtg	gcc	ttt	cat	ttc	aat	cct	cgt	ttc	aaa	agg	gcc	ggc	tgc	att	423																							
Asp	Val	Ala	Phe	His	Phe	Asn	Pro	Cys	Phe	Lys	Arg	Ala	Gly	Cys	Ile																								
																60											65											70	
gtt	tgc	aat	act	ttg	ata	aat	gaa	aaa	tgg	gga	cgg	gaa	gag	atc	acc	471																							
Val	Cys	Asn	Thr	Leu	Ile	Asn	Glu	Lys	Trp	Gly	Arg	Glu	Ile	Thr																									
																80											85											90	
tat	gac	acg	cct	ttc	aaa	aga	gaa	aag	tct	ttt	gag	atc	gtg	att	atg	519																							
Tyr	Asp	Thr	Pro	Phe	Lys	Arg	Glu	Lys	Ser	Phe	Glu	Ile	Val	Ile	Met																								
																95											100											105	
gtg	cta	aag	gac	aaa	ttc	cag	gtg	gct	gta	aat	gga	aaa	cat	act	ctg	567																							
Val	Leu	Lys	Asp	Lys	Phe	Gln	Val	Ala	Val	Asn	Gly	Lys	His	Thr	Leu																								
																110											115											120	
ctc	tat	ggc	cac	agg	atc	ggc	cca	cag	aaa	ata	gac	act	ctg	ggc	att	615																							
Leu	Tyr	Gly	His	Arg	Ile	Gly	Pro	Glu	Lys	Ile	Asp	Thr	Leu	Gly	Ile																								
																125											130											135	
tat	ggc	aaa	gtg	aat	att	cac	tca	aat	ggt	ttt	agc	ttc	agc	tcg	gac	663																							
Tyr	Gly	Lys	Val	Asn	Ile	His	Ser	Ile	Gly	Phe	Ser	Phe	Ser	Ser	Asp																								
																140											145											150	
tta	caa	agt	acc	caa	gca	tct	agt	ctg	gaa	cgt	aca	gag	ata	agt	aga	711																							
Leu	Gln	Ser	Thr	Gln	Ala	Ser	Ser	Leu	Glu	Leu	Thr	Glu	Ile	Ser	Arg																								
																160											165											170	
gaa	aat	gtt	cca	aag	tct	ggc	agc	ccc	cag	ctt	cct	agt	aat	aga	gga	759																							
Glu	Asn	Val	Pro	Lys	Ser	Gly	Thr	Pro	Gln	Leu	Pro	Ser	Asn	Arg	Gly																								
																175											180											185	
gga	gac	att	tct	aaa	atc	gca	ccc	aga	act	gtc	tac	acc	aag	agc	aaa	807																							
Gly	Asp	Ile	Ser	Lys	Ile	Ala	Pro	Arg	Thr	Val	Tyr	Thr	Lys	Ser	Lys																								
																190											195											200	
gat	tcg	act	gtc	aat	cac	act	ttg	act	tgc	acc	aaa	ata	cca	cct	atg	855																							
Asp	Ser	Thr	Val	Asn	His	Thr	Leu	Thr	Cys	Thr	Lys	Ile	Pro	Pro	Met																								
																205											210											215	
aac	tat	gtg	tca	aag	agc	ctg	cca	ttc	gct	gca	agg	ttg	aac	acc	ccc	903																							
Asn	Tyr	Val	Ser	Lys	Ser	Leu	Pro	Phe	Ala	Ala	Arg	Leu	Asn	Thr	Pro																								
																220											225											230	
att	ggc	cct	gga	cga	act	gtc	gct	gtt	aaa	gga	gaa	gtg	aat	gca	aat	951																							
Met	Gly	Pro	Gly	Arg	Thr	Val	Val	Val	Lys</																														

Lys	His	Arg	Phe	Lys	Glu	Leu	Ser	Ser	Ile	Asp	Thr	Leu	Glu	Ile	Asn	
			335					340					345			
gga	gac	atc	cac	tta	ctg	gaa	gta	agg	agc	tgg	tag	ctc	ac	taca		1285
Gly	Asp	Ile	His	Leu	Leu	Glu	Val	Arg	Ser	Trp	*					
		350					355									
cagctgctac	aaaaacccaa	atacagaatg	gcttctgtga	tactggcctt	gctgaaacgc											1345
atctcactgt	cattctattg	tttatattgt	taaaatgagc	ttgtgcccac	ttagatcctg											1405
ctgggtgttc	tcagtctctg	ccatgaagta	tggttggtgc	tagcaactgaa	tggtgaaact											1465
gggggcagca	acactttatg	ccagttaaag	ccactctgac	ctctctccca	ctttgggtga											1525
ctcttcaaga	tgcctattca	acaagtattt	atggagtacc	tactataata	cagttagctaa											1585
catgtattga	gcacagattt	tttttggtaa	aactgtgagg	agctaggata	tatatttggg											1645
gaacacaaac	agtatgttcc	ctgtctctct	gagctctgac	tcttctgtgc	ctattgtctg											1705
cgcaactggt	ttttctacag	cattacatca	actcctaagg	ggctcctctg	gattagttaa											1765
gcagctatta	aatcaccgca	agacactaat	ttacagaaga	cacaactcct	tcccagtgta											1825
tcactgtcat	aaccagtgct	ctacogtatt	ccatcactga	ggactgatgt	tgactgacat											1885
cattttatcg	taataaaact	gtggctctat	tagctgcaag	ctttaccaag	taattggcat											1945
gacatctgag	ccagagaatt	aaggcaaaaa	accaaagcaa	aacaaataca	tggtgctgaa											2005
attaactctg	tgccaaagcc	aaggcagctg	atttctgtgt	atttgaactt	agggcaaatc											2065
agagtctaca	cgacgcctca	gacaaaagtt	caggaagagg	caagatgtat	tcaatttgaa											2125
agatatattat	gggcaaccaa	gtaaggctcag	gattagaact	caggcaattca	taaggcaggc											2185
actatcagaa	agtgtagccc	aactaaagga	cccacaagc	aggcagagg	aatgcagaaa											2245
tcgtgtttgt	tcccatgaaa	tcaccaatca	aggcctcctg	tcttctcaag	attagtcctat											2305
catcatatgc	aactgagatc	aaagcactct	tccactttac	gtgattaaaa	tcaaacctgt											2365
atcagcaagt	taaatgtgttc	catcttctgt	atttttctat	tatttgaggg	gagttggcag											2425
aagttccatg	tatatgggat	ctttacaggt	cagatcttgt	tacaggaaat	ttcaaaaggt											2485
tggtgtgggg	gagggaataaa	agctcagctca	gtgagagtca	ttttatcaca	ttagactggg											2545
gcagaactct	gccaggattt	aggaatattt	tcagaacaga	ttttatagat	tattctctac											2605
catattattga	aaagaataacc	attgtcaact	ttattttttt	aaaagfactic	agtgtagaaa											2665
ttgttagccc	ttaattcttt	tccagctttt	catattaagt	tatgcagagt	ctcaccagac											2725
tcaaaagacac	tggttggggg	tggaaggggc	cacagggaaa	gctgtagaag	gcaagaagac											2785
tcgagaatcc	cccagagtta	ttttttccca	taaaagccat	cagagtgcct	aactgagctg											2845
ttggagactg	tgaggcattt	agggaaaaaa	tagccacttc	acatcattcc	ttttagactc											2905
taagtctcatt	ttcatitttac	gtggaggaaa	aaaattttaa	aagctattag	tatttatata											2965
tgaattttac	tgagacattt	cttagaataa	tgcacttcta	tactagcaag	ctctgtctct											3025
aaaatgcga	tggtgccttt	gcttgccaca	tttctgcatt	aaactctcat	attagctcca											3085
ggcctcttta	aactcaatgc	gaacatttca	cggttagtgc	ttagatgcct	ttaaaaaggg											3145
agcgagatct	ttcttatttg	aacctcact	ttccaaactc	accatgacc	agctactagag											3205
atttagggcac	ttcaaaagcat	tgaaaaaaat	ctactgatac	ttactttctt	agacaagtag											3265
ttcttagtga	accaccaatg	gaactgggtt	catctggaat	octggaggag	cttctctgtg											3325
ccaaccagtg	tttctggggc	ctctgtgtga	gcagccaggt	atagctgtgt	ttagaagcag											3385
cgtgttgctc	tcattctctc	cgtttcccaa	aagaacaaa	gataaaaggt	acagtccacac											3445
tcctgggtta	aaaaaaagcat	tccagaacca	cttctcttta	tggtgcacac	aaagaaacga											3505
aggctggaag	tcgctcacc	aaaaatgaaa	gtaggcttta	cagtcacaa	tactctgtct											3565
gattgtcaaa	taacttcaat	ttcttgaat	agagcaactt	tgagtgaagt	ctgcacacgt											3625
gtacacctgt	atataagata	ctgtctgtaca	gaagagttaa	ggcttacagt	gcaaatgagg											3685
cgtcagcttt	gggtgctaaa	attaacaagt	ctaataattt	taccatcaat	caggaaagata											3745
ataataaatg	tttaaacaaa	cacagcagtc	tgtataaaaa	taccgtgtat	catcttactc											3805
ttctgcagct	ctatcagata	ggcaggagga	gcttatgtgg	gcagcaagag	caggtggggga											3865
ttgtttaacg	aagtgtacaa	acatttgtaa	gtaatccaag	taggtgtatt	aggccaccaa											3925
aagtaaatct	gcaccocaaa	cccaaaaaata	aaaaatatga	atatgagtgt	gaactctgag											3985
tagagtatga	aacacccacg	aaagtcttag	aaatagctct	ggagtggctc	tcccaggaca											4045
gtttccagtt	gctgaaatag	cttttggcac	tgatgttcta	cttctctcaca	cttctctaaa											4105
aaaaaaaata	aaaaaaatca	aaataaaat	ctgagtgcgt	ctgcctgcgt	tggtctctcat											4165
tagtttaatt	cttaatgctt	tgcactttcc	agcaatcatt	caatcaaaag	agtgaaatga											4225
agcacattaa	caaaagcagg	ggcgccagct	accgctctcc	ttcacaccgc	tctctccgcc											4285
ttctatctct	gccccacagg	ttgcaactgga	agctgaataa	gaatccccaa	aactcaaaat											4345
tctatgggat	gccacccctt	tagtagctca	caectccccc	ctccaaagag	taagaaaacaa											4405
aggagaatgt	actttttagt	cttagataag	caatgaatct	gtaaaggagct	gactctactg											4465
ctccaccacc	ctccctctaa	taataaacatt	tactgttatt	tcttgggctc	agaacttatg											4525
ttccagaact	ctcacagctc	cccatgtcac	accacactagc	ttgtgatctt	tgctcaaataa											4585
ctgaatattct	ttaagcctct	agttctcttc	tttgtaaac	agagataaaa	tggtgtgggt											4645
tttaagtgag	ataatccaag	taaagcacct	aacatggagt	agtgaaatga	catcggttgc											4705

125													130													135													
Tat	ggc	aaa	gtg	aat	att	cac	tca	att	ggg	ttt	agc	ttc	agc	tcg	gac		663																						
Tyr	Gly	Lys	Val	Asn	Ile	His	Ser	Ile	Gly	Phe	Ser	Phe	Ser	Ser	Asp																								
140													145													150													
tta	caa	agt	acc	caa	gca	tct	agt	ctg	gaa	ctg	aca	gag	ata	agt	aga		711																						
Leu	Gln	Ser	Thr	Gln	Ala	Ser	Ser	Leu	Glu	Leu	Thr	Glu	Ile	Ser	Arg																								
													160													165													
gaa	aat	ggt	cca	aag	tct	ggc	acg	ccc	cag	ctt	agc	ctg	cca	tgt	gct		759																						
Glu	Asn	Val	Pro	Lys	Ser	Gly	Thr	Pro	Gln	Leu	Ser	Leu	Pro	Phe	Ala																								
													175													180													
gca	agg	ttg	aac	acc	ccc	atg	ggc	ctt	gga	cga	act	gtc	gtc	ggt	aaa		807																						
Ala	Arg	Leu	Ser	Asn	Thr	Pro	Met	Gly	Pro	Gly	Arg	Thr	Val	Val	Lys																								
													190													200													
gga	gaa	gtg	aat	gca	aat	gcc	aaa	agc	ttt	aat	gtt	gac	cta	cta	gca		855																						
Gly	Glu	Val	Asn	Ala	Asn	Ala	Lys	Ser	Phe	Asn	Val	Asp	Leu	Leu	Ala																								
													205													215													
gga	aaa	tca	aag	gat	att	gct	cta	cac	ttg	aac	cca	cgc	ctg	aat	att		903																						
Gly	Lys	Ser	Lys	Asp	Ile	Ala	His	Leu	Ser	Arg	Pro	Arg	Leu	Asn	Ile																								
220													225													230													
aaa	gca	ttt	gta	aga	aat	tct	ttt	ctt	cag	gag	tcc	tgg	gga	gaa	gaa		951																						
Lys	Ala	Phe	Val	Arg	Asn	Ser	Phe	Leu	Gln	Glu	Ser	Trp	Gly	Glu	Glu																								
													240													245													
gag	aga	aat	att	acc	tct	ttc	cca	ttt	agt	cct	ggg	atg	tac	ttt	gag		999																						
Glu	Arg	Asn	Ile	Thr	Ser	Phe	Pro	Phe	Ser	Pro	Gly	Met	Trp	Phe	Glu																								
													255													260													
atg	ata	att	tac	tgt	gat	ggt	aga	gaa	ttc	aag	gtt	aca	gta	aat	ggc		1047																						
Met	Ile	Ile	Tyr	Cys	Asp	Val	Arg	Gly	Phe	Lys	Val	Gla	Val	Asn	Gly																								
													270													275													
gta	cac	agc	ctg	gag	tac	aaa	cac	aga	ttt	aaa	gag	ctc	agc	agt	att		1095																						
Val	His	Ser	Leu	Glu	Tyr	Lys	His	Arg	Phe	Lys	Glu	Leu	Ser	Ser	Ile																								
													285													290													
gac	acg	ctg	gaa	att	aat	gga	gac	atc	cac	tta	ctg	gaa	caa	tca	ttc		1143																						
Asp	Thr	Leu	Glu	Ile	Asn	Gly	Asp	Ile	His	Leu	Leu	Glu	Gln	Ser	Phe																								
300													305													310													
aat	caa	aag	agt	gaa	atg	aag	cac	att	aac	aaa	gca	gga	ggc	gcc	acg		1191																						
Asn	Gln	Lys	Ser	Glu	Met	Lys	His	Ile	Asn	Lys	Ala	Gly	Gly	Ala	Thr																								
													320													325													
gac	cgc	ctc	cct	cca	cac	cgc	tcc	ttc	cgc	ctt	cat	tcc	ttg	ccc	aca		1239																						
Asp	Arg	Leu	Pro	Pro	His	Arg	Ser	Phe	Arg	Leu	His	Ser	Leu	Pro	Thr																								
													335													340													
ggc	ttg	cac	tgg	aag	ctg	aat	aag	aat	ccc	caa	aac	tca	aac	ttc	cta		1287																						
Gly	Leu	His	Trp	Lys	Leu	Asn	Lys	Asn	Pro	Gln	Asn	Ser	Asn	Phe	Leu																								
													350													355													
ggg	atg	cca	ccc	ctt	tag	tagctcacac	ctccccctc	caagagctaa										1335																					
Gly	Met	Pro	Pro	Leu	*																																		
													365																										
gaaacaaaag	agaatgtact					tttgtagctt					agataagcaa					tgaatcagta					aaggactgat					1395													
ctacttggtc	caccaccctc					cccttaataa					taacattttc					tgtttatttc					tgggcctaag					1455													
acttatgttc	cagaaactgtc					acagctctccc					atgtcacacc					cactagctgt					tgacttttgt					1515													
caaaataactg	aaatctttta					agcctcttagt					ttcttccttt					gtaaaacaga					gataaaactgt					1575													
tggtgttttt	aagtgagata					attccaagtga					agcacactaac					atggagttagt					gaatgaacat					1635													
cggttgctac	taaaagtggga					catcctaccg					catcctctaat					gccactgaagc					atttccatca					1695													
aatctggggga	ccaaaacttc					aatcatataa					atgtbtgagg					tcaataaaa					acactactgt					1755													
aatctcgttg	tdatgatcaca					aaccaccaca					aaagaaaaga					tcgtgaaagt					accactatga					1815													
acggactctc	aaatgatcac					gaggtgggtca					cttgcgaact					tgctctctcc					taccactctca					1875													
aaacagagc	tcagtcctgc					ctgtatttga					cagtcgagct					gcctgtatga					ggactggatc					1935													
aactcgtagt	cacgtttaat					ccaaattctg					attatcattgt					ggcacaaatt					cacagaaatt					1995													
tactgaatta	ttcctttaat					gtttaatgtg					ttgggaatagt					ttgcgaattt					ccttccatca					2055													
actctgcagta	gaaggaagtg					gatctctgta					cgaagacaat					ataattcttc					ttttagttttt					2115													
cagcgcgtgc	taacacagta					atcaaacgac					catcaacgaac					ctgaagaaagg					taaaagagca					2175													
aggaataataa	aagtagtggt					actgtatttta					tttatcttaag					agctgtactgt					actgtagaca					2235													
acgtctaaact	ttttaaacat					taqttcacac					cggtttatct					attctcaatt					gttcattaa					2295													

ctttcatcctt	agaataccag	tttcaccatt	tgggagctgt	ttgtaatatg	tgcaacctta	2355
taaatagtgt	tttccaaact	gtgtcccagg	actgcaaatc	tttaattgtg	aatgtctttt	2415
tataatctct	tcctttaaaa	aaaaccaata	aaataaaatg	ccacatgcaa	actc	2469

<210> 9
 <211> 281
 <212> DNA
 <213> Homo sapiens

<400> 9						
atatcacctg	taaagtcttc	tggccaaaaa	attaagccca	gccggacctt	attaaacctt	60
taaatctaac	aattagtctt	gaagctttta	cagattaaat	gaagctctgag	atttgcttca	120
aaatgaacca	gtggtgggga	ggaagtgggt	gaggtgtagg	tgaacaacaga	ttggccacctg	180
cgataattgc	tggagctggg	cgatgaaaag	acagttctag	aagcttgttt	ctcccacctg	240
aaaagactgg	atttgggaca	tgatcctgta	gaacttcgga	g		281

<210> 10
 <211> 515
 <212> DNA
 <213> Homo sapiens

<220>
 <221> 5'UTR
 <222> 1..384

<220>
 <221> CDS
 <222> 385..515

<400> 10						
tggacttggg	tccgaggcag	acgaggaagc	tgagaaaaacc	ctggcggttg	ccccgtggac	60
ctggggcgccc	cggaaggccc	agcgcttggt	ccaggcaggc	ggggcctgtg	cggtgaccac	120
cctgggtcctg	aaaagtccca	gccccgagcg	ccctccctcc	tagacctgga	ggcctggaac	180
agccagccgc	ccacggacgc	cagagccggg	aacctgacg	gcacttagct	gctgacaaac	240
aacctgtccc	gtggagcgcc	tgaaacacca	gtctttgggg	ccagtgcctc	agtttcaatc	300
caggtaacct	ttaaatgaaa	cttgccctaaa	atcttaggtc	atacacagaa	gagactccaa	360
tcgacaagaa	gctggaaaag	aatg atg ttg tcc tta aac aac cta cag aat				411
		Met Leu Ser Leu Asn Asn Leu Gln Asn				

atc atc tat aac ccg gta atc ccg tat gtt ggc acc att ccc gat cag	459
Ile Ile Tyr Asn Pro Val Ile Pro Tyr Val Gly Thr Ile Pro Asp Gln	
10 15 20 25	
ctg gat cct gga act ttg att gtg ata tgt ggg cat gtt cct agt gac	507
Leu Asp Pro Gly Thr Leu Ile Val Ile Cys Gly His Val Pro Ser Asp	
30 35 40	
gca gac ag	515
Ala Asp	

<210> 11
 <211> 304
 <212> DNA
 <213> Homo sapiens

<220>
 <221> 5'UTR
 <222> 1..173

<220>
 <221> CDS
 <222> 174..304

<400> 11

ttctagaagc ttgtttctcc cacctgaaaa gactggattt gggacatgat cctgtagaac 60
 ttccggagggc cagtgccctca gtttcaatcc aggtaacctt taaatgaaac ttgcctaaaa 120
 tcttaggtca tacacagaag agactccaat cgacaagaag ctggaaaaga atg atg 176
 Met

1
 ttg tcc tta aac aac cta cag aat atc atc tat aac ccg gta atc ccg 224
 Leu Ser Leu Asn Asn Leu Gln Asn Ile Ile Tyr Asn Pro Val Ile Pro
 5 10 15
 tat gtt ggc acc att ccc gat cag ctg gat cct gga act ttg att gtg 272
 Tyr Val Gly Thr Ile Pro Asp Gln Leu Asp Pro Gly Thr Leu Ile Val
 20 25 30
 ata tgt ggg cat gtt cct agt gac gca gac ag 304
 Ile Cys Gly His Val Pro Ser Asp Ala Asp
 35 40

<210> 12
 <211> 473
 <212> DNA
 <213> Homo sapiens

<220>
 <221> 5'UTR
 <222> 1..342

<220>
 <221> CDS
 <222> 343..473

<400> 12
 ttctagaagc ttgtttctcc cacctgaaaa gactggattt gggacatgat cctgtagaac 60
 ttccggagatt ggggaagata atccggaagag gtaaaagaca ccgtccatga cacttccctgg 120
 ggaagcagat gtatgtataa ggaatccgccc acggagaccca gagccgggaa ccttgacggc 180
 acttagctgc tgacaaaacaa cctgctccgt ggagcgcctg aaacaccagt ctttggggcc 240
 agtgccctcag tttcaatcca ggtaaccttt aaatgaaact tgccataaat cttaggtcat 300
 acacagaaga gactccaatc gacaagaagc tggaaaagaa tg atg ttg tcc tta 354
 Met Leu Ser Leu

1
 aac aac cta cag aat atc atc tat aac ccg gta atc ccg tat gtt ggc 402
 Asn Asn Leu Gln Asn Ile Ile Tyr Asn Pro Val Ile Pro Tyr Val Gly
 5 10 15 20
 acc att ccc gat cag ctg gat cct gga act ttg att gtg ata tgt ggg 450
 Thr Ile Pro Asp Gln Leu Asp Pro Gly Thr Leu Ile Val Ile Cys Gly
 25 30 35
 cat gtt cct agt gac gca gac ag 473
 His Val Pro Ser Asp Ala Asp
 40

<210> 13
 <211> 2077
 <212> DNA
 <213> Homo sapiens

<220>
 <221> 5'UTR
 <222> 1..265

<220>
 <221> CDS
 <222> 266..913

<220>
 <221> 3'UTR

<400> 13
 ttctagaagc ttgtttctcc cacctgaaaa gactggattt gggacatgat cctgtagaac 60
 ttccggagccg cccacggagc ccagagccgg gaacctctgac ggcacttagc tgctgacaaa 120
 caacctctct cgtggagcgc ctgaaacacc agtctttggg gccagtgcct cagctttcaat 180
 ccaggtaaac tttaatgaa acttgcttaa aatctttagg catacacaga agagactcca 240
 atcgacaaga agctggaanaa gaatg atg ttg tcc tta aac aac cta cag aat 292
 Met Leu Ser Leu Asn Asn Leu Gln Asn
 1 5
 atc atc tat aac ccg gta atc ccg tat gtt ggc acc att ccc gat cag 340
 Ile Ile Tyr Asn Pro Val Ile Pro Tyr Val Gly Thr Ile Pro Asp Gln
 10 15 20 25
 ctg gat cct gga act ttg att gtg ata tgt ggg cat gtt cct agt gac 388
 Leu Asp Pro Gly Thr Leu Ile Val Ile Cys Gly His Val Pro Ser Asp
 30 35 40
 gca gac aga ttc cag gtg gat ctg cag aat ggc agc agt gtg aaa cct 436
 Ala Asp Arg Phe Gln Val Asp Leu Gln Asn Gly Ser Ser Val Lys Pro
 45 50 55
 cga gcc gat gtg gcc ttt cat ttc aat cct cgt ttc aaa agg gcc ggc 484
 Arg Ala Asp Val Ala Phe His Phe Asn Pro Arg Phe Lys Arg Ala Gly
 60 65 70
 tgc att gtt tgc aat act ttg ata aat gaa aaa tgg gga cgg gaa gag 532
 Cys Ile Val Cys Asn Thr Leu Ile Asn Glu Lys Trp Gly Arg Glu Glu
 75 80 85
 atc acc tat gac acg cct ttc aaa aga gaa aag tct ttt gag atc gtg 580
 Ile Thr Tyr Asp Thr Pro Phe Lys Arg Glu Lys Ser Phe Glu Ile Val
 90 95 100 105
 att atg gtg cta aag gac aaa ttc cag atg ata att tac tgt gat gtt 628
 Ile Met Val Leu Lys Asp Lys Phe Gln Met Ile Ile Tyr Cys Asp Val
 110 115 120
 aga gaa ttc aag gtt gca gta aat ggc gta cac agc ctg gag tac aaa 676
 Arg Glu Phe Lys Val Ala Val Asn Gly Val His Ser Leu Glu Tyr Lys
 125 130 135
 cac aga ttt aaa gag ctc agc agt att gac acg ctg gaa att aat gga 724
 His Arg Phe Lys Glu Leu Ser Ser Ile Asp Thr Leu Glu Ile Asn Gly
 140 145 150
 gac atc cac tta ctg gaa caa tca ttc aat caa aag agt gaa atg aag 772
 Asp Ile His Leu Leu Glu Gln Ser Phe Asn Gln Lys Ser Glu Met Lys
 155 160 165
 cac att aac aaa gca gga ggc gcc acg gac cgc ctc cct cca cac cgc 820
 His Ile Asn Lys Ala Gly Gly Ala Thr Asp Arg Leu Pro Pro His Arg
 170 175 180 185
 tcc ttc cgc ctt cat tcc ttg ccc aca ggc ttg cac tgg aag ctg aat 868
 Ser Phe Arg Leu His Ser Leu Pro Thr Gly Leu His Trp Lys Leu Asn
 190 195 200
 aag aat ccc caa aac tca aac ttc cta ggg atg cca ccc ctt tag 913
 Lys Asn Pro Gln Asn Ser Asn Phe Leu Gly Met Pro Pro Leu *
 205 210 215
 tagctcacac ctccccctc caagagctaa gaaacaaaagg agaattgact ttgttagctt 973
 agataagcaa tgaatcagta aaggactgat ctacttgctc caccaccctc cccttaataa 1033
 taacattttc tgtttttccc tgggcttaag acttatgttc cagaactgtc agcctcttagt 1093
 atgtcacacc cactagcttg tgacttttgt caaataactg aaactcttta agcctctagt 1153
 ttcttctttt gtaaaacaga gataaaatgt tgtggttttt aagttagata atccaagtaa 1213
 agcacctaac atggagtagt gaatgaacat cggttgctac taaaagtggg catctaccg 1273
 catccttaat gccactaggc atttccatcac aatctgggga ccaaaacttc aatcatataa 1333
 atgtatgagg ttaattaaaa acactactgt aatctgcttg tatgatcaca aaccaccaca 1393
 aaagaaaaga tcgtgaagat tacactgttaa acggactctc aatgatcacg gagtggtgca 1453
 cttgcgaact tgcctccctc acccaactca aaacaggagc tcgagctcgc ctgtatttga 1513
 gactggagct gcctgtatga ggaactggatc aactgctagt cagcttaata ccaaatctgc 1573
 attatcattg ggcacattt cacagaattt tactgaatta ttcttaattg gtttaattggt 1633
 tgggaatagt ttgggaatta ccttccatca actctgctaa gaaaggaatg gattctggtg 1693

gcaagacaaat ataattctcc tttagttttt cagccagtcg taacacagta atcaaaagcag 1753
 caaatcgaaac ctgaaaggga taaaagagca aagaaataaa aagtagtggt actgtatttta 1813
 ttatctttaag agctgtactg acttgagaca agctctaact ttttaaacat tagttcacac 1873
 gcgtttattc acttcattat gttcattaag ctttcatctt agaataccag ttctaccatt 1933
 tgggagctgt ttgtaatatg tgcaacctta taaatagtg ttcccaaact gtgtcccagg 1993
 actgcaaatc tttaatgtga aatgtctttt tataatctct tcctttaaaa aaaaccaata 2053
 aaataaaatg ccacatgcaa actc 2077

<210> 14
 <211> 316
 <212> PRT
 <213> Homo sapiens

<400> 14
 Met Leu Ser Leu Asn Asn Leu Gln Asn Ile Ile Tyr Asn Pro Val Ile
 1 5 10 15
 Pro Tyr Val Gly Thr Ile Pro Asp Gln Leu Asp Pro Gly Thr Leu Ile
 20 25 30
 Val Ile Cys Gly His Val Pro Ser Asp Ala Asp Arg Phe Gln Val Asp
 35 40 45
 Leu Gln Asn Gly Ser Ser Val Lys Pro Arg Ala Asp Val Ala Phe His
 50 55 60
 Phe Asn Pro Arg Phe Lys Arg Ala Gly Cys Ile Val Cys Asn Thr Leu
 65 70 75
 Ile Asn Glu Lys Trp Gly Arg Glu Glu Ile Thr Tyr Asp Thr Pro Phe
 85 90 95
 Lys Arg Glu Lys Ser Phe Glu Ile Val Ile Met Val Leu Lys Asp Lys
 100 105 110
 Phe Gln Val Ala Val Asn Gly Lys His Thr Leu Leu Tyr Gly His Arg
 115 120 125
 Ile Gly Pro Glu Lys Ile Asp Thr Leu Gly Ile Tyr Gly Lys Val Asn
 130 135 140
 Ile His Ser Ile Gly Phe Ser Phe Ser Ser Asp Leu Gln Ser Thr Gln
 145 150 155
 Ala Ser Ser Leu Glu Leu Thr Glu Ile Ser Arg Glu Asn Val Pro Lys
 165 170 175
 Ser Gly Thr Pro Gln Leu Ser Leu Pro Phe Ala Ala Arg Leu Asn Thr
 180 185 190
 Pro Met Gly Pro Gly Arg Thr Val Val Val Lys Gly Glu Val Asn Ala
 195 200 205
 Asn Ala Lys Ser Phe Asn Val Asp Leu Leu Ala Gly Lys Ser Lys Asp
 210 215 220
 Ile Ala Leu His Leu Asn Pro Arg Leu Asn Ile Lys Ala Phe Val Arg
 225 230 235
 Asn Ser Phe Leu Gln Glu Ser Trp Gly Glu Glu Glu Arg Asn Ile Thr
 245 250 255
 Ser Phe Pro Phe Ser Pro Gly Met Tyr Phe Glu Met Ile Ile Tyr Cys
 260 265 270
 Asp Val Arg Glu Phe Lys Val Ala Val Asn Gly Val His Ser Leu Glu
 275 280 285
 Tyr Lys His Arg Phe Lys Glu Leu Ser Ser Ile Asp Thr Leu Glu Ile
 290 295 300
 Asn Gly Asp Ile His Leu Leu Glu Val Arg Ser Trp
 305 310 315

<210> 15
 <211> 358
 <212> PRT
 <213> Homo sapiens

<400> 15
 Met Leu Ser Leu Asn Asn Leu Gln Asn Ile Ile Tyr Asn Pro Val Ile

145 150 155 160
 Ser Phe Asn Gln Lys Ser Glu Met Lys His Ile Asn Lys Ala Gly Gly
 165 170 175
 Ala Thr Asp Arg Leu Pro Pro His Arg Ser Phe Arg Leu His Ser Leu
 180 185 190
 Pro Thr Gly Leu His Trp Lys Leu Asn Lys Asn Pro Gln Asn Ser Asn
 195 200 205
 Phe Leu Gly Met Pro Pro Leu
 210 215

<210> 18
 <211> 504
 <212> DNA
 <213> Homo sapiens

<220>
 <221> allele
 <222> 81
 <223> 99-7177-81 : polymorphic base C or T

<220>
 <221> misc_binding
 <222> 69..93
 <223> 99-7177-81.probe

<220>
 <221> primer_bind
 <222> 62..80
 <223> 99-7177-81.mis

<220>
 <221> primer_bind
 <222> 82..100
 <223> 99-7177-81.mis complement

<220>
 <221> primer_bind
 <222> 1..20
 <223> 99-7177.pu

<220>
 <221> primer_bind
 <222> 484..504
 <223> 99-7177.rp complement

<400> 18
 aatcctgacc cacctctctcc caagcacgca tgtagaggaa agaaagcaag agcgatagct 60
 gaggggatca gcctactaga yggaggcagg tgtttcaaga tgggtgttga agggcaagcc 120
 gagaactcta gtacggggga ggggaaaact aaaactttat tactgttaagc aaatatcaca 180
 gcaaatcagc cttaagttagg tataaaaagaa cccataaaaag aagacaaaat gtaaccaaaag 240
 ctaccagac cacagaagag tcatacctagg agtcggaaga cagacgcgct ggatcctgca 300
 gtaggagttg gggcatccccc cagcatagga caacagcaac cttcaatcct ccttcgtata 360
 agctcctttt attaatgcca attgttactt tgggcacccct ctgttggttg ctggtgaggg 420
 ccctccccc gcaagcaaca ctgaaacagt ggttctggga gcagcgtcct gggacgcgct 480
 ccaggacttg agttaatttc tggg 504

<210> 19
 <211> 488
 <212> DNA
 <213> Homo sapiens

<220>

<221> allele
 <222> 345
 <223> 99-7212-346 : polymorphic base C or T

<220>
 <221> misc_binding
 <222> 333..357
 <223> 99-7212-346.probe

<220>
 <221> primer_bind
 <222> 326..344
 <223> 99-7212-346.mis

<220>
 <221> primer_bind
 <222> 346..364
 <223> 99-7212-346.mis complement

<220>
 <221> primer_bind
 <222> 1..20
 <223> 99-7212.pu

<220>
 <221> primer_bind
 <222> 470..488
 <223> 99-7212.rp complement

<400> 19
 gctccttatg taattgaatg aatggatttt ttatcagatg ctttttaaaa gtcagtacac 60
 aattccatct atttcacagc aaattctaca gaaatagcag ctgacacagc ggaagctgtg 120
 gcttactgtt tagtgacttg tgattgtaat taaatgatta gtcttccact ccattccctc 180
 caactgtctt tgggtctggg gaggtaggga ggacaaatgc aaaaatccata gagtcaaggga 240
 tatagtgagg agtttacttt gccattgact ctgacaaatca atcgtcagtg agacatgctg 300
 attgtgatga gaacatgact aaagacaaga ttccttcaag gtagygctct cactgtttca 360
 ttcaatgaaa aactattggg gttgtataac ccaatgaatc attttgtat ttggaatctt 420
 taaaaatata tacaagtgtt attttgcttg aagtgtgttt tatttataag gttgacaatt 480
 aaactgac 488

<210> 20
 <211> 542
 <212> DNA
 <213> Homo sapiens

<220>
 <221> allele
 <222> 226
 <223> 99-7193-228 : polymorphic base G or C

<220>
 <221> misc_binding
 <222> 214..238
 <223> 99-7193-228.probe

<220>
 <221> primer_bind
 <222> 207..225
 <223> 99-7193-228.mis

<220>
 <221> primer_bind

Case	Age	Sex	Duration	Location	Findings
1	45	M	10 years	Left lower leg	Ulcer, ulceration, ulceration
2	55	F	15 years	Right lower leg	Ulcer, ulceration, ulceration
3	65	M	20 years	Left lower leg	Ulcer, ulceration, ulceration
4	75	F	25 years	Right lower leg	Ulcer, ulceration, ulceration
5	85	M	30 years	Left lower leg	Ulcer, ulceration, ulceration
6	95	F	35 years	Right lower leg	Ulcer, ulceration, ulceration

```
<220>
<221> primer_bind
<222> 522..542
<223> 99-7193.rp complement
```

<400> 20							
gaggtaaaaa	tagcaggcgag	gagaacagat	cttttaggat	tgtgaattgt	aatgtggaaac		60
aggtaaaactt	catcatcttc	tgtgtctgctg	ctagtctgac	ttaactcttg	ctgtataaaa		120
acacccccca	aaattagtga	tttgaacaaca	ctgtccccat	ttaattactc	atgatttttgc		180
agttctctcag	gaactttgtg	ggataactctg	actctgcttc	tcgcastgtt	gactcagggtc		240
atactctcgag	ctcacatctag	ctggcagctt	catttgggctt	ggaacacgaa	agacagcttc		300
ctcaacatac	ctggcacctc	agccaaagbt	gctgcaattg	ctggaggctt	actgggctct		360
tcaactctgt	tgtggtttctc	gtgatttcgt	agtcatactc	gaactcaatt	tcacgggaac		420
tggaatcgaa	aaagatgaaa	acagaagaat	caatgtctgc	gagacaagtt	cctgaactgtt		480
catcttctact	acacctatta	ctcactatta	gtcaaaaata	atcctctctc	caataactctt		540
ca							542

```
<210> 21
<211> 528
<212> DNA
<213> Homo sapiens
```

```
<220>
<221> allele
<222> 212
<223> 99-7186-212 : polymorphic base A or G
```

```
<220>  
<221> misc_binding  
<222> 200..224  
<223> 99-7186-212.probe
```

```
<220>
<221> primer_bind
<222> 193..211
<223> 99-7186-212.mis
```

```
<220>  
<221> primer_bind  
<222> 213..231  
<223> 99-7186-212.mis complement
```

```
<220>  
<221> primer_bind  
<222> 1..19  
<223> 99-7186.pu
```

```
<220>
<221> primer_bind
<222> 510..528
<223> 99-7186.rp complement
```

<400> 21
gagtaccata tttgataga ttgtttctg ggttttttc tttttgttac ttctgcaata 60

tttagaacac	tgactgacac	atatacaggca	ctcaataatt	atttgetgaa	tttctcaatg	120
tctcgatttg	gcataaggat	ttcattttcc	catgggtatat	tttcttccgt	ggattgtagg	180
gctagtacta	atttgcacgg	gtgtcttggg	grttcacaaat	catgggtttta	atgtccacgt	240
cccccttggc	tacaggaggt	acttgatcct	aggtagactaa	ggcagaaata	aatagaatgt	300
gtaggactcc	tctgggtgtaa	aaagtcatgg	gttccaaaag	ttcattttata	agtcaattgt	360
ttggacatcc	tgaacttatt	ttcagaacac	gattggggcac	agctagttaa	ctgcagggag	420
gcctgaggag	actggaaggt	gccagaacct	ggaaccagat	ctgccacta	ggacaggacc	480
agccctggaa	ggacaggagc	aggtgcactg	gattctaaag	gtgttcag		528

<210> 22
 <211> 531
 <212> DNA
 <213> Homo sapiens

<220>
 <221> allele
 <222> 49
 <223> 99-7182-49 : polymorphic base C or T

<220>
 <221> misc_binding
 <222> 37..61
 <223> 99-7182-49.probe

<220>
 <221> primer_bind
 <222> 30..48
 <223> 99-7182-49.mis

<220>
 <221> primer_bind
 <222> 50..68
 <223> 99-7182-49.mis complement

<220>
 <221> primer_bind
 <222> 1..20
 <223> 99-7182.pu

<220>
 <221> primer_bind
 <222> 511..531
 <223> 99-7182.rp complement

<400> 22						
gtgtgttagaaa	aagaaagatg	gctgtcattt	gagttgttaa	gaacagcayg	ctgcaatacc	60
aaaacatcaa	gctgtacatc	tcaaatatgt	atgattttca	tatgtgaatc	acatctcaat	120
aaagctgttta	gaaaaataaa	attaccatta	agtttaaaaa	aaaaaagaaa	aaaagaaaaa	180
aacaaccaca	gtcggggcaa	ggggccatgt	actagggccca	gggattttgc	caatgaagca	240
ggaacataga	gatccctagg	ccataaggaa	aagaagattc	aaggaaagcc	aggacatggg	300
aggggaatgaa	caaacctcag	tcttagaggt	ttagcagaga	ctagctggct	tcttgacgtg	360
aattaataaa	tgagaaaaaa	atctgagatc	acaataaaag	atctttactg	gtgcaagggc	420
caactctcac	cgtgttttga	ctgcttttgg	tcattcttta	gtaccttaag	ttttttatat	480
tttgtgaaga	ttttactatt	ttttwatctg	caagagagta	agttcaatca	a	531

<210> 23
 <211> 546
 <212> DNA
 <213> Homo sapiens

<220>
 <221> allele

```
<222> 372
<223> 99-1585-373 : polymorphic base C or T
```

```
<220>
<221> misc_binding
<222> 360..384
<223> 99-1585-373.probe
```

```

<222> 259..277
<223> 99-1587-281.mis

<220>
<221> primer_bind
<222> 279..297
<223> 99-1587-281.mis complement

<220>
<221> primer_bind
<222> 1..21
<223> 99-1587.pu

<220>
<221> primer_bind
<222> 377..396
<223> 99-1587.rp complement

<220>
<221> misc_feature
<222> 48
<223> n=a, g, c or t

<400> 24
taatggtagt tgatgaggtc ctatgtaata tgcatttcct tggttgcnaa tagcaaaatta      60
ctacacacac agaaaggaaa gccacactcc ccgacacdw c tacacacagg aggactcaca      120
caggaggagg actcaaagaa gccacgtgac ttttacattg ttagggtcta catggtcctg      180
ggattttcca ccagtactca aaagatcaat tgtatgaaca agtcaacctat ttttcggca      240
ctaaataaatt attattcaac aacatggaaa atatgtgrta gcagacctgg attttcctta      300
agagttattt ttatgtggta ctgccccctg ctggaatata acatctatac acatcctttc      360
tggctgggct gacatcctaa aaccagccca ggacca                                  396

<210> 25
<211> 447
<212> DNA
<213> Homo sapiens

<220>
<221> allele
<222> 283
<223> 99-13798-284 : polymorphic base A or G

<220>
<221> misc_binding
<222> 271..295
<223> 99-13798-284.probe

<220>
<221> primer_bind
<222> 264..282
<223> 99-13798-284.mis

<220>
<221> primer_bind
<222> 284..302
<223> 99-13798-284.mis complement

<220>
<221> primer_bind
<222> 1..20
<223> 99-13798.pu

```



```

<220>
<221> primer_bind
<222> 427..447
<223> 99-13798.rp complement

<220>
<221> misc_feature
<222> 34,416
<223> n=a, g, c or t

<400> 25
gaggaaaagg actttggatg tctggtgtca ctgnetgcac accaggcaca cagcaggtgc      60
tcaataagta ttgatgaat atatcaaatg aatgaggagt gtgacacagt tcaagaagaa      120
aatcaaatga aaaattaggc ttcttagcag cccgaaaaga gctctttatc tagaaattgt      180
caaaccagct gatgcaagtt tttttggtgt taacaaggca gccgcaagat tgctatggag      240
aggacaccgt gtaccatgga gattaacggc atgagcttta gcrgcagcta acccctgtga      300
gatgtgtgac ttggacaggt tactgagctt gctaagcccc tgtctcactc tccaaacagg      360
gataatgaca cctctctcac aagggtggtg tgaggattaa atgaggtaat cctttnaagc      420
tcccatccta gcacacgtaa gaagcat                                     447

<210> 26
<211> 506
<212> DNA
<213> Homo sapiens

<220>
<221> allele
<222> 402
<223> 99-1601-402 : polymorphic base A or T

<220>
<221> misc_binding
<222> 390..414
<223> 99-1601-402.probe

<220>
<221> primer_bind
<222> 383..401
<223> 99-1601-402.mis

<220>
<221> primer_bind
<222> 403..421
<223> 99-1601-402.mis complement

<220>
<221> primer_bind
<222> 1..18
<223> 99-1601.pu

<220>
<221> primer_bind
<222> 486..506
<223> 99-1601.rp complement

<400> 26
ttggcttggc agggcaacca gctcaccaga ctctctgcag acccgaagtc attacataca      60
gtatgataac agggaaatgga cccgaccagc atttgctgga gatgatatct ggtgtcagcc      120
cgacaggccc ctacctgctt ctcttgatat gcaggaaatcc ctccaagctc caacaagatc      180
tgtttaaatg actggagagt cctttagttc cttcctctaa ggggaaatca gatcgttctg      240
gttctgttgg taactcctta cttcatccct gatgggaagt ttatagaatg aggaaccagg      300
gctattacat gaaactataa aactgcctag agcacatact tggatatttt aacattgttg      360

```

agagggactc acttaattca gcottgcagc tattgcattc cwgtccaaac caacggcagg	420
ttctcaaaac aagcgggtgaa agggttcctg ttgcagagct gtctggacat ttaaagaagg	480
gagaggaaat ctccarggggt cgggtg	506

<210> 27
 <211> 546
 <212> DNA
 <213> Homo sapiens

<220>
 <221> allele
 <222> 79
 <223> 99-13808-80 : polymorphic base A or T

<220>
 <221> misc_binding
 <222> 67..91
 <223> 99-13808-80.probe

<220>
 <221> primer_bind
 <222> 60..78
 <223> 99-13808-80.mis

<220>
 <221> primer_bind
 <222> 80..98
 <223> 99-13808-80.mis complement

<220>
 <221> primer_bind
 <222> 1..20
 <223> 99-13808.pu

<220>
 <221> primer_bind
 <222> 526..546
 <223> 99-13808.rp complement

<220>
 <221> allele
 <222> 266
 <223> 99-13808-268 : polymorphic base A or C

<220>
 <221> misc_binding
 <222> 254..278
 <223> 99-13808-268.probe

<220>
 <221> primer_bind
 <222> 247..265
 <223> 99-13808-268.mis

<220>
 <221> primer_bind
 <222> 267..285
 <223> 99-13808-268.mis complement

<220>
 <221> allele
 <222> 419

99-13808-80.mis

<223> 99-13808-425 : polymorphic base G or C

<220>

<221> misc_binding

<222> 407..431

<223> 99-13808-425.probe

<220>

<221> primer_bind

<222> 400..418

<223> 99-13808-425.mis

<220>

<221> primer_bind

<222> 420..438

<223> 99-13808-425.mis complement

<220>

<221> allele

<222> 453

<223> 99-13808-455 : polymorphic base A or G

<220>

<221> misc_binding

<222> 441..465

<223> 99-13808-455.probe

<220>

<221> primer_bind

<222> 434..452

<223> 99-13808-455.mis

<220>

<221> primer_bind

<222> 454..472

<223> 99-13808-455.mis complement

<400> 27
gttgtgcctt aaagaatttg ctcacccaca gagggtccaac tgcattagaa agaaaaacaac 60
tctcctcttc aactcaccwg cattgatttt ctgtgtgttg catgtagaag agtattttcaa 120
agaatgaatg aaagctataa tatttatttag aagtaaaaaa gttctaaaga tatgctacct 180
tactgggatg cttagagacc atttgcaaac cctgtttatg atctagaaat cctgtttttc 240
attttttatt tgtaaaactc tataamtctc aaaaaatttt aggtgggatta tcatgtacct 300
aagggtaaaa tatagttgaa attattctta cctgattttt catatctgaa tttcgtgggc 360
agttcaaaagt aattgtatca cattcttcag ctaggaaaaa aaaaaagaaa gaaagaaasa 420
aacaagaagt gatttttaaaa agcacacact ccrtgggtgta agacctaaaa ttaagggttca 480
gtgtcacatg ctgccttggc atctggtaaa atcagaagag ctggactaca aatycctctc 540
caaaact 546

<210> 28

<211> 476

<212> DNA

<213> Homo sapiens

<220>

<221> allele

<222> 212

<223> 99-13810-214 : polymorphic base C or T

<220>

<221> misc_binding

<222> 200..224

<223> 99-13810-214.probe

<220>

<221> primer_bind

<222> 193..211

<223> 99-13810-214.mis

<220>

<221> primer_bind

<222> 213..231

<223> 99-13810-214.mis complement

<220>

<221> primer_bind

<222> 1..18

<223> 99-13810.pu

<220>

<221> primer_bind

<222> 458..476

<223> 99-13810.rp complement

<220>

<221> allele

<222> 168

<223> 99-13810-170 : polymorphic base A or T

<220>

<221> misc_binding

<222> 156..180

<223> 99-13810-170.probe

<220>

<221> primer_bind

<222> 149..167

<223> 99-13810-170.mis

<220>

<221> primer_bind

<222> 169..187

<223> 99-13810-170.mis complement

<400> 28

gcattcccag	attgtaacat	agttttaagt	aaacatccac	tgaaaagtctg	catggaagaa	60
cacagaagcc	agagcaagtt	cagggctcct	agaagacga	tgctggagct	agccctagag	120
aatggctgag	aattggatga	actcagaaga	agcagcaaa	tagttgcwgg	tggcaggcat	180
ggcaggagaa	gggctcaggt	ggctggaaga	gyggagggt	tagaactgaa	acagagagtc	240
tgttgagggt	ggacagagga	aggcgggatt	agatgagaaa	tgacggaccc	agtttctaag	300
aaagaccgaag	aaagataagc	aaagggattt	aggtgggatg	cccttctagg	ttctcgggaa	360
acttgctacc	tgecttgac	tgactttgca	tgaggggaaga	tgggtcaacac	agctttgcaa	420
gaagtacagac	aagcaggcaa	tgacaattct	ctgagatggc	aaatagggat	tgggct	476

<210> 29

<211> 454

<212> DNA

<213> Homo sapiens

<220>

<221> allele

<222> 127

<223> 99-13790-129 : polymorphic base C or T

<220>
 <221> misc_binding
 <222> 115..139
 <223> 99-13790-129.probe

<220>
 <221> primer_bind
 <222> 108..126
 <223> 99-13790-129.mis

<220>
 <221> primer_bind
 <222> 128..146
 <223> 99-13790-129.mis complement

<220>
 <221> primer_bind
 <222> 1..20
 <223> 99-13790.pu

<220>
 <221> primer_bind
 <222> 434..454
 <223> 99-13790.rp complement

<400> 29							
gtcatttttac	taagcctttc	agacagtaga	gagtgggatt	atacttgtcc	caacagctca		60
ccctccttaaa	ggtcaaacct	aaaccatttt	ggttctcttg	ttcaagttca	ggttgccagt		120
gaaaagyaaa	ggaacttgaa	attcatgtta	aacatttaac	atctttccat	atgaattgct		180
aggaagcaac	ttccattcca	aagttgtgtt	aacttcacag	ttttccacc	tgtggtgaag		240
atggtacaaa	atagcttaaa	aactgatatt	gttccatcag	attctaact	ttagtcacag		300
aattcaaggg	catactctaa	actttaaggt	tggcagaaat	atattataac	agaaaattta		360
gcaccatgta	aatgtttaaa	gttatttagc	cttaaataca	gaaccattta	actcaggggt		420
gaaaagtcag	gatgaagtga	gggwttgatt	gatt				454

<210> 30
 <211> 444
 <212> DNA
 <213> Homo sapiens

<220>
 <221> allele
 <222> 153
 <223> 99-13809-153 : polymorphic base A or G

<220>
 <221> misc_binding
 <222> 141..165
 <223> 99-13809-153.probe

<220>
 <221> primer_bind
 <222> 134..152
 <223> 99-13809-153.mis

<220>
 <221> primer_bind
 <222> 154..172
 <223> 99-13809-153.mis complement

<220>
 <221> primer_bind

<400> 36
 cccacctgaa aagactggat ttgggac 27

 <210> 37
 <211> 27
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> oligonucleotide PCTAexALF13n

 <400> 37
 ccacctgaaa agactggatt tgggaca 27

 <210> 38
 <211> 27
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> oligonucleotide PCTAexALR60

 <400> 38
 ctccgaagtt ctacaggatc atgtccc 27

 <210> 39
 <211> 27
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> oligonucleotide PCTAexALR12n

 <400> 39
 cccaaatcca gtcttttcag gtgggag 27

 <210> 40
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> oligonucleotide PCTAexBLF33

 <400> 40
 gaaaaccctg gcgttgaccc cgtgg 25

 <210> 41
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> oligonucleotide PCTAexBLF120n

 <400> 41
 caccctggtc ctgaaaagtc cagcc 25

 <210> 42
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> oligonucleotide PCTAexBLR140

 <400> 42
 taggaggggag ggagattcgg ggctg 25

 <210> 43
 <211> 26
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> oligonucleotide PCTAexBLR40n

 <400> 43
 tccacggggg caacgccagg gttttc 26

 <210> 44
 <211> 27
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> oligonucleotide PCTA5Ra220n

 <400> 44
 gggaatgggt ccaacatacg ggattac 27

 <210> 45
 <211> 26
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> oligonucleotide PCTA5Ra230

 <400> 45
 gctgatcggt aatgggtgcc acatac 26

 <210> 46
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> oligonucleotide PCTA_5Ra400

 <400> 46
 tcacctacac ctacccact tcctc 25

 <210> 47
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> oligonucleotide PCTA_5Ran_400

 <400> 47
 cctacacctc acccaettcc tcccc 25

<210> 48
 <211> 27
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> oligonucleotide PCTA_5Ra_394

 <400> 48
 cctccccacc actggttcat ttggaag 27

 <210> 49
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> oligonucleotide PCTA_exD5Ra

 <400> 49
 tcccccaggaa gtgtcatgga cggtg 25

 <210> 50
 <211> 27
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> oligonucleotide PCTA_exD5Ran

 <400> 50
 ggaagtgtca tggacggtgt cttctac 27

 <210> 51
 <211> 29
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> oligonucleotide PCTA_exC5Ra

 <400> 51
 gctttcatcg cccagctcca gcaattatc 29

 <210> 52
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> oligonucleotide PCTA_exC5Ran

 <400> 52
 tcgccagct ccagcaatta tcgac 25

 <210> 53
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> oligonucleotide PCTAex9terLR330

<400> 53
 acatggggag ctgtgacagt tctgg 25

 <210> 54
 <211> 29
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> oligonucleotide PCTAex9terLR325n

 <400> 54
 ggggagctgt gacagttctg gaacataag 29

 <210> 55
 <211> 27
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> oligonucleotide PCTAexCLF120

 <400> 55
 cttcaaaatg aaccagtggg ggggagg 27

 <210> 56
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> oligonucleotide PCTAexCLF130n

 <400> 56
 accagtgggt gggaggaagt ggggtg 25

 <210> 57
 <211> 20
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> oligonucleotide BAP28polyTcourt

 <400> 57
 tttttttttt tttttgtata 20

 <210> 58
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> oligonucleotide BAP281LF12.1

 <400> 58
 ccatgtggga agcgctgtga agagt 25

 <210> 59
 <211> 26
 <212> DNA

<213> Artificial Sequence
 <220>
 <223> oligonucleotide BAP28LR6726.1
 <400> 59
 cagctctata cgataggcag gagagg 26
 <210> 60
 <211> 38
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> oligonucleotide BAP28LF26SalI
 <400> 60
 cctgtgtcga ccgctgtgaa gagttgttc cttccaag 38
 <210> 61
 <211> 36
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> oligonucleotide BAP28LR6717SalI
 <400> 61
 actccgtcga ccgataggca ggagaggctt atgtgg 36
 <210> 62
 <211> 18
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> sequencing oligonucleotide PrimerPU
 <400> 62
 tgtaaaacga cggccagt 18
 <210> 63
 <211> 18
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> sequencing oligonucleotide PrimerRP
 <400> 63
 caggaaacag ctatgacc 18